{"PMC4659912": [["IntroductionVaccines constitute one of the greatest success stories within the health sector.", [["IntroductionVaccines", "TREATMENT", 0, 20]]], ["They form part of a multifaceted public health response to the emergence of pandemics.", [["pandemics", "PROBLEM", 76, 85]]], ["It highlights the major historical cornerstones in the development and progress of various types of vaccines since the beginning and through the ages until today.IntroductionIt recognizes the major pioneers whose work has made a difference in the advancement of this vital health field, despite all the anti-vaccination movements that appeared through the ages.", [["vaccines", "TREATMENT", 100, 108], ["major", "OBSERVATION_MODIFIER", 18, 23], ["historical", "OBSERVATION_MODIFIER", 24, 34], ["cornerstones", "OBSERVATION", 35, 47]]], ["Multiple reviews were encountered during our literature search; however, each of those reviews dealt with a specific aspect of vaccination like effectiveness of a particular vaccine, or side effects of another or even attitudes toward vaccines.", [["vaccination", "TREATMENT", 127, 138], ["a particular vaccine", "TREATMENT", 161, 181], ["vaccines", "TREATMENT", 235, 243]]], ["Consequently, this work tried to put together the major achievements through history stressing the importance, continuous vital role, and the need for immunization for health prevention and protection as well as its impact on human experience.IntroductionThe physiological mechanisms behind vaccination are well established.", [["human", "ORGANISM", 226, 231], ["human", "SPECIES", 226, 231], ["human", "SPECIES", 226, 231], ["immunization", "TREATMENT", 151, 163], ["health prevention", "TREATMENT", 168, 185], ["protection", "TREATMENT", 190, 200]]], ["Vaccination activates the immune system and induces both innate and adaptive immune responses thus leading to the production of antibodies, in the case of a humoral response, or to the generation of memory cells that will recognize the same antigen, if there is a later exposure.", [["immune system", "ANATOMY", 26, 39], ["memory cells", "ANATOMY", 199, 211], ["memory cells", "CELL", 199, 211], ["antibodies", "PROTEIN", 128, 138], ["memory cells", "CELL_TYPE", 199, 211], ["Vaccination", "TREATMENT", 0, 11], ["the production of antibodies", "PROBLEM", 110, 138], ["memory cells", "PROBLEM", 199, 211]]], ["Periodic repeat injections can improve the efficacy and effectiveness of inoculations (1).IntroductionThe approval of a vaccine abides by a set of well-established international rules and regulations.", [["Periodic repeat injections", "TREATMENT", 0, 26], ["a vaccine", "TREATMENT", 118, 127]]], ["Prior to their approval by the respective health authorities, scientists test vaccines extensively in order to ensure their efficacy, safety, and effectiveness.", [["scientists test vaccines", "TREATMENT", 62, 86]]], ["Next to antibiotics, vaccines are the best defense that we have to date against infectious diseases; however, no vaccine is actually 100% safe or effective for everyone.", [["infectious diseases", "DISEASE", 80, 99], ["antibiotics", "TREATMENT", 8, 19], ["vaccines", "TREATMENT", 21, 29], ["infectious diseases", "PROBLEM", 80, 99], ["vaccine", "TREATMENT", 113, 120]]], ["This is attributed to the fact that each body reacts to vaccines differently (2\u20134).", [["body", "ANATOMY", 41, 45], ["body", "ORGANISM_SUBDIVISION", 41, 45]]], ["Significant progress has been made over the years to monitor side effects and conduct research relevant to vaccine safety.", [["side effects", "PROBLEM", 61, 73], ["vaccine safety", "TREATMENT", 107, 121]]], ["In addition, vaccine licensing is a lengthy process that may take 10 years or longer.", [["vaccine", "TREATMENT", 13, 20]]], ["The Food and Drug Administration (FDA) and the National Institute of Health (NIH) require that vaccines undergo the required phases of clinical trials on human subjects prior to any use in the general public.", [["human", "ORGANISM", 154, 159], ["human", "SPECIES", 154, 159], ["human", "SPECIES", 154, 159], ["vaccines", "TREATMENT", 95, 103], ["clinical trials", "TREATMENT", 135, 150], ["human subjects", "TREATMENT", 154, 168]]], ["This process is becoming more complex as more caution and care is being allocated to the quality of the market product.IntroductionFurthermore, vaccines can be divided into different categories depending on the way that they are prepared including live-attenuated vaccines, inactivated vaccines, subunit vaccines, conjugate vaccines, and toxoids.Live-Attenuated VaccinesLive-attenuated vaccines are used more frequently for viruses rather than bacteria, since the former contain a lesser amount of genes and can be controlled more easily (5).", [["IntroductionFurthermore", "TREATMENT", 119, 142], ["vaccines", "TREATMENT", 144, 152], ["live-attenuated vaccines", "TREATMENT", 248, 272], ["inactivated vaccines", "TREATMENT", 274, 294], ["subunit vaccines", "TREATMENT", 296, 312], ["conjugate vaccines", "TREATMENT", 314, 332], ["toxoids", "TREATMENT", 338, 345], ["Attenuated VaccinesLive-attenuated vaccines", "TREATMENT", 351, 394], ["viruses", "PROBLEM", 424, 431], ["bacteria", "PROBLEM", 444, 452], ["more complex", "OBSERVATION_MODIFIER", 25, 37], ["lesser", "OBSERVATION_MODIFIER", 481, 487]]], ["The most common method in formulating live-attenuated vaccines involves passing the virus through successions of cell cultures to weaken it.", [["cell cultures", "ANATOMY", 113, 126], ["cell cultures", "CELL", 113, 126], ["cell cultures", "CELL_LINE", 113, 126], ["attenuated vaccines", "TREATMENT", 43, 62], ["the virus", "PROBLEM", 80, 89], ["cell cultures", "TEST", 113, 126]]], ["This will produce a form of the virus that is no longer able to replicate in human cells.", [["cells", "ANATOMY", 83, 88], ["human", "ORGANISM", 77, 82], ["cells", "CELL", 83, 88], ["human cells", "CELL_TYPE", 77, 88], ["human", "SPECIES", 77, 82], ["human", "SPECIES", 77, 82], ["the virus", "PROBLEM", 28, 37], ["virus", "OBSERVATION", 32, 37], ["no longer", "UNCERTAINTY", 46, 55], ["human cells", "OBSERVATION", 77, 88]]], ["However, it will still be recognized by the human immune system, hence protecting the body from future invasions.", [["immune system", "ANATOMY", 50, 63], ["body", "ANATOMY", 86, 90], ["human", "ORGANISM", 44, 49], ["immune system", "ANATOMICAL_SYSTEM", 50, 63], ["body", "ORGANISM_SUBDIVISION", 86, 90], ["human", "SPECIES", 44, 49], ["human", "SPECIES", 44, 49], ["invasions", "OBSERVATION", 103, 112]]], ["Examples of such vaccines are measles, rubella, mumps, varicella (more commonly known as chickenpox), and influenza.", [["measles, rubella, mumps", "DISEASE", 30, 53], ["varicella", "DISEASE", 55, 64], ["chickenpox", "DISEASE", 89, 99], ["influenza", "DISEASE", 106, 115], ["such vaccines", "TREATMENT", 12, 25], ["measles", "PROBLEM", 30, 37], ["rubella", "PROBLEM", 39, 46], ["mumps", "PROBLEM", 48, 53], ["varicella", "PROBLEM", 55, 64], ["chickenpox", "PROBLEM", 89, 99], ["influenza", "PROBLEM", 106, 115], ["influenza", "OBSERVATION", 106, 115]]], ["The disadvantage of using this technique is that the virus may transform into a more virulent form due to a certain mutation and cause illness once injected into the body.", [["body", "ANATOMY", 166, 170], ["body", "ORGANISM_SUBDIVISION", 166, 170], ["this technique", "TREATMENT", 26, 40], ["the virus", "PROBLEM", 49, 58], ["a certain mutation", "PROBLEM", 106, 124], ["illness", "PROBLEM", 135, 142], ["body", "ANATOMY", 166, 170]]], ["Although this rarely occurs, it must always be taken into consideration (6).Inactivated VaccinesBy using heat, radiation, or certain chemicals, one can inactivate a microbe.", [["VaccinesBy", "CHEMICAL", 88, 98], ["radiation", "TREATMENT", 111, 120], ["certain chemicals", "TREATMENT", 125, 142]]], ["The microbe will no longer cause illness but can still be recognized by the immune system.", [["immune system", "ANATOMY", 76, 89], ["immune system", "ANATOMICAL_SYSTEM", 76, 89], ["illness", "PROBLEM", 33, 40], ["no longer", "UNCERTAINTY", 17, 26]]], ["Poliovirus and Hepatitis A are common examples of inactivated vaccines.", [["Hepatitis A", "DISEASE", 15, 26], ["Poliovirus", "ORGANISM", 0, 10], ["Hepatitis A", "ORGANISM", 15, 26], ["Poliovirus", "SPECIES", 0, 10], ["Hepatitis A", "SPECIES", 15, 26], ["Poliovirus", "PROBLEM", 0, 10], ["Hepatitis A", "PROBLEM", 15, 26], ["inactivated vaccines", "TREATMENT", 50, 70], ["Hepatitis", "OBSERVATION", 15, 24]]], ["This type of vaccine has the disadvantage of being effective for a shorter period of time than live-attenuated vaccines.", [["vaccine", "TREATMENT", 13, 20], ["live-attenuated vaccines", "TREATMENT", 95, 119]]], ["Multiple boosters of the vaccine are sometimes required to improve effectiveness and sustainability (6).Subunit VaccinesA subunit vaccine contains only portions of the microbe that can be presented as antigens to the human immune system instead of the microbe as a whole.", [["immune system", "ANATOMY", 223, 236], ["VaccinesA", "GENE_OR_GENE_PRODUCT", 112, 121], ["human", "ORGANISM", 217, 222], ["immune system", "ANATOMICAL_SYSTEM", 223, 236], ["antigens", "PROTEIN", 201, 209], ["human", "SPECIES", 217, 222], ["human", "SPECIES", 217, 222], ["the vaccine", "TREATMENT", 21, 32], ["Subunit VaccinesA subunit vaccine", "TREATMENT", 104, 137]]], ["The antigens or the microbe portions that best activate the immune response are usually selected.", [["antigens", "PROTEIN", 4, 12], ["immune response", "OBSERVATION", 60, 75]]], ["An influenza vaccine in the form of shots is an example.", [["An influenza vaccine", "TREATMENT", 0, 20], ["influenza", "OBSERVATION", 3, 12]]], ["In addition, a recombinant subunit vaccine has been made for the hepatitis B virus.", [["hepatitis B", "DISEASE", 65, 76], ["hepatitis B virus", "ORGANISM", 65, 82], ["hepatitis B virus", "SPECIES", 65, 82], ["hepatitis B virus", "SPECIES", 65, 82], ["a recombinant subunit vaccine", "TREATMENT", 13, 42], ["the hepatitis B virus", "PROBLEM", 61, 82]]], ["Hepatitis B genes are injected into maker cells in culture.", [["cells", "ANATOMY", 42, 47], ["Hepatitis B", "ORGANISM", 0, 11], ["cells", "CELL", 42, 47], ["Hepatitis B genes", "DNA", 0, 17], ["maker cells", "CELL_TYPE", 36, 47], ["Hepatitis B genes", "PROBLEM", 0, 17], ["culture", "TEST", 51, 58]]], ["Once these cells reproduce, the desired antigens of the virus are produced as well, and these can be purified for use in vaccines (6).Conjugate VaccinesConjugate vaccines are designed from parts of the bacterial coat.", [["cells", "ANATOMY", 11, 16], ["cells", "CELL", 11, 16], ["the virus", "PROBLEM", 52, 61], ["Conjugate VaccinesConjugate vaccines", "TREATMENT", 134, 170], ["the bacterial coat", "TREATMENT", 198, 216], ["virus", "OBSERVATION", 56, 61], ["bacterial coat", "OBSERVATION", 202, 216]]], ["However, these parts may not produce an effective immune response when presented alone.", [["effective", "OBSERVATION_MODIFIER", 40, 49], ["immune response", "OBSERVATION", 50, 65]]], ["Hence, they are combined with a carrier protein.", [["carrier protein", "PROTEIN", 32, 47], ["a carrier protein", "TEST", 30, 47]]], ["These carrier proteins are chemically linked to the bacterial coat derivatives.", [["carrier proteins", "PROTEIN", 6, 22], ["the bacterial coat derivatives", "TREATMENT", 48, 78], ["bacterial coat derivatives", "OBSERVATION", 52, 78]]], ["Together, they generate a more potent response and can protect the body against future infections.", [["body", "ANATOMY", 67, 71], ["infections", "DISEASE", 87, 97], ["body", "ORGANISM_SUBDIVISION", 67, 71], ["future infections", "PROBLEM", 80, 97], ["infections", "OBSERVATION", 87, 97]]], ["Vaccines against pneumococcal bacteria used in children are an example of conjugate vaccines (6).ToxoidsSome bacteria release harmful toxins that cause illness in infected individuals.", [["illness in infected", "DISEASE", 152, 171], ["pneumococcal bacteria", "ORGANISM", 17, 38], ["children", "ORGANISM", 47, 55], ["children", "SPECIES", 47, 55], ["pneumococcal", "SPECIES", 17, 29], ["Vaccines", "TREATMENT", 0, 8], ["pneumococcal bacteria", "PROBLEM", 17, 38], ["conjugate vaccines", "TREATMENT", 74, 92], ["Toxoids", "TREATMENT", 97, 104], ["Some bacteria release harmful toxins", "PROBLEM", 104, 140], ["illness", "PROBLEM", 152, 159], ["infected individuals", "PROBLEM", 163, 183], ["infected", "OBSERVATION", 163, 171]]], ["Vaccinations against such types of bacteria are prepared by inactivating or weakening the toxin using heat or certain chemicals.", [["Vaccinations", "TREATMENT", 0, 12], ["bacteria", "PROBLEM", 35, 43]]], ["This will help prepare the immune system against future invasion.", [["immune system", "ANATOMY", 27, 40], ["the immune system", "TREATMENT", 23, 40], ["future invasion", "PROBLEM", 49, 64], ["invasion", "OBSERVATION", 56, 64]]], ["The vaccine against tetanus caused by the neurotoxin of Clostridium tetani is a good example of a toxoid (6).Vaccination: Its Determinants and Modulation with AgeThe generation of vaccine-mediated protection is a complex challenge.", [["tetanus", "DISEASE", 20, 27], ["Clostridium tetani", "ORGANISM", 56, 74], ["Clostridium tetani", "SPECIES", 56, 74], ["Clostridium tetani", "SPECIES", 56, 74], ["The vaccine", "TREATMENT", 0, 11], ["tetanus", "PROBLEM", 20, 27], ["Clostridium tetani", "PROBLEM", 56, 74], ["vaccine-mediated protection", "TREATMENT", 180, 207], ["a complex challenge", "TREATMENT", 211, 230]]], ["Effective early protection is conferred primarily by the induction of antigen-specific antibodies.", [["antigen", "GENE_OR_GENE_PRODUCT", 70, 77], ["antigen-specific antibodies", "PROTEIN", 70, 97]]], ["Efficacy requires long-term protection, namely, the persistence of vaccine antibodies and/or the generation of immune memory cells capable of rapid and effective reactivation upon subsequent microbial exposure (7).Vaccination: Its Determinants and Modulation with AgeThe exponential development of new vaccines raises many questions about their impact on the immune system.", [["immune memory cells", "ANATOMY", 111, 130], ["immune system", "ANATOMY", 359, 372], ["immune memory cells", "CELL", 111, 130], ["immune system", "ANATOMICAL_SYSTEM", 359, 372], ["vaccine antibodies", "PROTEIN", 67, 85], ["immune memory cells", "CELL_TYPE", 111, 130], ["long-term protection", "TREATMENT", 18, 38], ["vaccine antibodies", "TREATMENT", 67, 85], ["immune memory cells", "PROBLEM", 111, 130], ["rapid and effective reactivation", "PROBLEM", 142, 174], ["new vaccines", "TREATMENT", 298, 310], ["long-term protection", "OBSERVATION_MODIFIER", 18, 38], ["new", "OBSERVATION_MODIFIER", 298, 301]]], ["Such questions related to immunological safety of vaccines as well as triggering conditions such as allergy, autoimmunity, or even premature death (7).", [["allergy", "DISEASE", 100, 107], ["autoimmunity", "DISEASE", 109, 121], ["premature death", "DISEASE", 131, 146], ["immunological safety of vaccines", "TREATMENT", 26, 58], ["allergy", "PROBLEM", 100, 107], ["even premature death", "PROBLEM", 126, 146]]], ["Such issues were always looked for and monitored and some vaccines were even stopped because of these issues.Vaccination: Its Determinants and Modulation with AgeRecent vaccine models rely on both a cell-mediated response and a humoral immune response with highly specific antibodies and have shown an adequate amount of success.", [["cell", "ANATOMY", 199, 203], ["cell", "CELL", 199, 203], ["antibodies", "PROTEIN", 273, 283], ["Such issues", "PROBLEM", 0, 11], ["some vaccines", "TREATMENT", 53, 66], ["AgeRecent vaccine models", "TREATMENT", 159, 183], ["adequate", "OBSERVATION_MODIFIER", 302, 310], ["amount", "OBSERVATION_MODIFIER", 311, 317]]], ["This, however, has not been the case for a few diseases such as tuberculosis where the humoral immunity mounted by the bacille Calmette\u2013Guerin (BCG), the only currently used human vaccine, is inefficient in conferring proper immunization (8).", [["tuberculosis", "DISEASE", 64, 76], ["Calmette\u2013Guerin", "CHEMICAL", 127, 142], ["BCG", "CHEMICAL", 144, 147], ["bacille Calmette\u2013Guerin", "ORGANISM", 119, 142], ["BCG", "ORGANISM", 144, 147], ["human", "ORGANISM", 174, 179], ["human", "SPECIES", 174, 179], ["human", "SPECIES", 174, 179], ["a few diseases", "PROBLEM", 41, 55], ["tuberculosis", "PROBLEM", 64, 76], ["the humoral immunity", "TREATMENT", 83, 103], ["the bacille Calmette\u2013Guerin (BCG", "TREATMENT", 115, 147], ["human vaccine", "TREATMENT", 174, 187], ["tuberculosis", "OBSERVATION", 64, 76]]], ["However, T cells do take part indirectly in the production of antibodies and of secreted biological molecules (e.g., Interferon) for protection.", [["T cells", "ANATOMY", 9, 16], ["T cells", "CELL", 9, 16], ["Interferon", "GENE_OR_GENE_PRODUCT", 117, 127], ["T cells", "CELL_TYPE", 9, 16], ["antibodies", "PROTEIN", 62, 72], ["secreted biological molecules", "PROTEIN", 80, 109], ["Interferon", "PROTEIN", 117, 127], ["T cells", "PROBLEM", 9, 16], ["secreted biological molecules", "PROBLEM", 80, 109], ["Interferon)", "TREATMENT", 117, 128], ["protection", "TREATMENT", 133, 143]]], ["It seems that a proper mounted immunity is better achieved by vaccine-induced antibodies, whereas a T cell immune response is needed for disease attenuation.", [["T cell", "ANATOMY", 100, 106], ["T cell", "CELL", 100, 106], ["vaccine-induced antibodies", "PROTEIN", 62, 88], ["induced antibodies", "PROBLEM", 70, 88], ["a T cell immune response", "TREATMENT", 98, 122], ["disease attenuation", "PROBLEM", 137, 156]]], ["Hence, a robust understanding of B and T cell function is needed for proper immunization (9).Vaccination: Its Determinants and Modulation with AgeMultiple determinants modulate the primary vaccine antibody response in healthy individuals; they include the vaccine type, live versus inactivated, protein versus polysaccharide, and use of adjuvants (10).", [["T cell", "ANATOMY", 39, 45], ["B", "CELL", 33, 34], ["T cell", "CELL", 39, 45], ["AgeMultiple determinants", "PROTEIN", 143, 167], ["proper immunization", "TREATMENT", 69, 88], ["AgeMultiple determinants", "TREATMENT", 143, 167], ["the vaccine type", "TREATMENT", 252, 268], ["polysaccharide", "TREATMENT", 310, 324], ["adjuvants", "TREATMENT", 337, 346]]], ["They also include the nature of the antigen and its intrinsic immunogenicity (11), the dose of the antigen, the route of administration, the vaccine schedule, and the age at administration (12).", [["the antigen", "TEST", 32, 43], ["the antigen", "TREATMENT", 95, 106], ["the vaccine schedule", "TREATMENT", 137, 157]]], ["In addition, genes play a direct role in the body\u2019s response to vaccination even in healthy individuals (13, 14).", [["body", "ANATOMY", 45, 49], ["body", "ORGANISM_SUBDIVISION", 45, 49], ["vaccination", "TREATMENT", 64, 75]]], ["For each of the above determinants, there might be a particular mechanism involved and is further influenced by other factors including extremes of life, acute or chronic diseases, immunosuppression, and nutrition status (12).Vaccination: Its Determinants and Modulation with AgeEarly life immune responses are limited by (1) limited magnitude of antibody responses to polysaccharides and proteins, (2) short persistence of antibody responses to protein, (3) influence of maternal antibodies, and (4) limited CD8+ T cell and interferon-gamma responses.", [["CD8+ T cell", "ANATOMY", 509, 520], ["immunosuppression", "DISEASE", 181, 198], ["CD8", "GENE_OR_GENE_PRODUCT", 509, 512], ["interferon-gamma", "GENE_OR_GENE_PRODUCT", 525, 541], ["maternal antibodies", "PROTEIN", 472, 491], ["CD8", "PROTEIN", 509, 512], ["interferon", "PROTEIN", 525, 535], ["acute or chronic diseases", "PROBLEM", 154, 179], ["immunosuppression", "TREATMENT", 181, 198], ["antibody responses", "TEST", 347, 365], ["polysaccharides", "TEST", 369, 384], ["proteins", "TEST", 389, 397], ["short persistence of antibody responses", "PROBLEM", 403, 442], ["protein", "TEST", 446, 453], ["maternal antibodies", "TEST", 472, 491], ["acute", "OBSERVATION_MODIFIER", 154, 159], ["chronic", "OBSERVATION_MODIFIER", 163, 170], ["diseases", "OBSERVATION", 171, 179]]], ["Such factors are difficult to study in human infants due to neonatal immune immaturity and the inhibitory influence of maternal antibodies, which increase with gestational age and wane a few months post-natal (7).Vaccination: Its Determinants and Modulation with AgeOn the other hand, in elderly persons, the immune system undergoes characteristic changes, termed immunosenescence, which leads to increased incidence and severity of infectious diseases and to insufficient protection following vaccination (15).", [["immune system", "ANATOMY", 309, 322], ["infectious diseases", "DISEASE", 433, 452], ["human", "ORGANISM", 39, 44], ["infants", "ORGANISM", 45, 52], ["persons", "ORGANISM", 296, 303], ["immune system", "ANATOMICAL_SYSTEM", 309, 322], ["maternal antibodies", "PROTEIN", 119, 138], ["human", "SPECIES", 39, 44], ["infants", "SPECIES", 45, 52], ["persons", "SPECIES", 296, 303], ["human", "SPECIES", 39, 44], ["Such factors", "PROBLEM", 0, 12], ["neonatal immune immaturity", "PROBLEM", 60, 86], ["maternal antibodies", "PROBLEM", 119, 138], ["infectious diseases", "PROBLEM", 433, 452], ["vaccination", "TREATMENT", 494, 505], ["increased", "OBSERVATION_MODIFIER", 397, 406], ["infectious", "OBSERVATION", 433, 443]]], ["Vaccines induce both innate (non-specific) and adaptive (specific) immune responses, which decline substantially with age thus leading to the decreased efficacy of vaccines in elderly persons.", [["persons", "ORGANISM", 184, 191], ["persons", "SPECIES", 184, 191], ["Vaccines", "TREATMENT", 0, 8], ["vaccines", "TREATMENT", 164, 172]]], ["In the elderly, the innate immune response will witness a reduced phagocytic capacity of neutrophils and macrophages, a decrease in their oxidative burst, and impairment in the up-regulation of MHC class II expression among other parameters (16).", [["neutrophils", "ANATOMY", 89, 100], ["macrophages", "ANATOMY", 105, 116], ["neutrophils", "CELL", 89, 100], ["macrophages", "CELL", 105, 116], ["MHC class II", "GENE_OR_GENE_PRODUCT", 194, 206], ["neutrophils", "CELL_TYPE", 89, 100], ["macrophages", "CELL_TYPE", 105, 116], ["MHC class II", "PROTEIN", 194, 206], ["a reduced phagocytic capacity of neutrophils", "PROBLEM", 56, 100], ["macrophages", "PROBLEM", 105, 116], ["a decrease in their oxidative burst", "PROBLEM", 118, 153], ["reduced", "OBSERVATION_MODIFIER", 58, 65], ["phagocytic capacity", "OBSERVATION", 66, 85], ["macrophages", "OBSERVATION", 105, 116], ["decrease", "OBSERVATION_MODIFIER", 120, 128], ["oxidative burst", "OBSERVATION", 138, 153]]], ["In addition, persistent inflammatory processes occur with increasing age and may reduce the capacity to recognize stimuli induced by pathogens or vaccines.", [["persistent inflammatory processes", "PROBLEM", 13, 46], ["the capacity", "PROBLEM", 88, 100], ["pathogens", "PROBLEM", 133, 142], ["vaccines", "TREATMENT", 146, 154], ["persistent", "OBSERVATION_MODIFIER", 13, 23], ["inflammatory", "OBSERVATION", 24, 36], ["increasing", "OBSERVATION_MODIFIER", 58, 68]]], ["For the elderly, improved special antigen delivery systems are needed to overcome these limitations (12).Vaccination: Its Determinants and Modulation with AgeFurthermore, the adaptive immune response is functionally defective in the elderly.", [["special antigen delivery systems", "TREATMENT", 26, 58], ["AgeFurthermore", "TREATMENT", 155, 169], ["functionally defective", "PROBLEM", 203, 225], ["functionally defective", "OBSERVATION", 203, 225]]], ["The involution of the thymus with aging leads to a decrease in content and in output of mature na\u00efve T cells into the periphery, which hampers the induction of adaptive immune responses to neoantigens.", [["thymus", "ANATOMY", 22, 28], ["T cells", "ANATOMY", 101, 108], ["periphery", "ANATOMY", 118, 127], ["thymus", "ORGAN", 22, 28], ["na\u00efve T cells", "CELL", 95, 108], ["mature na\u00efve T cells", "CELL_TYPE", 88, 108], ["the thymus", "PROBLEM", 18, 28], ["a decrease in content", "PROBLEM", 49, 70], ["involution", "OBSERVATION", 4, 14], ["thymus", "ANATOMY", 22, 28], ["decrease", "OBSERVATION_MODIFIER", 51, 59], ["content", "OBSERVATION_MODIFIER", 63, 70], ["output", "OBSERVATION_MODIFIER", 78, 84], ["mature", "OBSERVATION_MODIFIER", 88, 94], ["na\u00efve T cells", "OBSERVATION", 95, 108], ["periphery", "ANATOMY_MODIFIER", 118, 127]]], ["In the context of primary vaccination, this causes reduced response rate (7\u201312).", [["primary vaccination", "TREATMENT", 18, 37], ["reduced response rate", "PROBLEM", 51, 72], ["reduced", "OBSERVATION_MODIFIER", 51, 58], ["response rate", "OBSERVATION", 59, 72]]], ["B cells also undergo age-related changes that aggravate the functionality of B cells colonies.", [["B cells", "ANATOMY", 0, 7], ["B cells colonies", "ANATOMY", 77, 93], ["B cells", "CELL", 0, 7], ["B cells", "CELL", 77, 84], ["B cells", "CELL_TYPE", 0, 7], ["B cells colonies", "CELL_TYPE", 77, 93], ["related changes", "PROBLEM", 25, 40], ["B cells colonies", "PROBLEM", 77, 93], ["B cells colonies", "OBSERVATION", 77, 93]]], ["As effector B cells accumulate, na\u00efve B cells decrease in number and this leads to a reduction in the diversity of antibody responses.", [["B cells", "ANATOMY", 12, 19], ["B cells", "ANATOMY", 38, 45], ["B cells", "CELL", 12, 19], ["na\u00efve B cells", "CELL", 32, 45], ["effector B cells", "CELL_TYPE", 3, 19], ["na\u00efve B cells", "CELL_TYPE", 32, 45], ["na\u00efve B cells decrease", "PROBLEM", 32, 54], ["a reduction", "TREATMENT", 83, 94], ["cells", "OBSERVATION_MODIFIER", 40, 45], ["decrease", "OBSERVATION_MODIFIER", 46, 54]]], ["In brief, vaccines tailored to the needs of the elderly will have to be developed, taking into consideration these limitations in order to improve protection in this population.Vaccine Efficacy and Effectiveness in the Context of the Translational Research MapIn 2010, Weinberg and Szilagyl eloquently approached the issues of efficacy and effectiveness clarifying the road to correctly answer the relevant but complex question: \u201cHow well does the candidate vaccine prevent the disease for which it was developed?\u201d", [["vaccines", "TREATMENT", 10, 18], ["Vaccine Efficacy", "TREATMENT", 177, 193], ["Weinberg", "TREATMENT", 269, 277], ["Szilagyl", "TREATMENT", 282, 290], ["the disease", "PROBLEM", 474, 485], ["disease", "OBSERVATION", 478, 485]]], ["At about the same time, Curns et al. elaborated on the distinction between the epidemiologic concepts of vaccine efficacy and effectiveness within the context of translational research (17).", [["vaccine efficacy", "TREATMENT", 105, 121]]], ["Such concepts were also addressed earlier, but slightly differently, by Clemens and co-workers in two separate publications in 1984 and 1996, and also by Orenstein et al. in 1989 (18\u201320).Vaccine Efficacy and Effectiveness in the Context of the Translational Research MapAccordingly, vaccine efficacy is measured as the proportionate reduction in disease attack rate when comparing vaccinated and unvaccinated populations.", [["Vaccine Efficacy", "TREATMENT", 187, 203], ["the Translational Research MapAccordingly", "TREATMENT", 240, 281], ["vaccine efficacy", "TREATMENT", 283, 299], ["disease attack rate", "PROBLEM", 346, 365], ["proportionate", "OBSERVATION_MODIFIER", 319, 332], ["reduction", "OBSERVATION_MODIFIER", 333, 342]]], ["Vaccine efficacy studies always have rigorous control for biases through randomized prospective studies and vigilant monitoring for attack rates (15).", [["Vaccine efficacy studies", "TEST", 0, 24], ["rigorous control", "TREATMENT", 37, 53], ["randomized prospective studies", "TEST", 73, 103], ["vigilant monitoring", "TEST", 108, 127], ["attack rates", "TEST", 132, 144]]], ["In addition to proportionate reduction in attack rates, these studies can furthermore assess outcomes through hospitalization rates, medical visits, and costs.", [["proportionate reduction in attack rates", "PROBLEM", 15, 54], ["these studies", "TEST", 56, 69], ["proportionate", "OBSERVATION_MODIFIER", 15, 28], ["reduction", "OBSERVATION_MODIFIER", 29, 38]]], ["Despite the complexity and expenses that arise from the initial trials, they are needed to establish vaccine efficacy (15).Vaccine Efficacy and Effectiveness in the Context of the Translational Research MapOn the other hand, the related but distinct concept of vaccine effectiveness has always been compared to a \u201creal world\u201d view of how a vaccine reduces disease in a population.", [["Vaccine Efficacy", "TREATMENT", 123, 139], ["vaccine effectiveness", "TREATMENT", 261, 282], ["disease", "PROBLEM", 356, 363]]], ["As such, it can evaluate risks versus benefits behind a vaccination program under more natural field conditions rather than in a controlled clinical trial.", [["a vaccination program", "TREATMENT", 54, 75]]], ["Vaccination program efficiency is proportional to vaccine potency or efficacy in addition to the degree and success of immunization of the target groups in the population.", [["Vaccination program efficiency", "TREATMENT", 0, 30], ["immunization", "TREATMENT", 119, 131]]], ["The \u201creal world\u201d picture provided by vaccine effectiveness data is desirable in planning public health initiatives, an advantage that makes these studies attractive.", [["these studies", "TEST", 140, 153]]], ["Consequently, a new expanded definition of translational research, consisting of four steps was proposed, which fits nicely within the continuum of vaccine research (21).", [["new", "OBSERVATION_MODIFIER", 16, 19], ["expanded", "OBSERVATION_MODIFIER", 20, 28]]], ["In this new process of phase I to phase IV clinical trials, safety, immunogenicity, efficacy, and post-licensure effectiveness of a particular vaccine are assessed ending up in phase IV with the burden of the disease (15).Vaccine Efficacy and Effectiveness in the Context of the Translational Research MapVaccines stood the test of time and many techniques have been introduced into the world of vaccination.", [["phase IV clinical trials", "TREATMENT", 34, 58], ["a particular vaccine", "TREATMENT", 130, 150], ["the disease", "PROBLEM", 205, 216], ["Vaccine Efficacy", "TREATMENT", 222, 238], ["disease", "OBSERVATION", 209, 216]]], ["According to John Kirkup, vaccinators and physicians used various instruments and techniques to inject the vaccinating material into the human body.", [["body", "ANATOMY", 143, 147], ["human", "ORGANISM", 137, 142], ["body", "ORGANISM_SUBDIVISION", 143, 147], ["human", "SPECIES", 137, 142], ["human", "SPECIES", 137, 142], ["vaccinators", "TREATMENT", 26, 37], ["various instruments", "TREATMENT", 58, 77], ["techniques", "TREATMENT", 82, 92], ["human", "ANATOMY", 137, 142], ["body", "ANATOMY_MODIFIER", 143, 147]]], ["More than 45 different vaccinating instruments have been recorded in British, American, German, and French catalogs between the years 1866 and 1920; most of them are out of use nowadays (22).Beginning of VaccinesThere are multiple major landmarks in the history of vaccines.", [["Vaccines", "TREATMENT", 204, 212], ["vaccines", "TREATMENT", 265, 273], ["multiple", "OBSERVATION_MODIFIER", 222, 230], ["major", "OBSERVATION_MODIFIER", 231, 236]]], ["It was reported that the origin goes as far back as Hippocrates, the father of modern medicine, 400 B.C. He described mumps, diphtheria, and epidemic jaundice among other conditions (23).", [["mumps", "DISEASE", 118, 123], ["diphtheria", "DISEASE", 125, 135], ["jaundice", "DISEASE", 150, 158], ["mumps", "PROBLEM", 118, 123], ["diphtheria", "PROBLEM", 125, 135], ["epidemic jaundice", "PROBLEM", 141, 158], ["epidemic", "OBSERVATION_MODIFIER", 141, 149], ["jaundice", "OBSERVATION", 150, 158]]], ["The earliest methods of immunization and protection against smallpox date back to about 1000 A.D., and are attributed to the Chinese.", [["smallpox", "DISEASE", 60, 68], ["immunization", "TREATMENT", 24, 36], ["protection", "TREATMENT", 41, 51]]], ["It has been said that the son of a Chinese statesman was inoculated against smallpox by blowing powdered smallpox sores into his nostrils (24).", [["smallpox", "DISEASE", 76, 84], ["smallpox sores", "DISEASE", 105, 119], ["smallpox", "ORGANISM", 76, 84], ["nostrils", "ORGANISM_SUBDIVISION", 129, 137], ["nostrils", "ANATOMY", 129, 137]]], ["Another method used for inoculation was the removal of fluid from the pustules of an infected individual and subsequently rubbing it into a skin scratch of a healthy individual.", [["pustules", "ANATOMY", 70, 78], ["skin", "ANATOMY", 140, 144], ["fluid", "ORGANISM_SUBSTANCE", 55, 60], ["pustules", "PATHOLOGICAL_FORMATION", 70, 78], ["skin", "ORGAN", 140, 144], ["Another method", "TREATMENT", 0, 14], ["inoculation", "PROBLEM", 24, 35], ["the removal of fluid", "TREATMENT", 40, 60], ["the pustules", "PROBLEM", 66, 78], ["an infected individual", "PROBLEM", 82, 104], ["fluid", "OBSERVATION", 55, 60], ["pustules", "OBSERVATION", 70, 78], ["infected", "OBSERVATION", 85, 93], ["skin", "ANATOMY", 140, 144], ["scratch", "OBSERVATION", 145, 152]]], ["This procedure was later introduced into Turkey around 1672, long before reaching Europe (25).", [["This procedure", "TREATMENT", 0, 14]]], ["It took six centuries for variolation to be introduced to Great Britain, in 1721 (26).Through the Eighteenth CenturyThe eighteenth century was marked by several major events that started with the spread of variolation from Turkey and China to England and America, followed, in the late eighteenth century, by Edward Jenner\u2019s breakthrough of vaccination.Variolation from Turkey to EnglandVariolation, derived from the Latin word varus, meaning \u201cmark on the skin,\u201d or inoculation, derived from the Latin word inoculare, meaning \u201cto graft,\u201d are two words that were used interchangeably in describing the aforementioned immunization process.", [["skin", "ANATOMY", 456, 460], ["Variolation", "DISEASE", 353, 364], ["skin", "ORGAN", 456, 460], ["graft", "TISSUE", 530, 535], ["Latin word inoculare", "SPECIES", 496, 516], ["variolation", "TREATMENT", 26, 37], ["inoculation", "PROBLEM", 466, 477], ["graft", "TREATMENT", 530, 535], ["the aforementioned immunization process", "TREATMENT", 597, 636], ["marked", "OBSERVATION_MODIFIER", 143, 149], ["skin", "ANATOMY", 456, 460], ["graft", "OBSERVATION", 530, 535]]], ["By 1715, variolation was introduced to England after the pursuit of an English aristocrat, Lady Mary Wortley Montague, who had been personally inflicted with an episode of smallpox.", [["smallpox", "DISEASE", 172, 180], ["smallpox", "PROBLEM", 172, 180]]], ["After being informed of the method of variolation, she made the embassy surgeon, Charles Maitland, perform the procedure on her 5-year-old son in 1718 in Turkey.", [["the procedure", "TREATMENT", 107, 120]]], ["In 1721, Dr. Charles Maitland performed the first English variolation on Lady Montague\u2019s 4-year-old daughter after their return to London (27).Variolation from Turkey to EnglandLady Montague became a great proponent of the procedure and worked thoroughly on advocating this process for its ability to protect against the spread of smallpox.Variolation from Turkey to EnglandData from the U.S. National Library of Medicine and the NIH showed that 1\u20132% of those variolated died as compared to 30% of those who contracted the disease naturally.", [["smallpox", "DISEASE", 331, 339], ["the procedure", "TREATMENT", 219, 232], ["the disease naturally", "PROBLEM", 519, 540], ["disease", "OBSERVATION", 523, 530]]], ["Correspondingly, Rev. Cotton Mather and Dr. Zabdiel Boylston introduced variolation in America and were also great advocates of this procedure especially since, in the same year, there was a smallpox epidemic in Boston that killed hundreds (28).", [["this procedure", "TREATMENT", 128, 142]]], ["However, Lady Montague, Rev. Mather, and Dr. Boylston faced great opposition regarding their promotion of variolation even with the presentation of the comparative analysis of fatality rates, which reached 2% for those variolated compared to 14% for the naturally occurring disease (27).Spreading the WordDespite some variolation-related deaths, the word of inoculation kept spreading along with data suggesting that variolation was still the safeguard against the spread of smallpox.", [["variolation", "DISEASE", 318, 329], ["deaths", "DISEASE", 338, 344], ["smallpox", "DISEASE", 475, 483], ["fatality rates", "TEST", 176, 190], ["the naturally occurring disease", "PROBLEM", 250, 281], ["inoculation", "PROBLEM", 358, 369], ["variolation", "PROBLEM", 417, 428]]], ["In 1759, Dr. William Heberden, at his own expense and with the support of Benjamin Franklin, wrote a pamphlet entitled \u201cSome Account of the Success of Inoculation for the Small-Pox in England and America: together with plain instructions by which any person may be enabled to perform the operation and conduct the patient through the distemper\u201d (29).Edward Jenner\u2019s BreakthroughToward the late eighteenth century came Jenner\u2019s breakthrough in finding a safer immunizing technique than variolation, which is vaccination.Edward Jenner\u2019s BreakthroughThe method of variolation had low yet significant death rates; therefore, physicians were on the quest of finding a new and more secure method of immunization with minimal or no death rates.", [["distemper", "DISEASE", 334, 343], ["death", "DISEASE", 597, 602], ["death", "DISEASE", 725, 730], ["patient", "ORGANISM", 314, 321], ["distemper", "ORGANISM", 334, 343], ["person", "SPECIES", 251, 257], ["patient", "SPECIES", 314, 321], ["Inoculation", "TREATMENT", 151, 162], ["the operation", "TREATMENT", 284, 297], ["a safer immunizing technique", "TREATMENT", 451, 479], ["significant death rates", "PROBLEM", 585, 608], ["immunization", "TREATMENT", 693, 705], ["death rates", "PROBLEM", 725, 736], ["Small", "OBSERVATION_MODIFIER", 171, 176], ["late", "OBSERVATION_MODIFIER", 389, 393], ["Breakthrough", "OBSERVATION_MODIFIER", 535, 547]]], ["On this basis, an English physician named Edward Jenner (1748\u20131823) searched for a cure for smallpox, a debilitating disease that rendered the world helpless.", [["smallpox", "DISEASE", 92, 100], ["smallpox", "PROBLEM", 92, 100], ["a debilitating disease", "PROBLEM", 102, 124], ["debilitating", "OBSERVATION_MODIFIER", 104, 116], ["disease", "OBSERVATION", 117, 124]]], ["Jenner became interested in certain individuals who were immune to smallpox because they had contracted cowpox in the past.", [["smallpox", "DISEASE", 67, 75], ["cowpox", "DISEASE", 104, 110], ["cowpox", "ORGANISM", 104, 110], ["smallpox", "TREATMENT", 67, 75], ["cowpox", "OBSERVATION", 104, 110]]], ["He personally witnessed this when he learned of a dairymaid that was immune to smallpox due to her previous infection with the cowpox virus, usually transmitted from infected cattle.", [["dairymaid", "DISEASE", 50, 59], ["smallpox", "DISEASE", 79, 87], ["infection", "DISEASE", 108, 117], ["cowpox virus", "ORGANISM", 127, 139], ["cattle", "ORGANISM", 175, 181], ["cattle", "SPECIES", 175, 181], ["cowpox virus", "SPECIES", 127, 139], ["cattle", "SPECIES", 175, 181], ["a dairymaid", "TREATMENT", 48, 59], ["smallpox", "TREATMENT", 79, 87], ["her previous infection", "PROBLEM", 95, 117], ["the cowpox virus", "PROBLEM", 123, 139], ["infection", "OBSERVATION", 108, 117], ["cowpox virus", "OBSERVATION", 127, 139]]], ["During that time, an English farmer named Benjamin Jesty personally took charge of inoculating his wife and children with fresh matter from a cowpox lesion in one of his cows out of fear of having his wife and children become victims of the smallpox epidemic.", [["cowpox lesion", "DISEASE", 142, 155], ["smallpox", "DISEASE", 241, 249], ["children", "ORGANISM", 108, 116], ["cowpox", "ORGANISM", 142, 148], ["children", "ORGANISM", 210, 218], ["children", "SPECIES", 108, 116], ["children", "SPECIES", 210, 218], ["fresh matter", "PROBLEM", 122, 134], ["a cowpox lesion", "PROBLEM", 140, 155], ["lesion", "OBSERVATION", 149, 155]]], ["He applied this method after having contracted cowpox himself and believing he was immune to smallpox.", [["smallpox", "DISEASE", 93, 101], ["cowpox", "ORGANISM", 47, 53], ["this method", "TREATMENT", 11, 22]]], ["He never published his results even though his wife and children did not show symptoms after being exposed to smallpox (27).", [["smallpox", "DISEASE", 110, 118], ["children", "ORGANISM", 56, 64], ["children", "SPECIES", 56, 64], ["symptoms", "PROBLEM", 78, 86]]], ["During these years, there were still outbreaks of smallpox.", [["smallpox", "DISEASE", 50, 58], ["smallpox", "PROBLEM", 50, 58]]], ["George Washington, after surviving smallpox, ordered mandatory inoculation for his troops in 1777 (27).Edward Jenner\u2019s BreakthroughAfter many speculations on the role of cowpox and its immunizing effect against smallpox, Jenner, in 1796, inoculated an 8-year-old boy named James Phipps using matter from a fresh cowpox lesion on the hands of a dairymaid named Sarah Nelms who caught them from her infected cattle.", [["smallpox", "DISEASE", 35, 43], ["cowpox", "DISEASE", 170, 176], ["smallpox", "DISEASE", 211, 219], ["cowpox lesion", "DISEASE", 312, 325], ["cowpox", "ORGANISM", 170, 176], ["boy", "ORGANISM", 263, 266], ["cowpox", "ORGANISM", 312, 318], ["hands", "ORGANISM_SUBDIVISION", 333, 338], ["cattle", "ORGANISM", 406, 412], ["boy", "SPECIES", 263, 266], ["cattle", "SPECIES", 406, 412], ["cattle", "SPECIES", 406, 412], ["cowpox", "PROBLEM", 170, 176], ["a fresh cowpox lesion", "PROBLEM", 304, 325], ["cowpox", "OBSERVATION", 170, 176], ["cowpox lesion", "OBSERVATION", 312, 325]]], ["After several days, Jenner inoculated the boy again but this time with fresh matter from a smallpox lesion and noted that the boy did not acquire the disease proving that he was completely protected (27).", [["boy", "ORGANISM", 42, 45], ["boy", "ORGANISM", 126, 129], ["boy", "SPECIES", 42, 45], ["boy", "SPECIES", 126, 129], ["fresh matter", "PROBLEM", 71, 83], ["a smallpox lesion", "PROBLEM", 89, 106], ["the disease", "PROBLEM", 146, 157], ["disease", "OBSERVATION", 150, 157]]], ["A few years later, word of his success circulated among the public, and Jenner wrote \u201cAn Inquiry into the Causes and Effects of the Variolae Vaccinae, a Disease Discovered in some of the Western Counties of England, particularly Gloucestershire and Known by the Name of CowPox,\u201d after adding several cases to his initial achievement with the boy Phipps.", [["Disease", "DISEASE", 153, 160], ["a Disease", "PROBLEM", 151, 160]]], ["At first, his publication and achievement did not stir any interest in his community, but with time, word of Jenner\u2019s breakthrough began spreading (27).Edward Jenner\u2019s BreakthroughThe late eighteenth century was characterized by the implementation of the new process of immunization, vaccination, which required the inoculation of fresh matter from cowpox lesions into the skin of healthy individuals.Through the Nineteenth CenturyThe nineteenth century was a major landmark in the history of vaccines since it witnessed discoveries made by Louis Pasteur, the father of microbiology, and Robert Koch, the scientist who discovered the germ responsible for tuberculosis (26).Vaccination Versus VariolationIn the beginning of the nineteenth century, the term \u201cVaccination\u201d was introduced by Richard Dunning from the Latin word for cow \u201cVacca.\u201d", [["lesions", "ANATOMY", 356, 363], ["skin", "ANATOMY", 373, 377], ["germ", "ANATOMY", 634, 638], ["cowpox lesions", "DISEASE", 349, 363], ["tuberculosis", "DISEASE", 655, 667], ["cowpox", "ORGANISM", 349, 355], ["lesions", "PATHOLOGICAL_FORMATION", 356, 363], ["skin", "ORGAN", 373, 377], ["germ", "TISSUE", 634, 638], ["cow", "ORGANISM", 828, 831], ["cow", "SPECIES", 828, 831], ["cow", "SPECIES", 828, 831], ["immunization", "TREATMENT", 270, 282], ["vaccination", "TREATMENT", 284, 295], ["the inoculation of fresh matter", "TREATMENT", 312, 343], ["cowpox lesions", "PROBLEM", 349, 363], ["vaccines", "TREATMENT", 493, 501], ["tuberculosis", "PROBLEM", 655, 667], ["Vaccination", "TREATMENT", 673, 684], ["Breakthrough", "OBSERVATION_MODIFIER", 168, 180], ["late", "OBSERVATION_MODIFIER", 184, 188], ["fresh matter", "OBSERVATION_MODIFIER", 331, 343], ["cowpox lesions", "OBSERVATION", 349, 363], ["skin", "ANATOMY", 373, 377]]], ["After becoming aware of the fact that vaccination was more secure than variolation, several physicians initiated movements against the use of variolation and advocated for its eradication.", [["vaccination", "TREATMENT", 38, 49], ["variolation", "TREATMENT", 142, 153], ["its eradication", "TREATMENT", 172, 187]]], ["Dr. Jean de Carro, for example, aided in the elimination of variolation and its substitution with vaccination.", [["variolation", "TREATMENT", 60, 71], ["its substitution with vaccination", "TREATMENT", 76, 109]]], ["Some of the major efforts implemented in America were initiated by Dr. Benjamin Waterhouse, who received the vaccine from Edward Jenner and vaccinated his own family.", [["major", "OBSERVATION_MODIFIER", 12, 17]]], ["He later proved that they acquired immunity when they remained asymptomatic after he infected them with smallpox.", [["smallpox", "DISEASE", 104, 112], ["asymptomatic", "PROBLEM", 63, 75], ["smallpox", "TREATMENT", 104, 112]]], ["Waterhouse worked effectively on making vaccination universal in the U.S. Unfortunately, like any other medical breakthrough, problems arose both because Waterhouse aimed at making profit and the public was not ready to implement these procedures.", [["any other medical breakthrough", "PROBLEM", 94, 124], ["these procedures", "TREATMENT", 230, 246]]], ["However, after breaking his initial monopoly, Waterhouse accepted to share his vaccines and made the supplies available to other physicians (24).", [["his vaccines", "TREATMENT", 75, 87]]], ["Despite all these efforts, smallpox epidemics continued to occur and Jenner stated in a pamphlet that he wrote, \u201cThe annihilation of the small pox, the most dreadful scourge of the human species, must be the final result of this practice.\u201d", [["smallpox", "DISEASE", 27, 35], ["human", "ORGANISM", 181, 186], ["human", "SPECIES", 181, 186], ["human", "SPECIES", 181, 186], ["smallpox epidemics", "PROBLEM", 27, 45], ["the small pox", "PROBLEM", 133, 146], ["the human species", "PROBLEM", 177, 194], ["small", "OBSERVATION_MODIFIER", 137, 142]]], ["Eradication was finally achieved 176 years later.", [["Eradication", "TREATMENT", 0, 11]]], ["The time it took could be attributed to the fact that Jenner did not think of the necessity of revaccination nor of the instability of vaccines, which made them unable to handle different environmental conditions, including countries other than England (30).Vaccination Versus VariolationThe late nineteenth century was distinguished by Pasteur\u2019s achievements that made him the father of vaccines after creating the first laboratory vaccine.", [["revaccination", "TREATMENT", 95, 108], ["the instability of vaccines", "PROBLEM", 116, 143], ["Vaccination", "TREATMENT", 258, 269], ["vaccines", "TREATMENT", 388, 396]]], ["Louis Pasteur (1822\u20131895), a French chemist and microbiologist, was the first to propose the \u201cGerm Theory\u201d of disease in addition to discovering the foundations of vaccination (26).", [["disease", "PROBLEM", 110, 117], ["disease", "OBSERVATION", 110, 117]]], ["He studied chicken cholera and received strains of bacteria causing anthrax and septic Vibrio.", [["chicken cholera", "DISEASE", 11, 26], ["anthrax", "DISEASE", 68, 75], ["chicken", "ORGANISM", 11, 18], ["chicken", "SPECIES", 11, 18], ["chicken", "SPECIES", 11, 18], ["bacteria", "PROBLEM", 51, 59], ["anthrax", "PROBLEM", 68, 75], ["septic Vibrio", "PROBLEM", 80, 93], ["septic Vibrio", "OBSERVATION", 80, 93]]], ["Pasteur started his experiments by intentionally infecting chickens by feeding them cholera-polluted meals and then recording the fatal progression of the illness.", [["illness", "DISEASE", 155, 162], ["chickens", "ORGANISM", 59, 67], ["chickens", "SPECIES", 59, 67], ["chickens", "SPECIES", 59, 67], ["the illness", "PROBLEM", 151, 162], ["fatal", "OBSERVATION_MODIFIER", 130, 135], ["progression", "OBSERVATION_MODIFIER", 136, 147], ["illness", "OBSERVATION", 155, 162]]], ["At first, Pasteur was using fresh cultures of the bacteria to inoculate the chickens, most of which did not survive.", [["chickens", "ORGANISM", 76, 84], ["chickens", "SPECIES", 76, 84], ["chickens", "SPECIES", 76, 84], ["fresh cultures", "TEST", 28, 42], ["the bacteria", "PROBLEM", 46, 58]]], ["During that time, Pasteur had to go on a holiday, so he placed his assistant in charge of injecting the chickens with fresh cultures.", [["chickens", "ORGANISM", 104, 112], ["chickens", "SPECIES", 104, 112], ["chickens", "SPECIES", 104, 112], ["fresh cultures", "TEST", 118, 132]]], ["However, his assistant accidentally forgot to perform the injections, and the bacterial cultures were left in a medium that was exposed to room air for about a month.", [["cultures", "ANATOMY", 88, 96], ["bacterial cultures", "CELL_LINE", 78, 96], ["the injections", "TREATMENT", 54, 68], ["the bacterial cultures", "TEST", 74, 96], ["left", "ANATOMY_MODIFIER", 102, 106]]], ["Later, the attendant injected the chickens with the now \u201cattenuated\u201d strain of bacteria resulting in mild, non-fatal symptoms.", [["chickens", "ORGANISM", 34, 42], ["chickens", "SPECIES", 34, 42], ["chickens", "SPECIES", 34, 42], ["bacteria", "PROBLEM", 79, 87], ["mild, non-fatal symptoms", "PROBLEM", 101, 125], ["bacteria", "OBSERVATION", 79, 87], ["mild", "OBSERVATION_MODIFIER", 101, 105]]], ["Pasteur later re-injected these chickens, but this time with fresh bacteria.", [["chickens", "ORGANISM", 32, 40], ["chickens", "SPECIES", 32, 40], ["chickens", "SPECIES", 32, 40], ["fresh bacteria", "PROBLEM", 61, 75], ["chickens", "OBSERVATION", 32, 40]]], ["Ultimately, Pasteur reasoned that what made the bacteria less deadly was exposure to air, mainly oxygen.", [["oxygen", "CHEMICAL", 97, 103], ["oxygen", "CHEMICAL", 97, 103], ["oxygen", "SIMPLE_CHEMICAL", 97, 103], ["the bacteria", "PROBLEM", 44, 56], ["oxygen", "OBSERVATION_MODIFIER", 97, 103]]], ["Pasteur used the French verb \u201cvacciner\u201d during the years 1879 and 1880 to describe how he was able to provide total body immunity through vaccination by inoculation of an attenuated virulence which was the first vaccine made by a human in the laboratory (31).Vaccination Versus VariolationPasteur also developed the anthrax vaccine in his laboratory, not long after performing his studies on chicken cholera.", [["body", "ANATOMY", 116, 120], ["anthrax", "DISEASE", 316, 323], ["cholera", "DISEASE", 400, 407], ["body", "ORGANISM_SUBDIVISION", 116, 120], ["human", "ORGANISM", 230, 235], ["anthrax", "ORGANISM", 316, 323], ["chicken", "ORGANISM", 392, 399], ["human", "SPECIES", 230, 235], ["chicken", "SPECIES", 392, 399], ["human", "SPECIES", 230, 235], ["chicken", "SPECIES", 392, 399], ["total body immunity through vaccination", "TREATMENT", 110, 149], ["an attenuated virulence", "PROBLEM", 168, 191], ["Vaccination", "TREATMENT", 259, 270], ["the anthrax vaccine", "TREATMENT", 312, 331], ["his studies", "TEST", 377, 388]]], ["In 1881, Pasteur used his own anthrax vaccine, which contained attenuated live bacterial cultures in addition to carbolic acid, and demonstrated that all vaccinated animals survived while the control group died (32).", [["cultures", "ANATOMY", 89, 97], ["anthrax", "DISEASE", 30, 37], ["carbolic acid", "CHEMICAL", 113, 126], ["carbolic acid", "CHEMICAL", 113, 126], ["anthrax", "ORGANISM", 30, 37], ["carbolic acid", "SIMPLE_CHEMICAL", 113, 126], ["his own anthrax vaccine", "TREATMENT", 22, 45], ["bacterial cultures", "TEST", 79, 97], ["carbolic acid", "PROBLEM", 113, 126]]], ["During the same year, Louis Pasteur in France and George Miller Sternberg in the U.S. almost simultaneously and independently isolated and grew the pneumococcus organism.", [["the pneumococcus organism", "PROBLEM", 144, 169], ["pneumococcus organism", "OBSERVATION", 148, 169]]], ["Later in 1884, Pasteur successfully fought rabies that was endangering the European livestock by using his attenuated rabies vaccine obtained from desiccated brain tissue inactivated with formaldehyde, which provided immunity to dogs against rabies in his experiments (26).", [["brain tissue", "ANATOMY", 158, 170], ["rabies", "DISEASE", 43, 49], ["formaldehyde", "CHEMICAL", 188, 200], ["rabies", "DISEASE", 242, 248], ["formaldehyde", "CHEMICAL", 188, 200], ["rabies", "ORGANISM", 43, 49], ["rabies", "ORGANISM", 118, 124], ["brain tissue", "TISSUE", 158, 170], ["formaldehyde", "SIMPLE_CHEMICAL", 188, 200], ["dogs", "ORGANISM", 229, 233], ["rabies", "ORGANISM", 242, 248], ["dogs", "SPECIES", 229, 233], ["rabies", "SPECIES", 43, 49], ["rabies", "SPECIES", 118, 124], ["rabies", "SPECIES", 242, 248], ["his attenuated rabies vaccine", "TREATMENT", 103, 132], ["desiccated brain tissue", "PROBLEM", 147, 170], ["formaldehyde", "TREATMENT", 188, 200], ["brain tissue", "ANATOMY", 158, 170]]], ["He reported his success to the Academy of Sciences in France, and a year later, he applied his original vaccine 60 h after a 9-year-old boy was bitten several times by a rabid dog.", [["boy", "ORGANISM", 136, 139], ["dog", "ORGANISM", 176, 179], ["boy", "SPECIES", 136, 139], ["dog", "SPECIES", 176, 179], ["rabid dog", "SPECIES", 170, 179], ["his original vaccine", "TREATMENT", 91, 111]]], ["The boy survived after being first inoculated with the most attenuated organisms, then subsequently with less attenuated organisms each day for 10 days (33).", [["boy", "ORGANISM", 4, 7], ["boy", "SPECIES", 4, 7], ["the most attenuated organisms", "PROBLEM", 51, 80]]], ["In 1888, the Pasteur Institute was established as a rabies treatment center as well as an infectious diseases research and training institute.From Live Vaccines to Killed VaccinesAfter Pasteur\u2019s successful live vaccines, a new type of vaccine was introduced in the last few years of the nineteenth century.", [["infectious diseases", "DISEASE", 90, 109], ["a rabies treatment center", "TREATMENT", 50, 75], ["Live Vaccines", "TREATMENT", 147, 160], ["live vaccines", "TREATMENT", 206, 219], ["a new type of vaccine", "TREATMENT", 221, 242], ["infectious", "OBSERVATION", 90, 100]]], ["These were killed vaccines, which were directed against three chief bacterial causes of human morbidity: cholera, typhoid, and the plague.", [["cholera", "DISEASE", 105, 112], ["typhoid", "DISEASE", 114, 121], ["human", "ORGANISM", 88, 93], ["human", "SPECIES", 88, 93], ["human", "SPECIES", 88, 93], ["cholera", "PROBLEM", 105, 112], ["typhoid", "PROBLEM", 114, 121]]], ["The first cholera vaccine used to immunize humans was actually a live vaccine developed by Jaime Ferran (1852\u20131929), which provided a high level of protection during the 1884 epidemic in Spain.", [["humans", "ORGANISM", 43, 49], ["humans", "SPECIES", 43, 49], ["humans", "SPECIES", 43, 49], ["The first cholera vaccine", "TREATMENT", 0, 25], ["a live vaccine", "TREATMENT", 63, 77]]], ["However, the first killed vaccine for cholera was developed in 1896 by Wilhelm Kolle (1868\u20131935) and was used in Japan in 1902 with over 80% efficiency.", [["cholera", "DISEASE", 38, 45], ["cholera", "SPECIES", 38, 45], ["cholera", "PROBLEM", 38, 45]]], ["The credit for developing the killed typhoid vaccine during the 1890s goes to both Richard Pfeiffer and Almroth Wright who made great contributions.", [["typhoid", "DISEASE", 37, 44], ["the killed typhoid vaccine", "TREATMENT", 26, 52]]], ["Wright was later credited for carrying out the \u201cfirst large-scale vaccination using a killed typhoid vaccine\u201d (34).", [["typhoid", "DISEASE", 93, 100], ["the \u201cfirst large-scale vaccination", "TREATMENT", 43, 77], ["a killed typhoid vaccine", "TREATMENT", 84, 108]]], ["Finally, the killed vaccine for plague was first developed in 1896 by Haffkine, who was one of Pasteur\u2019s followers, when an epidemic struck Bombay.Late Nineteenth and Twentieth CenturyDuring this period, vaccine production was taken over by factory-type laboratories, which formed the precursors of the biological products supply houses.", [["the killed vaccine", "TREATMENT", 9, 27], ["plague", "PROBLEM", 32, 38], ["vaccine production", "TREATMENT", 204, 222]]], ["Many types were produced.ToxoidPaul Ehrlich (1854\u20131915), a German physician and scientist who worked under a contractual collaboration with Behring, noted the existence of toxoids in the late 1890s.", [["toxoids", "TREATMENT", 172, 179]]], ["He also promoted enrichment and standardization protocols.", [["standardization protocols", "TREATMENT", 32, 57], ["enrichment", "OBSERVATION", 17, 27]]], ["These protocols enabled the exact determination of quality of the diphtheria antitoxins.", [["diphtheria antitoxins", "SIMPLE_CHEMICAL", 66, 87], ["diphtheria antitoxins", "PROTEIN", 66, 87], ["These protocols", "TREATMENT", 0, 15], ["the diphtheria antitoxins", "TREATMENT", 62, 87]]], ["In 1907, it was demonstrated that toxoids could be used to durably immunize guinea pigs.", [["guinea pigs", "ORGANISM", 76, 87], ["guinea pigs", "SPECIES", 76, 87], ["guinea pigs", "SPECIES", 76, 87], ["toxoids", "TREATMENT", 34, 41]]], ["It is crucial to briefly address the historical background of the bacterial infections that led to some of the earliest and most successful use of toxoids, inactivated forms of bacterial toxins, for the purpose of immunization.", [["bacterial infections", "DISEASE", 66, 86], ["the bacterial infections", "PROBLEM", 62, 86], ["toxoids", "TREATMENT", 147, 154], ["bacterial toxins", "PROBLEM", 177, 193], ["immunization", "TREATMENT", 214, 226], ["bacterial", "OBSERVATION_MODIFIER", 66, 75], ["infections", "OBSERVATION", 76, 86]]], ["Until the twentieth century, diphtheria, tetanus, and pertussis proved to be significant causes of illness and death with no effective treatments or prevention in sight.", [["diphtheria", "DISEASE", 29, 39], ["tetanus", "DISEASE", 41, 48], ["pertussis", "DISEASE", 54, 63], ["illness", "DISEASE", 99, 106], ["death", "DISEASE", 111, 116], ["diphtheria", "ORGANISM", 29, 39], ["pertussis", "SPECIES", 54, 63], ["diphtheria", "PROBLEM", 29, 39], ["tetanus", "TREATMENT", 41, 48], ["pertussis", "PROBLEM", 54, 63], ["illness", "PROBLEM", 99, 106], ["death", "PROBLEM", 111, 116], ["effective treatments", "TREATMENT", 125, 145]]], ["Fortunately, advances in 1890 improved the prognosis of numerous future patients (35).", [["patients", "ORGANISM", 72, 80], ["patients", "SPECIES", 72, 80]]], ["At the end of the nineteenth century, especially in 1896 and 1897, the cholera and typhoid vaccines were developed, followed by the introduction of the plague vaccine.", [["cholera", "DISEASE", 71, 78], ["typhoid", "DISEASE", 83, 90], ["typhoid vaccines", "TREATMENT", 83, 99], ["the plague vaccine", "TREATMENT", 148, 166]]], ["The latter was preceded by the preparation of anti plague horse serum at the Pasteur Institute by Alexandre Yersin.ToxoidYersin demonstrated disease protection in animals.", [["serum", "ANATOMY", 64, 69], ["ToxoidYersin", "CHEMICAL", 115, 127], ["horse", "ORGANISM", 58, 63], ["serum", "ORGANISM_SUBSTANCE", 64, 69], ["ToxoidYersin", "SIMPLE_CHEMICAL", 115, 127], ["horse", "SPECIES", 58, 63], ["ToxoidYersin", "TREATMENT", 115, 127], ["disease protection", "TREATMENT", 141, 159], ["disease", "OBSERVATION", 141, 148]]], ["Later, he went to China to try his vaccine on humans during a plague epidemic (26).DiphtheriaDiphtheria is a potentially fatal disease that primarily involves tissues of the upper respiratory tract and kills its victims slowly by suffocation.", [["tissues", "ANATOMY", 159, 166], ["upper respiratory tract", "ANATOMY", 174, 197], ["plague", "DISEASE", 62, 68], ["DiphtheriaDiphtheria", "CHEMICAL", 83, 103], ["suffocation", "DISEASE", 230, 241], ["humans", "ORGANISM", 46, 52], ["tissues", "TISSUE", 159, 166], ["upper respiratory", "ORGANISM_SUBDIVISION", 174, 191], ["tract", "ORGANISM_SUBDIVISION", 192, 197], ["humans", "SPECIES", 46, 52], ["humans", "SPECIES", 46, 52], ["his vaccine", "TREATMENT", 31, 42], ["a potentially fatal disease", "PROBLEM", 107, 134], ["suffocation", "PROBLEM", 230, 241], ["potentially", "UNCERTAINTY", 109, 120], ["fatal", "OBSERVATION_MODIFIER", 121, 126], ["disease", "OBSERVATION", 127, 134], ["upper", "ANATOMY_MODIFIER", 174, 179], ["respiratory tract", "ANATOMY", 180, 197], ["suffocation", "OBSERVATION", 230, 241]]], ["In 1884, a German physician, Edwin Klebs (1834\u20131913), was able to successfully isolate the bacteria that proved to be the etiological agent of the disease.", [["the bacteria", "PROBLEM", 87, 99], ["the disease", "PROBLEM", 143, 154], ["disease", "OBSERVATION", 147, 154]]], ["It was later proved that toxin production is initiated only after the bacteria are themselves infected by a specific virus or a bacteriophage carrying the toxin\u2019s genetic instructions (35).DiphtheriaIn France, during the year 1888, Emile Roux discovered the diphtheria toxin.", [["toxin", "SIMPLE_CHEMICAL", 25, 30], ["diphtheria toxin", "GENE_OR_GENE_PRODUCT", 258, 274], ["toxin", "PROTEIN", 155, 160], ["diphtheria toxin", "PROTEIN", 258, 274], ["toxin production", "PROBLEM", 25, 41], ["the bacteria", "PROBLEM", 66, 78], ["themselves infected", "PROBLEM", 83, 102], ["a specific virus", "PROBLEM", 106, 122], ["a bacteriophage", "TREATMENT", 126, 141], ["the diphtheria toxin", "PROBLEM", 254, 274]]], ["His discovery led to the development of passive serum therapies through the scientific contributions of many, including Emil Von Behring and Paul Ehrlich (26).", [["serum", "ANATOMY", 48, 53], ["serum", "ORGANISM_SUBSTANCE", 48, 53], ["passive serum therapies", "TREATMENT", 40, 63]]], ["Similarly, the etiological agent of Pertussis, commonly known as the \u201cwhooping cough,\u201d was found to be a bacterium isolated from infected patient tissues in 1906 (36).", [["tissues", "ANATOMY", 146, 153], ["Pertussis", "DISEASE", 36, 45], ["whooping cough", "DISEASE", 70, 84], ["Pertussis", "ORGANISM", 36, 45], ["patient", "ORGANISM", 138, 145], ["tissues", "TISSUE", 146, 153], ["patient", "SPECIES", 138, 145], ["Pertussis", "PROBLEM", 36, 45], ["the \u201cwhooping cough", "PROBLEM", 65, 84], ["a bacterium", "PROBLEM", 103, 114], ["Pertussis", "OBSERVATION", 36, 45], ["bacterium", "OBSERVATION", 105, 114], ["infected", "OBSERVATION_MODIFIER", 129, 137]]], ["Tetanus was similarly a significant cause of mortality usually resulting from dysfunction of the autonomic nervous system or the respiratory muscles (37).", [["autonomic nervous system", "ANATOMY", 97, 121], ["respiratory muscles", "ANATOMY", 129, 148], ["Tetanus", "DISEASE", 0, 7], ["dysfunction of the autonomic nervous system", "DISEASE", 78, 121], ["autonomic nervous system", "ANATOMICAL_SYSTEM", 97, 121], ["respiratory muscles", "ORGANISM_SUBDIVISION", 129, 148], ["Tetanus", "TREATMENT", 0, 7], ["mortality", "PROBLEM", 45, 54], ["dysfunction of the autonomic nervous system", "PROBLEM", 78, 121], ["significant", "OBSERVATION_MODIFIER", 24, 35], ["mortality", "OBSERVATION", 45, 54], ["dysfunction", "OBSERVATION", 78, 89], ["autonomic nervous", "ANATOMY", 97, 114], ["respiratory muscles", "ANATOMY", 129, 148]]], ["In 1884, another German scientist, Arthur Nicolaier (1862\u20131942), correlated tetanus with an anaerobic soil bacterium found in wounds.", [["wounds", "ANATOMY", 126, 132], ["tetanus", "DISEASE", 76, 83], ["wounds", "PATHOLOGICAL_FORMATION", 126, 132], ["an anaerobic soil bacterium", "PROBLEM", 89, 116], ["wounds", "PROBLEM", 126, 132], ["wounds", "OBSERVATION", 126, 132]]], ["At the beginning of World War I in 1914, the tetanus toxoid was introduced following the development of an effective therapeutic serum against tetanus by Emil Von Behring and Shibasaburo Kitasato.", [["serum", "ANATOMY", 129, 134], ["tetanus", "DISEASE", 45, 52], ["tetanus", "DISEASE", 143, 150], ["tetanus toxoid", "ORGANISM", 45, 59], ["serum", "ORGANISM_SUBSTANCE", 129, 134], ["the tetanus toxoid", "TREATMENT", 41, 59], ["Shibasaburo Kitasato", "TREATMENT", 175, 195]]], ["The rabies and typhoid vaccines were then licensed in the U.S. as the etiology of these destructive diseases was slowly being uncovered, by Shibasaburo Kitasato along with Emil von Behring (26).", [["rabies", "DISEASE", 4, 10], ["typhoid", "DISEASE", 15, 22], ["rabies", "ORGANISM", 4, 10], ["rabies", "SPECIES", 4, 10], ["The rabies", "TREATMENT", 0, 10], ["typhoid vaccines", "TREATMENT", 15, 31], ["these destructive diseases", "PROBLEM", 82, 108], ["destructive", "OBSERVATION_MODIFIER", 88, 99], ["diseases", "OBSERVATION", 100, 108]]], ["They discovered that the serum of animals that had been exposed to sub-lethal doses of the bacteria involved in tetanus and diphtheria was protective against the lethal effects associated with these pathogens by having an antitoxin effect when injected into another animal.", [["serum", "ANATOMY", 25, 30], ["tetanus", "DISEASE", 112, 119], ["diphtheria", "DISEASE", 124, 134], ["serum", "ORGANISM_SUBSTANCE", 25, 30], ["antitoxin", "PROTEIN", 222, 231], ["the bacteria", "PROBLEM", 87, 99], ["tetanus", "PROBLEM", 112, 119], ["diphtheria", "PROBLEM", 124, 134], ["the lethal effects", "PROBLEM", 158, 176], ["these pathogens", "PROBLEM", 193, 208], ["an antitoxin effect", "TREATMENT", 219, 238]]], ["Additionally, this discovery, which earned Behring the inaugural Nobel Prize for Physiology and Medicine in 1901, was the concept of passive transfer in addition to serum therapy.", [["serum", "ANATOMY", 165, 170], ["serum", "ORGANISM_SUBSTANCE", 165, 170], ["passive transfer", "TREATMENT", 133, 149], ["serum therapy", "TREATMENT", 165, 178]]], ["He proved that serum could be acquired from immune animals and transferred to others as protection (38).", [["serum", "ANATOMY", 15, 20], ["serum", "ORGANISM_SUBSTANCE", 15, 20], ["immune animals", "PROBLEM", 44, 58]]], ["Once this concept made its way to clinical practice in 1891, technical problems were faced while developing the right antitoxin concentration and potency.", [["antitoxin", "PROTEIN", 118, 127], ["technical problems", "PROBLEM", 61, 79], ["the right antitoxin concentration", "TREATMENT", 108, 141], ["right", "ANATOMY_MODIFIER", 112, 117]]], ["As a result, in the early twentieth century, the U.S. Congress enacted the Biologics Control Act legislation \u201cto regulate the sale of viruses, serums, toxins, and similar products\u201d to ensure medication quality control.", [["serums", "ORGANISM_SUBSTANCE", 143, 149], ["toxins", "TREATMENT", 151, 157], ["similar products", "TREATMENT", 163, 179], ["medication quality control", "TREATMENT", 191, 217]]], ["Nevertheless, with the increasing use and popularity of antitoxins derived from animal serum, scientists began to observe a syndrome now called serum sickness, or a reaction to immune-complexes formed from combining high concentrations of antigens with antibodies.", [["serum", "ANATOMY", 87, 92], ["serum", "ANATOMY", 144, 149], ["serum sickness", "DISEASE", 144, 158], ["antitoxins", "SIMPLE_CHEMICAL", 56, 66], ["serum", "ORGANISM_SUBSTANCE", 87, 92], ["serum", "ORGANISM_SUBSTANCE", 144, 149], ["immune-complexes", "PROTEIN", 177, 193], ["antigens", "PROTEIN", 239, 247], ["antibodies", "PROTEIN", 253, 263], ["antitoxins", "TREATMENT", 56, 66], ["animal serum", "TEST", 80, 92], ["a syndrome", "PROBLEM", 122, 132], ["serum sickness", "PROBLEM", 144, 158], ["a reaction", "PROBLEM", 163, 173], ["immune-complexes", "PROBLEM", 177, 193], ["combining high concentrations of antigens with antibodies", "PROBLEM", 206, 263]]], ["This eventually led to the use of human rather than animal serum in order to decrease the frequency of adverse events; still, serum therapy was not perfect in preventing disease due to the frequency of adverse events and its brief duration of action.", [["serum", "ANATOMY", 59, 64], ["serum", "ANATOMY", 126, 131], ["human", "ORGANISM", 34, 39], ["serum", "ORGANISM_SUBSTANCE", 59, 64], ["serum", "ORGANISM_SUBSTANCE", 126, 131], ["human", "SPECIES", 34, 39], ["human", "SPECIES", 34, 39], ["animal serum", "TEST", 52, 64], ["adverse events", "PROBLEM", 103, 117], ["serum therapy", "TREATMENT", 126, 139], ["disease", "PROBLEM", 170, 177], ["adverse events", "PROBLEM", 202, 216]]], ["Later on, combining diphtheria toxin and antitoxin in the same syringe proved much more effective in decreasing mortality rate.", [["diphtheria toxin", "CHEMICAL", 20, 36], ["diphtheria toxin", "GENE_OR_GENE_PRODUCT", 20, 36], ["antitoxin", "GENE_OR_GENE_PRODUCT", 41, 50], ["diphtheria toxin", "PROTEIN", 20, 36], ["antitoxin", "PROTEIN", 41, 50], ["combining diphtheria toxin", "TREATMENT", 10, 36], ["antitoxin", "TREATMENT", 41, 50]]], ["This was the first step in the shift from passive to active immunization (35).", [["active immunization", "TREATMENT", 53, 72]]], ["In 1923, Gaston Ramon (1886\u20131963), a French veterinarian working at the Pasteur Institute, used a diphtheria toxoid produced by formalin and heat inactivation without the use of antitoxin to safely induce active immunity in humans.", [["diphtheria toxoid", "DISEASE", 98, 115], ["formalin", "CHEMICAL", 128, 136], ["formalin", "CHEMICAL", 128, 136], ["formalin", "SIMPLE_CHEMICAL", 128, 136], ["humans", "ORGANISM", 224, 230], ["antitoxin", "PROTEIN", 178, 187], ["humans", "SPECIES", 224, 230], ["humans", "SPECIES", 224, 230], ["a diphtheria toxoid", "TREATMENT", 96, 115], ["heat inactivation", "TREATMENT", 141, 158], ["antitoxin", "TREATMENT", 178, 187]]], ["This product, termed anatoxine, was the basis for the novel and clinically effective toxoid vaccine against diphtheria.", [["anatoxine", "CHEMICAL", 21, 30], ["diphtheria", "DISEASE", 108, 118], ["anatoxine", "CHEMICAL", 21, 30], ["anatoxine", "SIMPLE_CHEMICAL", 21, 30], ["diphtheria", "ORGANISM", 108, 118], ["clinically effective toxoid vaccine", "TREATMENT", 64, 99], ["diphtheria", "PROBLEM", 108, 118]]], ["Experiments followed to improve the durability of the protective response of the vaccine, and in 1926, the importance of aluminum salts as an adjuvant added to the vaccine to augment the immune response to the antigen, became apparent (38).", [["aluminum salts", "CHEMICAL", 121, 135], ["aluminum salts", "CHEMICAL", 121, 135], ["aluminum salts", "SIMPLE_CHEMICAL", 121, 135], ["the vaccine", "TREATMENT", 77, 88], ["aluminum salts", "TREATMENT", 121, 135], ["an adjuvant", "TREATMENT", 139, 150], ["the vaccine", "TREATMENT", 160, 171], ["the antigen", "TEST", 206, 217]]], ["This was discovered by Alexander Thomas Glenny (1882\u20131965) who proved that toxoid alone produced a lower level of antibody and immunity than desired, whereas better immunity was achieved when an inflammatory reaction was triggered.", [["toxoid", "TREATMENT", 75, 81], ["a lower level of antibody", "PROBLEM", 97, 122], ["an inflammatory reaction", "PROBLEM", 192, 216], ["inflammatory", "OBSERVATION", 195, 207]]], ["With these significant improvements, tetanus and diphtheria toxoids became routinely used across America and Europe in the 1930s and 1940s (35).DiphtheriaSince then, refinements have been made to these vaccines to yield higher purity and reduce the number of booster doses.", [["tetanus", "DISEASE", 37, 44], ["diphtheria toxoids", "CHEMICAL", 49, 67], ["diphtheria toxoids", "ORGANISM", 49, 67], ["tetanus", "TREATMENT", 37, 44], ["diphtheria toxoids", "TREATMENT", 49, 67], ["these vaccines", "TREATMENT", 196, 210], ["booster doses", "TREATMENT", 259, 272], ["significant", "OBSERVATION_MODIFIER", 11, 22], ["improvements", "OBSERVATION", 23, 35]]], ["Nowadays, widespread childhood vaccination is reducing the burden of these diseases.", [["widespread childhood vaccination", "PROBLEM", 10, 42], ["these diseases", "PROBLEM", 69, 83], ["widespread", "OBSERVATION_MODIFIER", 10, 20], ["childhood", "OBSERVATION_MODIFIER", 21, 30], ["vaccination", "OBSERVATION", 31, 42], ["diseases", "OBSERVATION", 75, 83]]], ["While this is a huge advantage, vaccines may potentially produce adverse effects that can discourage their acceptance by some populations.", [["a huge advantage", "TREATMENT", 14, 30], ["vaccines", "TREATMENT", 32, 40]]], ["This has led to numerous safety movements which culminated in the congressionally legislated National Childhood Vaccine Injury Act in the 1980s created to compensate families for selected adverse events potentially related to mandatory childhood vaccinations (37).", [["Injury", "DISEASE", 120, 126], ["numerous safety movements", "PROBLEM", 16, 41], ["selected adverse events", "PROBLEM", 179, 202], ["numerous", "OBSERVATION_MODIFIER", 16, 24], ["safety movements", "OBSERVATION", 25, 41]]], ["Nevertheless, global recommendations continue to call for routine immunization of children against diphtheria, tetanus, and pertussis with the combined DTP vaccine to sustain immunity in childhood and adolescence.", [["diphtheria", "DISEASE", 99, 109], ["tetanus", "DISEASE", 111, 118], ["pertussis", "DISEASE", 124, 133], ["DTP", "CHEMICAL", 152, 155], ["children", "ORGANISM", 82, 90], ["diphtheria", "ORGANISM", 99, 109], ["children", "SPECIES", 82, 90], ["pertussis", "SPECIES", 124, 133], ["routine immunization", "TREATMENT", 58, 78], ["diphtheria", "PROBLEM", 99, 109], ["tetanus", "TREATMENT", 111, 118], ["pertussis", "TREATMENT", 124, 133], ["the combined DTP vaccine", "TREATMENT", 139, 163]]], ["DTP has, therefore, become one of the most widely used vaccines to achieve widespread immunity across age groups (35).Tuberculosis and BCGTuberculosis, otherwise known as the \u201cGreat White Plague,\u201d is another disease that started spreading as an epidemic once industrialization began.", [["DTP", "CHEMICAL", 0, 3], ["Tuberculosis", "DISEASE", 118, 130], ["BCGTuberculosis", "DISEASE", 135, 150], ["Plague", "DISEASE", 188, 194], ["DTP", "CHEMICAL", 0, 3], ["DTP", "SIMPLE_CHEMICAL", 0, 3], ["DTP", "PROBLEM", 0, 3], ["vaccines", "TREATMENT", 55, 63], ["Tuberculosis", "PROBLEM", 118, 130], ["BCGTuberculosis", "PROBLEM", 135, 150], ["another disease", "PROBLEM", 200, 215], ["White", "OBSERVATION_MODIFIER", 182, 187], ["Plague", "OBSERVATION", 188, 194], ["disease", "OBSERVATION", 208, 215]]], ["This disease caused approximately 15% of deaths in the eighteenth and nineteenth centuries across all socioeconomic groups (39).Tuberculosis and BCGA French physician named Jean Antoine Villemin (1827\u20131892) demonstrated that the mode of transmission of disease is through the respiratory system.", [["respiratory system", "ANATOMY", 276, 294], ["deaths", "DISEASE", 41, 47], ["Tuberculosis", "DISEASE", 128, 140], ["This disease", "PROBLEM", 0, 12], ["Tuberculosis", "PROBLEM", 128, 140], ["disease", "PROBLEM", 253, 260], ["disease", "OBSERVATION", 253, 260], ["respiratory system", "ANATOMY", 276, 294]]], ["Robert Koch (1843\u20131910), known as the founder of modern bacteriology, revealed in 1882 that the causative agent of the disease is Mycobacterium tuberculosis, which later became known as Koch\u2019s bacillus (40).", [["Mycobacterium tuberculosis", "DISEASE", 130, 156], ["Mycobacterium tuberculosis", "ORGANISM", 130, 156], ["Mycobacterium tuberculosis", "SPECIES", 130, 156], ["Mycobacterium tuberculosis", "SPECIES", 130, 156], ["the disease", "PROBLEM", 115, 126], ["Mycobacterium tuberculosis", "PROBLEM", 130, 156], ["disease", "OBSERVATION", 119, 126], ["Mycobacterium tuberculosis", "OBSERVATION", 130, 156]]], ["Following this discovery, Koch created what later came to be known as Koch\u2019s postulates, which listed the criteria necessary for proof of bacterial causality: \u201cthe organism must be present in diseased tissues; it must be isolated and grown in pure culture; and the cultured organisms must induce the disease when inoculated into healthy experimental animals\u201d (39).Tuberculosis and BCGIn 1908, two bacteriologists working in the Pasteur Institute in Lille, Albert Calmette (1863\u20131933) and Camile Guerin (1872\u20131961), announced their discovery of Mycobacterium bovis, which is a strain of tubercle bacilli that could be used to create a vaccine against tuberculosis.", [["tissues", "ANATOMY", 201, 208], ["tubercle bacilli", "ANATOMY", 586, 602], ["Tuberculosis", "DISEASE", 364, 376], ["Mycobacterium bovis", "DISEASE", 544, 563], ["tuberculosis", "DISEASE", 650, 662], ["diseased tissues", "TISSUE", 192, 208], ["Mycobacterium bovis", "ORGANISM", 544, 563], ["Mycobacterium bovis", "SPECIES", 544, 563], ["Mycobacterium bovis", "SPECIES", 544, 563], ["bacterial causality", "PROBLEM", 138, 157], ["the organism", "PROBLEM", 160, 172], ["pure culture", "TEST", 243, 255], ["the cultured organisms", "PROBLEM", 261, 283], ["the disease", "PROBLEM", 296, 307], ["Tuberculosis", "PROBLEM", 364, 376], ["Mycobacterium bovis", "PROBLEM", 544, 563], ["a strain of tubercle bacilli", "PROBLEM", 574, 602], ["a vaccine", "TREATMENT", 632, 641], ["tuberculosis", "PROBLEM", 650, 662], ["diseased", "OBSERVATION", 192, 200], ["Mycobacterium bovis", "OBSERVATION", 544, 563], ["tubercle bacilli", "OBSERVATION", 586, 602]]], ["This occurred after it became evident that different forms of the bacterium were required to prevent or treat tuberculosis, including non-pathogenic, attenuated, or killed tubercle bacilli from different sources, including human, bovine, and equine.", [["tuberculosis", "DISEASE", 110, 122], ["human", "ORGANISM", 223, 228], ["bovine", "ORGANISM", 230, 236], ["equine", "ORGANISM", 242, 248], ["human", "SPECIES", 223, 228], ["bovine", "SPECIES", 230, 236], ["equine", "SPECIES", 242, 248], ["human", "SPECIES", 223, 228], ["bovine", "SPECIES", 230, 236], ["the bacterium", "PROBLEM", 62, 75], ["tuberculosis", "PROBLEM", 110, 122], ["non-pathogenic", "PROBLEM", 134, 148], ["killed tubercle bacilli", "PROBLEM", 165, 188], ["human, bovine", "TREATMENT", 223, 236], ["tuberculosis", "OBSERVATION", 110, 122], ["tubercle bacilli", "OBSERVATION", 172, 188]]], ["This strain had an attenuated virulence while maintaining its antigenicity and became known as BCG (40).Tuberculosis and BCGBacille Calmette\u2013Guerin vaccinations proved to be successful in animal studies in 1921 and were soon used as an oral vaccine to immunize humans against tuberculosis.", [["oral", "ANATOMY", 236, 240], ["Tuberculosis", "DISEASE", 104, 116], ["BCGBacille Calmette\u2013Guerin", "CHEMICAL", 121, 147], ["tuberculosis", "DISEASE", 276, 288], ["BCGBacille Calmette\u2013Guerin", "ORGANISM", 121, 147], ["oral", "ORGANISM_SUBDIVISION", 236, 240], ["humans", "ORGANISM", 261, 267], ["humans", "SPECIES", 261, 267], ["humans", "SPECIES", 261, 267], ["an attenuated virulence", "PROBLEM", 16, 39], ["BCG", "TEST", 95, 98], ["Tuberculosis", "PROBLEM", 104, 116], ["BCGBacille Calmette", "TREATMENT", 121, 140], ["Guerin vaccinations", "TREATMENT", 141, 160], ["an oral vaccine", "TREATMENT", 233, 248], ["tuberculosis", "PROBLEM", 276, 288], ["attenuated", "OBSERVATION_MODIFIER", 19, 29], ["virulence", "OBSERVATION", 30, 39], ["tuberculosis", "OBSERVATION", 276, 288]]], ["In 1927, the BCG vaccine, constituted by the live-attenuated M. bovis, was first used in newborns.", [["M. bovis", "ORGANISM", 61, 69], ["newborns", "ORGANISM", 89, 97], ["M. bovis", "SPECIES", 61, 69], ["M. bovis", "SPECIES", 61, 69], ["the BCG vaccine", "TREATMENT", 9, 24], ["bovis", "OBSERVATION", 64, 69]]], ["It has become the most widely administered of all vaccines in the WHO Expanded Program for Immunization, but has been estimated to prevent only 5% of all potentially vaccine-preventable deaths due to tuberculosis (26).", [["deaths", "DISEASE", 186, 192], ["tuberculosis", "DISEASE", 200, 212], ["all vaccines", "TREATMENT", 46, 58], ["Immunization", "TREATMENT", 91, 103], ["tuberculosis", "PROBLEM", 200, 212], ["most widely", "OBSERVATION_MODIFIER", 18, 29], ["tuberculosis", "OBSERVATION", 200, 212]]], ["Despite its imperfections, BCG remains the only effective vaccination for protection against human tuberculosis (39).Yellow FeverYellow fever is a highly fatal infection caused by a small, enveloped, single-stranded RNA virus and results in renal, hepatic, and myocardial injury, along with hemorrhage and shock (41).", [["renal", "ANATOMY", 241, 246], ["hepatic", "ANATOMY", 248, 255], ["myocardial", "ANATOMY", 261, 271], ["tuberculosis", "DISEASE", 99, 111], ["FeverYellow fever", "DISEASE", 124, 141], ["infection", "DISEASE", 160, 169], ["renal, hepatic, and myocardial injury", "DISEASE", 241, 278], ["hemorrhage", "DISEASE", 291, 301], ["shock", "DISEASE", 306, 311], ["human", "ORGANISM", 93, 98], ["Yellow FeverYellow fever", "ORGANISM", 117, 141], ["renal", "ORGAN", 241, 246], ["hepatic", "MULTI-TISSUE_STRUCTURE", 248, 255], ["myocardial", "MULTI-TISSUE_STRUCTURE", 261, 271], ["human", "SPECIES", 93, 98], ["human", "SPECIES", 93, 98], ["its imperfections", "PROBLEM", 8, 25], ["BCG", "PROBLEM", 27, 30], ["human tuberculosis", "PROBLEM", 93, 111], ["Yellow FeverYellow fever", "PROBLEM", 117, 141], ["a highly fatal infection", "PROBLEM", 145, 169], ["a small, enveloped, single-stranded RNA virus", "PROBLEM", 180, 225], ["myocardial injury", "PROBLEM", 261, 278], ["hemorrhage", "PROBLEM", 291, 301], ["shock", "PROBLEM", 306, 311], ["tuberculosis", "OBSERVATION", 99, 111], ["highly", "OBSERVATION_MODIFIER", 147, 153], ["fatal", "OBSERVATION_MODIFIER", 154, 159], ["infection", "OBSERVATION", 160, 169], ["small", "OBSERVATION_MODIFIER", 182, 187], ["RNA virus", "OBSERVATION", 216, 225], ["renal", "ANATOMY", 241, 246], ["hepatic", "ANATOMY", 248, 255], ["myocardial", "ANATOMY", 261, 271], ["injury", "OBSERVATION", 272, 278], ["hemorrhage", "OBSERVATION", 291, 301], ["shock", "OBSERVATION_MODIFIER", 306, 311]]], ["Unlike previously mentioned diseases, the history of yellow fever is highly uncertain and filled with misconceptions.", [["yellow fever", "DISEASE", 53, 65], ["previously mentioned diseases", "PROBLEM", 7, 36], ["yellow fever", "PROBLEM", 53, 65], ["diseases", "OBSERVATION", 28, 36]]], ["Early work on immunization against the disease began with Carlos Finlay (1833\u20131915) in the 1870s and 1880s when Koch\u2019s postulates were becoming increasingly accepted.", [["immunization", "TREATMENT", 14, 26], ["the disease", "PROBLEM", 35, 46]]], ["Finlay proposed that mosquitos carried the yellow fever \u201cgerm.\u201d", [["germ", "ANATOMY", 57, 61], ["yellow fever", "DISEASE", 43, 55], ["mosquitos", "ORGANISM", 21, 30], ["the yellow fever", "PROBLEM", 39, 55]]], ["He attempted to prove it by feeding mosquitos that had fed on yellow fever patients.", [["yellow fever", "DISEASE", 62, 74], ["mosquitos", "ORGANISM", 36, 45], ["patients", "ORGANISM", 75, 83], ["patients", "SPECIES", 75, 83]]], ["However, it was later revealed that his process failed due to the lack of an incubation period within the mosquito, which is a transmission requirement that Finlay was unaware of (42).Yellow FeverSince 1900, significant advances have been made in creating a vaccine by the Yellow Fever Commission, which was originally led by Walter Reed (1851\u20131902) along with Jesse Lazear, Aristedes Agramonte, and James Carroll.", [["Fever", "DISEASE", 280, 285], ["his process", "PROBLEM", 36, 47], ["a vaccine", "TREATMENT", 256, 265]]], ["When mosquitos bite non-immune individuals after feeding on individuals who had yellow fever, none of the non-immune subjects died and very few suffered disease.", [["yellow fever", "DISEASE", 80, 92], ["yellow fever", "PROBLEM", 80, 92], ["very few suffered disease", "PROBLEM", 135, 160]]], ["This led the Commission of investigators to a major discovery, namely, the identification of the Asibi strain, which is the parent strain of the present 17D vaccine, obtained via continuous indirect passage through the Aegypti mosquitos and direct passage through monkeys.", [["Asibi strain", "ORGANISM", 97, 109], ["monkeys", "ORGANISM", 264, 271], ["the Asibi strain", "PROBLEM", 93, 109], ["the Aegypti mosquitos", "TREATMENT", 215, 236]]], ["In addition to identifying the etiological agent of the disease, the Commission also identified rhesus monkeys as susceptible hosts, hence providing a means for testing future vaccine attempts.", [["rhesus", "ORGANISM", 96, 102], ["monkeys", "ORGANISM", 103, 110], ["rhesus monkeys", "SPECIES", 96, 110], ["rhesus monkeys", "SPECIES", 96, 110], ["the disease", "PROBLEM", 52, 63], ["testing future vaccine attempts", "TREATMENT", 161, 192], ["disease", "OBSERVATION", 56, 63]]], ["This paved the way for Max Theiler and other Rockefeller Foundation scientists to develop a successful live-attenuated vaccine for yellow fever in 1937.", [["yellow fever", "DISEASE", 131, 143], ["Max Theiler", "ORGANISM", 23, 34], ["Theiler", "SPECIES", 27, 34], ["Theiler", "SPECIES", 27, 34], ["Max Theiler", "TREATMENT", 23, 34], ["a successful live-attenuated vaccine", "TREATMENT", 90, 126], ["yellow fever", "PROBLEM", 131, 143]]], ["\u201cThe most important experimental passage series \u2013 designated 17D \u2013 used a virus that had been subcultured eighteen times in whole mouse embryos, followed by 58 passages in whole-minced chick embryo cultures, after which the virus was passed in minced chick embryo depleted of nervous tissue.\u201d", [["embryos", "ANATOMY", 136, 143], ["embryo cultures", "ANATOMY", 191, 206], ["embryo", "ANATOMY", 257, 263], ["nervous tissue", "ANATOMY", 276, 290], ["mouse", "ORGANISM", 130, 135], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 136, 143], ["chick", "ORGANISM", 185, 190], ["embryo cultures", "CELL", 191, 206], ["chick", "ORGANISM", 251, 256], ["embryo", "DEVELOPING_ANATOMICAL_STRUCTURE", 257, 263], ["nervous tissue", "TISSUE", 276, 290], ["17D", "CELL_LINE", 61, 64], ["whole-minced chick embryo cultures", "CELL_LINE", 172, 206], ["mouse", "SPECIES", 130, 135], ["mouse", "SPECIES", 130, 135], ["a virus", "PROBLEM", 72, 79], ["whole-minced chick embryo cultures", "TREATMENT", 172, 206], ["the virus", "PROBLEM", 220, 229], ["chick embryo depleted", "OBSERVATION", 251, 272], ["nervous tissue", "OBSERVATION", 276, 290]]], ["Theiler himself was actually one of the first individuals to be successfully vaccinated.", [["Theiler", "ORGANISM", 0, 7], ["Theiler", "SPECIES", 0, 7], ["Theiler", "SPECIES", 0, 7]]], ["The vaccine was quickly implemented, and alternative vaccines shown to be more dangerous were discontinued (42).InfluenzaInfluenza has proved to be very difficult to trace back in history due to its non-specific symptoms and features.", [["InfluenzaInfluenza", "CHEMICAL", 112, 130], ["The vaccine", "TREATMENT", 0, 11], ["alternative vaccines", "TREATMENT", 41, 61], ["InfluenzaInfluenza", "TREATMENT", 112, 130], ["its non-specific symptoms", "PROBLEM", 195, 220]]], ["It was not until the early twentieth century that influenza outbreaks began to be systematically studied due to well-documented clinical descriptions and epidemiological data.", [["influenza outbreaks", "DISEASE", 50, 69], ["influenza outbreaks", "PROBLEM", 50, 69], ["epidemiological data", "TEST", 154, 174]]], ["In 1918, the \u201cSpanish flu\u201d influenza pandemic was responsible for 25\u201350 million deaths worldwide and more than one-half million in the U.S. This virus was unusual because it spread so quickly, was so deadly (26).", [["influenza pandemic", "DISEASE", 27, 45], ["deaths", "DISEASE", 80, 86], ["influenza pandemic", "PROBLEM", 27, 45], ["This virus", "PROBLEM", 140, 150]]], ["Richard E. Shope (1901\u20131966), a physician who conducted his research in the Department of Animal Pathology at The Rockefeller Institute in Princeton, was the first to isolate influenza virus; a member of the orthomyxovirus family, from a mammalian host in 1931 (43).", [["influenza virus", "DISEASE", 175, 190], ["influenza virus", "ORGANISM", 175, 190], ["influenza virus", "SPECIES", 175, 190], ["influenza virus", "SPECIES", 175, 190], ["influenza virus", "PROBLEM", 175, 190]]], ["He was able to induce the syndrome of swine influenza in pigs by applying respiratory secretions intranasally.", [["respiratory secretions", "ANATOMY", 74, 96], ["swine influenza", "DISEASE", 38, 53], ["He", "ORGANISM", 0, 2], ["swine influenza", "ORGANISM", 38, 53], ["pigs", "ORGANISM", 57, 61], ["swine", "SPECIES", 38, 43], ["pigs", "SPECIES", 57, 61], ["swine", "SPECIES", 38, 43], ["pigs", "SPECIES", 57, 61], ["the syndrome", "PROBLEM", 22, 34], ["swine influenza", "PROBLEM", 38, 53], ["respiratory secretions intranasally", "PROBLEM", 74, 109], ["influenza", "OBSERVATION", 44, 53]]], ["He also isolated a bacterium from the respiratory tract of infected pigs called Haemophilus influenzae suis.", [["respiratory tract", "ANATOMY", 38, 55], ["Haemophilus influenzae suis", "DISEASE", 80, 107], ["respiratory tract", "ORGANISM_SUBDIVISION", 38, 55], ["pigs", "ORGANISM", 68, 72], ["Haemophilus influenzae suis", "ORGANISM", 80, 107], ["pigs", "SPECIES", 68, 72], ["Haemophilus influenzae suis", "SPECIES", 80, 107], ["pigs", "SPECIES", 68, 72], ["Haemophilus influenzae suis", "SPECIES", 80, 107], ["a bacterium", "PROBLEM", 17, 28], ["the respiratory tract", "PROBLEM", 34, 55], ["Haemophilus influenzae suis", "PROBLEM", 80, 107], ["bacterium", "OBSERVATION_MODIFIER", 19, 28], ["respiratory tract", "ANATOMY", 38, 55], ["infected pigs", "OBSERVATION", 59, 72]]], ["When this bacterium was combined with a filterable agent and inoculated, the pigs developed the clinical manifestations of swine influenza.", [["swine influenza", "DISEASE", 123, 138], ["pigs", "ORGANISM", 77, 81], ["swine influenza", "ORGANISM", 123, 138], ["pigs", "SPECIES", 77, 81], ["swine", "SPECIES", 123, 128], ["pigs", "SPECIES", 77, 81], ["swine", "SPECIES", 123, 128], ["this bacterium", "PROBLEM", 5, 19], ["a filterable agent", "TREATMENT", 38, 56], ["swine influenza", "PROBLEM", 123, 138], ["influenza", "OBSERVATION", 129, 138]]], ["These two agents seemed to act synergistically with the virus to damage the respiratory tract hence creating the suitable environment needed for the virus to exercise its pathological effects.", [["respiratory tract", "ANATOMY", 76, 93], ["respiratory tract", "ORGANISM_SUBDIVISION", 76, 93], ["the virus", "PROBLEM", 52, 61], ["the respiratory tract", "PROBLEM", 72, 93], ["the virus", "PROBLEM", 145, 154], ["respiratory tract", "ANATOMY", 76, 93]]], ["In 1933, scientists from the British National Institute for Medical Research including Christopher Andrews, Wilson Smith, and Patrick Laidlaw successfully isolated and transmitted the influenza virus from humans.", [["influenza virus", "DISEASE", 184, 199], ["influenza virus", "ORGANISM", 184, 199], ["humans", "ORGANISM", 205, 211], ["influenza virus", "SPECIES", 184, 199], ["humans", "SPECIES", 205, 211], ["humans", "SPECIES", 205, 211], ["the influenza virus", "PROBLEM", 180, 199], ["influenza virus", "OBSERVATION", 184, 199]]], ["Throughout this year, \u201cBurnet has successfully cultivated the organism in chick embryos; other influenza types had been recognized; neutralizing antibodies had been identified and quantitated; and viral surface glycoproteins, H and N had been described\u201d (43).InfluenzaThese discoveries led scientists to introduce the inactivated vaccine in the mid-1940s that is still used to this day (44).", [["embryos", "ANATOMY", 80, 87], ["surface", "ANATOMY", 203, 210], ["influenza", "DISEASE", 95, 104], ["chick", "ORGANISM", 74, 79], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 80, 87], ["neutralizing antibodies", "PROTEIN", 132, 155], ["viral surface glycoproteins", "PROTEIN", 197, 224], ["chick embryos", "PROBLEM", 74, 87], ["other influenza types", "PROBLEM", 89, 110], ["neutralizing antibodies", "TEST", 132, 155], ["viral surface glycoproteins", "TEST", 197, 224], ["the inactivated vaccine", "TREATMENT", 314, 337], ["chick embryos", "OBSERVATION", 74, 87]]], ["The influenza A/B vaccine was initially presented to the Armed Forces Epidemiological Board in 1942.", [["influenza A/B", "ORGANISM", 4, 17], ["The influenza A/B vaccine", "TREATMENT", 0, 25]]], ["It was licensed following the war and used for civilians in 1945 in the U.S. Starting 1985, a series of vaccines were licensed for Haemophilus influenza type b (Hib) polysaccharide vaccines.", [["Haemophilus influenza type b", "DISEASE", 131, 159], ["Haemophilus influenza type b", "ORGANISM", 131, 159], ["Hib", "ORGANISM", 161, 164], ["Haemophilus influenza", "SPECIES", 131, 152], ["Haemophilus influenza type b (Hib)", "SPECIES", 131, 165], ["a series of vaccines", "TREATMENT", 92, 112], ["Haemophilus influenza type b (Hib) polysaccharide vaccines", "TREATMENT", 131, 189]]], ["These vaccines are recommended routinely for children at 15 and 24 months of age.", [["children", "ORGANISM", 45, 53], ["children", "SPECIES", 45, 53], ["These vaccines", "TREATMENT", 0, 14]]], ["The vaccine was, however, not consistently immunogenic in children <18 months of age.", [["children", "ORGANISM", 58, 66], ["children", "SPECIES", 58, 66], ["The vaccine", "TREATMENT", 0, 11]]], ["In 1987, the protein-conjugated Hib vaccine was licensed and in the next 2 years, it became available.", [["the protein-conjugated Hib vaccine", "TREATMENT", 9, 43]]], ["During 1996, a combined vaccine Hib conjugate and Hepatitis B was licensed.", [["Hepatitis B", "DISEASE", 50, 61], ["Hib", "ORGANISM", 32, 35], ["Hepatitis B", "ORGANISM", 50, 61], ["Hepatitis B", "SPECIES", 50, 61], ["a combined vaccine Hib conjugate", "TREATMENT", 13, 45], ["Hepatitis B", "TREATMENT", 50, 61]]], ["Later on, in 2003, the first nasally administered influenza vaccine was licensed.", [["influenza vaccine", "TREATMENT", 50, 67]]], ["This live influenza A and B virus vaccine was indicated for healthy, non-pregnant persons ages 5\u201349 years.", [["live influenza A", "ORGANISM", 5, 21], ["B virus", "ORGANISM", 26, 33], ["persons", "ORGANISM", 82, 89], ["B virus vaccine", "SPECIES", 26, 41], ["persons", "SPECIES", 82, 89], ["B virus", "SPECIES", 26, 33], ["This live influenza A and B virus vaccine", "TREATMENT", 0, 41]]], ["The contracts to develop vaccine against the H5N1 avian influenza virus were awarded to Aventis Pasteur and to Chiron in 2004.", [["H5N1 avian influenza virus", "DISEASE", 45, 71], ["H5N1", "ORGANISM", 45, 49], ["avian influenza virus", "ORGANISM", 50, 71], ["H5N1 avian influenza virus", "SPECIES", 45, 71], ["H5N1 avian influenza virus", "SPECIES", 45, 71], ["vaccine", "TREATMENT", 25, 32], ["the H5N1 avian influenza virus", "PROBLEM", 41, 71]]], ["During the following year, an inactivated, injectable influenza vaccine was licensed.", [["influenza", "DISEASE", 54, 63], ["an inactivated, injectable influenza vaccine", "TREATMENT", 27, 71]]], ["It was indicated for adults 18 years of age and older.InfluenzaDuring the same year, the FDA approved Afluria, a new inactivated influenza vaccine, for use in people aged 18 years and older.", [["Afluria", "CHEMICAL", 102, 109], ["influenza", "DISEASE", 129, 138], ["Afluria", "SIMPLE_CHEMICAL", 102, 109], ["people", "ORGANISM", 159, 165], ["people", "SPECIES", 159, 165], ["a new inactivated influenza vaccine", "TREATMENT", 111, 146]]], ["Two years later in 2009, the Department of Health and Human Services, supported the building of a facility to manufacture cell-based influenza vaccine.", [["cell", "ANATOMY", 122, 126], ["Human", "ORGANISM", 54, 59], ["cell", "CELL", 122, 126], ["Human", "SPECIES", 54, 59], ["cell-based influenza vaccine", "TREATMENT", 122, 150]]], ["It also directed toward development of a vaccine for novel influenza A (H1N1).", [["influenza A", "DISEASE", 59, 70], ["influenza A (H1N1", "ORGANISM", 59, 76], ["influenza A (H1N1", "SPECIES", 59, 76], ["a vaccine", "TREATMENT", 39, 48], ["novel influenza A", "PROBLEM", 53, 70]]], ["During the same year, the FDA approved four vaccines against the H1N1 influenza virus high-dose inactivated influenza vaccine (Fluzone High-Dose) for people aged 65 years and older.", [["influenza", "DISEASE", 108, 117], ["Fluzone", "CHEMICAL", 127, 134], ["H1N1 influenza virus", "ORGANISM", 65, 85], ["people", "ORGANISM", 150, 156], ["H1N1 influenza virus", "SPECIES", 65, 85], ["influenza vaccine", "SPECIES", 108, 125], ["people", "SPECIES", 150, 156], ["H1N1 influenza virus", "SPECIES", 65, 85], ["the FDA", "TREATMENT", 22, 29], ["four vaccines", "TREATMENT", 39, 52], ["the H1N1 influenza virus", "TREATMENT", 61, 85], ["influenza vaccine", "TREATMENT", 108, 125], ["Fluzone", "TREATMENT", 127, 134]]], ["In 2012, the FDA approved several vaccines: HibMenCY a new combination of meningococcal and Hib vaccine for infants; Flucelvax, which is the first seasonal influenza vaccine, manufactured using cell culture technology and a quadrivalent formulation of Fluarix (26).InfluenzaUnfortunately, one of the difficulties in dealing with influenza is the continuous mutability of the viral genome necessitating annual reassessments and reformulations of the vaccine.", [["cell", "ANATOMY", 194, 198], ["HibMenCY", "CHEMICAL", 44, 52], ["Flucelvax", "CHEMICAL", 117, 126], ["Fluarix", "CHEMICAL", 252, 259], ["influenza", "DISEASE", 329, 338], ["HibMenCY", "SIMPLE_CHEMICAL", 44, 52], ["meningococcal", "ORGANISM", 74, 87], ["Hib", "ORGANISM", 92, 95], ["infants", "ORGANISM", 108, 115], ["Flucelvax", "SIMPLE_CHEMICAL", 117, 126], ["cell", "CELL", 194, 198], ["viral genome", "DNA", 375, 387], ["infants", "SPECIES", 108, 115], ["meningococcal", "SPECIES", 74, 87], ["HibMenCY", "TREATMENT", 44, 52], ["meningococcal and Hib vaccine", "TREATMENT", 74, 103], ["Flucelvax", "TREATMENT", 117, 126], ["the first seasonal influenza vaccine", "TREATMENT", 137, 173], ["cell culture technology", "TREATMENT", 194, 217], ["a quadrivalent formulation of Fluarix", "TREATMENT", 222, 259], ["influenza", "PROBLEM", 329, 338], ["the viral genome", "PROBLEM", 371, 387], ["annual reassessments", "TREATMENT", 402, 422], ["the vaccine", "TREATMENT", 445, 456], ["viral genome", "OBSERVATION", 375, 387]]], ["This has led to a suboptimal effectiveness of influenza vaccines, which are only successful against strains included in the vaccine formulation or strains of homogenous subtype.", [["influenza vaccines", "TREATMENT", 46, 64], ["strains", "PROBLEM", 100, 107], ["the vaccine formulation", "TREATMENT", 120, 143], ["homogenous subtype", "OBSERVATION", 158, 176]]], ["Several pandemics were caused by the influenza virus: during the years 1957\u20131958, The \u201cAsian\u201d influenza pandemic caused by H2N2 influenza virus resulted in an estimated 70,000 deaths in the U.S. alone and in the years 1968\u20131969, the \u201cHong Kong\u201d influenza pandemic caused by an H3N2 influenza virus induced roughly 34,000 deaths in the U.S. (26).", [["influenza virus", "DISEASE", 37, 52], ["influenza pandemic", "DISEASE", 94, 112], ["H2N2 influenza virus", "DISEASE", 123, 143], ["deaths", "DISEASE", 176, 182], ["influenza pandemic", "DISEASE", 245, 263], ["influenza", "DISEASE", 282, 291], ["deaths", "DISEASE", 321, 327], ["influenza virus", "ORGANISM", 37, 52], ["H2N2 influenza virus", "ORGANISM", 123, 143], ["H3N2 influenza virus", "ORGANISM", 277, 297], ["influenza virus", "SPECIES", 37, 52], ["H2N2 influenza virus", "SPECIES", 123, 143], ["H3N2 influenza virus", "SPECIES", 277, 297], ["H2N2 influenza virus", "SPECIES", 123, 143], ["H3N2 influenza virus", "SPECIES", 277, 297], ["Several pandemics", "PROBLEM", 0, 17], ["the influenza virus", "PROBLEM", 33, 52], ["influenza pandemic", "PROBLEM", 94, 112], ["H2N2 influenza virus", "PROBLEM", 123, 143], ["influenza", "PROBLEM", 245, 254], ["an H3N2 influenza virus", "PROBLEM", 274, 297], ["pandemics", "OBSERVATION", 8, 17]]], ["Future studies should focus on producing vaccines protective against variant strains and creating surveillance systems to detect novel strains in time to formulate the proper vaccines.PoliomyelitisPoliomyelitis, or Polio, is an intestinal infection spread between humans through the fecal\u2013oral route.", [["intestinal", "ANATOMY", 228, 238], ["PoliomyelitisPoliomyelitis", "DISEASE", 184, 210], ["intestinal infection", "DISEASE", 228, 248], ["intestinal", "ORGAN", 228, 238], ["humans", "ORGANISM", 264, 270], ["humans", "SPECIES", 264, 270], ["humans", "SPECIES", 264, 270], ["Future studies", "TEST", 0, 14], ["producing vaccines", "TREATMENT", 31, 49], ["variant strains", "PROBLEM", 69, 84], ["creating surveillance systems", "TEST", 89, 118], ["novel strains", "PROBLEM", 129, 142], ["the proper vaccines", "TREATMENT", 164, 183], ["PoliomyelitisPoliomyelitis", "PROBLEM", 184, 210], ["Polio", "PROBLEM", 215, 220], ["an intestinal infection", "PROBLEM", 225, 248], ["Poliomyelitis", "OBSERVATION", 197, 210], ["intestinal", "ANATOMY", 228, 238], ["infection", "OBSERVATION", 239, 248]]], ["It is a disease of the developed nations striking younger individuals most frequently in warmer weather.", [["disease", "OBSERVATION", 8, 15]]], ["One of the most famous polio victims, President Franklin D. Roosevelt, founded the National Foundation for Infantile Paralysis in 1938, later known as the March of Dimes (26).", [["Infantile Paralysis", "DISEASE", 107, 126], ["Infantile Paralysis", "PROBLEM", 107, 126]]], ["It is well established that better hygiene decreases childhood exposure to the disease, when infection would usually be milder since protective maternal antibodies are present (45).", [["infection", "DISEASE", 93, 102], ["maternal antibodies", "PROTEIN", 144, 163], ["the disease", "PROBLEM", 75, 86], ["infection", "PROBLEM", 93, 102], ["protective maternal antibodies", "PROBLEM", 133, 163], ["disease", "OBSERVATION", 79, 86]]], ["In 1954, the Nobel Prize in Medicine was awarded to John Enders, Thomas Weller, and Fredrick Robbins for their discovery of the ability of poliomyelitis viruses to grow in tissue cultures (26).", [["tissue cultures", "ANATOMY", 172, 187], ["poliomyelitis", "DISEASE", 139, 152], ["tissue cultures", "CELL", 172, 187], ["poliomyelitis viruses", "PROBLEM", 139, 160], ["tissue cultures", "TEST", 172, 187], ["poliomyelitis", "OBSERVATION", 139, 152]]], ["Two major lifelong competitors were involved in the race for the Polio vaccine, Jonas Salk (1914\u20131995) and Albert Sabin (1906\u20131993).", [["the Polio vaccine", "TREATMENT", 61, 78]]], ["Salk took a more traditional route using a killed-virus approach, which did not involve natural infection in acquiring immunity.", [["infection", "DISEASE", 96, 105], ["a killed-virus approach", "TREATMENT", 41, 64], ["natural infection", "PROBLEM", 88, 105], ["infection", "OBSERVATION", 96, 105]]], ["Instead, his approach involved a fully inactivated virus that still had the ability to induce protective antibodies.", [["protective antibodies", "PROTEIN", 94, 115], ["a fully inactivated virus", "PROBLEM", 31, 56]]], ["Sabin, on the other hand, set out to create a live-virus vaccine based on the belief that this would trigger natural immunity and provide a lasting protection.", [["Sabin", "ORGANISM", 0, 5], ["a live-virus vaccine", "TREATMENT", 44, 64], ["a lasting protection", "TREATMENT", 138, 158]]], ["Salk had speed, simplicity, and safety on his side since a killed-virus did not have the ability to revert to virulence, whereas the live-virus vaccine could be given orally, establish longer lasting immunity, and offer passive vaccination through the excreted weakened virus potentially immunizing a large portion of non-vaccinated communities (46).PoliomyelitisNot surprisingly, Salk\u2019s vaccine was the first to make it to the population.", [["Poliomyelitis", "DISEASE", 350, 363], ["live-virus", "ORGANISM", 133, 143], ["a killed-virus", "PROBLEM", 57, 71], ["virulence", "PROBLEM", 110, 119], ["the live-virus vaccine", "TREATMENT", 129, 151], ["passive vaccination", "TREATMENT", 220, 239], ["the excreted weakened virus", "PROBLEM", 248, 275], ["Poliomyelitis", "PROBLEM", 350, 363]]], ["Following successful clinical trials in 1954, six companies began mass production of the vaccine.", [["the vaccine", "TREATMENT", 85, 96]]], ["Unfortunately, Salk\u2019s vaccines were soon suspended and recalled when contaminated samples were found in the market due to poor monitoring and control in some laboratories leading to serious health consequences and national panic.", [["samples", "ANATOMY", 82, 89], ["panic", "DISEASE", 223, 228], ["Salk\u2019s vaccines", "ORGANISM", 15, 30], ["Salk\u2019s vaccines", "TREATMENT", 15, 30], ["national panic", "PROBLEM", 214, 228]]], ["The first Cutter polio vaccine incident was reported on April 25, 1955 with 5 more cases reported just a day later with the number eventually rising to 94 of those vaccinated and in 166 of their close contacts.", [["The first Cutter polio vaccine", "TREATMENT", 0, 30]]], ["On May 7, the Surgeon General recommended that all polio vaccinations be suspended pending inspection of each manufacturing facility and thorough review of the procedures for testing vaccine safety.", [["all polio vaccinations", "TREATMENT", 47, 69], ["the procedures", "TEST", 156, 170], ["testing vaccine safety", "TREATMENT", 175, 197]]], ["The investigation found that live polio virus had survived in two batches of vaccines produced by Cutter Laboratories.", [["live polio virus", "ORGANISM", 29, 45], ["polio virus", "SPECIES", 34, 45], ["The investigation", "TEST", 0, 17], ["live polio virus", "PROBLEM", 29, 45]]], ["Large-scale polio vaccinations resumed in the fall of 1955 (26).", [["Large-scale polio vaccinations", "TREATMENT", 0, 30], ["-scale", "OBSERVATION_MODIFIER", 5, 11]]], ["At the same time, Sabin had been making great advances with his live-virus vaccine since 1951.", [["Sabin", "ORGANISM", 18, 23], ["live-virus", "ORGANISM", 64, 74], ["his live-virus vaccine", "TREATMENT", 60, 82]]], ["After successful clinical trials conducted in the Soviet Union that left polio virtually wiped out with no safety issues, it soon became the vaccine of choice in the West.", [["left polio", "PROBLEM", 68, 78], ["left", "ANATOMY_MODIFIER", 68, 72]]], ["The Polio Vaccination Assistance Act was enacted by Congress and was the first federal involvement in immunization activities.", [["immunization activities", "TREATMENT", 102, 125]]], ["It allowed Congress to appropriate funds to the Communicable Diseases Center [later the Centers for Disease Control and Prevention (CDC)] to help states and local communities acquire and administer vaccines.", [["Disease Control", "TREATMENT", 100, 115], ["vaccines", "TREATMENT", 198, 206]]], ["At the beginning of the 1960s, the oral polio vaccine types 1, 2, and 3 as well as the trivalent product were licensed in the U.S. The first 2 were developed by Sabin and grown in monkey kidney cell culture, while the trivalent oral polio was developed to improve upon the killed Salk vaccine (26).", [["oral", "ANATOMY", 35, 39], ["kidney cell culture", "ANATOMY", 187, 206], ["oral", "ANATOMY", 228, 232], ["oral", "ORGANISM_SUBDIVISION", 35, 39], ["Sabin", "ORGANISM", 161, 166], ["monkey", "ORGANISM", 180, 186], ["kidney cell", "CELL", 187, 198], ["oral", "ORGANISM_SUBDIVISION", 228, 232], ["polio", "ORGANISM", 233, 238], ["monkey kidney cell culture", "CELL_LINE", 180, 206], ["the oral polio vaccine types", "TREATMENT", 31, 59], ["the trivalent product", "TREATMENT", 83, 104], ["Sabin", "PROBLEM", 161, 166], ["monkey kidney cell culture", "TEST", 180, 206], ["the trivalent oral polio", "PROBLEM", 214, 238], ["the killed Salk vaccine", "TREATMENT", 269, 292], ["kidney", "ANATOMY", 187, 193], ["cell culture", "OBSERVATION", 194, 206]]], ["As a result, in the late 1990s, the CDC recommended switching back to Salk\u2019s killed-virus polio vaccine, while the WHO also advocated the switch for polio-free nations and the continued use of the favored live-virus vaccine for routine immunization (45).PoliomyelitisThe last two cases of wild type polio were reported in an unvaccinated Amish in 1979 and in a 5-year-old boy from Peru in 1991 (26).", [["Poliomyelitis", "DISEASE", 254, 267], ["polio", "DISEASE", 299, 304], ["Salk\u2019s killed-virus polio", "ORGANISM", 70, 95], ["live-virus", "ORGANISM", 205, 215], ["wild type polio", "ORGANISM", 289, 304], ["boy", "ORGANISM", 372, 375], ["virus polio vaccine", "SPECIES", 84, 103], ["boy", "SPECIES", 372, 375], ["Salk\u2019s killed", "TREATMENT", 70, 83], ["virus polio vaccine", "TREATMENT", 84, 103], ["polio-free nations", "TREATMENT", 149, 167], ["the favored live-virus vaccine", "TREATMENT", 193, 223], ["routine immunization", "TREATMENT", 228, 248], ["Poliomyelitis", "PROBLEM", 254, 267], ["wild type polio", "PROBLEM", 289, 304]]], ["In 1990, the enhanced-potency inactivated poliovirus vaccine was licensed.Measles, Mumps, and RubellaFollowing successful developments in the polio vaccine, attention soon shifted to three other common viral diseases of childhood: measles, mumps, and rubella.Measles, Mumps, and RubellaThe measles virus is an RNA virus from the genus Morbillivirus belonging to the Paramyxooviridae family.", [["Measles", "DISEASE", 74, 81], ["viral diseases", "DISEASE", 202, 216], ["measles, mumps, and rubella", "DISEASE", 231, 258], ["Measles", "DISEASE", 259, 266], ["Rubella", "DISEASE", 279, 286], ["measles virus", "DISEASE", 290, 303], ["poliovirus", "ORGANISM", 42, 52], ["Rubella", "ORGANISM", 279, 286], ["measles virus", "ORGANISM", 290, 303], ["Paramyxooviridae", "GENE_OR_GENE_PRODUCT", 366, 382], ["measles virus", "SPECIES", 290, 303], ["poliovirus", "SPECIES", 42, 52], ["Rubella", "SPECIES", 279, 286], ["measles virus", "SPECIES", 290, 303], ["poliovirus vaccine", "TREATMENT", 42, 60], ["Measles", "PROBLEM", 74, 81], ["Mumps", "PROBLEM", 83, 88], ["the polio vaccine", "TREATMENT", 138, 155], ["measles", "PROBLEM", 231, 238], ["mumps", "PROBLEM", 240, 245], ["rubella", "PROBLEM", 251, 258], ["Measles", "PROBLEM", 259, 266], ["Mumps", "PROBLEM", 268, 273], ["Rubella", "PROBLEM", 279, 286], ["The measles virus", "PROBLEM", 286, 303], ["an RNA virus", "PROBLEM", 307, 319], ["measles virus", "OBSERVATION", 290, 303], ["RNA virus", "OBSERVATION", 310, 319]]], ["It causes an acute illness that includes fever, cough, malaise, coryza, and conjunctivitis, in addition to a maculopapular rash.", [["maculopapular", "ANATOMY", 109, 122], ["fever", "DISEASE", 41, 46], ["cough", "DISEASE", 48, 53], ["coryza", "DISEASE", 64, 70], ["conjunctivitis", "DISEASE", 76, 90], ["rash", "DISEASE", 123, 127], ["an acute illness", "PROBLEM", 10, 26], ["fever", "PROBLEM", 41, 46], ["cough", "PROBLEM", 48, 53], ["malaise", "PROBLEM", 55, 62], ["coryza", "PROBLEM", 64, 70], ["conjunctivitis", "PROBLEM", 76, 90], ["a maculopapular rash", "PROBLEM", 107, 127], ["acute", "OBSERVATION_MODIFIER", 13, 18], ["illness", "OBSERVATION", 19, 26], ["fever", "OBSERVATION", 41, 46], ["coryza", "ANATOMY", 64, 70], ["conjunctivitis", "OBSERVATION", 76, 90], ["maculopapular", "OBSERVATION_MODIFIER", 109, 122], ["rash", "OBSERVATION", 123, 127]]], ["In general, measles is a mild disease but, like many others, has the potential to cause serious complications.", [["measles", "DISEASE", 12, 19], ["a mild disease", "PROBLEM", 23, 37], ["serious complications", "PROBLEM", 88, 109], ["mild", "OBSERVATION_MODIFIER", 25, 29], ["disease", "OBSERVATION", 30, 37]]], ["In addition, measles is known to be one of the most contagious human diseases causing major outbreaks to occur very often.", [["measles", "DISEASE", 13, 20], ["human", "ORGANISM", 63, 68], ["human", "SPECIES", 63, 68], ["human", "SPECIES", 63, 68], ["the most contagious human diseases", "PROBLEM", 43, 77]]], ["Until the year 2000, measles was still the leading cause of vaccine-preventable childhood deaths worldwide (47).Measles, Mumps, and RubellaJohn Enders (1897\u20131985), known as the \u201cFather of Modern Vaccines\u201d had a particular interest in revealing the virus responsible for measles.", [["measles", "DISEASE", 21, 28], ["deaths", "DISEASE", 90, 96], ["Measles", "DISEASE", 112, 119], ["measles", "DISEASE", 270, 277], ["Measles", "PROBLEM", 112, 119], ["Mumps", "PROBLEM", 121, 126], ["Modern Vaccines", "TREATMENT", 188, 203], ["the virus", "PROBLEM", 244, 253], ["measles", "PROBLEM", 270, 277]]], ["He isolated the Edmonston strain of the virus in 1954, which was named after the child from whom it was isolated.", [["child", "ORGANISM", 81, 86]]], ["A formalin-inactivated measles virus vaccine derived from this strain was subsequently licensed in the U.S. in 1963.", [["formalin", "CHEMICAL", 2, 10], ["formalin", "CHEMICAL", 2, 10], ["formalin", "SIMPLE_CHEMICAL", 2, 10], ["measles virus", "ORGANISM", 23, 36], ["measles virus vaccine", "SPECIES", 23, 44], ["measles virus", "SPECIES", 23, 36], ["A formalin", "TREATMENT", 0, 10], ["inactivated measles virus vaccine", "TREATMENT", 11, 44], ["this strain", "PROBLEM", 58, 69]]], ["However, following the discontinuation of this vaccine in 1967 due to short-lived and incomplete immunity, over 20 further attenuated vaccines were developed and used throughout the world, most of which were also derived from the Edmonston strain (48).", [["this vaccine", "TREATMENT", 42, 54], ["further attenuated vaccines", "TREATMENT", 115, 142]]], ["The first live-virus measles vaccine, Rubeovax, was licensed in 1963.", [["Rubeovax", "CHEMICAL", 38, 46], ["live-virus", "ORGANISM", 10, 20], ["measles", "ORGANISM", 21, 28], ["virus measles", "SPECIES", 15, 28], ["The first live-virus measles vaccine", "TREATMENT", 0, 36]]], ["Other live-attenuated virus measles vaccines were eventually licensed in the U.S. in 1965.", [["Other live-attenuated virus measles vaccines", "TREATMENT", 0, 44]]], ["The recommended age for routine administration was changed from 9 to 12 months of age.Measles, Mumps, and RubellaThe first national measles vaccine campaign was launched in 1966.", [["Measles", "DISEASE", 86, 93], ["Rubella", "DISEASE", 106, 113], ["Rubella", "ORGANISM", 106, 113], ["Rubella", "SPECIES", 106, 113], ["routine administration", "TREATMENT", 24, 46], ["Measles", "PROBLEM", 86, 93], ["Mumps", "PROBLEM", 95, 100], ["Rubella", "PROBLEM", 106, 113], ["The first national measles vaccine", "TREATMENT", 113, 147]]], ["In 1968, a second live, further attenuated measles virus vaccine was also licensed.", [["measles virus", "ORGANISM", 43, 56], ["measles virus vaccine", "SPECIES", 43, 64], ["measles virus", "SPECIES", 43, 56], ["further attenuated measles virus vaccine", "TREATMENT", 24, 64]]], ["In 1989, both the Advisory Committee on Immunization Practices (ACIP) and the American Academy of Pediatrics (AAP) issued recommendations for a routine second dose of the measles vaccine.", [["ACIP", "SPECIES", 64, 68], ["Immunization Practices", "TREATMENT", 40, 62], ["the measles vaccine", "TREATMENT", 167, 186]]], ["During the mid-to-late 1980s, a high proportion of reported measles cases were in school-aged children (5\u201319 years) who had been appropriately vaccinated.", [["measles", "DISEASE", 60, 67], ["children", "ORGANISM", 94, 102], ["children", "SPECIES", 94, 102]]], ["These vaccine failures led to new national recommendations of a second dose of measles-containing vaccine (26).Measles, Mumps, and RubellaMumps is another acute viral illness.", [["Measles", "DISEASE", 111, 118], ["RubellaMumps", "DISEASE", 131, 143], ["acute viral illness", "DISEASE", 155, 174], ["These vaccine failures", "PROBLEM", 0, 22], ["a second dose of measles-containing vaccine", "TREATMENT", 62, 105], ["Measles", "PROBLEM", 111, 118], ["Mumps", "PROBLEM", 120, 125], ["another acute viral illness", "PROBLEM", 147, 174], ["Mumps", "OBSERVATION", 120, 125], ["acute", "OBSERVATION_MODIFIER", 155, 160], ["viral illness", "OBSERVATION", 161, 174]]], ["It is the only virus known to cause epidemic parotiditis in humans accompanied by fever, anorexia, headache, and malaise.", [["parotiditis", "DISEASE", 45, 56], ["fever", "DISEASE", 82, 87], ["anorexia", "DISEASE", 89, 97], ["headache", "DISEASE", 99, 107], ["humans", "ORGANISM", 60, 66], ["humans", "SPECIES", 60, 66], ["humans", "SPECIES", 60, 66], ["epidemic parotiditis", "PROBLEM", 36, 56], ["fever", "PROBLEM", 82, 87], ["anorexia", "PROBLEM", 89, 97], ["headache", "PROBLEM", 99, 107], ["malaise", "PROBLEM", 113, 120], ["virus", "OBSERVATION", 15, 20], ["epidemic", "OBSERVATION_MODIFIER", 36, 44], ["parotiditis", "OBSERVATION", 45, 56], ["fever", "OBSERVATION", 82, 87], ["anorexia", "OBSERVATION", 89, 97], ["headache", "OBSERVATION", 99, 107], ["malaise", "OBSERVATION", 113, 120]]], ["K. Habel and John Enders isolated the virus in 1945 (26), and trials of formalin-inactivated mumps vaccine in humans began the same year by Joseph Stokes and colleagues and by Enders.", [["K", "CHEMICAL", 0, 1], ["formalin", "CHEMICAL", 72, 80], ["mumps", "DISEASE", 93, 98], ["formalin", "CHEMICAL", 72, 80], ["K", "GENE_OR_GENE_PRODUCT", 0, 1], ["formalin", "SIMPLE_CHEMICAL", 72, 80], ["mumps", "ORGANISM", 93, 98], ["humans", "ORGANISM", 110, 116], ["humans", "SPECIES", 110, 116], ["humans", "SPECIES", 110, 116], ["K", "TEST", 0, 1], ["formalin", "TREATMENT", 72, 80], ["inactivated mumps vaccine", "TREATMENT", 81, 106]]], ["This approach was abandoned in the 1950s due to short-lived immunity, and work began to develop live-attenuated mumps vaccines in 1959 by the vaccinologist Maurice Hilleman (1919\u20132005) and colleagues (48).", [["mumps", "DISEASE", 112, 117], ["mumps", "ORGANISM", 112, 117]]], ["Hilleman isolated the wild type virus from his daughter, Jeryl Lynn, who contracted the virus at the age of 5 and was recovering from it.", [["wild type virus", "ORGANISM", 22, 37], ["the virus", "PROBLEM", 84, 93], ["wild type virus", "OBSERVATION", 22, 37]]], ["It became known as the Jeryl Lynn strain of mumps virus.", [["mumps virus", "DISEASE", 44, 55], ["mumps virus", "ORGANISM", 44, 55], ["mumps virus", "SPECIES", 44, 55], ["the Jeryl Lynn strain of mumps virus", "PROBLEM", 19, 55], ["mumps virus", "OBSERVATION", 44, 55]]], ["The mumps live-virus vaccine was licensed in December 28, 1967 (26).", [["mumps live-virus", "ORGANISM", 4, 20], ["mumps live-virus", "SPECIES", 4, 20], ["The mumps live-virus vaccine", "TREATMENT", 0, 28]]], ["Trials with this attenuated virus resulted in 100% protective efficacy and the vaccine was licensed in the U.S. in 1967.", [["this attenuated virus", "PROBLEM", 12, 33], ["the vaccine", "TREATMENT", 75, 86]]], ["This strain is still used to produce mumps vaccines until this day.", [["mumps", "ORGANISM", 37, 42], ["mumps vaccines", "TREATMENT", 37, 51]]], ["It is given as part of the measles, mumps, and rubella (MMR) vaccine (49).Measles, Mumps, and RubellaRubella is a rash disease in children and adolescents caused by a filterable virus.", [["measles, mumps, and rubella", "DISEASE", 27, 54], ["Measles", "DISEASE", 74, 81], ["RubellaRubella", "CHEMICAL", 94, 108], ["rash disease", "DISEASE", 114, 126], ["children", "ORGANISM", 130, 138], ["children", "SPECIES", 130, 138], ["adolescents", "SPECIES", 143, 154], ["the measles", "PROBLEM", 23, 34], ["mumps", "PROBLEM", 36, 41], ["rubella", "PROBLEM", 47, 54], ["Measles", "PROBLEM", 74, 81], ["Mumps", "PROBLEM", 83, 88], ["a rash disease in children", "PROBLEM", 112, 138], ["a filterable virus", "PROBLEM", 165, 183], ["Mumps", "OBSERVATION", 83, 88], ["rash", "OBSERVATION", 114, 118], ["filterable virus", "OBSERVATION", 167, 183]]], ["It poses a severe threat to pregnant women and their children by potentially causing congenital deafness and cataracts.", [["congenital deafness", "DISEASE", 85, 104], ["cataracts", "DISEASE", 109, 118], ["women", "ORGANISM", 37, 42], ["children", "ORGANISM", 53, 61], ["women", "SPECIES", 37, 42], ["children", "SPECIES", 53, 61], ["congenital deafness", "PROBLEM", 85, 104], ["cataracts", "PROBLEM", 109, 118], ["severe", "OBSERVATION_MODIFIER", 11, 17], ["deafness", "OBSERVATION", 96, 104], ["cataracts", "OBSERVATION", 109, 118]]], ["In 1964, a rubella epidemic swept the U.S. resulting in 12.5 million cases of rubella infection, with an estimated 20,000 newborns having congenital rubella syndrome (CRS), along with fetal and neonatal deaths in the thousands (26).", [["fetal", "ANATOMY", 184, 189], ["rubella", "DISEASE", 11, 18], ["rubella infection", "DISEASE", 78, 95], ["congenital rubella syndrome", "DISEASE", 138, 165], ["CRS", "DISEASE", 167, 170], ["deaths", "DISEASE", 203, 209], ["rubella", "ORGANISM", 78, 85], ["fetal", "ANATOMICAL_SYSTEM", 184, 189], ["rubella", "SPECIES", 78, 85], ["rubella infection", "PROBLEM", 78, 95], ["congenital rubella syndrome", "PROBLEM", 138, 165], ["CRS", "PROBLEM", 167, 170], ["fetal and neonatal deaths", "PROBLEM", 184, 209], ["rubella infection", "OBSERVATION", 78, 95], ["congenital", "OBSERVATION_MODIFIER", 138, 148], ["rubella syndrome", "OBSERVATION", 149, 165]]], ["The rubella virus was detected and isolated by two groups of scientists, Thomas Weller and Franklin Neva at Harvard Medical School, in addition to Paul Parkman and colleagues at the Walter Reed Army Institute of Research (WRAIR).", [["rubella virus", "DISEASE", 4, 17], ["rubella virus", "ORGANISM", 4, 17], ["rubella virus", "SPECIES", 4, 17], ["The rubella virus", "PROBLEM", 0, 17], ["rubella virus", "OBSERVATION", 4, 17]]], ["Similar to measles and mumps, inactivated whole virus vaccines proved ineffective, so efforts turned to discovering a live-attenuated vaccine (26).Measles, Mumps, and RubellaIn 1963, Paul Parkman left WRAIR and joined Harry Meyer Jr. at the NIH Division of Biological Standards, and the pair developed the first live-attenuated rubella vaccine in 1966, HPV-77, which was subsequently included in the initial MMR vaccine used in the U.S. in the 1970s (26).", [["measles and mumps", "DISEASE", 11, 28], ["Measles", "DISEASE", 147, 154], ["rubella", "DISEASE", 328, 335], ["HPV-77", "CHEMICAL", 353, 359], ["whole virus", "ORGANISM", 42, 53], ["rubella", "ORGANISM", 328, 335], ["HPV-77", "ORGANISM", 353, 359], ["HPV-77", "SPECIES", 353, 359], ["measles", "PROBLEM", 11, 18], ["mumps", "PROBLEM", 23, 28], ["inactivated whole virus vaccines", "TREATMENT", 30, 62], ["a live-attenuated vaccine", "TREATMENT", 116, 141], ["attenuated rubella vaccine", "TREATMENT", 317, 343], ["HPV", "TEST", 353, 356], ["the initial MMR vaccine", "TREATMENT", 396, 419]]], ["Maurice Hilleman discovered the superior RA 27/3 vaccine that became the only vaccine used outside of Japan starting in the late 1970s.", [["the superior RA 27/3 vaccine", "TREATMENT", 28, 56]]], ["This vaccine maintained its preference due to many factors including increased durability and harmlessness to fetuses of inadvertently vaccinated pregnant women (47).", [["fetuses", "ANATOMY", 110, 117], ["fetuses", "ORGANISM", 110, 117], ["women", "ORGANISM", 155, 160], ["women", "SPECIES", 155, 160], ["This vaccine", "TREATMENT", 0, 12], ["many factors", "PROBLEM", 46, 58], ["increased durability", "PROBLEM", 69, 89], ["increased", "OBSERVATION_MODIFIER", 69, 78], ["durability", "OBSERVATION", 79, 89]]], ["In 1969, three rubella virus strains were licensed in the U.S.: HPV-77 strain grown in dog-kidney culture, HPV-77 grown in duck-embryo culture, and Cendehill strain grown in rabbit-kidney culture.", [["kidney", "ANATOMY", 91, 97], ["embryo culture", "ANATOMY", 128, 142], ["kidney", "ANATOMY", 181, 187], ["rubella virus", "DISEASE", 15, 28], ["HPV-77", "CHEMICAL", 107, 113], ["rubella virus", "ORGANISM", 15, 28], ["HPV-77 strain", "ORGANISM", 64, 77], ["dog", "ORGANISM", 87, 90], ["kidney", "ORGAN", 91, 97], ["HPV-77", "ORGANISM", 107, 113], ["duck", "ORGANISM", 123, 127], ["embryo culture", "CELL", 128, 142], ["rabbit", "ORGANISM", 174, 180], ["kidney", "ORGAN", 181, 187], ["rubella virus", "SPECIES", 15, 28], ["dog", "SPECIES", 87, 90], ["duck", "SPECIES", 123, 127], ["rabbit", "SPECIES", 174, 180], ["rubella virus", "SPECIES", 15, 28], ["HPV-77", "SPECIES", 64, 70], ["dog", "SPECIES", 87, 90], ["HPV-77", "SPECIES", 107, 113], ["duck", "SPECIES", 123, 127], ["rabbit", "SPECIES", 174, 180], ["three rubella virus strains", "PROBLEM", 9, 36], ["HPV", "TEST", 64, 67], ["strain", "PROBLEM", 71, 77], ["dog", "TEST", 87, 90], ["kidney culture", "TEST", 91, 105], ["HPV", "TEST", 107, 110], ["embryo culture", "TEST", 128, 142], ["Cendehill strain", "PROBLEM", 148, 164], ["kidney culture", "TEST", 181, 195], ["kidney", "ANATOMY", 91, 97], ["kidney", "ANATOMY", 181, 187]]], ["A decade later, in 1979, the RA 27/3 (human diploid fibroblast) strain of rubella vaccine (Meruvax II) by Merck was licensed.", [["fibroblast", "ANATOMY", 52, 62], ["rubella", "DISEASE", 74, 81], ["Meruvax II", "CHEMICAL", 91, 101], ["RA 27/3", "CELL", 29, 36], ["human", "ORGANISM", 38, 43], ["fibroblast", "CELL", 52, 62], ["rubella", "ORGANISM", 74, 81], ["human", "SPECIES", 38, 43], ["human", "SPECIES", 38, 43], ["the RA", "TREATMENT", 25, 31], ["human diploid fibroblast)", "TREATMENT", 38, 63], ["rubella vaccine (Meruvax II", "TREATMENT", 74, 101], ["RA", "ANATOMY", 29, 31]]], ["All other strains were discontinued.", [["All other strains", "PROBLEM", 0, 17], ["strains", "OBSERVATION", 10, 17]]], ["Merck\u2019s combined trivalent MMR as well as the combined measles and rubella vaccine (M-RVax) developed by Maurice Hilleman and colleagues, was licensed by the U.S. government in 1971 (26), and is still in use today.", [["measles and rubella", "DISEASE", 55, 74], ["M-RVax", "CHEMICAL", 84, 90], ["Merck\u2019s combined trivalent MMR", "TREATMENT", 0, 30], ["the combined measles", "TREATMENT", 42, 62], ["rubella vaccine", "TREATMENT", 67, 82]]], ["Moreover, the age for routine vaccination with MMR vaccine was changed from 12 to 15 months in the year of 1976.", [["routine vaccination", "TREATMENT", 22, 41], ["MMR vaccine", "TREATMENT", 47, 58]]], ["The next vaccine that combined measles, mumps, rubella, and varicella antigens (Proquad) was licensed in 2005.", [["measles, mumps, rubella, and varicella antigens", "DISEASE", 31, 78], ["measles", "ORGANISM", 31, 38], ["mumps", "ORGANISM", 40, 45], ["rubella", "ORGANISM", 47, 54], ["varicella antigens", "ORGANISM", 60, 78], ["The next vaccine", "TREATMENT", 0, 16], ["combined measles", "PROBLEM", 22, 38], ["mumps", "PROBLEM", 40, 45], ["rubella", "PROBLEM", 47, 54], ["varicella antigens", "PROBLEM", 60, 78]]], ["It was indicated for use in children 12 months to 12 years.", [["children", "ORGANISM", 28, 36], ["children", "SPECIES", 28, 36]]], ["In response to the association of this vaccine with autism, in 2004, the eighth and final report of the Immunization Safety Review Committee was issued by the Institute of Medicine concluded that the body of epidemiological evidence favors rejection of a causal relationship between the MMR vaccine and autism (26).", [["autism", "DISEASE", 52, 58], ["autism", "DISEASE", 303, 309], ["this vaccine", "TREATMENT", 34, 46], ["rejection", "PROBLEM", 240, 249], ["the MMR vaccine", "TREATMENT", 283, 298], ["rejection", "OBSERVATION", 240, 249]]], ["Combination vaccines hold many advantages including reduced need for several injections, therefore, reducing the incidence of vaccination site reaction (48).HepatitisThe etiological agent of clinical hepatitis, identified by its distinguishing yellow jaundice, was found to be infectious in the early 1900s.", [["Hepatitis", "DISEASE", 157, 166], ["hepatitis", "DISEASE", 200, 209], ["jaundice", "DISEASE", 251, 259], ["Combination vaccines", "TREATMENT", 0, 20], ["many advantages", "TREATMENT", 26, 41], ["several injections", "TREATMENT", 69, 87], ["vaccination site reaction", "PROBLEM", 126, 151], ["Hepatitis", "PROBLEM", 157, 166], ["clinical hepatitis", "PROBLEM", 191, 209], ["yellow jaundice", "PROBLEM", 244, 259], ["infectious", "PROBLEM", 277, 287], ["hepatitis", "OBSERVATION", 200, 209], ["yellow", "OBSERVATION_MODIFIER", 244, 250], ["jaundice", "OBSERVATION", 251, 259], ["infectious", "OBSERVATION", 277, 287]]], ["The different hepatitis strains, A and B, were first differentiated in 1942 (26).", [["hepatitis", "DISEASE", 14, 23], ["B", "CELL", 39, 40], ["The different hepatitis strains", "PROBLEM", 0, 31], ["different", "OBSERVATION_MODIFIER", 4, 13], ["hepatitis strains", "OBSERVATION", 14, 31]]], ["In the mid-1960s, Blumberg and co-workers and Prince discovered hepatitis B surface antigen in the circulating blood of carriers of the infection.", [["blood", "ANATOMY", 111, 116], ["hepatitis B surface antigen", "CHEMICAL", 64, 91], ["infection", "DISEASE", 136, 145], ["hepatitis B surface antigen", "GENE_OR_GENE_PRODUCT", 64, 91], ["blood", "ORGANISM_SUBSTANCE", 111, 116], ["hepatitis B surface antigen", "PROTEIN", 64, 91], ["hepatitis B surface antigen", "PROBLEM", 64, 91], ["the infection", "PROBLEM", 132, 145], ["hepatitis", "OBSERVATION", 64, 73], ["infection", "OBSERVATION", 136, 145]]], ["Deinhardt et al. soon followed this discovery with that of the hepatitis A virus (49).", [["hepatitis A", "DISEASE", 63, 74], ["hepatitis A virus", "ORGANISM", 63, 80], ["hepatitis A virus", "SPECIES", 63, 80], ["hepatitis A virus", "SPECIES", 63, 80], ["the hepatitis A virus", "PROBLEM", 59, 80], ["hepatitis", "OBSERVATION", 63, 72]]], ["Provost et al. successfully prepared a killed hepatitis A vaccine in 1986, which proved to be safe and highly effective in extensive clinical trials.", [["hepatitis A", "DISEASE", 46, 57], ["hepatitis A", "SPECIES", 46, 57], ["a killed hepatitis A vaccine", "TREATMENT", 37, 65]]], ["The first inactivated hepatitis A vaccine (Havrix) was licensed in 1995.", [["hepatitis A", "DISEASE", 22, 33], ["hepatitis A", "ORGANISM", 22, 33], ["hepatitis A", "SPECIES", 22, 33], ["The first inactivated hepatitis A vaccine", "TREATMENT", 0, 41]]], ["The following year, a second inactivated vaccine (Vaqta) also became available (50).HepatitisHepatitis B, on the other hand, rarely causes any severe risk as a primary infection.", [["HepatitisHepatitis B", "DISEASE", 84, 104], ["primary infection", "DISEASE", 160, 177], ["HepatitisHepatitis B", "ORGANISM", 84, 104], ["a second inactivated vaccine", "TREATMENT", 20, 48], ["HepatitisHepatitis B", "PROBLEM", 84, 104], ["a primary infection", "PROBLEM", 158, 177], ["Hepatitis", "OBSERVATION", 93, 102], ["primary", "OBSERVATION_MODIFIER", 160, 167], ["infection", "OBSERVATION", 168, 177]]], ["However, those who develop a chronic persistent infection may continue to have severe disease for the rest of their lives.", [["infection", "DISEASE", 48, 57], ["a chronic persistent infection", "PROBLEM", 27, 57], ["severe disease", "PROBLEM", 79, 93], ["chronic", "OBSERVATION_MODIFIER", 29, 36], ["persistent", "OBSERVATION_MODIFIER", 37, 47], ["infection", "OBSERVATION", 48, 57], ["severe", "OBSERVATION_MODIFIER", 79, 85], ["disease", "OBSERVATION", 86, 93]]], ["This may even lead to cirrhotic destruction of the liver due to host immune response to the virus.", [["liver", "ANATOMY", 51, 56], ["cirrhotic destruction of the liver", "DISEASE", 22, 56], ["liver", "ORGAN", 51, 56], ["cirrhotic destruction of the liver", "PROBLEM", 22, 56], ["the virus", "PROBLEM", 88, 97], ["cirrhotic", "OBSERVATION_MODIFIER", 22, 31], ["destruction", "OBSERVATION", 32, 43], ["liver", "ANATOMY", 51, 56], ["host immune response", "OBSERVATION", 64, 84]]], ["The discovery of the surface antigen particles of the hepatitis B virus by Blumberg and colleagues in the plasma of human carriers was followed by attempts to create a vaccine.", [["surface", "ANATOMY", 21, 28], ["plasma", "ANATOMY", 106, 112], ["hepatitis B", "DISEASE", 54, 65], ["hepatitis B virus", "ORGANISM", 54, 71], ["plasma", "ORGANISM_SUBSTANCE", 106, 112], ["human", "ORGANISM", 116, 121], ["hepatitis B virus", "SPECIES", 54, 71], ["human", "SPECIES", 116, 121], ["hepatitis B virus", "SPECIES", 54, 71], ["human", "SPECIES", 116, 121], ["the surface antigen particles", "TREATMENT", 17, 46], ["the hepatitis B virus", "PROBLEM", 50, 71], ["a vaccine", "TREATMENT", 166, 175], ["hepatitis", "OBSERVATION", 54, 63]]], ["In 1968, a killed hepatitis B vaccine was developed and clinical trials began in 1975 proving the safety and efficacy of the vaccine.", [["hepatitis B", "DISEASE", 18, 29], ["hepatitis B", "ORGANISM", 18, 29], ["a killed hepatitis B vaccine", "TREATMENT", 9, 37], ["the vaccine", "TREATMENT", 121, 132]]], ["Merck and Pasteur Institute subsequently independently licensed the plasma-derived vaccine in 1981 (50).", [["plasma", "ANATOMY", 68, 74], ["plasma", "ORGANISM_SUBSTANCE", 68, 74]]], ["On July 23rd 1986, the recombinant hepatitis B vaccine (Recombivax HB) was licensed.", [["hepatitis B", "DISEASE", 35, 46], ["Recombivax HB", "CHEMICAL", 56, 69], ["recombinant", "ORGANISM", 23, 34], ["hepatitis B vaccine", "ORGANISM", 35, 54], ["Recombivax HB", "ORGANISM", 56, 69], ["the recombinant hepatitis B vaccine (Recombivax HB)", "TREATMENT", 19, 70]]], ["Using recombinant DNA technology, Merck scientists developed a hepatitis B surface antigen subunit vaccine.", [["hepatitis B surface antigen", "CHEMICAL", 63, 90], ["DNA", "CELLULAR_COMPONENT", 18, 21], ["hepatitis B surface antigen", "GENE_OR_GENE_PRODUCT", 63, 90], ["hepatitis B surface antigen subunit", "PROTEIN", 63, 98], ["a hepatitis B surface antigen subunit vaccine", "TREATMENT", 61, 106]]], ["Three years later, on August 28th 1989, the recombinant hepatitis B vaccine (Engerix-B) was licensed.", [["hepatitis B", "DISEASE", 56, 67], ["Engerix-B", "CHEMICAL", 77, 86], ["recombinant", "ORGANISM", 44, 55], ["hepatitis B vaccine", "ORGANISM", 56, 75], ["Engerix-B", "CELL", 77, 86], ["the recombinant hepatitis B vaccine (Engerix-B)", "TREATMENT", 40, 87]]], ["A decade later in 1999, the FDA approved a two-dose schedule of hepatitis B vaccination for adolescents 11\u201315 years of age using Recombivax HB (by Merck) with the 10-\u03bcg (adult) dose at 0 and 4\u20136 months later.", [["hepatitis B", "DISEASE", 64, 75], ["Recombivax HB", "CHEMICAL", 129, 142], ["hepatitis B", "ORGANISM", 64, 75], ["adolescents", "SPECIES", 92, 103], ["hepatitis B", "SPECIES", 64, 75], ["hepatitis B vaccination", "TREATMENT", 64, 87], ["Recombivax HB", "TREATMENT", 129, 142]]], ["At the beginning of the new millennium, in 2001, a combined hepatitis A inactivated and hepatitis B (recombinant) vaccine, Twinrix was licensed.", [["hepatitis A", "DISEASE", 60, 71], ["hepatitis B", "DISEASE", 88, 99], ["Twinrix", "CHEMICAL", 123, 130], ["hepatitis B", "ORGANISM", 88, 99], ["Twinrix", "SIMPLE_CHEMICAL", 123, 130], ["hepatitis A", "SPECIES", 60, 71], ["hepatitis B", "SPECIES", 88, 99], ["a combined hepatitis A", "TREATMENT", 49, 71], ["hepatitis B (recombinant) vaccine", "TREATMENT", 88, 121], ["hepatitis", "OBSERVATION", 60, 69]]], ["The following year, a vaccine combining diphtheria, tetanus, acellular pertussis, inactivated polio, and hepatitis B antigens (Pediarix) was licensed (26).", [["diphtheria", "DISEASE", 40, 50], ["tetanus", "DISEASE", 52, 59], ["acellular pertussis", "DISEASE", 61, 80], ["polio", "DISEASE", 94, 99], ["hepatitis B", "DISEASE", 105, 116], ["Pediarix", "CHEMICAL", 127, 135], ["diphtheria", "ORGANISM", 40, 50], ["acellular pertussis", "ORGANISM", 61, 80], ["hepatitis B antigens", "GENE_OR_GENE_PRODUCT", 105, 125], ["hepatitis B antigens", "PROTEIN", 105, 125], ["acellular pertussis", "SPECIES", 61, 80], ["hepatitis B", "SPECIES", 105, 116], ["a vaccine combining diphtheria", "TREATMENT", 20, 50], ["tetanus", "PROBLEM", 52, 59], ["acellular pertussis", "PROBLEM", 61, 80], ["inactivated polio", "PROBLEM", 82, 99], ["hepatitis B antigens", "TREATMENT", 105, 125]]], ["In conclusion, fortunately, both hepatitis A and B are now preventable due to the discovery of these highly effective vaccines that proved to maintain long-term immunity in vaccinated individuals (50).MID Twentieth and Twenty-First CenturyIn 1966, the World Health Assembly called for global smallpox eradication, which was launched the following year.", [["hepatitis A and B", "DISEASE", 33, 50], ["hepatitis A", "ORGANISM", 33, 44], ["B", "CANCER", 49, 50], ["hepatitis A", "SPECIES", 33, 44], ["these highly effective vaccines", "TREATMENT", 95, 126], ["global smallpox eradication", "TREATMENT", 285, 312], ["hepatitis", "OBSERVATION", 33, 42]]], ["During the first year of the program 217,218 cases of polio were reported in 31 countries that were endemic to smallpox.", [["polio", "DISEASE", 54, 59], ["smallpox", "DISEASE", 111, 119], ["polio", "PROBLEM", 54, 59]]], ["Four years later, the CDC recommended discontinuation of routine vaccination for smallpox in the U.S. following a greatly reduced risk of disease (26).MID Twentieth and Twenty-First CenturyDuring the 70s, especially in 1974, the Expanded Program on Immunization was created within WHO, in response to poor immunization levels in developing countries (<5% of children in 1974).", [["smallpox", "DISEASE", 81, 89], ["children", "ORGANISM", 358, 366], ["children", "SPECIES", 358, 366], ["routine vaccination", "TREATMENT", 57, 76], ["smallpox", "TREATMENT", 81, 89], ["disease", "PROBLEM", 138, 145], ["Immunization", "TREATMENT", 249, 261], ["poor immunization levels", "PROBLEM", 301, 325], ["disease", "OBSERVATION", 138, 145]]], ["The following vaccines were used by the Expanded Program on Immunization: BCG, Polio, DTP, measles (often MMR vaccine), yellow fever (in endemic countries), and hepatitis B. Three years later, in October 1977, the last case of naturally acquired smallpox occurred in the Merca District of Somalia.", [["DTP", "CHEMICAL", 86, 89], ["measles", "DISEASE", 91, 98], ["yellow fever", "DISEASE", 120, 132], ["hepatitis B.", "DISEASE", 161, 173], ["smallpox", "DISEASE", 246, 254], ["Polio", "ORGANISM", 79, 84], ["yellow fever", "ORGANISM", 120, 132], ["hepatitis B.", "SPECIES", 161, 173], ["The following vaccines", "TREATMENT", 0, 22], ["Immunization", "TREATMENT", 60, 72], ["BCG", "PROBLEM", 74, 77], ["Polio", "PROBLEM", 79, 84], ["DTP", "PROBLEM", 86, 89], ["measles", "PROBLEM", 91, 98], ["MMR vaccine", "TREATMENT", 106, 117], ["yellow fever", "PROBLEM", 120, 132], ["hepatitis B.", "PROBLEM", 161, 173], ["naturally acquired smallpox", "PROBLEM", 227, 254], ["smallpox", "OBSERVATION", 246, 254], ["Somalia", "ANATOMY", 289, 296]]], ["In the same year, the first pneumococcal vaccine was licensed, containing 14 serotypes (of the 83 known serological groups) that composed 80% of all bacteremic pneumococcal infections in the U.S. (26).MID Twentieth and Twenty-First CenturyOn May 8 1980, the World Health Assembly declared the world free of naturally occurring smallpox.", [["pneumococcal infections", "DISEASE", 160, 183], ["smallpox", "DISEASE", 327, 335], ["pneumococcal", "ORGANISM", 28, 40], ["pneumococcal", "SPECIES", 28, 40], ["pneumococcal", "SPECIES", 160, 172], ["the first pneumococcal vaccine", "TREATMENT", 18, 48], ["all bacteremic pneumococcal infections", "PROBLEM", 145, 183], ["bacteremic", "OBSERVATION_MODIFIER", 149, 159], ["pneumococcal", "OBSERVATION_MODIFIER", 160, 172], ["infections", "OBSERVATION", 173, 183]]], ["On the other hand, in July 1983, two enhanced pneumococcal polysaccharide vaccines (Pneumovax 23 and Pnu-imune 23) were certified.", [["pneumococcal", "SPECIES", 46, 58], ["two enhanced pneumococcal polysaccharide vaccines", "TREATMENT", 33, 82], ["Pneumovax", "TREATMENT", 84, 93], ["pneumococcal", "OBSERVATION_MODIFIER", 46, 58], ["polysaccharide vaccines", "OBSERVATION", 59, 82]]], ["These vaccines included 23 purified capsular polysaccharide antigens of Streptococcus pneumoniae and replaced the 14-valent polysaccharide vaccine licensed in 1977.", [["Streptococcus pneumoniae", "DISEASE", 72, 96], ["Streptococcus pneumoniae", "ORGANISM", 72, 96], ["Streptococcus pneumoniae", "SPECIES", 72, 96], ["Streptococcus pneumoniae", "SPECIES", 72, 96], ["These vaccines", "TREATMENT", 0, 14], ["23 purified capsular polysaccharide antigens", "TREATMENT", 24, 68], ["Streptococcus pneumoniae", "PROBLEM", 72, 96], ["the 14-valent polysaccharide vaccine", "TREATMENT", 110, 146], ["Streptococcus pneumoniae", "OBSERVATION", 72, 96]]], ["A few years later, in 1988, the World Health Assembly passed a resolution to eradicate polio by the year 2000 (26).", [["polio", "DISEASE", 87, 92]]], ["Later on, in 1992, the Japanese encephalitis (JE) inactivated virus vaccine (JE-Vax) was licensed.MID Twentieth and Twenty-First CenturyDuring the year 1994, The Expanded Program for Vaccine Development and the Vaccine Supply and Quality Program were merged creating the Global Program for Vaccines and Immunization.", [["encephalitis", "DISEASE", 32, 44], ["JE", "DISEASE", 46, 48], ["Japanese encephalitis", "ORGANISM", 23, 44], ["JE) inactivated virus", "ORGANISM", 46, 67], ["Japanese encephalitis (JE) inactivated virus", "SPECIES", 23, 67], ["the Japanese encephalitis (JE)", "TREATMENT", 19, 49], ["virus vaccine", "TREATMENT", 62, 75], ["JE-Vax)", "TREATMENT", 77, 84], ["Vaccine", "TREATMENT", 183, 190], ["the Vaccine Supply", "TREATMENT", 207, 225], ["Vaccines", "TREATMENT", 290, 298], ["Immunization", "TREATMENT", 303, 315]]], ["During the same year, the Western Hemisphere was finally labeled as \u201cpolio-free\u201d by the International Commission for the Certification of Polio-Eradication.MID Twentieth and Twenty-First CenturyThe 1996 was another monumental year with the launching of the International AIDS Vaccine Initiative (IAVI) that called for the speedy development of a human immunodeficiency virus (HIV) vaccine for use worldwide.", [["AIDS", "DISEASE", 271, 275], ["human immunodeficiency virus (HIV) vaccine", "DISEASE", 346, 388], ["human immunodeficiency virus", "ORGANISM", 346, 374], ["HIV", "ORGANISM", 376, 379], ["human immunodeficiency virus (HIV", "SPECIES", 346, 379], ["human immunodeficiency virus", "SPECIES", 346, 374], ["HIV", "SPECIES", 376, 379], ["Polio-Eradication", "TREATMENT", 138, 155], ["the International AIDS Vaccine", "TREATMENT", 253, 283], ["a human immunodeficiency virus (HIV) vaccine", "TREATMENT", 344, 388]]], ["This in turn led to the introduction of the Scientific Blueprint for AIDS Vaccine Development.", [["AIDS", "DISEASE", 69, 73], ["AIDS Vaccine", "TREATMENT", 69, 81]]], ["It is a Collaborating Center of the Joint United Nations Program on HIV/AIDS (UNAIDS) whose efforts led finally lead to the first possible vaccine against HIV (Aidsvax) which reached Phase III trials, the largest recorded human HIV vaccine trial at that time.", [["HIV/AIDS", "DISEASE", 68, 76], ["HIV", "ORGANISM", 155, 158], ["human", "ORGANISM", 222, 227], ["HIV", "SPECIES", 68, 71], ["HIV", "SPECIES", 155, 158], ["human", "SPECIES", 222, 227], ["HIV", "SPECIES", 68, 71], ["HIV", "SPECIES", 155, 158], ["human", "SPECIES", 222, 227], ["HIV", "SPECIES", 228, 231], ["HIV/AIDS", "TREATMENT", 68, 76], ["vaccine", "TREATMENT", 139, 146], ["HIV (Aidsvax", "TREATMENT", 155, 167], ["Phase III trials", "TREATMENT", 183, 199], ["human HIV vaccine trial", "TREATMENT", 222, 245], ["Joint", "ANATOMY", 36, 41]]], ["The trial involved 5400 volunteers from the U.S., Canada, and the Netherlands, the majority of whom were men who have sex with men (26).", [["volunteers", "ORGANISM", 24, 34], ["men", "ORGANISM", 105, 108], ["men", "ORGANISM", 127, 130], ["men", "SPECIES", 105, 108], ["men", "SPECIES", 127, 130]]], ["Preliminary results from the trial of AIDS VAX (VaxGen) vaccine were reported in early 2003.", [["AIDS", "DISEASE", 38, 42], ["VAX", "CHEMICAL", 43, 46], ["VaxGen", "CHEMICAL", 48, 54], ["VAX", "SIMPLE_CHEMICAL", 43, 46], ["VaxGen", "SIMPLE_CHEMICAL", 48, 54], ["AIDS VAX (VaxGen) vaccine", "TREATMENT", 38, 63]]], ["While the vaccine was shown to be protective amongst non-Caucasian populations, especially African-Americans, the same effect was not reproducible in Caucasians (26).MID Twentieth and Twenty-First CenturyDuring the same year, the Children\u2019s Vaccine Program was established at WHO\u2019s Program for Appropriate Technology in Health (PATH).", [["Children", "SPECIES", 230, 238], ["the vaccine", "TREATMENT", 6, 17]]], ["The program\u2019s goal was to provide vaccines to children in the developing world and to accelerate research and development of new vaccines.", [["children", "ORGANISM", 46, 54], ["children", "SPECIES", 46, 54], ["vaccines", "TREATMENT", 34, 42], ["new vaccines", "TREATMENT", 125, 137]]], ["The first vaccines purchased were Hib, Hepatitis B, Rotavirus, and Pneumococcal, which were not commonly used in the developing world (26).MID Twentieth and Twenty-First CenturyAt the beginning of the new millennium, the Western Pacific Region of the world was certified as polio-free.", [["Hepatitis B", "DISEASE", 39, 50], ["Rotavirus", "DISEASE", 52, 61], ["Hib", "ORGANISM", 34, 37], ["Hepatitis B", "ORGANISM", 39, 50], ["Rotavirus", "ORGANISM", 52, 61], ["Hepatitis B", "SPECIES", 39, 50], ["The first vaccines", "TREATMENT", 0, 18], ["Hib", "TREATMENT", 34, 37], ["Hepatitis B", "TREATMENT", 39, 50], ["Rotavirus", "TREATMENT", 52, 61], ["Pneumococcal", "TREATMENT", 67, 79]]], ["In 2006, the FDA licensed the first vaccine developed to prevent cervical cancer (Gardesil), precancerous genital lesions and genital warts due to human papillomavirus (HPV) types 6, 11, 16, and 18.", [["cervical cancer", "ANATOMY", 65, 80], ["precancerous genital lesions", "ANATOMY", 93, 121], ["genital warts", "ANATOMY", 126, 139], ["cervical cancer", "DISEASE", 65, 80], ["precancerous genital lesions", "DISEASE", 93, 121], ["genital warts", "DISEASE", 126, 139], ["human papillomavirus (HPV)", "DISEASE", 147, 173], ["cervical cancer", "CANCER", 65, 80], ["Gardesil", "CANCER", 82, 90], ["precancerous genital lesions", "PATHOLOGICAL_FORMATION", 93, 121], ["genital warts", "PATHOLOGICAL_FORMATION", 126, 139], ["human papillomavirus", "ORGANISM", 147, 167], ["HPV", "ORGANISM", 169, 172], ["human", "SPECIES", 147, 152], ["papillomavirus", "SPECIES", 153, 167], ["human papillomavirus", "SPECIES", 147, 167], ["HPV", "SPECIES", 169, 172], ["the first vaccine", "TREATMENT", 26, 43], ["cervical cancer (Gardesil)", "PROBLEM", 65, 91], ["precancerous genital lesions", "PROBLEM", 93, 121], ["genital warts", "PROBLEM", 126, 139], ["human papillomavirus", "PROBLEM", 147, 167], ["cervical", "ANATOMY", 65, 73], ["cancer", "OBSERVATION", 74, 80], ["precancerous", "OBSERVATION_MODIFIER", 93, 105], ["genital", "ANATOMY", 106, 113], ["lesions", "OBSERVATION", 114, 121], ["genital", "ANATOMY", 126, 133]]], ["The first smallpox vaccine for certain immune-compromised populations was delivered under Project BioShield on July 10th 2010.", [["The first smallpox vaccine", "TREATMENT", 0, 26], ["certain immune", "TREATMENT", 31, 45], ["compromised populations", "PROBLEM", 46, 69]]], ["The following year 2010, the WHO declared the \u201cDecade of Vaccines\u201d and in 2012, the United Nations Foundation launched Shot@Life campaign (26).Varicella Zoster: Herpes VirusVaricella (\u201cchickenpox\u201d) is caused by the varicella zoster virus (VZV).", [["Varicella Zoster", "DISEASE", 143, 159], ["Herpes VirusVaricella", "DISEASE", 161, 182], ["chickenpox", "DISEASE", 185, 195], ["varicella zoster", "DISEASE", 215, 231], ["VZV", "DISEASE", 239, 242], ["Varicella Zoster", "ORGANISM", 143, 159], ["Herpes VirusVaricella", "ORGANISM", 161, 182], ["varicella zoster virus", "ORGANISM", 215, 237], ["VZV", "ORGANISM", 239, 242], ["varicella zoster virus", "SPECIES", 215, 237], ["varicella zoster virus", "SPECIES", 215, 237], ["VZV", "SPECIES", 239, 242], ["Vaccines", "TREATMENT", 57, 65], ["Varicella Zoster", "PROBLEM", 143, 159], ["Herpes VirusVaricella", "PROBLEM", 161, 182], ["the varicella zoster virus", "PROBLEM", 211, 237], ["Zoster", "OBSERVATION", 153, 159], ["Herpes VirusVaricella", "OBSERVATION", 161, 182], ["varicella zoster", "OBSERVATION", 215, 231]]], ["Michiaki Takahashi, Professor of Virology at the Research Institute for Microbial Diseases at Osaka University, successfully produced the Oka vaccine strain of live, attenuated varicella vaccine in the 1970s.", [["Microbial Diseases", "DISEASE", 72, 90], ["varicella", "DISEASE", 177, 186], ["Microbial Diseases", "PROBLEM", 72, 90], ["attenuated varicella vaccine", "TREATMENT", 166, 194], ["varicella", "OBSERVATION", 177, 186]]], ["Takahashi was able to make this remarkable advance at a time when very few viruses had been attenuated to produce efficacious live-virus vaccines including yellow fever, polio, measles, mumps, and rubella as previously mentioned.", [["yellow fever", "DISEASE", 156, 168], ["polio", "DISEASE", 170, 175], ["measles, mumps, and rubella", "DISEASE", 177, 204], ["live-virus", "ORGANISM", 126, 136], ["yellow fever", "ORGANISM", 156, 168], ["mumps", "ORGANISM", 186, 191], ["yellow fever", "SPECIES", 156, 168], ["very few viruses", "PROBLEM", 66, 82], ["virus vaccines", "TREATMENT", 131, 145], ["yellow fever", "PROBLEM", 156, 168], ["polio", "PROBLEM", 170, 175], ["measles", "PROBLEM", 177, 184], ["mumps", "PROBLEM", 186, 191], ["rubella", "PROBLEM", 197, 204]]], ["The VZV vaccine is the first and only licensed live, attenuated herpesvirus vaccine in the world.", [["VZV", "ORGANISM", 4, 7], ["herpesvirus", "ORGANISM", 64, 75], ["VZV", "SPECIES", 4, 7], ["The VZV vaccine", "TREATMENT", 0, 15], ["attenuated herpesvirus vaccine", "TREATMENT", 53, 83], ["VZV", "OBSERVATION", 4, 7]]], ["Numerous trials in the early 1970s continued to prove the safety and efficacy of the vaccine in both healthy and immunocompromised, high-risk individuals.", [["the vaccine", "TREATMENT", 81, 92], ["immunocompromised", "PROBLEM", 113, 130]]], ["As a result of these successful trials, the live varicella virus vaccine (Varivax) was licensed in 1995 for the active immunization of persons 12 months of age and older (51).", [["varicella virus", "DISEASE", 49, 64], ["live", "ORGANISM", 44, 48], ["varicella virus", "ORGANISM", 49, 64], ["Varivax", "ORGANISM", 74, 81], ["persons", "ORGANISM", 135, 142], ["varicella virus vaccine", "SPECIES", 49, 72], ["persons", "SPECIES", 135, 142], ["varicella virus", "SPECIES", 49, 64], ["these successful trials", "TREATMENT", 15, 38], ["the live varicella virus vaccine", "TREATMENT", 40, 72]]], ["About 10 years later, in 2006, VariZIG, a new immune globulin product for post-exposure prophylaxis of varicella, became available under an Investigational New Drug Application Expanded Access Protocol (26).Varicella Zoster: Herpes VirusAs a herpesvirus, VZV possesses the unique ability to establish latent infection subsequent to primary infection.", [["VariZIG", "CHEMICAL", 31, 38], ["varicella", "DISEASE", 103, 112], ["Varicella Zoster", "DISEASE", 207, 223], ["Herpes VirusAs", "DISEASE", 225, 239], ["herpesvirus", "DISEASE", 242, 253], ["infection", "DISEASE", 308, 317], ["primary infection", "DISEASE", 332, 349], ["VariZIG", "SIMPLE_CHEMICAL", 31, 38], ["Varicella Zoster", "ORGANISM", 207, 223], ["Herpes VirusAs", "ORGANISM", 225, 239], ["herpesvirus", "ORGANISM", 242, 253], ["VZV", "ORGANISM", 255, 258], ["VZV", "SPECIES", 255, 258], ["a new immune globulin product", "TREATMENT", 40, 69], ["varicella", "PROBLEM", 103, 112], ["Varicella Zoster", "PROBLEM", 207, 223], ["Herpes VirusAs", "PROBLEM", 225, 239], ["a herpesvirus", "PROBLEM", 240, 253], ["VZV", "PROBLEM", 255, 258], ["latent infection", "PROBLEM", 301, 317], ["primary infection", "PROBLEM", 332, 349], ["varicella", "OBSERVATION", 103, 112], ["Zoster", "OBSERVATION", 217, 223], ["Herpes VirusAs", "OBSERVATION", 225, 239], ["latent", "OBSERVATION_MODIFIER", 301, 307], ["infection", "OBSERVATION", 308, 317], ["primary", "OBSERVATION_MODIFIER", 332, 339], ["infection", "OBSERVATION", 340, 349]]], ["Zoster results from reactivation of latent VZV that spreads through nerves to the skin.", [["nerves", "ANATOMY", 68, 74], ["skin", "ANATOMY", 82, 86], ["VZV", "ORGANISM", 43, 46], ["nerves", "MULTI-TISSUE_STRUCTURE", 68, 74], ["skin", "ORGAN", 82, 86], ["VZV", "SPECIES", 43, 46], ["Zoster", "PROBLEM", 0, 6], ["latent VZV", "PROBLEM", 36, 46], ["latent", "OBSERVATION_MODIFIER", 36, 42], ["VZV", "OBSERVATION", 43, 46], ["nerves", "ANATOMY", 68, 74], ["skin", "ANATOMY", 82, 86]]], ["Therefore, one fear associated with this vaccination was the possibility that it could increase the incidence and/or severity of zoster when compared to natural disease.", [["zoster", "DISEASE", 129, 135], ["zoster", "ORGANISM", 129, 135], ["this vaccination", "TREATMENT", 36, 52], ["zoster", "PROBLEM", 129, 135], ["natural disease", "PROBLEM", 153, 168], ["zoster", "OBSERVATION", 129, 135]]], ["Conversely, it was actually shown that following vaccination, zoster is less common than after natural infection (51).", [["zoster", "DISEASE", 62, 68], ["infection", "DISEASE", 103, 112], ["zoster", "ORGANISM", 62, 68], ["vaccination", "TREATMENT", 49, 60], ["zoster", "PROBLEM", 62, 68], ["natural infection", "PROBLEM", 95, 112], ["zoster", "OBSERVATION", 62, 68], ["less common", "OBSERVATION_MODIFIER", 72, 83], ["infection", "OBSERVATION", 103, 112]]], ["In 2006, the FDA licensed a new vaccine to reduce the risk of shingles in the elderly.", [["shingles", "DISEASE", 62, 70], ["a new vaccine", "TREATMENT", 26, 39], ["shingles", "PROBLEM", 62, 70], ["shingles", "OBSERVATION", 62, 70]]], ["The vaccine, Zostavax was approved for use in people aged 60 years of age and older (26).RotavirusRotavirus is the leading cause of severe diarrhea and vomiting (severe acute gastroenteritis) among young infants and children worldwide.", [["Zostavax", "CHEMICAL", 13, 21], ["RotavirusRotavirus", "CHEMICAL", 89, 107], ["diarrhea", "DISEASE", 139, 147], ["vomiting", "DISEASE", 152, 160], ["gastroenteritis", "DISEASE", 175, 190], ["Zostavax", "SIMPLE_CHEMICAL", 13, 21], ["people", "ORGANISM", 46, 52], ["infants", "ORGANISM", 204, 211], ["children", "ORGANISM", 216, 224], ["people", "SPECIES", 46, 52], ["infants", "SPECIES", 204, 211], ["children", "SPECIES", 216, 224], ["The vaccine", "TREATMENT", 0, 11], ["Zostavax", "TREATMENT", 13, 21], ["RotavirusRotavirus", "TREATMENT", 89, 107], ["severe diarrhea", "PROBLEM", 132, 147], ["vomiting (severe acute gastroenteritis", "PROBLEM", 152, 190], ["leading cause of", "UNCERTAINTY", 115, 131], ["severe", "OBSERVATION_MODIFIER", 132, 138], ["diarrhea", "OBSERVATION", 139, 147], ["severe", "OBSERVATION_MODIFIER", 162, 168], ["acute", "OBSERVATION_MODIFIER", 169, 174], ["gastroenteritis", "OBSERVATION", 175, 190]]], ["No significant difference was found in the incidence of rotavirus in industrialized and developing countries, suggesting that vaccination may be the only way to control the impact of this severe disease.", [["rotavirus", "DISEASE", 56, 65], ["rotavirus", "SPECIES", 56, 65], ["rotavirus", "PROBLEM", 56, 65], ["vaccination", "TREATMENT", 126, 137], ["this severe disease", "PROBLEM", 183, 202], ["significant", "OBSERVATION_MODIFIER", 3, 14], ["difference", "OBSERVATION", 15, 25], ["rotavirus", "OBSERVATION", 56, 65], ["severe", "OBSERVATION_MODIFIER", 188, 194], ["disease", "OBSERVATION", 195, 202]]], ["Dr. Ruth Bishop and colleagues were the first to describe rotavirus in humans in 1973.", [["rotavirus", "DISEASE", 58, 67], ["rotavirus", "ORGANISM", 58, 67], ["humans", "ORGANISM", 71, 77], ["humans", "SPECIES", 71, 77], ["humans", "SPECIES", 71, 77]]], ["It was clear, early on, that a naturally acquired first infection, whether symptomatic or asymptomatic, was the most effective defense against severe reinfection, and subsequent infections progressively created greater protection.", [["infection", "DISEASE", 56, 65], ["reinfection", "DISEASE", 150, 161], ["infections", "DISEASE", 178, 188], ["a naturally acquired first infection", "PROBLEM", 29, 65], ["asymptomatic", "PROBLEM", 90, 102], ["severe reinfection", "PROBLEM", 143, 161], ["subsequent infections", "PROBLEM", 167, 188], ["clear", "OBSERVATION", 7, 12], ["infection", "OBSERVATION", 56, 65], ["symptomatic", "OBSERVATION_MODIFIER", 75, 86], ["severe", "OBSERVATION_MODIFIER", 143, 149], ["reinfection", "OBSERVATION", 150, 161], ["infections", "OBSERVATION", 178, 188], ["greater", "OBSERVATION_MODIFIER", 211, 218], ["protection", "OBSERVATION_MODIFIER", 219, 229]]], ["Therefore, the goal was to create a vaccination that mimicked the effectiveness of naturally acquired immunity following infection.", [["infection", "DISEASE", 121, 130], ["a vaccination", "TREATMENT", 34, 47], ["infection", "PROBLEM", 121, 130], ["infection", "OBSERVATION", 121, 130]]], ["The development of live, attenuated, oral, safe, and effective rotavirus vaccines was then attempted starting in the mid-1970s.", [["oral", "ANATOMY", 37, 41], ["oral", "ORGANISM_SUBDIVISION", 37, 41], ["rotavirus", "ORGANISM", 63, 72], ["rotavirus", "SPECIES", 63, 72], ["oral, safe", "TREATMENT", 37, 47], ["effective rotavirus vaccines", "TREATMENT", 53, 81], ["attenuated", "OBSERVATION_MODIFIER", 25, 35]]], ["Dr. Albert Kapikian and colleagues, at the NIH, developed the RRV strain that was subsequently used to develop the RRV-TV, or the RotaShield, live oral, and tetravalent vaccine licensed in 1998 to be used in infants at 2, 4, and 6 months of age (26).", [["oral", "ANATOMY", 147, 151], ["RotaShield", "CHEMICAL", 130, 140], ["RRV", "ORGANISM", 62, 65], ["RRV", "ORGANISM", 115, 118], ["oral", "ORGANISM_SUBDIVISION", 147, 151], ["infants", "ORGANISM", 208, 215], ["infants", "SPECIES", 208, 215], ["RRV", "SPECIES", 62, 65], ["RRV", "SPECIES", 115, 118], ["the RRV strain", "PROBLEM", 58, 72], ["tetravalent vaccine", "TREATMENT", 157, 176], ["RRV strain", "OBSERVATION", 62, 72]]], ["However, due to several reported cases of vaccine-associated intestinal intussusception, RotaShield was pulled off the market in the U.S. 14 months after its introduction on the 16th of October, 1999.", [["intestinal", "ANATOMY", 61, 71], ["intestinal intussusception", "DISEASE", 61, 87], ["intestinal", "ORGAN", 61, 71], ["vaccine", "TREATMENT", 42, 49], ["intestinal intussusception", "PROBLEM", 61, 87], ["intestinal", "ANATOMY", 61, 71], ["intussusception", "OBSERVATION", 72, 87]]], ["In 2004, the National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH, awarded a new license agreement for RotaShield to BIOVIRx, Inc. of Minneapolis, MN, USA, which planned its global commercialization.", [["Allergy and Infectious Diseases", "DISEASE", 35, 66], ["Infectious", "OBSERVATION_MODIFIER", 47, 57]]], ["In 2011, history of intussusception was added as a contraindication for rotavirus vaccination (26).", [["intussusception", "DISEASE", 20, 35], ["rotavirus", "ORGANISM", 72, 81], ["rotavirus", "SPECIES", 72, 81], ["intussusception", "PROBLEM", 20, 35], ["rotavirus vaccination", "TREATMENT", 72, 93], ["intussusception", "OBSERVATION", 20, 35]]], ["Clark, Offit, and Plotkin then produced the RotaTeq vaccine by Merck based on their bovine strain WC3 in 1992, which was licensed in 2006 by the U.S. FDA.", [["bovine", "ORGANISM", 84, 90], ["bovine", "SPECIES", 84, 90], ["Plotkin", "TREATMENT", 18, 25], ["the RotaTeq vaccine", "TREATMENT", 40, 59]]], ["This vaccine, live oral and pentavalent, is destined for use in infants ages 6\u201332 weeks (26).", [["oral", "ANATOMY", 19, 23], ["pentavalent", "CHEMICAL", 28, 39], ["oral", "ORGANISM_SUBDIVISION", 19, 23], ["infants", "ORGANISM", 64, 71], ["infants", "SPECIES", 64, 71], ["This vaccine", "TREATMENT", 0, 12], ["pentavalent", "TREATMENT", 28, 39]]], ["Another vaccine, Rotarix, was also licensed in 2008.", [["Rotarix", "CHEMICAL", 17, 24], ["Rotarix", "SIMPLE_CHEMICAL", 17, 24], ["Another vaccine", "TREATMENT", 0, 15], ["Rotarix", "TREATMENT", 17, 24]]], ["It is a liquid given in a two-dose series to infants from 6 to 24 weeks of age.", [["infants", "ORGANISM", 45, 52], ["infants", "SPECIES", 45, 52]]], ["Before being licensed, both vaccines were shown to be safe and effective in rigorous clinical trials (52).Response to Emerging Diseases in the Twenty-First CenturyDuring the past two decades, improvements in environmental health have contributed tremendously to disease vector control.", [["both vaccines", "TREATMENT", 23, 36], ["Emerging Diseases", "PROBLEM", 118, 135], ["disease vector control", "TREATMENT", 262, 284], ["Diseases", "OBSERVATION", 127, 135]]], ["However, substantial challenges remain in dealing with the newly emerging diseases such as severe acute respiratory syndrome (SARS), H1N1, H7N9, and H5N1 influenza, middle east respiratory syndrome (MERS-CoV), rotavirus, Ebola virus, and a variety of other viral, bacterial, and protozoal diseases (53).Response to Emerging Diseases in the Twenty-First CenturyThe role of vaccines in the control and protection from the above mentioned emerging diseases cannot be overemphasized.", [["acute respiratory syndrome", "DISEASE", 98, 124], ["SARS", "DISEASE", 126, 130], ["H1N1", "DISEASE", 133, 137], ["H7N9", "DISEASE", 139, 143], ["H5N1 influenza", "DISEASE", 149, 163], ["middle east respiratory syndrome", "DISEASE", 165, 197], ["rotavirus, Ebola virus", "DISEASE", 210, 232], ["viral, bacterial, and protozoal diseases", "DISEASE", 257, 297], ["H5N1 influenza", "ORGANISM", 149, 163], ["middle east respiratory", "ORGANISM", 165, 188], ["MERS-CoV", "ORGANISM", 199, 207], ["rotavirus", "ORGANISM", 210, 219], ["Ebola virus", "ORGANISM", 221, 232], ["H5N1 influenza", "SPECIES", 149, 163], ["rotavirus", "SPECIES", 210, 219], ["Ebola virus", "SPECIES", 221, 232], ["H7N9", "SPECIES", 139, 143], ["MERS-CoV", "SPECIES", 199, 207], ["Ebola virus", "SPECIES", 221, 232], ["the newly emerging diseases", "PROBLEM", 55, 82], ["severe acute respiratory syndrome", "PROBLEM", 91, 124], ["SARS", "PROBLEM", 126, 130], ["H1N1", "PROBLEM", 133, 137], ["H7N9", "PROBLEM", 139, 143], ["H5N1 influenza", "PROBLEM", 149, 163], ["middle east respiratory syndrome", "PROBLEM", 165, 197], ["rotavirus", "PROBLEM", 210, 219], ["Ebola virus", "PROBLEM", 221, 232], ["other viral, bacterial, and protozoal diseases", "PROBLEM", 251, 297], ["Emerging Diseases", "PROBLEM", 315, 332], ["vaccines", "TREATMENT", 372, 380], ["protection", "TREATMENT", 400, 410], ["emerging diseases", "PROBLEM", 436, 453], ["substantial", "OBSERVATION_MODIFIER", 9, 20], ["severe", "OBSERVATION_MODIFIER", 91, 97], ["acute", "OBSERVATION_MODIFIER", 98, 103], ["respiratory syndrome", "OBSERVATION", 104, 124], ["middle", "ANATOMY_MODIFIER", 165, 171], ["respiratory syndrome", "OBSERVATION", 177, 197], ["Ebola virus", "OBSERVATION", 221, 232], ["viral", "OBSERVATION", 257, 262], ["bacterial", "OBSERVATION_MODIFIER", 264, 273], ["protozoal diseases", "OBSERVATION", 279, 297], ["Diseases", "OBSERVATION", 324, 332], ["diseases", "OBSERVATION", 445, 453]]], ["Actually, the importance of inducing protective immunity through vaccination came out to be the most powerful tool and effective strategy to prevent the spread of emerging viruses among populations, in particular, among people that are immunologically na\u00efve and susceptible hosts.", [["people", "ORGANISM", 220, 226], ["people", "SPECIES", 220, 226], ["inducing protective immunity through vaccination", "TREATMENT", 28, 76]]], ["Such emerging diseases represent a major public health concern; they affect livestock and humans thus threatening the world\u2019s economy and public health.", [["humans", "ORGANISM", 90, 96], ["humans", "SPECIES", 90, 96], ["humans", "SPECIES", 90, 96], ["Such emerging diseases", "PROBLEM", 0, 22]]], ["Vaccine strategies for emerging pathologies are limited by sudden appearance of the pathogen and the delayed time consuming traditional vaccine development process.", [["Vaccine strategies", "TREATMENT", 0, 18], ["emerging pathologies", "PROBLEM", 23, 43], ["the pathogen", "PROBLEM", 80, 92], ["traditional vaccine development process", "TREATMENT", 124, 163]]], ["Novel methods to rapidly develop vaccine are being experimented, whereby investigators are working to achieve a better understanding of the nature of the interactions between the immune system and a panel of novel harmful microbes.", [["immune system", "ANATOMY", 179, 192], ["vaccine", "TREATMENT", 33, 40], ["a panel", "TEST", 197, 204]]], ["Such strategies included the use of (1) recombinant proteins, or nanoparticles like in SARS-CoV and MERS-CoV, (2) synthetic peptides like the case of influenza virus, (3) virus-like particles, (4) multimeric presentation of viral antigens like the case of Hepatitis, (5) replication of competent viral vectors like in the Rift Valley Fever virus or the EBOLA viruses, (6) recombinant bacteria for Listeria and Salmonella among others, and (7) nucleic acid vaccines for EBOLA or Dengue or Rift Valley Fever viruses (54).Response to Emerging Diseases in the Twenty-First CenturyIn managing or even in preventing the emergence of new infectious diseases, a plan should be developed to strengthen surveillance and promote a multi-partners response within local, national, and global programs.Response to Emerging Diseases in the Twenty-First CenturyWith the high burden of emerging infectious diseases (EID) it becomes an essential part to find an effective method of either preventing or controlling their spread, that is where the role of vaccines prevails.", [["influenza virus", "DISEASE", 150, 165], ["Hepatitis", "DISEASE", 256, 265], ["Fever", "DISEASE", 334, 339], ["Listeria", "CHEMICAL", 397, 405], ["nucleic acid", "CHEMICAL", 443, 455], ["EBOLA", "CHEMICAL", 469, 474], ["Dengue", "DISEASE", 478, 484], ["Rift Valley Fever", "DISEASE", 488, 505], ["infectious diseases", "DISEASE", 631, 650], ["infectious diseases", "DISEASE", 878, 897], ["EID", "DISEASE", 899, 902], ["SARS-CoV", "ORGANISM", 87, 95], ["MERS-CoV", "ORGANISM", 100, 108], ["influenza virus", "ORGANISM", 150, 165], ["Rift Valley Fever virus", "ORGANISM", 322, 345], ["EBOLA viruses", "ORGANISM", 353, 366], ["nucleic acid", "SIMPLE_CHEMICAL", 443, 455], ["Dengue", "ORGANISM", 478, 484], ["Rift Valley Fever viruses", "ORGANISM", 488, 513], ["recombinant proteins", "PROTEIN", 40, 60], ["viral antigens", "PROTEIN", 224, 238], ["influenza virus", "SPECIES", 150, 165], ["Rift Valley Fever virus", "SPECIES", 322, 345], ["SARS-CoV", "SPECIES", 87, 95], ["MERS-CoV", "SPECIES", 100, 108], ["influenza virus", "SPECIES", 150, 165], ["Rift Valley Fever virus", "SPECIES", 322, 345], ["EBOLA viruses", "SPECIES", 353, 366], ["Salmonella", "SPECIES", 410, 420], ["Rift Valley Fever viruses", "SPECIES", 488, 513], ["1) recombinant proteins", "TREATMENT", 37, 60], ["nanoparticles", "TREATMENT", 65, 78], ["SARS", "PROBLEM", 87, 91], ["synthetic peptides", "TREATMENT", 114, 132], ["influenza virus", "PROBLEM", 150, 165], ["virus-like particles", "PROBLEM", 171, 191], ["viral antigens", "PROBLEM", 224, 238], ["Hepatitis", "PROBLEM", 256, 265], ["competent viral vectors", "PROBLEM", 286, 309], ["the Rift Valley Fever virus", "PROBLEM", 318, 345], ["the EBOLA viruses", "PROBLEM", 349, 366], ["recombinant bacteria", "PROBLEM", 372, 392], ["Listeria", "PROBLEM", 397, 405], ["Salmonella", "PROBLEM", 410, 420], ["nucleic acid vaccines", "TREATMENT", 443, 464], ["EBOLA", "PROBLEM", 469, 474], ["Dengue", "PROBLEM", 478, 484], ["Rift Valley Fever viruses", "PROBLEM", 488, 513], ["Emerging Diseases", "PROBLEM", 531, 548], ["new infectious diseases", "PROBLEM", 627, 650], ["Emerging Diseases", "PROBLEM", 800, 817], ["emerging infectious diseases", "PROBLEM", 869, 897], ["vaccines", "TREATMENT", 1037, 1045], ["influenza virus", "OBSERVATION", 150, 165], ["viral antigens", "OBSERVATION", 224, 238], ["Hepatitis", "OBSERVATION", 256, 265], ["viral vectors", "OBSERVATION", 296, 309], ["EBOLA viruses", "OBSERVATION", 353, 366], ["Diseases", "OBSERVATION", 540, 548], ["new", "OBSERVATION_MODIFIER", 627, 630], ["infectious", "OBSERVATION", 631, 641], ["Diseases", "OBSERVATION", 809, 817], ["high", "OBSERVATION_MODIFIER", 854, 858], ["burden", "OBSERVATION_MODIFIER", 859, 865], ["infectious", "OBSERVATION", 878, 888]]], ["It is significant to mention that the average case fatality rate for Ebola is around 50% and outbreaks are affecting both developed and developing countries.", [["Ebola", "DISEASE", 69, 74], ["Ebola", "ORGANISM", 69, 74], ["Ebola", "PROBLEM", 69, 74], ["outbreaks", "PROBLEM", 93, 102], ["significant", "OBSERVATION_MODIFIER", 6, 17]]], ["Another emerging disease, MERS-CoV, has caused the death of around 36% of people reported to have contracted the disease.", [["death", "DISEASE", 51, 56], ["MERS-CoV", "ORGANISM", 26, 34], ["people", "ORGANISM", 74, 80], ["people", "SPECIES", 74, 80], ["MERS-CoV", "SPECIES", 26, 34], ["Another emerging disease", "PROBLEM", 0, 24], ["the death", "PROBLEM", 47, 56], ["the disease", "PROBLEM", 109, 120], ["disease", "OBSERVATION", 17, 24], ["disease", "OBSERVATION", 113, 120]]], ["Another disease with high health and economic burden would be rotavirus which was estimated to have annual direct and indirect costs of around $1 billion with \u201cmore than 400,000 physician visits, more than 200,000 emergency department (ED) visits, 55,000 to 70,000 hospitalizations, and 20 to 60 deaths each year in children younger than 5 years\u201d (CDC, 2015).", [["deaths", "DISEASE", 296, 302], ["rotavirus", "ORGANISM", 62, 71], ["children", "ORGANISM", 316, 324], ["children", "SPECIES", 316, 324], ["rotavirus", "SPECIES", 62, 71], ["Another disease", "PROBLEM", 0, 15], ["high health", "PROBLEM", 21, 32], ["economic burden", "PROBLEM", 37, 52], ["rotavirus", "PROBLEM", 62, 71], ["disease", "OBSERVATION", 8, 15], ["high", "OBSERVATION_MODIFIER", 21, 25]]], ["These are few of the facts regarding the affliction of EID most of which have no approved vaccine yet.", [["few", "OBSERVATION_MODIFIER", 10, 13]]], ["On the other hand, the influenza virus which was estimated to cause an average of 23,607 deaths annually with a $12 billion cost of an epidemic, showed that with the introduction of its vaccine, studies proved it to be 80% effective in preventing death (55).", [["deaths", "DISEASE", 89, 95], ["death", "DISEASE", 247, 252], ["influenza virus", "ORGANISM", 23, 38], ["influenza virus", "SPECIES", 23, 38], ["the influenza virus", "PROBLEM", 19, 38], ["its vaccine", "TREATMENT", 182, 193], ["studies", "TEST", 195, 202], ["influenza virus", "OBSERVATION", 23, 38]]], ["These figures have managed to influence many governmental and non-profit organizations to intervene either through governmental funding of vaccines where the congress provides yearly international EID funding to several U.S. governmental agencies or through international non-profit organizations which are the leaders in global health innovation (56).Disease Burden: Different Influential AspectsVaccines remain among the most reliable and effective medical interventions in providing the means to fight debilitating and preventable diseases thus ensuring the continuity of mankind and saving lives.", [["vaccines", "TREATMENT", 139, 147], ["Disease Burden", "PROBLEM", 352, 366], ["effective medical interventions", "TREATMENT", 441, 472], ["preventable diseases", "PROBLEM", 522, 542]]], ["Through reviewing the factsheets provided by the World Health Organization, which provide statistical data on the mortality and morbidity percentages before and after the introduction of the vaccines, one can comprehend the vital role vaccines have played up till this day.", [["the vaccines", "TREATMENT", 187, 199]]], ["Some of the figures that depict the impact of vaccines in decreasing mortality and morbidity include more than 99% decrease in Polio cases since 1988, with cases reaching 350,000 from over 125 endemic countries down to 359 cases as reported in 2014 with only 2 endemic countries, measles vaccine has prevented the death of around 15.6 million children during 2000\u20132013, in general vaccines prevent around 6 million deaths annually worldwide (57).", [["death", "DISEASE", 314, 319], ["deaths", "DISEASE", 415, 421], ["children", "ORGANISM", 343, 351], ["children", "SPECIES", 343, 351], ["vaccines", "TREATMENT", 46, 54], ["decreasing mortality", "PROBLEM", 58, 78], ["morbidity", "PROBLEM", 83, 92], ["measles vaccine", "TREATMENT", 280, 295], ["general vaccines", "TREATMENT", 373, 389]]], ["Vaccination programs require excessive funding to ensure proper handling and maintenance of vaccines, adequate staffing and ongoing provision over efficacy and safety of vaccines and the development of newer vaccines (58).", [["Vaccination programs", "TREATMENT", 0, 20], ["excessive funding", "TREATMENT", 29, 46], ["maintenance of vaccines", "TREATMENT", 77, 100], ["safety of vaccines", "TREATMENT", 160, 178], ["newer vaccines", "TREATMENT", 202, 216]]], ["Nevertheless, the economic and social burden related to the expenses in hospitalizing affected unvaccinated people still outweighs the aforementioned burden.", [["people", "ORGANISM", 108, 114], ["people", "SPECIES", 108, 114], ["the economic and social burden", "PROBLEM", 14, 44], ["economic", "OBSERVATION_MODIFIER", 18, 26]]], ["Moreover, better health in the society would promote economic growth and productivity.", [["economic", "OBSERVATION_MODIFIER", 53, 61], ["growth", "OBSERVATION_MODIFIER", 62, 68]]], ["Consequently, public awareness and public efforts agree on the importance of vaccination and the implementation of policies regarding mandatory vaccinations as a way to decrease outbreaks of preventable diseases and improve global health and prosperity.Turning Point: Vaccine ControversiesAs early as the introduction of vaccines, campaigns against vaccination were raging.", [["vaccination", "TREATMENT", 77, 88], ["mandatory vaccinations", "TREATMENT", 134, 156], ["preventable diseases", "PROBLEM", 191, 211], ["Vaccine", "TREATMENT", 268, 275], ["the introduction of vaccines", "TREATMENT", 301, 329], ["vaccination", "TREATMENT", 349, 360]]], ["As with any new medical intervention there are safety concerns that arise which might be deleterious to the public health.", [["any new medical intervention", "TREATMENT", 8, 36]]], ["Concerns regarding vaccines often follow a path that starts with the hypothesis of a potential adverse event that is impulsively announced to the public without having reproducible studies to confirm this hypothesis, and thus it would take the public several years to regain trust in the vaccine.", [["vaccines", "TREATMENT", 19, 27], ["a potential adverse event", "PROBLEM", 83, 108], ["reproducible studies", "TEST", 168, 188], ["this hypothesis", "PROBLEM", 200, 215], ["the vaccine", "TREATMENT", 284, 295]]], ["A notable example in the recent history would be of the paper published by Andrew Wakefield in the British medical journal the Lancet in 1998, linking the MMR vaccine to autism.", [["autism", "DISEASE", 170, 176], ["the MMR vaccine", "TREATMENT", 151, 166], ["notable", "OBSERVATION_MODIFIER", 2, 9]]], ["However, his research was discredited and the paper was retracted from the journal after it was proven that actually there is no link between MMR vaccine and autism as per the systemic review by the Cochrane library (59).", [["autism", "DISEASE", 158, 164], ["MMR vaccine", "TREATMENT", 142, 153], ["no link", "UNCERTAINTY", 126, 133]]], ["The battle against vaccines did not reach a halt, and there are still ongoing campaigns that come from religious, political, community-based, and even individual-based grounds raising even ethical issues regarding the mandatory vaccinations proposed by the government.", [["vaccines", "TREATMENT", 19, 27], ["ethical issues", "PROBLEM", 189, 203], ["the mandatory vaccinations", "TREATMENT", 214, 240]]], ["According to the CDC, this year 95% of the children were vaccinated in the U.S., leaving 5% unvaccinated due to religious and philosophical exemptions or even parental refusal due to the fear of vaccine\u2019s side effects and concerns regarding autism from vaccines (60); this is still a critical number since the unvaccinated would pose risk of outbreaks even among the immunized, which necessitates the need for additional awareness campaigns regarding the importance of vaccination since vaccines remain the only plausible measure of protection against preventable diseases.", [["autism", "DISEASE", 241, 247], ["children", "ORGANISM", 43, 51], ["children", "SPECIES", 43, 51], ["vaccine", "TREATMENT", 195, 202], ["side effects", "PROBLEM", 205, 217], ["autism from vaccines", "TREATMENT", 241, 261], ["outbreaks", "PROBLEM", 342, 351], ["additional awareness campaigns", "TREATMENT", 410, 440], ["vaccination", "TREATMENT", 469, 480], ["vaccines", "TREATMENT", 487, 495], ["preventable diseases", "PROBLEM", 552, 572]]], ["Actually, a trend was reported in the health news lately, in the U.S., that pediatricians refuse to offer medical care for children whose parents declined their vaccination.ConclusionVaccination has been of great importance throughout centuries (Tables 1 and 2).", [["children", "ORGANISM", 123, 131], ["children", "SPECIES", 123, 131], ["medical care", "TREATMENT", 106, 118]]], ["People started with inoculation techniques dating back to 1000 A.D. with the Chinese, Turks, and Asians.", [["People", "ORGANISM", 0, 6], ["People", "SPECIES", 0, 6], ["inoculation techniques", "TREATMENT", 20, 42]]], ["With every century and with every curious physician, inoculation techniques improved gradually giving rise to newer vaccination techniques with Edward Jenner and later on, Louis Pasteur and others.", [["newer vaccination techniques", "TREATMENT", 110, 138]]], ["However, there is still plenty of room for improvement with the presence of ongoing epidemics and the spread of newly emerging diseases.", [["ongoing epidemics", "PROBLEM", 76, 93], ["newly emerging diseases", "PROBLEM", 112, 135]]], ["One important goal is to strengthen the science base for vaccine development and for public health action and disease prevention.", [["vaccine development", "TREATMENT", 57, 76], ["public health action", "TREATMENT", 85, 105], ["disease prevention", "TREATMENT", 110, 128]]], ["Despite the common belief that infectious diseases were virtually eliminated by the middle of the twentieth century, new and reemerging infections are appearing along with drug resistant infections in the past two decades in the various parts of the world and whose incidence threatens to increase in the near future, due to changes in human demographics and behavior, immigration, and speed of international travel among other things (61\u201363).", [["infectious diseases", "DISEASE", 31, 50], ["infections", "DISEASE", 136, 146], ["infections", "DISEASE", 187, 197], ["human", "ORGANISM", 336, 341], ["human", "SPECIES", 336, 341], ["human", "SPECIES", 336, 341], ["infectious diseases", "PROBLEM", 31, 50], ["reemerging infections", "PROBLEM", 125, 146], ["drug resistant infections", "PROBLEM", 172, 197], ["infectious", "OBSERVATION", 31, 41], ["middle", "ANATOMY_MODIFIER", 84, 90], ["new", "OBSERVATION_MODIFIER", 117, 120], ["infections", "OBSERVATION", 136, 146], ["resistant", "OBSERVATION_MODIFIER", 177, 186], ["infections", "OBSERVATION", 187, 197], ["increase", "OBSERVATION_MODIFIER", 289, 297]]], ["The importance of vaccine safety continued to grow throughout the twenty-first century, with the development and licensure of new vaccines added to the already robust immunization armamentarium.", [["vaccine safety", "TREATMENT", 18, 32], ["new vaccines", "TREATMENT", 126, 138], ["the already robust immunization armamentarium", "TREATMENT", 148, 193]]], ["Scientists also perfected new ways of administering immunizations including edible vaccines and needleless injections.", [["administering immunizations", "TREATMENT", 38, 65], ["edible vaccines", "TREATMENT", 76, 91], ["needleless injections", "TREATMENT", 96, 117]]], ["However, formulated or delivered, vaccines will remain the most effective tool we possess for preventing disease and improving public health in the future.", [["vaccines", "TREATMENT", 34, 42], ["disease", "PROBLEM", 105, 112]]], ["Despite the anti-vaccination campaign and the association of vaccines with some side effects, vaccines continue to remain a cornerstone in global health.ConclusionThe distinctions between national and international health problems are losing ground and could be misleading, the \u201cworld is a village.\u201d", [["the anti-vaccination campaign", "TREATMENT", 8, 37], ["vaccines", "TREATMENT", 61, 69], ["some side effects", "PROBLEM", 75, 92], ["vaccines", "TREATMENT", 94, 102]]], ["Actually, good examples of the necessity of such collaboration is the emergence of SARS-CoV and MERS-CoV, it shows clearly how coronaviruses can spillover from animals into humans at any time, causing lethal diseases.", [["SARS", "DISEASE", 83, 87], ["SARS-CoV", "ORGANISM", 83, 91], ["MERS-CoV", "ORGANISM", 96, 104], ["coronaviruses", "ORGANISM", 127, 140], ["humans", "ORGANISM", 173, 179], ["humans", "SPECIES", 173, 179], ["SARS-CoV", "SPECIES", 83, 91], ["MERS-CoV", "SPECIES", 96, 104], ["humans", "SPECIES", 173, 179], ["SARS", "PROBLEM", 83, 87], ["lethal diseases", "PROBLEM", 201, 216], ["lethal diseases", "OBSERVATION", 201, 216]]], ["Foodborne diseases could lead to regional and international outbreaks which might constitute a threat to national and global security.Author ContributionsIH is the first author.", [["Foodborne diseases", "DISEASE", 0, 18], ["Foodborne diseases", "PROBLEM", 0, 18], ["regional and international outbreaks", "PROBLEM", 33, 69]]], ["NC and SC did the literature search for the eighteenth and nineteenth century and the respective preliminary writing about this period.", [["NC", "TREATMENT", 0, 2]]], ["SS and RB did the literature search for the twenty-first century, and about general aspects of vaccination and the respective preliminary writing about this period.", [["vaccination", "TREATMENT", 95, 106]]], ["MR did the literature search regarding vaccine efficacy and effectiveness in the context of the transnational research map and regarding vaccination instruments and inoculating techniques.", [["MR", "PROTEIN", 0, 2], ["MR", "TEST", 0, 2], ["vaccine efficacy", "TREATMENT", 39, 55], ["vaccination instruments", "TREATMENT", 137, 160], ["inoculating techniques", "TREATMENT", 165, 187]]], ["AG did the literature search and the preliminary writing for the early history of vaccination and wrote a draft of a manuscript about this period.", [["vaccination", "TREATMENT", 82, 93]]]], "639c6af66be023c0c687e1d4858899fd30aa3ce9": [["Evidence-based DHIHollis and colleagues [1] summarized 21 former meta-analyses and reviews from the beginning of the development of DHI in the 1990s until the end of 2015 in their meta-review and additionally updated a systematic review analysing 30 randomized controlled trials (RCT) using DHI.", [["DHI", "PROBLEM", 291, 294], ["DHIHollis", "OBSERVATION", 15, 24]]], ["Their review represents an outstanding comprehensive approach and has recently been complemented by a systematic literature search of our own work group [2] , strictly following the criteria established in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement.Evidence-based DHIThe work by Hollis and colleagues and our own search revealed that most robust evidence exists for interventions for anxiety disorders and mild to moderate depression (especially computerized cognitive behavioural therapy (cCBT) approaches).Evidence-based DHIRCT for ADHD in children and adolescents revealed rather heterogeneous results which might be explained by their highly heterogeneous approaches.", [["anxiety disorders", "DISEASE", 431, 448], ["depression", "DISEASE", 470, 480], ["ADHD", "DISEASE", 581, 585], ["children", "ORGANISM", 589, 597], ["children", "SPECIES", 589, 597], ["adolescents", "SPECIES", 602, 613], ["anxiety disorders", "PROBLEM", 431, 448], ["mild to moderate depression", "PROBLEM", 453, 480], ["computerized cognitive behavioural therapy", "TREATMENT", 493, 535], ["ADHD", "PROBLEM", 581, 585], ["mild", "OBSERVATION_MODIFIER", 453, 457], ["moderate", "OBSERVATION_MODIFIER", 461, 469], ["depression", "OBSERVATION", 470, 480], ["heterogeneous", "OBSERVATION_MODIFIER", 630, 643], ["might be explained", "UNCERTAINTY", 658, 676], ["highly", "OBSERVATION_MODIFIER", 686, 692], ["heterogeneous", "OBSERVATION", 693, 706]]], ["The studies ranged from neurofeedback trainings to executive functioning trainings and interventions targeting everyday organization and planning skills.", [["The studies", "TEST", 0, 11], ["neurofeedback trainings", "TREATMENT", 24, 47], ["executive functioning trainings", "TREATMENT", 51, 82], ["interventions", "TREATMENT", 87, 100]]], ["They show comparable (inconsistent) effects to nonpharmacological face-to-face therapy [1, 2] .Evidence-based DHIIncreasing evidence emerges for DHI targeting autism spectrum disorders which include DHI for children from preschool age to adolescence and their parents [1, 2] .", [["autism spectrum disorders", "DISEASE", 159, 184], ["children", "ORGANISM", 207, 215], ["children", "SPECIES", 207, 215], ["nonpharmacological face", "TREATMENT", 47, 70], ["DHI targeting autism spectrum disorders", "PROBLEM", 145, 184]]], ["DHI for children and adolescents with ASD involve parents more frequently than DHI for other diagnoses.Evidence-based DHIStudies investigating DHI for other diagnoses such as eating disorders, psychosis, obsessive compulsive disorders, dyslexia, coordination disorders, conduct disorders with disruptive behaviour, tic disorders, insomnia or trichotillomania in children and adolescents are rather scarce.", [["ASD", "DISEASE", 38, 41], ["eating disorders", "DISEASE", 175, 191], ["psychosis", "DISEASE", 193, 202], ["obsessive compulsive disorders", "DISEASE", 204, 234], ["dyslexia", "DISEASE", 236, 244], ["coordination disorders", "DISEASE", 246, 268], ["conduct disorders", "DISEASE", 270, 287], ["disruptive behaviour", "DISEASE", 293, 313], ["tic disorders", "DISEASE", 315, 328], ["insomnia", "DISEASE", 330, 338], ["trichotillomania", "DISEASE", 342, 358], ["children", "ORGANISM", 8, 16], ["children", "ORGANISM", 362, 370], ["children", "SPECIES", 8, 16], ["adolescents", "SPECIES", 21, 32], ["children", "SPECIES", 362, 370], ["adolescents", "SPECIES", 375, 386], ["eating disorders", "PROBLEM", 175, 191], ["psychosis", "PROBLEM", 193, 202], ["obsessive compulsive disorders", "PROBLEM", 204, 234], ["dyslexia", "PROBLEM", 236, 244], ["coordination disorders", "PROBLEM", 246, 268], ["conduct disorders", "PROBLEM", 270, 287], ["disruptive behaviour", "PROBLEM", 293, 313], ["tic disorders", "PROBLEM", 315, 328], ["insomnia", "PROBLEM", 330, 338], ["trichotillomania", "PROBLEM", 342, 358]]], ["But the few available studies show promising results, though more high-quality studies are needed for a profound evaluation of DHI for those disorders.Evidence-based DHILooking at the technical aspects, most studies use personal computers, which offer the broadest range of applications, ranging from psychoeducation in serious games or in video or written modules over training of cognitive functions to video sessions [1, 2] .", [["a profound evaluation", "TEST", 102, 123], ["DHI", "PROBLEM", 127, 130], ["those disorders", "PROBLEM", 135, 150], ["based DHILooking at the technical aspects", "PROBLEM", 160, 201]]], ["Smartphone usage is on the rise, allowing ambulatory assessment of mood or experience in everyday life [1, 2] .", [["ambulatory assessment", "TEST", 42, 63]]], ["Tablets are mainly used for trainings to improve attention or social and communicative skills via apps [1, 2] .Evidence-based DHIMost published DHI studies were conducted in the Western Hemisphere and Asia, with only few studies from South American and African countries [2] .", [["Tablets", "TREATMENT", 0, 7], ["DHI studies", "TEST", 144, 155]]], ["Due to the advantages of DHI in providing treatment over extensive distances and an increasingly evolving IT-infrastructure for example in African countries, more use of DHI can be expected worldwide.Practical aspects in using DHIImplementing DHI in clinical practice requires careful consideration of a variety of prerequisites and precautions [3] .", [["DHI", "PROBLEM", 25, 28], ["treatment", "TREATMENT", 42, 51], ["DHI", "TREATMENT", 170, 173]]], ["Table 1 gives an overview of practical prerequisites, ranging from personal aspects over data security and regional legal frameworks to the relevance of instable therapeutic situations including suicidality.", [["suicidality", "DISEASE", 195, 206], ["suicidality", "PROBLEM", 195, 206]]], ["DHI provide unique benefits, as proven during the SARS-CoV2-19 lock-down, but also bring potential pitfalls.", [["SARS", "DISEASE", 50, 54], ["the SARS", "TEST", 46, 54], ["CoV2", "TEST", 55, 59]]], ["Table 2 gives an overview on aspects regarding accessibility, the implementation of interventions itself, the evidence regarding interventions as well as economic aspects [4] .Practical aspects in using DHIIn summary, DHI are promising therapeutic interventions for children and adolescents with psychiatric disorders, with already robust data regarding depression and anxiety disorders.", [["psychiatric disorders", "DISEASE", 296, 317], ["depression", "DISEASE", 354, 364], ["anxiety disorders", "DISEASE", 369, 386], ["children", "ORGANISM", 266, 274], ["children", "SPECIES", 266, 274], ["adolescents", "SPECIES", 279, 290], ["interventions", "TREATMENT", 84, 97], ["interventions", "TREATMENT", 129, 142], ["therapeutic interventions", "TREATMENT", 236, 261], ["psychiatric disorders", "PROBLEM", 296, 317], ["depression", "PROBLEM", 354, 364], ["anxiety disorders", "PROBLEM", 369, 386]]], ["SARS-CoV2-19 catalyses the integration of DHI into the standard repertoire of child and adolescent psychiatry and psychotherapy.", [["SARS", "DISEASE", 0, 4], ["SARS-CoV2-19", "DNA", 0, 12], ["psychotherapy", "TREATMENT", 114, 127]]], ["Nevertheless, for using DHI in daily therapeutic work there are still challenges to overcome, ranging from technical aspects, e.g. general availability of the technical prerequisites, to the most demanding therapeutic tasks like the stabilisation of patients in acute crises.", [["patients", "ORGANISM", 250, 258], ["patients", "SPECIES", 250, 258], ["DHI", "TREATMENT", 24, 27], ["acute crises", "PROBLEM", 262, 274], ["acute", "OBSERVATION_MODIFIER", 262, 267], ["crises", "OBSERVATION", 268, 274]]], ["Blended treatment formats using a combination of traditional face-to-face sessions with e.g. intermittent video conferences might be the silver bullet in integrating DHI and taking advantage of their strengths.Practical aspects in using DHIFortunately, at least one partner in therapy, the children and adolescents, are often accustomed to and sometimes highly trained in digitally delivered communication.", [["silver", "CHEMICAL", 137, 143], ["children", "ORGANISM", 290, 298], ["children", "SPECIES", 290, 298], ["adolescents", "SPECIES", 303, 314], ["traditional face", "TREATMENT", 49, 65]]], ["So, it Increase of the frequency of synchronous communication e.g. via video conferencing as a tool to deliver support during vulnerable episodes At least one parent has to be present in the house during video therapy sessions Therapist needs patient's/parents' contact information at hand to be able to initiate emergency services when needed Cooperation with local professionals (paediatrician, psychiatrists) for emergency support is up to us to use our profound expertise in traditional psychotherapy to create the digital pathways for reaching out to them.", [["patient", "ORGANISM", 243, 250], ["hand", "ORGANISM_SUBDIVISION", 285, 289], ["patient", "SPECIES", 243, 250], ["vulnerable episodes", "PROBLEM", 126, 145], ["video therapy sessions", "TREATMENT", 204, 226], ["traditional psychotherapy", "TREATMENT", 479, 504], ["Increase", "OBSERVATION_MODIFIER", 7, 15]]], ["Let's go.Practical aspects in using DHIAcknowledgements Open Access funding provided by Projekt DEAL.Practical aspects in using DHIOpen Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.", [["DHIOpen Access", "TREATMENT", 128, 142]]], ["The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material.", [["The images", "TEST", 0, 10]]], ["To view a copy of this licence, visit http://creat iveco mmons .org/licen ses/by/4.0/.", [["licen", "ORGANISM", 68, 73]]]], "PMC7231547": [["In response to the covid-19 pandemic, many countries have adopted a broad spectrum of containment measures, from recommendations to stay at home to quarantines of large geographic regions.", [["containment measures", "TREATMENT", 86, 106], ["large", "OBSERVATION_MODIFIER", 163, 168]]], ["More than 3.4 billion people in 84 countries have been confined to their homes, as estimated in late March 2020, which potentially translates to many millions of workers temporarily exposed to telecommuting.", [["people", "ORGANISM", 22, 28], ["people", "SPECIES", 22, 28]]], ["Since 2000, the emergence of digital and broadband internet has facilitated the development of home telework.", [["home telework", "TREATMENT", 95, 108]]]], "ff2fd2574c9bf979abd51e4fe45cc088803cfe86": [["Approximately 900 tick species exist worldwide, parasitizing a broad array of mammals, including humans, and thereby playing a significant role in the transmission of infectious diseases (1) .", [["infectious diseases", "DISEASE", 167, 186], ["humans", "ORGANISM", 97, 103], ["humans", "SPECIES", 97, 103], ["humans", "SPECIES", 97, 103], ["infectious diseases", "PROBLEM", 167, 186], ["infectious", "OBSERVATION", 167, 177]]], ["In the United States, tick-borne diseases are generally seasonal and geographically distributed.", [["tick-borne diseases", "DISEASE", 22, 41], ["tick-borne diseases", "PROBLEM", 22, 41], ["borne diseases", "OBSERVATION", 27, 41], ["geographically", "OBSERVATION_MODIFIER", 69, 83]]]], "PMC2779504": [["IntroductionCommunicable diseases such as measles, influenza or tuberculosis are a fact of modern life.", [["IntroductionCommunicable diseases", "DISEASE", 0, 33], ["measles", "DISEASE", 42, 49], ["influenza", "DISEASE", 51, 60], ["tuberculosis", "DISEASE", 64, 76], ["IntroductionCommunicable diseases", "PROBLEM", 0, 33], ["measles", "PROBLEM", 42, 49], ["influenza", "PROBLEM", 51, 60], ["tuberculosis", "PROBLEM", 64, 76], ["tuberculosis", "OBSERVATION", 64, 76]]], ["Some diseases, such as chicken pox, usually have mild symptoms and vanish of their own accord.", [["chicken", "ORGANISM", 23, 30], ["chicken pox", "SPECIES", 23, 34], ["chicken pox", "SPECIES", 23, 34], ["Some diseases", "PROBLEM", 0, 13], ["chicken pox", "PROBLEM", 23, 34], ["mild symptoms", "PROBLEM", 49, 62], ["diseases", "OBSERVATION", 5, 13], ["mild", "OBSERVATION_MODIFIER", 49, 53], ["symptoms", "OBSERVATION", 54, 62]]], ["Others, such as Ebola (recurrently) and SARS, have appeared, causing a significant number of deaths, and then disappeared, but not before giving rise to fears of catastrophic spread.", [["Ebola", "DISEASE", 16, 21], ["SARS", "DISEASE", 40, 44], ["deaths", "DISEASE", 93, 99], ["Ebola", "ORGANISM", 16, 21], ["Ebola", "PROBLEM", 16, 21], ["SARS", "PROBLEM", 40, 44], ["catastrophic spread", "PROBLEM", 162, 181], ["significant", "OBSERVATION_MODIFIER", 71, 82], ["catastrophic", "OBSERVATION_MODIFIER", 162, 174], ["spread", "OBSERVATION", 175, 181]]], ["The prevalence and effects of many diseases in resource-constrained countries are probably less well-known but may be of even more importance.", [["many diseases", "PROBLEM", 30, 43], ["many", "OBSERVATION_MODIFIER", 30, 34], ["diseases", "OBSERVATION", 35, 43]]], ["Every year, millions of people die of measles, respiratory infections, diarrhea and other diseases that are easily treated and not considered dangerous in the Western world.", [["respiratory", "ANATOMY", 47, 58], ["measles", "DISEASE", 38, 45], ["respiratory infections", "DISEASE", 47, 69], ["diarrhea", "DISEASE", 71, 79], ["people", "ORGANISM", 24, 30], ["people", "SPECIES", 24, 30], ["measles", "PROBLEM", 38, 45], ["respiratory infections", "PROBLEM", 47, 69], ["diarrhea", "PROBLEM", 71, 79], ["other diseases", "PROBLEM", 84, 98], ["respiratory", "ANATOMY", 47, 58], ["infections", "OBSERVATION", 59, 69], ["diseases", "OBSERVATION", 90, 98]]], ["Diseases such as malaria, typhus, cholera, schistosomiasis and sleeping sickness are endemic in many parts of the world.", [["malaria", "DISEASE", 17, 24], ["typhus", "DISEASE", 26, 32], ["cholera", "DISEASE", 34, 41], ["schistosomiasis", "DISEASE", 43, 58], ["sleeping sickness", "DISEASE", 63, 80], ["Diseases", "PROBLEM", 0, 8], ["malaria", "PROBLEM", 17, 24], ["typhus", "PROBLEM", 26, 32], ["cholera", "PROBLEM", 34, 41], ["schistosomiasis", "PROBLEM", 43, 58], ["sleeping sickness", "PROBLEM", 63, 80], ["malaria", "OBSERVATION", 17, 24], ["typhus", "OBSERVATION_MODIFIER", 26, 32], ["schistosomiasis", "OBSERVATION", 43, 58]]], ["The effects of high disease mortality on mean lifespans, and of disease debilitation and mortality on the economy in afflicted countries are considerable.", [["debilitation", "DISEASE", 72, 84], ["high disease mortality", "PROBLEM", 15, 37], ["mean lifespans", "TREATMENT", 41, 55], ["disease debilitation", "PROBLEM", 64, 84], ["high", "OBSERVATION_MODIFIER", 15, 19], ["disease", "OBSERVATION", 20, 27]]], ["A case in point is the AIDS epidemic, which has devastated life in much of Africa.IntroductionFor some diseases, there are management methods, which may involve prevention (such as vaccination) or treatment of symptomatic patients.", [["AIDS", "DISEASE", 23, 27], ["patients", "ORGANISM", 222, 230], ["patients", "SPECIES", 222, 230], ["some diseases", "PROBLEM", 98, 111], ["management methods", "TREATMENT", 123, 141], ["vaccination", "TREATMENT", 181, 192], ["symptomatic patients", "PROBLEM", 210, 230]]], ["For diseases with no known treatment, it is possible to attempt control by isolation of diagnosed patients and quarantine of suspected victims to decrease transmission.", [["patients", "ORGANISM", 98, 106], ["patients", "SPECIES", 98, 106], ["diseases", "PROBLEM", 4, 12], ["known treatment", "TREATMENT", 21, 36]]], ["However, it is not possible to do experiments to compare possible management strategies; the only way to attempt to compare the effectiveness of different approaches may be to formulate a mathematical model and use it to make predictions.", [["management strategies", "TREATMENT", 66, 87], ["not possible", "UNCERTAINTY", 15, 27]]], ["Currently, HIV/AIDS causes many deaths and is a significant aspect in the social and economic structure of some countries, notably in Africa.", [["HIV/AIDS", "DISEASE", 11, 19], ["deaths", "DISEASE", 32, 38], ["HIV", "ORGANISM", 11, 14], ["HIV", "SPECIES", 11, 14], ["HIV", "SPECIES", 11, 14], ["HIV/AIDS", "PROBLEM", 11, 19], ["many deaths", "PROBLEM", 27, 38], ["significant", "OBSERVATION_MODIFIER", 48, 59]]], ["Because of the long time scale on which HIV runs, a clinical trial to compare control strategies would take many years for results to be obtained.", [["HIV", "SPECIES", 40, 43], ["a clinical trial", "TREATMENT", 50, 66], ["control strategies", "TREATMENT", 78, 96]]], ["In order to provide useful information, models for the transmission of infectious diseases must be quantitative; this points to a need to develop mathematical models.IntroductionThere have been many advances in disease management that have come from mathematical modelling.", [["infectious diseases", "DISEASE", 71, 90], ["infectious diseases", "PROBLEM", 71, 90], ["disease management", "TREATMENT", 211, 229], ["infectious", "OBSERVATION", 71, 81], ["disease", "OBSERVATION", 211, 218]]], ["Two of the most striking are the recognition that mosquito management is the key to malaria control in a region and the realization that smallpox could be eradicated.", [["malaria", "DISEASE", 84, 91], ["smallpox", "DISEASE", 137, 145], ["mosquito management", "TREATMENT", 50, 69], ["malaria control", "TREATMENT", 84, 99], ["smallpox", "TREATMENT", 137, 145], ["most striking", "OBSERVATION_MODIFIER", 11, 24], ["malaria", "OBSERVATION", 84, 91]]], ["However, there are many others.Communicable diseases in historyThroughout the course of history, communicable diseases have had major effects on human development.", [["Communicable diseases", "DISEASE", 31, 52], ["communicable diseases", "DISEASE", 97, 118], ["human", "ORGANISM", 145, 150], ["human", "SPECIES", 145, 150], ["human", "SPECIES", 145, 150], ["Communicable diseases", "PROBLEM", 31, 52], ["communicable diseases", "PROBLEM", 97, 118], ["many", "OBSERVATION_MODIFIER", 19, 23], ["others", "OBSERVATION_MODIFIER", 24, 30], ["diseases", "OBSERVATION", 44, 52]]], ["The Book of Exodus describes the plagues that Moses brought down upon Egypt; there are many other biblical references to diseases as historical influences, such as the decision of Sennacherib, the king of Assyria, to abandon his attempt to capture Jerusalem about 700 BC because of the illness of his soldiers (Isaiah 37,36-38).", [["BC", "DISEASE", 268, 270], ["Isaiah", "TEST", 311, 317], ["Exodus", "OBSERVATION", 12, 18]]], ["The fall of empires has been attributed directly or indirectly to epidemic diseases.", [["The fall of empires", "PROBLEM", 0, 19], ["epidemic diseases", "PROBLEM", 66, 83], ["fall", "OBSERVATION", 4, 8]]], ["In the second century AD, the so-called Antonine plagues (possibly measles and smallpox) invaded the Roman Empire, causing drastic population reductions and economic hardships, leading to disintegration of the empire because of disorganization, which facilitated invasions of barbarians.", [["AD", "DISEASE", 22, 24], ["Antonine plagues", "DISEASE", 40, 56], ["measles and smallpox", "DISEASE", 67, 87], ["drastic population reductions", "TREATMENT", 123, 152], ["disorganization", "PROBLEM", 228, 243], ["Roman Empire", "OBSERVATION", 101, 113], ["drastic", "OBSERVATION_MODIFIER", 123, 130], ["population", "OBSERVATION_MODIFIER", 131, 141], ["reductions", "OBSERVATION_MODIFIER", 142, 152], ["disorganization", "OBSERVATION", 228, 243], ["invasions", "OBSERVATION_MODIFIER", 263, 272]]], ["The Han empire in China collapsed in the third century AD after a very similar sequence of events.", [["AD", "DISEASE", 55, 57]]], ["The population of China decreased from 123,000,000 to 65,000,000 around 1200 AD because of a combination of war with the Mongols and plague.Communicable diseases in historyThe defeat of a population of millions of Aztecs by Cortez and his 600 followers in 1519 can be explained, in part, by a smallpox epidemic that devastated the Aztecs but had almost no effect on the invading Spaniards, thanks to their built-in immunities.", [["AD", "DISEASE", 77, 79], ["Communicable diseases", "DISEASE", 140, 161], ["smallpox", "DISEASE", 293, 301], ["the Mongols", "TREATMENT", 117, 128], ["Communicable diseases", "PROBLEM", 140, 161], ["Aztecs", "TREATMENT", 214, 220], ["population", "OBSERVATION_MODIFIER", 4, 14], ["China", "OBSERVATION_MODIFIER", 18, 23], ["decreased", "OBSERVATION_MODIFIER", 24, 33], ["diseases", "OBSERVATION", 153, 161], ["defeat", "OBSERVATION_MODIFIER", 176, 182]]], ["The Aztecs were not only weakened by disease but also confounded by what they interpreted as a divine force favouring the invaders.", [["disease", "PROBLEM", 37, 44], ["not only", "UNCERTAINTY", 16, 24], ["invaders", "OBSERVATION", 122, 130]]], ["Smallpox then spread southward to the Incas in Peru and was an important factor in the success of Pizarro's invasion a few years later in 1532.", [["Pizarro's invasion", "TREATMENT", 98, 116], ["spread", "OBSERVATION_MODIFIER", 14, 20], ["southward", "OBSERVATION_MODIFIER", 21, 30]]], ["Smallpox was followed by other diseases, such as measles and diphtheria, that were imported from Europe to North America.", [["measles and diphtheria", "DISEASE", 49, 71], ["Smallpox", "TREATMENT", 0, 8], ["other diseases", "PROBLEM", 25, 39], ["measles", "PROBLEM", 49, 56], ["diphtheria", "PROBLEM", 61, 71], ["diseases", "OBSERVATION", 31, 39]]], ["In some regions, the indigenous populations were reduced to one tenth of their previous levels by these diseases; between 1519 and 1530 the native population of Mexico was reduced from 30 million to 3 million.Communicable diseases in historyThe Black Death (bubonic plague) spread from Asia throughout Europe in several waves during the fourteenth century, beginning in 1346, and is estimated to have caused the deaths of as much as one-third of the population of Europe between 1346 and 1350.", [["Communicable diseases", "DISEASE", 209, 230], ["Death", "DISEASE", 251, 256], ["bubonic plague", "DISEASE", 258, 272], ["deaths", "DISEASE", 412, 418], ["these diseases", "PROBLEM", 98, 112], ["Communicable diseases", "PROBLEM", 209, 230], ["The Black Death (bubonic plague", "PROBLEM", 241, 272], ["some", "OBSERVATION_MODIFIER", 3, 7], ["regions", "ANATOMY_MODIFIER", 8, 15], ["indigenous", "OBSERVATION_MODIFIER", 21, 31], ["populations", "OBSERVATION_MODIFIER", 32, 43], ["reduced", "OBSERVATION_MODIFIER", 49, 56], ["diseases", "OBSERVATION", 104, 112]]], ["The disease recurred regularly in various parts of Europe for more than 300 years, notably as the Great Plague of London (1665-1666).", [["The disease", "PROBLEM", 0, 11], ["disease", "OBSERVATION", 4, 11]]], ["It then gradually withdrew from Europe.", [["gradually", "OBSERVATION_MODIFIER", 8, 17], ["withdrew", "OBSERVATION_MODIFIER", 18, 26]]], ["As the plague struck some regions harshly while avoiding others, it had a profound effect on political and economic developments in medieval times.", [["profound", "OBSERVATION_MODIFIER", 74, 82], ["effect", "OBSERVATION_MODIFIER", 83, 89]]], ["In the last bubonic plague epidemic in France (1720-1722), half the population of Marseilles, 60 percent of the population in nearby Toulon, 44 percent of the population of Arles and 30 percent of the population of Aix and Avignon died, but the epidemic did not spread beyond Provence.Communicable diseases in historyThe first attempt to construct the Panama Canal (1881-88) had to be abandoned because of yellow fever and malaria; the second attempt, beginning in 1907, was successful because of eradication of the mosquitoes which acted as vectors to spread these diseases.Communicable diseases in historyCurrent concerns about a possible influenza pandemic are magnified by knowledge of the 1918 influenza pandemic, which caused a number of deaths estimated as between 50,000,000 and 100,000,000.Communicable diseases in historyThe historian W.H. McNeill argues, especially in his book [1], that the spread of communicable diseases frequently has been an important influence in history.", [["bubonic plague", "DISEASE", 12, 26], ["Communicable diseases", "DISEASE", 285, 306], ["fever", "DISEASE", 413, 418], ["malaria", "DISEASE", 423, 430], ["Communicable diseases", "DISEASE", 575, 596], ["influenza", "DISEASE", 641, 650], ["influenza pandemic", "DISEASE", 699, 717], ["deaths", "DISEASE", 744, 750], ["Communicable diseases", "DISEASE", 799, 820], ["communicable diseases", "DISEASE", 913, 934], ["Marseilles", "TEST", 82, 92], ["Arles", "TEST", 173, 178], ["the epidemic", "PROBLEM", 241, 253], ["Communicable diseases", "PROBLEM", 285, 306], ["yellow fever", "PROBLEM", 406, 418], ["malaria", "PROBLEM", 423, 430], ["the mosquitoes", "PROBLEM", 512, 526], ["these diseases", "PROBLEM", 560, 574], ["Communicable diseases", "PROBLEM", 575, 596], ["influenza pandemic", "PROBLEM", 641, 659], ["Communicable diseases", "PROBLEM", 799, 820], ["communicable diseases", "PROBLEM", 913, 934], ["bubonic", "OBSERVATION_MODIFIER", 12, 19], ["plague", "OBSERVATION_MODIFIER", 20, 26], ["epidemic", "OBSERVATION_MODIFIER", 27, 35], ["diseases", "OBSERVATION", 298, 306], ["Panama Canal", "ANATOMY", 352, 364], ["malaria", "OBSERVATION", 423, 430], ["diseases", "OBSERVATION", 588, 596], ["possible", "UNCERTAINTY", 632, 640], ["diseases", "OBSERVATION", 812, 820]]], ["For example, there was a sharp population increase throughout the world in the 18th century; the population of China increased from 150 million in 1760 to 313 million in 1794 and the population of Europe increased from 118 million in 1700 to 187 million in 1800.", [["a sharp population increase", "PROBLEM", 23, 50], ["sharp", "OBSERVATION_MODIFIER", 25, 30], ["population", "OBSERVATION_MODIFIER", 31, 41], ["increase", "OBSERVATION_MODIFIER", 42, 50], ["population", "OBSERVATION_MODIFIER", 97, 107], ["China", "OBSERVATION_MODIFIER", 111, 116], ["increased", "OBSERVATION_MODIFIER", 117, 126]]], ["There were many factors involved in this increase, including changes in marriage age and technological improvements leading to increased food supplies, but these factors are not sufficient to explain the increase.", [["increased food supplies", "PROBLEM", 127, 150], ["increased", "OBSERVATION_MODIFIER", 127, 136], ["food supplies", "OBSERVATION", 137, 150]]], ["Demographic studies indicate that a satisfactory explanation requires recognition of a decrease in the mortality caused by periodic epidemic infections.", [["infections", "DISEASE", 141, 151], ["Demographic studies", "TEST", 0, 19], ["a decrease in the mortality", "PROBLEM", 85, 112], ["periodic epidemic infections", "PROBLEM", 123, 151], ["decrease", "OBSERVATION_MODIFIER", 87, 95], ["periodic", "OBSERVATION_MODIFIER", 123, 131], ["epidemic", "OBSERVATION_MODIFIER", 132, 140], ["infections", "OBSERVATION", 141, 151]]], ["This decrease came about partly through improvements in medicine, but a more important influence was probably the fact that more people developed immunities against infection as increased travel intensified the circulation and co-circulation of diseases.Communicable diseases in historyWhile epidemics may cause many deaths in a short time before disappearing, new diseases may also appear and become endemic.", [["immunities", "DISEASE", 146, 156], ["infection", "DISEASE", 165, 174], ["Communicable diseases", "DISEASE", 254, 275], ["deaths", "DISEASE", 317, 323], ["people", "ORGANISM", 129, 135], ["people", "SPECIES", 129, 135], ["infection", "PROBLEM", 165, 174], ["diseases", "PROBLEM", 245, 253], ["Communicable diseases", "PROBLEM", 254, 275], ["new diseases", "PROBLEM", 361, 373], ["endemic", "PROBLEM", 401, 408], ["diseases", "OBSERVATION", 245, 253], ["diseases", "OBSERVATION", 267, 275], ["new", "OBSERVATION_MODIFIER", 361, 364], ["diseases", "OBSERVATION", 365, 373], ["endemic", "OBSERVATION_MODIFIER", 401, 408]]], ["The appearance of AIDS about 1981, apparently initially in the population of men having sex with men in San Francisco, was such an event.", [["AIDS", "DISEASE", 18, 22], ["men", "ORGANISM", 77, 80], ["men", "ORGANISM", 97, 100], ["men", "SPECIES", 77, 80], ["men", "SPECIES", 97, 100], ["AIDS", "PROBLEM", 18, 22], ["AIDS", "OBSERVATION", 18, 22]]], ["It was identified as an immune disorder in the blood which could be spread in many ways: through sexual contact, shared needles for drug injections, transfusions with infected blood and by vertical transmission from mother to unborn child.", [["blood", "ANATOMY", 47, 52], ["blood", "ANATOMY", 176, 181], ["immune disorder", "DISEASE", 24, 39], ["infected blood", "DISEASE", 167, 181], ["blood", "ORGANISM_SUBSTANCE", 47, 52], ["blood", "ORGANISM_SUBSTANCE", 176, 181], ["an immune disorder in the blood", "PROBLEM", 21, 52], ["drug injections", "TREATMENT", 132, 147], ["transfusions", "TREATMENT", 149, 161], ["infected blood", "PROBLEM", 167, 181], ["immune disorder", "OBSERVATION", 24, 39], ["blood", "ANATOMY", 47, 52]]], ["It took two years for scientists to identify a virus, which became known as HIV, linked to AIDS.", [["AIDS", "DISEASE", 91, 95], ["HIV", "ORGANISM", 76, 79], ["HIV", "SPECIES", 76, 79], ["HIV", "SPECIES", 76, 79], ["a virus", "PROBLEM", 45, 52], ["HIV", "PROBLEM", 76, 79], ["virus", "OBSERVATION", 47, 52]]], ["In 1987, a new drug (AZT) was developed which delayed progression of the disease, but many patients developed drug resistance.", [["AZT", "CHEMICAL", 21, 24], ["AZT", "CHEMICAL", 21, 24], ["AZT", "SIMPLE_CHEMICAL", 21, 24], ["patients", "ORGANISM", 91, 99], ["patients", "SPECIES", 91, 99], ["a new drug (AZT)", "TREATMENT", 9, 25], ["the disease", "PROBLEM", 69, 80], ["drug resistance", "PROBLEM", 110, 125], ["progression", "OBSERVATION_MODIFIER", 54, 65], ["disease", "OBSERVATION", 73, 80], ["drug resistance", "OBSERVATION", 110, 125]]], ["New drugs and combinations of drugs renewed hope, but they offered only improved length and quality of life, not a cure.", [["New drugs", "TREATMENT", 0, 9], ["drugs", "TREATMENT", 30, 35], ["drugs", "OBSERVATION", 4, 9]]], ["It is estimated that in 2007 there were more than two million deaths from AIDS worldwide and more than 33, 000, 000 persons living with AIDS, including 330, 000 children.", [["deaths", "DISEASE", 62, 68], ["AIDS", "DISEASE", 74, 78], ["AIDS", "DISEASE", 136, 140], ["children", "ORGANISM", 161, 169], ["persons", "SPECIES", 116, 123], ["children", "SPECIES", 161, 169]]], ["More than three quarters of these deaths were in sub-Saharan Africa.", [["deaths", "DISEASE", 34, 40], ["these deaths", "PROBLEM", 28, 40]]], ["It is not an exaggeration to say that HIV/AIDS is the most urgent health problem for the entire world.", [["HIV/AIDS", "DISEASE", 38, 46], ["HIV", "ORGANISM", 38, 41], ["HIV", "SPECIES", 38, 41], ["HIV", "SPECIES", 38, 41], ["HIV/AIDS", "PROBLEM", 38, 46]]], ["While AIDS treatment rates have increased in some parts of the world, they remain very low in Africa and resource-poor countries.Communicable diseases in historyDescriptions of epidemics in ancient and medieval times frequently used the term \"plague\" because of a general belief that epidemics represented divine retribution for sinful living.", [["AIDS", "DISEASE", 6, 10], ["Communicable diseases", "DISEASE", 129, 150], ["AIDS treatment rates", "TREATMENT", 6, 26], ["Communicable diseases", "PROBLEM", 129, 150], ["epidemics", "PROBLEM", 177, 186], ["epidemics", "PROBLEM", 284, 293], ["increased", "OBSERVATION_MODIFIER", 32, 41], ["diseases", "OBSERVATION", 142, 150]]], ["This view has not disappeared entirely.", [["not disappeared", "UNCERTAINTY", 14, 29]]], ["Some have described AIDS as punishment for sinful activities and such views have delayed or hampered attempts to control this modern epidemic.Communicable diseases in historyIn view of the importance of communicable diseases in history, it is natural that people would make efforts to understand the causes of diseases and search for treatments.", [["AIDS", "DISEASE", 20, 24], ["Communicable diseases", "DISEASE", 142, 163], ["communicable diseases", "DISEASE", 203, 224], ["people", "ORGANISM", 256, 262], ["people", "SPECIES", 256, 262], ["such views", "TEST", 65, 75], ["Communicable diseases", "PROBLEM", 142, 163], ["communicable diseases", "PROBLEM", 203, 224], ["diseases", "PROBLEM", 310, 318], ["treatments", "TREATMENT", 334, 344], ["diseases", "OBSERVATION", 155, 163]]], ["This search leads naturally to an effort to construct models that focus on the main properties of a disease without necessarily attempting to include all the details.Why should we model?A model is an attempt to answer a question that begins with \"Why?\"", [["a disease", "PROBLEM", 98, 107], ["disease", "OBSERVATION", 100, 107]]], ["The relation between problems and models in science may be described by the \"flow chart\" in Figure 1 (adapted from a similar flowchart in [2], by permission).Why should we model?The normal process of scientific progress is to observe a phenomenon, hypothesize an explanation and then devise an experiment to test the hypothesis.", [["a phenomenon", "PROBLEM", 234, 246], ["normal", "OBSERVATION", 182, 188]]], ["This comparison usually requires numerical simulations to give predictions which may be compared with observed data.Why should we model?It has been observed in many epidemics that the disease spreads into a population and then disappears without infecting the entire population.", [["the disease", "PROBLEM", 180, 191], ["many", "OBSERVATION_MODIFIER", 160, 164], ["epidemics", "OBSERVATION", 165, 174], ["disease", "OBSERVATION", 184, 191]]], ["Intuitively, one might think that epidemics die out because there are no people left in the location of the epidemic to be infected, but there is much evidence to contradict this explanation.", [["people", "ORGANISM", 73, 79], ["people", "SPECIES", 73, 79], ["infected", "OBSERVATION", 123, 131]]], ["In order to explain why part of the population escapes infection during an epidemic, it is natural to try to give a description of how the disease spreads.", [["infection", "DISEASE", 55, 64], ["the population escapes infection", "PROBLEM", 32, 64], ["the disease spreads", "PROBLEM", 135, 154], ["infection", "OBSERVATION", 55, 64], ["disease", "OBSERVATION", 139, 146]]], ["Such a description, or model, does not necessarily try to include all the details of the epidemic spread, but attempts to incorporate the factors that appear to be the most important.", [["the epidemic spread", "PROBLEM", 85, 104]]], ["This mathematical problem is a model of the epidemic.Why should we model?For example, Kermack and McKendrick set out to try to explain why epidemics pass through a population without affecting the entire population [3].", [["Kermack", "TEST", 86, 93]]], ["Their mathematical model assumed mass-action incidence to describe the acquisition of infection followed by a period of infectivity and then recovery with immunity against reinfection.", [["infection", "DISEASE", 86, 95], ["reinfection", "DISEASE", 172, 183], ["infection", "PROBLEM", 86, 95], ["infectivity", "PROBLEM", 120, 131], ["reinfection", "PROBLEM", 172, 183], ["infection", "OBSERVATION", 86, 95]]], ["The simplest mathematical formulation of these assumptions is a pair of ordinary differential equations for the number of susceptible (uninfected) and the number of infected (and infectious) members of the population.", [["susceptible", "OBSERVATION_MODIFIER", 122, 133], ["infected", "OBSERVATION_MODIFIER", 165, 173], ["infectious", "OBSERVATION_MODIFIER", 179, 189]]], ["This mathematical solution leads to the prediction that if the basic reproduction number is less than one, the number of infectives will tend to zero; if the basic reproduction number exceeds one, the number of infectives will increase initially before tending to zero, while the number of susceptibles decreases but never reaches zero.", [["This mathematical solution", "TREATMENT", 0, 26]]], ["This prediction not only matches observations but also gives a criterion for whether a disease outbreak will develop into an epidemic or die out.", [["a disease outbreak", "PROBLEM", 85, 103]]], ["In order to make more detailed predictions about the number of people infected in an epidemic, it would be necessary to make more detailed assumptions about the situation to give a more complicated mathematical model.", [["people", "ORGANISM", 63, 69], ["people", "SPECIES", 63, 69]]], ["Such a model would probably be sufficiently complicated that an exact solution would be impossible; numerical simulations would be needed to obtain predictions that could be compared with observations.", [["an exact solution", "TREATMENT", 61, 78]]], ["For example, we might wish to compare two different management strategies for a disease outbreak.", [["different management strategies", "TREATMENT", 42, 73], ["a disease outbreak", "PROBLEM", 78, 96]]], ["Experiments in epidemiology with controls are often difficult or impossible to design; even if it is possible to arrange an experiment, there are serious ethical questions involved in withholding treatment from a control group.", [["withholding treatment", "TREATMENT", 184, 205], ["a control group", "TREATMENT", 211, 226]]], ["In order to describe the course of a future disease outbreak, formulation and analysis of a mathematical model may be the only way to compare the effect of different management strategies.", [["a future disease outbreak", "PROBLEM", 35, 60], ["a mathematical model", "TEST", 90, 110], ["different management strategies", "TREATMENT", 156, 187]]], ["Mathematical modelling in epidemiology provides understanding of the underlying mechanisms that influence the spread of disease and, in the process, it suggests control strategies.", [["disease", "PROBLEM", 120, 127]]], ["This may occur because data are non-reproducible and the number of data points is limited and subject to errors in measurement.Why should we model?In the mathematical modelling of disease transmission, as in most other areas of mathematical modelling, there is always a trade-off between simple models, which omit most details and are designed only to highlight general qualitative behavior, and detailed models, usually designed for specific situations including short-term quantitative predictions.", [["disease transmission", "PROBLEM", 180, 200], ["disease", "OBSERVATION", 180, 187], ["mathematical modelling", "OBSERVATION", 228, 250]]], ["There is a tendency on the part of mathematicians to want to study models which are too simple to capture the essential properties of a disease, while there is a tendency on the part of epidemiologists to want complete models which may be too difficult to analyze properly.", [["a tendency", "PROBLEM", 9, 19], ["study models", "TEST", 61, 73], ["a disease", "PROBLEM", 134, 143], ["tendency", "OBSERVATION_MODIFIER", 11, 19], ["disease", "OBSERVATION", 136, 143]]], ["Detailed models are generally difficult or impossible to solve analytically; hence, their usefulness for theoretical purposes is limited, although their strategic value may be high.", [["theoretical purposes", "TEST", 105, 125]]], ["Also, more detailed models contain more parameters and therefore it may be more difficult to fit parameters to the model.", [["more parameters", "OBSERVATION_MODIFIER", 35, 50]]], ["In order to be useful, a disease model should have a level of complexity appropriate to the amount of known information and the results desired.", [["a disease model", "PROBLEM", 23, 38]]], ["Ideally, a model should also have a level of complexity appropriate to the specific questions the model is designed to answer; however, these two requirements may not be compatible.History of epidemiological modellingThe idea of invisible living creatures as agents of disease goes back at least to the writings of Aristotle (384 BC-322 BC).", [["BC-322 BC", "CANCER", 330, 339], ["disease", "PROBLEM", 269, 276], ["BC", "TEST", 330, 332], ["BC", "TEST", 337, 339]]], ["The existence of microorganisms was demonstrated by Leeuwenhoek (1632-1723), with the aid of the first microscopes.", [["microorganisms", "PROBLEM", 17, 31], ["microorganisms", "OBSERVATION", 17, 31]]], ["The first expression of the germ theory of disease by Jacob Henle (1809-1885) came in 1840 and was developed by Robert Koch (1843-1910), Joseph Lister (1827-1912), and Louis Pasteur (1827-1875) in the latter part of the nineteenth century and the early part of the twentieth century.History of epidemiological modellingThe mechanism of transmission of infections is now known for most diseases.", [["germ", "ANATOMY", 28, 32], ["infections", "DISEASE", 352, 362], ["infections", "PROBLEM", 352, 362], ["most diseases", "PROBLEM", 380, 393], ["infections", "OBSERVATION", 352, 362]]], ["Generally, diseases transmitted by viral agents, such as influenza, measles, rubella (German measles) and chicken pox, confer immunity against reinfection, while diseases transmitted by bacteria, such as tuberculosis, meningitis and gonorrhea, confer no immunity against reinfection.", [["influenza", "DISEASE", 57, 66], ["measles, rubella", "DISEASE", 68, 84], ["measles", "DISEASE", 93, 100], ["chicken pox", "DISEASE", 106, 117], ["reinfection", "DISEASE", 143, 154], ["tuberculosis", "DISEASE", 204, 216], ["meningitis", "DISEASE", 218, 228], ["gonorrhea", "DISEASE", 233, 242], ["German measles", "ORGANISM", 86, 100], ["chicken pox", "ORGANISM", 106, 117], ["chicken pox", "SPECIES", 106, 117], ["chicken", "SPECIES", 106, 113], ["diseases", "PROBLEM", 11, 19], ["viral agents", "TREATMENT", 35, 47], ["influenza", "PROBLEM", 57, 66], ["measles", "PROBLEM", 68, 75], ["rubella", "PROBLEM", 77, 84], ["chicken pox", "TREATMENT", 106, 117], ["reinfection", "PROBLEM", 143, 154], ["bacteria", "PROBLEM", 186, 194], ["tuberculosis", "PROBLEM", 204, 216], ["meningitis", "PROBLEM", 218, 228], ["gonorrhea", "PROBLEM", 233, 242], ["reinfection", "PROBLEM", 271, 282], ["diseases", "OBSERVATION", 11, 19], ["viral agents", "OBSERVATION", 35, 47], ["tuberculosis", "OBSERVATION", 204, 216], ["meningitis", "OBSERVATION", 218, 228], ["gonorrhea", "OBSERVATION", 233, 242]]], ["Other diseases, such as malaria, are transmitted not directly from human to human but by vectors, agents (usually insects) that are infected by humans and subsequently transmit the disease back to humans.History of epidemiological modellingThe first mathematical model in epidemiology was the work of Daniel Bernoulli [4] on the effect of variolation against smallpox in increasing life expectancy.", [["malaria", "DISEASE", 24, 31], ["smallpox", "DISEASE", 359, 367], ["human", "ORGANISM", 67, 72], ["human", "ORGANISM", 76, 81], ["humans", "ORGANISM", 144, 150], ["humans", "ORGANISM", 197, 203], ["human", "SPECIES", 67, 72], ["human", "SPECIES", 76, 81], ["humans", "SPECIES", 144, 150], ["humans", "SPECIES", 197, 203], ["human", "SPECIES", 67, 72], ["human", "SPECIES", 76, 81], ["humans", "SPECIES", 144, 150], ["humans", "SPECIES", 197, 203], ["Other diseases", "PROBLEM", 0, 14], ["malaria", "PROBLEM", 24, 31], ["the disease", "PROBLEM", 177, 188], ["variolation", "TREATMENT", 339, 350], ["diseases", "OBSERVATION", 6, 14], ["malaria", "OBSERVATION", 24, 31], ["infected", "OBSERVATION", 132, 140]]], ["His work contained the idea of differential mortality to estimate the rate of deaths attributable to a given disease, a method which has been used to estimate disease death-rates of past epidemics, such as the 1918 influenza pandemic.History of epidemiological modellingThe foundations of mathematical epidemiology were laid in the late nineteenth and early twentieth centuries by public-health physicians and biological scientists such as P.D. En'ko [5], W.H. Hamer [6], J. Brownlee [7], Sir R.A. Ross [8], A.G. McKendrick and W.O. Kermack [3,9,10].", [["deaths", "DISEASE", 78, 84], ["death", "DISEASE", 167, 172], ["influenza pandemic", "DISEASE", 215, 233], ["disease", "PROBLEM", 109, 116], ["a method", "TREATMENT", 118, 126], ["disease death", "PROBLEM", 159, 172], ["past epidemics", "PROBLEM", 182, 196]]], ["En'ko developed a discrete chain binomial model for the spread of infection in a susceptible population in 1889 [11].History of epidemiological modellingTwo of the landmarks in the development of mathematical epidemiology, illustrating the dichotomy between models for a specific disease and models for general classes of diseases, are the work of Ross on malaria, and the epidemic models of Kermack and McKendrick for classes of disease.", [["infection", "DISEASE", 66, 75], ["malaria", "DISEASE", 356, 363], ["a discrete chain binomial model", "PROBLEM", 16, 47], ["infection", "PROBLEM", 66, 75], ["a specific disease", "PROBLEM", 269, 287], ["diseases", "PROBLEM", 322, 330], ["malaria", "PROBLEM", 356, 363], ["disease", "PROBLEM", 430, 437], ["discrete", "OBSERVATION_MODIFIER", 18, 26], ["chain binomial model", "OBSERVATION", 27, 47], ["infection", "OBSERVATION", 66, 75], ["diseases", "OBSERVATION", 322, 330], ["disease", "OBSERVATION", 430, 437]]], ["Ross showed that malaria was transmitted through mosquitos and developed a model to describe the spread of malaria [8].", [["malaria", "DISEASE", 17, 24], ["malaria", "DISEASE", 107, 114], ["malaria", "PROBLEM", 17, 24], ["malaria", "PROBLEM", 107, 114], ["malaria", "OBSERVATION", 17, 24], ["malaria", "OBSERVATION", 107, 114]]], ["He then deduced from this model that reducing the mosquito population could control malaria in a region.", [["malaria", "DISEASE", 84, 91], ["the mosquito population", "PROBLEM", 46, 69], ["malaria", "PROBLEM", 84, 91], ["malaria", "OBSERVATION", 84, 91]]], ["This model was probably the first example of the threshold concept, which has been central in epidemiology ever since.", [["central", "OBSERVATION_MODIFIER", 83, 90]]], ["The idea is that most mathematical epidemic models, including those that include a high degree of heterogeneity, usually exhibit \"threshold\" behaviour.", [["a high degree of heterogeneity", "PROBLEM", 81, 111], ["high degree", "OBSERVATION_MODIFIER", 83, 94], ["heterogeneity", "OBSERVATION", 98, 111]]], ["In epidemiological terms, these can be stated as follows: If the average number of secondary infections caused by a single infective introduced into a wholly susceptible population is less than one a disease will die out, while if it exceeds one there will be an epidemic.", [["infections", "DISEASE", 93, 103], ["secondary infections", "PROBLEM", 83, 103], ["a single infective", "PROBLEM", 114, 132], ["secondary", "OBSERVATION_MODIFIER", 83, 92], ["infections", "OBSERVATION", 93, 103], ["epidemic", "OBSERVATION", 263, 271]]], ["This broad principle, consistent with observations and quantified via epidemiological models, has been used regularly to estimate the effectiveness of vaccination policies and the likelihood that a disease may be eliminated or eradicated.", [["vaccination policies", "TREATMENT", 151, 171], ["a disease", "PROBLEM", 196, 205], ["consistent with", "UNCERTAINTY", 22, 37], ["disease", "OBSERVATION", 198, 205]]], ["Hence, even if it is not possible to verify hypotheses accurately, agreement with hypotheses of a qualitative nature is often valuable.History of epidemiological modellingThe threshold principle is described quantitatively by the idea that the average number of secondary infections caused by an average infective is known as the basic reproduction number or basic reproductive ratio and denoted by \u211b0 [12].", [["infections", "DISEASE", 272, 282], ["secondary infections", "PROBLEM", 262, 282], ["an average infective", "PROBLEM", 293, 313], ["basic reproductive ratio", "TEST", 359, 383], ["secondary", "OBSERVATION_MODIFIER", 262, 271], ["infections", "OBSERVATION", 272, 282], ["average", "OBSERVATION_MODIFIER", 296, 303], ["infective", "OBSERVATION", 304, 313]]], ["Its calculation for a given model and its estimation from observations are central in the analysis of models and the interpretation of data.", [["Its calculation", "TEST", 0, 15]]], ["If the basic reproduction number is less than one, then the infection dies out; if it exceeds one, then the infection persists.History of epidemiological modellingThe concept of the basic reproduction number was extended greatly in the work of Kermack and McKendrick [3,9,10] on general compartmental models, both for diseases in which recovery from infection conferred immunity against reinfection - commonly the case for diseases spread by viral infections - and for diseases in which recovered individuals are susceptible to reinfection, as is common for diseases transmitted by bacterial agents and for sexually transmitted diseases.", [["infection", "DISEASE", 60, 69], ["infection", "DISEASE", 108, 117], ["infection", "DISEASE", 350, 359], ["viral infections", "DISEASE", 442, 458], ["reinfection", "DISEASE", 528, 539], ["sexually transmitted diseases", "DISEASE", 607, 636], ["individuals", "ORGANISM", 497, 508], ["the infection", "PROBLEM", 56, 69], ["the infection", "PROBLEM", 104, 117], ["general compartmental models", "TREATMENT", 279, 307], ["diseases", "PROBLEM", 318, 326], ["infection", "PROBLEM", 350, 359], ["reinfection", "PROBLEM", 387, 398], ["diseases", "PROBLEM", 423, 431], ["viral infections", "PROBLEM", 442, 458], ["diseases", "PROBLEM", 469, 477], ["reinfection", "PROBLEM", 528, 539], ["diseases", "PROBLEM", 558, 566], ["bacterial agents", "TREATMENT", 582, 598], ["sexually transmitted diseases", "PROBLEM", 607, 636], ["infection", "OBSERVATION", 60, 69], ["infection", "OBSERVATION", 108, 117], ["infection", "OBSERVATION", 350, 359]]], ["What are usually described as the Kermack-McKendrick models are actually very special cases of the models in these papers, which included infectivity depending on age of infection and temporary immunity [13].", [["infection", "DISEASE", 170, 179], ["infectivity", "PROBLEM", 138, 149], ["infection", "PROBLEM", 170, 179]]], ["An offshoot of this work was the attempt by Soper [14] to explain the oscillations that had been observed in measles prevalence in many places.", [["measles", "DISEASE", 109, 116], ["the oscillations", "PROBLEM", 66, 82]]], ["While Soper's explanation was flawed, it led to many other attempts to describe plausible models for measles [15-19] to explain the observed oscillations.History of epidemiological modellingAfter the work of Kermack and McKendrick, there were many extensions of the basic models.", [["measles", "DISEASE", 101, 108], ["measles", "PROBLEM", 101, 108], ["the observed oscillations", "PROBLEM", 128, 153]]], ["Some of these refinements were made to give more realistic descriptions of microparasitic diseases by adding compartments.", [["microparasitic diseases", "DISEASE", 75, 98], ["microparasitic diseases", "PROBLEM", 75, 98], ["microparasitic diseases", "OBSERVATION", 75, 98]]], ["One such refinement was the incorporation of an exposed (latent) period, a time during which members of a population who have been infected do not pass on the infection to others.", [["infection", "DISEASE", 159, 168], ["the infection", "PROBLEM", 155, 168], ["infected", "OBSERVATION", 131, 139], ["infection", "OBSERVATION", 159, 168]]], ["Another refinement was to models with temporary immunity against reinfection or to the assumption of a sequence of removed stages [26].History of epidemiological modellingAnother important aspect has been the question of a suitable representation for the rate of transmission of infection from an infective to a susceptible individual.", [["infection", "DISEASE", 279, 288], ["temporary immunity", "TREATMENT", 38, 56], ["reinfection", "PROBLEM", 65, 76], ["infection", "PROBLEM", 279, 288], ["an infective", "PROBLEM", 294, 306], ["infection", "OBSERVATION", 279, 288], ["infective", "OBSERVATION", 297, 306]]], ["The earliest models assumed a mass-action incidence law, possibly suggested by Hamer [6] and certainly present in the Ross malaria model.", [["malaria", "DISEASE", 123, 130], ["a mass", "PROBLEM", 28, 34], ["mass", "OBSERVATION", 30, 34], ["Ross", "ANATOMY", 118, 122], ["malaria", "OBSERVATION", 123, 130]]], ["This law assumes that the average number of contacts sufficient to produce infection per individual in unit time is proportional to the population density.", [["infection", "DISEASE", 75, 84], ["infection", "PROBLEM", 75, 84], ["infection", "OBSERVATION", 75, 84], ["population", "OBSERVATION_MODIFIER", 136, 146], ["density", "OBSERVATION", 147, 154]]], ["More recently, it has been noted that actual contact rates are not strongly dependent on population density.", [["density", "OBSERVATION", 100, 107]]], ["This suggests other forms for transmission rates, such as \"standard incidence\", in which it is assumed that the average number of contacts per individual in unit time is constant, or some sort of saturating contact rate [27,28]; see also [29-31] for recent references.History of epidemiological modellingOne main focus of mathematical epidemiology has been on the understanding and computation of the basic reproduction number in models with various kinds of heterogeneity.", [["transmission rates", "PROBLEM", 30, 48], ["main", "OBSERVATION_MODIFIER", 308, 312], ["various kinds", "OBSERVATION_MODIFIER", 442, 455], ["heterogeneity", "OBSERVATION", 459, 472]]], ["The addition of more structure in an epidemic model makes the interpretation and calculation of the basic reproduction number more difficult.", [["more structure", "OBSERVATION_MODIFIER", 16, 30]]], ["The basic reproduction number, now universally denoted by \u211b0, is undoubtedly the most central idea in mathematical epidemiology, and its importance lies in its broad generality.History of epidemiological modellingIn an epidemic situation, where the time scale is short enough that there is are no births and no recruitment of new susceptibles into the population, and where recovery from disease confers full immunity against reinfection, the basic reproduction number marks a threshold between disappearance of the infection (basic reproduction number less than one) and the outbreak of an epidemic (basic reproduction number greater than one).History of epidemiological modellingIf there is a flow into the population of new susceptibles, the situation is different.", [["reinfection", "DISEASE", 426, 437], ["infection", "DISEASE", 516, 525], ["disease", "PROBLEM", 388, 395], ["reinfection", "PROBLEM", 426, 437], ["the infection", "PROBLEM", 512, 525], ["an epidemic", "PROBLEM", 588, 599], ["broad", "OBSERVATION_MODIFIER", 160, 165], ["epidemic", "OBSERVATION_MODIFIER", 219, 227], ["no", "UNCERTAINTY", 294, 296], ["infection", "OBSERVATION", 516, 525], ["epidemic", "OBSERVATION_MODIFIER", 591, 599], ["new", "OBSERVATION_MODIFIER", 723, 726], ["different", "OBSERVATION_MODIFIER", 758, 767]]], ["If the basic reproduction number is less than one, there is a disease-free equilibrium and the infection dies out; if the basic reproduction number exceeds one, there is an endemic equilibrium and the disease may remain in the population.", [["infection", "DISEASE", 95, 104], ["a disease-free equilibrium", "PROBLEM", 60, 86], ["the infection", "PROBLEM", 91, 104], ["an endemic equilibrium", "PROBLEM", 170, 192], ["the disease", "PROBLEM", 197, 208], ["disease", "OBSERVATION", 62, 69], ["free equilibrium", "OBSERVATION", 70, 86], ["infection", "OBSERVATION", 95, 104], ["endemic", "OBSERVATION_MODIFIER", 173, 180], ["equilibrium", "OBSERVATION", 181, 192], ["disease", "OBSERVATION", 201, 208]]], ["Some of the Kermack-McKendrick models [3,9,10] included proportional birth and death rates, which could allow exponential population growth in the absence of disease.", [["death", "DISEASE", 79, 84], ["death rates", "TEST", 79, 90], ["exponential population growth", "PROBLEM", 110, 139], ["disease", "PROBLEM", 158, 165], ["disease", "OBSERVATION", 158, 165]]], ["For highly endemic diseases in resource-constrained countries, this is a plausible assumption.", [["highly endemic diseases", "PROBLEM", 4, 27], ["endemic", "OBSERVATION_MODIFIER", 11, 18], ["diseases", "OBSERVATION", 19, 27]]], ["The question of whether and how an infectious disease alters the pattern of population growth is of particular concern [37].", [["infectious disease", "DISEASE", 35, 53], ["an infectious disease alters", "PROBLEM", 32, 60], ["population growth", "PROBLEM", 76, 93], ["infectious", "OBSERVATION", 35, 45]]], ["However, in countries with more resources, it is more natural to expect bounded population size, suggesting nonlinear demographics.", [["population", "OBSERVATION_MODIFIER", 80, 90], ["size", "OBSERVATION_MODIFIER", 91, 95], ["suggesting", "UNCERTAINTY", 97, 107], ["nonlinear demographics", "OBSERVATION", 108, 130]]], ["A first step is to assume a balance between births and deaths, keeping a constant total population size [22,38,39].", [["deaths", "DISEASE", 55, 61], ["size", "OBSERVATION_MODIFIER", 99, 103]]], ["However, if there are deaths due to disease or a disease-related reduction of births, then it is not possible to keep the total population size constant and it is natural to assume nonlinear demographics, with density-dependent birth rates.", [["deaths", "DISEASE", 22, 28], ["disease", "PROBLEM", 36, 43], ["a disease", "PROBLEM", 47, 56], ["reduction", "OBSERVATION_MODIFIER", 65, 74], ["not possible", "UNCERTAINTY", 97, 109], ["size", "OBSERVATION_MODIFIER", 139, 143]]], ["An important direction of generalization has been the addition of more heterogeneity of various kinds in models.", [["various kinds", "OBSERVATION_MODIFIER", 88, 101]]], ["One kind of heterogeneity is heterogeneity of behaviour and the possibility that different subsets of a population may mix with different frequencies.", [["heterogeneity of behaviour", "PROBLEM", 29, 55], ["heterogeneity", "OBSERVATION", 12, 25], ["heterogeneity", "OBSERVATION_MODIFIER", 29, 42], ["different", "OBSERVATION_MODIFIER", 81, 90], ["subsets", "OBSERVATION_MODIFIER", 91, 98]]], ["This idea has been especially important in the study of sexually transmitted diseases [43-48], a topic of continuing interest.", [["sexually transmitted diseases", "DISEASE", 56, 85], ["sexually transmitted diseases", "PROBLEM", 56, 85]]], ["An important aspect of sexually transmitted diseases is that there is often a \"core\" group of very highly active individuals who are responsible for most of the disease transmission; control efforts aimed at this core group are likely to be most effective for control.", [["sexually transmitted diseases", "DISEASE", 23, 52], ["sexually transmitted diseases", "PROBLEM", 23, 52], ["the disease transmission", "PROBLEM", 157, 181]]], ["This was analyzed in models in [49,50] and the translation of this analysis into action has been effective, especially for gonorrhea.History of epidemiological modellingOther heterogeneities are also important.", [["gonorrhea", "DISEASE", 123, 132], ["this analysis", "TEST", 62, 75], ["gonorrhea", "PROBLEM", 123, 132], ["epidemiological modellingOther heterogeneities", "PROBLEM", 144, 190], ["heterogeneities", "OBSERVATION", 175, 190]]], ["Many \"childhood\" diseases are transmitted mainly in school between children of the same age.", [["children", "ORGANISM", 67, 75], ["children", "SPECIES", 67, 75], ["Many \"childhood\" diseases", "PROBLEM", 0, 25], ["diseases", "OBSERVATION", 17, 25]]], ["The incorporation of age structure leads to possibilities of behaviour that are not possible without the age dependence, such as sustained oscillations [19,58,59].", [["sustained oscillations", "PROBLEM", 129, 151], ["not possible", "UNCERTAINTY", 80, 92]]], ["However, there is no indication of period-doubling or chaotic behaviour unless seasonal variation of contacts is assumed [16,60].", [["chaotic behaviour", "PROBLEM", 54, 71], ["no indication of", "UNCERTAINTY", 18, 34]]], ["Age structure is an important aspect in the transmission of childhood diseases [61], e.g., for pertussis [62], rubella [29] and varicella [63]; it must be included in models designed to suggest realistic vaccination strategies.", [["pertussis", "DISEASE", 95, 104], ["rubella", "DISEASE", 111, 118], ["varicella", "DISEASE", 128, 137], ["rubella", "ORGANISM", 111, 118], ["childhood diseases", "PROBLEM", 60, 78], ["pertussis", "TEST", 95, 104], ["rubella", "TEST", 111, 118], ["varicella", "TEST", 128, 137], ["realistic vaccination strategies", "TREATMENT", 194, 226], ["important", "OBSERVATION_MODIFIER", 20, 29]]], ["Optimal ages of vaccination are considered in [64,65].", [["vaccination", "TREATMENT", 16, 27]]], ["Age structure can also be incorporated as the time since becoming infected (age of infection) [66].", [["infection", "DISEASE", 83, 92], ["infection", "PROBLEM", 83, 92], ["infected", "OBSERVATION", 66, 74]]], ["This is an important characteristic of HIV/AIDS models [67].History of epidemiological modellingSpatial heterogeneity in disease models takes two forms.", [["HIV/AIDS", "DISEASE", 39, 47], ["HIV", "ORGANISM", 39, 42], ["HIV", "SPECIES", 39, 42], ["HIV/AIDS models", "PROBLEM", 39, 54], ["epidemiological modellingSpatial heterogeneity in disease models", "PROBLEM", 71, 135], ["Spatial heterogeneity", "OBSERVATION", 96, 117], ["disease", "OBSERVATION", 121, 128]]], ["One is local, namely diffusion in space.", [["local", "OBSERVATION_MODIFIER", 7, 12], ["diffusion", "OBSERVATION_MODIFIER", 21, 30]]], ["An introduction to models for the spatial spread of epidemics may be found in [[68], Chapter 20]; other references are [34,51,69-71].", [["epidemics", "PROBLEM", 52, 61]]], ["One characteristic feature of such models is the appearance of traveling waves, which have been observed frequently in the spread of epidemics through Europe from medieval times to the more recent studies of fox rabies [68,72].", [["rabies", "DISEASE", 212, 218], ["fox rabies", "ORGANISM", 208, 218], ["fox rabies", "SPECIES", 208, 218], ["such models", "PROBLEM", 30, 41], ["such models", "OBSERVATION", 30, 41]]], ["The asymptotic speed of spread of disease is the minimum wave speed [73-79].", [["disease", "PROBLEM", 34, 41], ["asymptotic", "OBSERVATION_MODIFIER", 4, 14], ["speed", "OBSERVATION_MODIFIER", 15, 20], ["spread", "OBSERVATION_MODIFIER", 24, 30], ["disease", "OBSERVATION", 34, 41]]], ["Models describing spatial spread and including age of infection are analyzed in [68,80,81].History of epidemiological modellingA second form of spatial heterogeneity is related to travel.", [["infection", "DISEASE", 54, 63], ["spatial spread", "PROBLEM", 18, 32], ["infection", "PROBLEM", 54, 63], ["spatial heterogeneity", "PROBLEM", 144, 165], ["spatial", "OBSERVATION_MODIFIER", 18, 25], ["spread", "OBSERVATION_MODIFIER", 26, 32], ["infection", "OBSERVATION", 54, 63], ["spatial", "OBSERVATION_MODIFIER", 144, 151], ["heterogeneity", "OBSERVATION", 152, 165]]], ["With the advent of intercontinental air travel, it is possible for diseases to move from one location to a completely separate location very rapidly; this has led to the study of metapopulation models or models with patchy environments and movement between patches [82-88].History of epidemiological modellingFor some diseases (e.g., Chagas' disease), the epidemiological unit may not be an individual, but the essential question may be whether a household is infected [89]; see also [90-92] for more recent stochastic models that include household structure.History of epidemiological modellingGeneral models for diseases with vector transmission [24,93,94] grew out of the Ross malaria model.", [["Chagas' disease", "DISEASE", 334, 349], ["malaria", "DISEASE", 680, 687], ["intercontinental air travel", "TREATMENT", 19, 46], ["diseases", "PROBLEM", 67, 75], ["the study", "TEST", 166, 175], ["metapopulation models", "TEST", 179, 200], ["patchy environments", "PROBLEM", 216, 235], ["some diseases", "PROBLEM", 313, 326], ["Chagas' disease", "PROBLEM", 334, 349], ["diseases", "PROBLEM", 614, 622], ["vector transmission", "TEST", 628, 647], ["the Ross malaria model", "PROBLEM", 671, 693], ["air travel", "OBSERVATION", 36, 46], ["patchy", "OBSERVATION_MODIFIER", 216, 222], ["Ross malaria", "OBSERVATION", 675, 687]]], ["Vector transmission means simply that infection goes back and forth between two populations rather than being transmitted directly.", [["infection", "DISEASE", 38, 47], ["infection", "PROBLEM", 38, 47], ["infection", "OBSERVATION", 38, 47]]], ["Vector models are also appropriate in the study of heterosexually transmitted diseases, where the two populations are the males and females of the same species.History of epidemiological modellingVertical transmission, where newborn members of a population are infected, is a feature of many diseases, such as HIV/AIDS and Chagas' disease.", [["heterosexually transmitted diseases", "DISEASE", 51, 86], ["HIV/AIDS", "DISEASE", 310, 318], ["Chagas' disease", "DISEASE", 323, 338], ["HIV", "SPECIES", 310, 313], ["HIV", "SPECIES", 310, 313], ["Vector models", "TREATMENT", 0, 13], ["the study", "TEST", 38, 47], ["heterosexually transmitted diseases", "PROBLEM", 51, 86], ["many diseases", "PROBLEM", 287, 300], ["HIV/AIDS", "PROBLEM", 310, 318], ["Chagas' disease", "PROBLEM", 323, 338], ["diseases", "OBSERVATION", 78, 86], ["two", "OBSERVATION_MODIFIER", 98, 101], ["populations", "OBSERVATION_MODIFIER", 102, 113], ["males", "OBSERVATION", 122, 127], ["infected", "OBSERVATION", 261, 269], ["many", "OBSERVATION_MODIFIER", 287, 291], ["diseases", "OBSERVATION", 292, 300]]], ["A thorough description of diseases and models that include vertical transmission may be found in [95].History of epidemiological modellingThe original compartmental models assumed the rate of movement out of a compartment to be proportional to the number of members in the compartment.", [["diseases and models", "PROBLEM", 26, 45], ["epidemiological modelling", "PROBLEM", 113, 138], ["diseases", "OBSERVATION", 26, 34], ["compartment", "ANATOMY", 273, 284]]], ["This is equivalent to the assumption of an exponentially distributed time spent in the compartment and leads to an ordinary differential equation model.", [["exponentially", "OBSERVATION_MODIFIER", 43, 56], ["distributed", "OBSERVATION_MODIFIER", 57, 68], ["time", "OBSERVATION_MODIFIER", 69, 73], ["compartment", "ANATOMY", 87, 98]]], ["For many diseases, a fixed time in a compartment, corresponding to a differential-difference equation model, is more realistic [96-100].", [["many diseases", "PROBLEM", 4, 17], ["many", "OBSERVATION_MODIFIER", 4, 8], ["diseases", "OBSERVATION", 9, 17]]], ["More generally, an arbitrary distribution of times spent in a compartment can be assumed (see [102] and the bibliographical remarks there), leading to an integral equation or integro-differential equation model.", [["an integral equation", "TEST", 151, 171]]], ["The qualitative analysis of such models leads to questions of the location of roots of a transcendental equation.", [["roots", "ANATOMY", 78, 83], ["roots", "ORGAN", 78, 83], ["The qualitative analysis", "TEST", 0, 24]]], ["One consequence of results for such models is the possibility of unstable equilibria and sustained oscillations for some parameter sets in epidemic models.", [["such models", "PROBLEM", 31, 42], ["unstable equilibria and sustained oscillations", "PROBLEM", 65, 111], ["unstable", "OBSERVATION_MODIFIER", 65, 73], ["equilibria", "OBSERVATION", 74, 84], ["sustained", "OBSERVATION_MODIFIER", 89, 98], ["oscillations", "OBSERVATION", 99, 111]]], ["As these oscillations may have large amplitude and long period, they would be very troublesome in disease management.", [["disease management", "TREATMENT", 98, 116], ["large", "OBSERVATION_MODIFIER", 31, 36], ["amplitude", "OBSERVATION_MODIFIER", 37, 46], ["long period", "OBSERVATION_MODIFIER", 51, 62]]], ["There have been several surveys of results of this nature [101,107], and work in this area continues [108,109].History of epidemiological modellingContinuing in the tradition of Ross, there have been studies that focussed on specific diseases; see, for example, [35,49,110-114].", [["specific diseases", "PROBLEM", 225, 242]]], ["However, it should not be overlooked that some fundamental ideas of practical importance, such as the relation between mean age at infection and the basic reproduction number, the concept of herd immunity, and the formulation of immunization strategies, were developed from simple, general models.", [["infection", "DISEASE", 131, 140], ["mean age at infection", "PROBLEM", 119, 140], ["herd immunity", "TREATMENT", 191, 204], ["immunization strategies", "TREATMENT", 229, 252], ["infection", "OBSERVATION", 131, 140]]], ["For example, from data on smallpox, an estimated \u211b0 can be used to show that an immunization coverage of 70-80% should be sufficient to eradicate the disease [[111], Table 5.1].", [["smallpox", "DISEASE", 26, 34], ["smallpox", "TREATMENT", 26, 34], ["an immunization coverage", "TEST", 77, 101], ["the disease", "PROBLEM", 146, 157]]], ["The eradication of smallpox, declared in 1980 [115], was achieved by worldwide vaccination, and was a triumph for public health.", [["smallpox", "DISEASE", 19, 27], ["smallpox", "TREATMENT", 19, 27]]], ["We will not go into the description and development of such models here, but some useful references are [20,90-92,114,116-124].History of epidemiological modellingAnother, relatively recent, development in disease transmission modelling has been the use of network models and detailed study of the network of contacts of an individual.", [["detailed study", "TEST", 276, 290], ["disease", "OBSERVATION", 206, 213]]], ["Again, we do not go into the description and development but merely cite references [125-131] for the theoretical background and [132-136] for some simulations using network models for predictions of influenza pandemics.", [["influenza pandemics", "DISEASE", 200, 219], ["influenza pandemics", "PROBLEM", 200, 219]]], ["The origins of the study of mathematical epidemiology come from outside mathematics.", [["the study", "TEST", 15, 24]]], ["Another important source of information about mathematical epidemiology is [111], which includes both descriptions of the properties of many communicable diseases and mathematical models.", [["communicable diseases", "DISEASE", 141, 162], ["many communicable diseases", "PROBLEM", 136, 162]]], ["We may hope that if mathematicians and epidemiologists can come together, a history written in a few years would be radically different from a history that might be written today.What has modelling accomplished?We have already mentioned two of the most striking contributions of mathematical modelling to disease management: the control of malaria through control of mosquitoes [8] and the elimination of smallpox by a sufficiently high vaccination rate [115].", [["malaria", "DISEASE", 340, 347], ["smallpox", "DISEASE", 405, 413], ["disease management", "TREATMENT", 305, 323], ["malaria", "PROBLEM", 340, 347], ["smallpox", "TREATMENT", 405, 413]]], ["Sir R. A. Ross was awarded the second Nobel prize in Medicine in 1902 for his work, beginning in 1882, in which he established that malaria was spread through contacts between humans and mosquitoes.", [["malaria", "DISEASE", 132, 139], ["humans", "ORGANISM", 176, 182], ["humans", "SPECIES", 176, 182], ["humans", "SPECIES", 176, 182], ["malaria", "PROBLEM", 132, 139], ["malaria", "OBSERVATION", 132, 139]]], ["Even though this discovery was honoured in the medical community, his conclusion that control of mosquitoes would be an aid in controlling malaria was not accepted because it was felt that it would be impossible to rid a region of mosquitoes and keep it mosquito-free.", [["malaria", "DISEASE", 139, 146], ["mosquitoes", "ORGANISM", 97, 107], ["mosquitoes", "TREATMENT", 97, 107], ["controlling malaria", "PROBLEM", 127, 146], ["mosquitoes", "PROBLEM", 231, 241]]], ["Only after Ross described a mathematical model [8] indicating that it was not necessary to remove the entire mosquito population to control the disease was this strategy adopted, with great success.", [["the disease", "PROBLEM", 140, 151], ["disease", "OBSERVATION", 144, 151]]], ["In fact, Ross's model proved to be such a robust description of malaria that it remained current for about 50 years until it was updated by MacDonald [137].What has modelling accomplished?Vaccination for smallpox, the world's first vaccine, was begun in 1796 by Edward Jenner, who had observed that people who had been infected with cowpox did not get smallpox.", [["malaria", "DISEASE", 64, 71], ["smallpox", "DISEASE", 204, 212], ["smallpox", "DISEASE", 352, 360], ["people", "ORGANISM", 299, 305], ["cowpox", "ORGANISM", 333, 339], ["people", "SPECIES", 299, 305], ["cowpox", "SPECIES", 333, 339], ["malaria", "PROBLEM", 64, 71], ["Vaccination", "TREATMENT", 188, 199], ["smallpox", "TREATMENT", 204, 212], ["cowpox", "PROBLEM", 333, 339], ["malaria", "OBSERVATION", 64, 71], ["infected", "OBSERVATION", 319, 327]]], ["The recognition, from a smallpox model involving herd immunity, that vaccination of 70 - 80% of a population would eliminate smallpox, led to an eradication program by the World Health Organization beginning in 1967; the last case in the Americas was in 1971 and the last case worldwide was in Somalia in 1977 [8,115,138-140].What has modelling accomplished?Measles is a childhood disease which is easily controlled by vaccination, but in many resource-constrained countries, few children are vaccianted against measles and there are a million deaths from smallpox worldwide.", [["smallpox", "DISEASE", 24, 32], ["smallpox", "DISEASE", 125, 133], ["Measles", "DISEASE", 358, 365], ["measles", "DISEASE", 512, 519], ["deaths", "DISEASE", 544, 550], ["smallpox", "DISEASE", 556, 564], ["herd", "ORGANISM_SUBDIVISION", 49, 53], ["children", "ORGANISM", 480, 488], ["children", "SPECIES", 480, 488], ["vaccination", "TREATMENT", 69, 80], ["an eradication program", "TREATMENT", 142, 164], ["a childhood disease", "PROBLEM", 369, 388], ["childhood", "OBSERVATION_MODIFIER", 371, 380], ["disease", "OBSERVATION", 381, 388]]], ["Models with age structure have compared a strategy of a single dose of vaccine to a two-dose strategy; epidemiologists have concluded that a two-dose strategy of doses at age 12 to 15 months and 4 to 6 years is more effective.", [["vaccine", "TREATMENT", 71, 78], ["a two-dose strategy", "TREATMENT", 82, 101], ["a two-dose strategy of doses", "TREATMENT", 139, 167]]], ["However, herd immunity would require an immune fraction of at least 0.94.", [["an immune fraction", "TEST", 37, 55]]], ["Since vaccine efficacy for measles is about 0.95, it is unlikely that this can be achieved [29,141].", [["measles", "DISEASE", 27, 34], ["vaccine efficacy", "TREATMENT", 6, 22], ["measles", "PROBLEM", 27, 34]]], ["Thus, elimination of measles is unlikely to be achievable.What has modelling accomplished?Another example of an important contribution of mathematical modelling is the control of sexually transmitted diseases through concentration on the most active members of the population [49].", [["measles", "DISEASE", 21, 28], ["sexually transmitted diseases", "DISEASE", 179, 208], ["measles", "ORGANISM", 21, 28], ["measles", "PROBLEM", 21, 28], ["sexually transmitted diseases", "PROBLEM", 179, 208], ["measles", "OBSERVATION", 21, 28], ["unlikely to be", "UNCERTAINTY", 32, 46]]], ["Others include the management of bovine hoof and mouth disease in Great Britain through a process of culling infected herds of cattle as suggested by models [142,143].What has modelling accomplished?To epidemiologists, the measure of whether a disease outbreak has been controlled is whether the reproduction number has been reduced to a value less than one.", [["hoof", "ANATOMY", 40, 44], ["mouth", "ANATOMY", 49, 54], ["bovine hoof and mouth disease", "DISEASE", 33, 62], ["bovine", "ORGANISM", 33, 39], ["hoof", "ORGANISM_SUBDIVISION", 40, 44], ["mouth", "ORGAN", 49, 54], ["cattle", "ORGANISM", 127, 133], ["bovine", "SPECIES", 33, 39], ["cattle", "SPECIES", 127, 133], ["bovine", "SPECIES", 33, 39], ["cattle", "SPECIES", 127, 133], ["the management", "TREATMENT", 15, 29], ["bovine hoof", "PROBLEM", 33, 44], ["mouth disease", "PROBLEM", 49, 62], ["a disease outbreak", "PROBLEM", 242, 260], ["bovine hoof", "OBSERVATION", 33, 44], ["mouth", "ANATOMY", 49, 54], ["disease", "OBSERVATION", 55, 62], ["disease", "OBSERVATION", 244, 251]]], ["During the SARS epidemic of 2002-2003, the estimation of \u211b0 was the focus of many studies [144-146] and, after the epidemic had passed, models to compare the contribution of contact tracing and quarantine of suspected cases with the contribution of diagnosed infectives were studied.", [["SARS", "DISEASE", 11, 15], ["infectives", "DISEASE", 259, 269], ["infectives", "CANCER", 259, 269], ["many studies", "TEST", 77, 89], ["contact tracing", "TEST", 174, 189], ["diagnosed infectives", "PROBLEM", 249, 269]]], ["The conclusion appears to be that isolation was more effective and much less costly, partly because fewer than 5% of the people identified by contact tracing developed disease [147].", [["people", "ORGANISM", 121, 127], ["people", "SPECIES", 121, 127], ["disease", "PROBLEM", 168, 175], ["appears to be", "UNCERTAINTY", 15, 28], ["isolation", "OBSERVATION", 34, 43]]], ["However, if infectivity had developed before the appearance of symptoms, which is now considered not to have been the case for SARS, contact tracing would have been more useful.", [["SARS", "DISEASE", 127, 131], ["infectivity", "PROBLEM", 12, 23], ["symptoms", "PROBLEM", 63, 71], ["SARS", "PROBLEM", 127, 131], ["contact tracing", "TEST", 133, 148]]], ["The lessons learned from SARS are being applied to planning for a possible influenza pandemic.What has modelling accomplished?For most disease transmission models, the expected situation is that if the basic reproduction number is less than one, then there is a globally asymptotic disease-free equilibrium, while if the basic reproduction number exceeds one, there is an endemic equilibrium.", [["SARS", "DISEASE", 25, 29], ["influenza", "DISEASE", 75, 84], ["SARS", "PROBLEM", 25, 29], ["influenza pandemic", "PROBLEM", 75, 93], ["most disease transmission models", "PROBLEM", 130, 162], ["a globally asymptotic disease", "PROBLEM", 260, 289], ["an endemic equilibrium", "PROBLEM", 369, 391], ["globally", "OBSERVATION_MODIFIER", 262, 270], ["asymptotic", "OBSERVATION_MODIFIER", 271, 281], ["disease", "OBSERVATION", 282, 289], ["free equilibrium", "OBSERVATION", 290, 306], ["endemic", "OBSERVATION_MODIFIER", 372, 379], ["equilibrium", "OBSERVATION", 380, 391]]], ["There are some situations [148-154] in which there may be a backward bifurcation for some parameter values as the basic reproduction number passes through one.", [["some situations", "PROBLEM", 10, 25], ["some parameter values", "PROBLEM", 85, 106], ["may be", "UNCERTAINTY", 51, 57], ["backward bifurcation", "OBSERVATION", 60, 80]]], ["In such cases, there may be an endemic equilibrium when the basic reproduction number is less than one (ruling out global asymptotic stability of the disease-free equilibrium) with discontinuities in behaviour as the basic reproduction number changes.", [["an endemic equilibrium", "PROBLEM", 28, 50], ["the disease", "PROBLEM", 146, 157], ["discontinuities in behaviour", "PROBLEM", 181, 209], ["may be", "UNCERTAINTY", 21, 27], ["endemic", "OBSERVATION_MODIFIER", 31, 38], ["equilibrium", "OBSERVATION", 39, 50]]], ["Such behaviour is very unsettling for disease management and it is important to know from models when it can occur so that control evaluation can allow for the possibility.", [["disease management", "TREATMENT", 38, 56], ["control evaluation", "TEST", 123, 141]]], ["It can arise if there are groups with different susceptibility to infection or different contact rates as in models with partially effective vaccination [44,45,148,155,156].What has modelling accomplished?Expressions for the basic reproductive number for HIV in various populations have been used to test the possible effectiveness of vaccines that may provide temporary protection by reducing either HIV-infectiousness or susceptibility to HIV.", [["infection", "DISEASE", 66, 75], ["HIV-infectiousness", "DISEASE", 401, 419], ["HIV", "DISEASE", 441, 444], ["HIV", "ORGANISM", 255, 258], ["HIV", "ORGANISM", 441, 444], ["HIV", "SPECIES", 255, 258], ["HIV", "SPECIES", 401, 404], ["HIV", "SPECIES", 441, 444], ["HIV", "SPECIES", 255, 258], ["HIV", "SPECIES", 401, 404], ["HIV", "SPECIES", 441, 444], ["different susceptibility to infection", "PROBLEM", 38, 75], ["HIV in various populations", "PROBLEM", 255, 281], ["vaccines", "TREATMENT", 335, 343], ["temporary protection", "TREATMENT", 361, 381], ["infectiousness", "PROBLEM", 405, 419], ["HIV", "PROBLEM", 441, 444], ["infection", "OBSERVATION", 66, 75]]], ["Models are used to estimate how widespread a vaccination plan must be to prevent or reduce the spread of HIV.Challenges for the futureWhile there are many infectious diseases which may pose huge problems in the near future, perhaps the two of most current concern are pandemic influenza and HIV/AIDS.", [["HIV", "DISEASE", 105, 108], ["influenza", "DISEASE", 277, 286], ["HIV/AIDS", "DISEASE", 291, 299], ["HIV", "ORGANISM", 105, 108], ["HIV", "SPECIES", 105, 108], ["HIV", "SPECIES", 291, 294], ["HIV", "SPECIES", 105, 108], ["HIV", "SPECIES", 291, 294], ["a vaccination plan", "TREATMENT", 43, 61], ["HIV", "PROBLEM", 105, 108], ["many infectious diseases", "PROBLEM", 150, 174], ["pandemic influenza", "PROBLEM", 268, 286], ["HIV/AIDS", "PROBLEM", 291, 299], ["many", "OBSERVATION_MODIFIER", 150, 154], ["infectious", "OBSERVATION", 155, 165], ["huge", "OBSERVATION_MODIFIER", 190, 194]]], ["For both, there are serious logistical questions concerning the availability and distribution of resources for management.", [["management", "TREATMENT", 111, 121]]], ["Some basic questions are:Challenges for the future\u2022 How large a supply of drugs and medicines is needed?Challenges for the future\u2022 How can the necessary drugs and medicines be distributed?Challenges for the future\u2022 What happens to management strategies if the supply is insufficient?Challenges for the future\u2022 What might be the effects of the development of drug-resistant strains of infection?Challenges for the future\u2022 Can social distancing initiatives be helpful in disease management?Challenges for the futureFor HIV, one of whose aspects is the variation of infectivity with time since infection, detailed models will require an understanding of the development of virus in a host; models will need to link immunology and the cell level with infection and the individual level.", [["cell", "ANATOMY", 731, 735], ["infection", "DISEASE", 384, 393], ["infection", "DISEASE", 591, 600], ["infection", "DISEASE", 747, 756], ["cell", "CELL", 731, 735], ["HIV", "SPECIES", 517, 520], ["HIV", "SPECIES", 517, 520], ["drugs", "TREATMENT", 74, 79], ["medicines", "TREATMENT", 84, 93], ["the necessary drugs", "TREATMENT", 139, 158], ["medicines", "TREATMENT", 163, 172], ["management strategies", "TREATMENT", 231, 252], ["drug-resistant strains of infection", "PROBLEM", 358, 393], ["disease management", "TREATMENT", 469, 487], ["HIV", "PROBLEM", 517, 520], ["infectivity", "PROBLEM", 563, 574], ["infection", "PROBLEM", 591, 600], ["virus", "PROBLEM", 670, 675], ["infection", "PROBLEM", 747, 756], ["infection", "OBSERVATION", 384, 393], ["infection", "OBSERVATION", 591, 600], ["virus", "OBSERVATION", 670, 675], ["infection", "OBSERVATION", 747, 756]]], ["Another difficulty in understanding HIV is that HIV can be a dormant virus in immune cells.", [["immune cells", "ANATOMY", 78, 90], ["HIV", "ORGANISM", 36, 39], ["HIV", "ORGANISM", 48, 51], ["immune cells", "CELL", 78, 90], ["immune cells", "CELL_TYPE", 78, 90], ["HIV", "SPECIES", 36, 39], ["HIV", "SPECIES", 48, 51], ["HIV", "SPECIES", 36, 39], ["HIV", "SPECIES", 48, 51], ["HIV", "PROBLEM", 48, 51], ["a dormant virus in immune cells", "PROBLEM", 59, 90], ["immune cells", "OBSERVATION", 78, 90]]], ["The study of HIV on a cell level is well under way, but there is much more to be done; some basic references are [157-162].", [["cell", "ANATOMY", 22, 26], ["HIV", "ORGANISM", 13, 16], ["cell", "CELL", 22, 26], ["HIV", "SPECIES", 13, 16], ["HIV", "SPECIES", 13, 16], ["The study", "TEST", 0, 9], ["HIV", "PROBLEM", 13, 16], ["a cell level", "TEST", 20, 32]]], ["Another aspect of HIV is the recognition that transmission depends strongly on the heterogeneity of contacts.", [["HIV", "ORGANISM", 18, 21], ["HIV", "SPECIES", 18, 21], ["HIV", "SPECIES", 18, 21], ["HIV", "PROBLEM", 18, 21], ["HIV", "OBSERVATION", 18, 21]]], ["Because HIV/AIDS is a disease with complicated scientific properties, it is of great interest to theoretical modelers, and because HIV/AIDS is so widespread and devastating, it is of great interest to scientists and also to governments.", [["HIV/AIDS", "DISEASE", 8, 16], ["HIV/AIDS", "DISEASE", 131, 139], ["HIV", "ORGANISM", 8, 11], ["HIV", "SPECIES", 8, 11], ["HIV", "SPECIES", 8, 11], ["HIV", "SPECIES", 131, 134], ["HIV/AIDS", "PROBLEM", 8, 16], ["a disease", "PROBLEM", 20, 29], ["HIV/AIDS", "PROBLEM", 131, 139], ["devastating", "OBSERVATION_MODIFIER", 161, 172]]], ["It is reasonable to hope that sufficient funding for research and treatment may be forthcoming.Challenges for the futureMathematical modelling has been a vital link between mathematics and physics for many years.", [["treatment", "TREATMENT", 66, 75]]]], "PMC7121307": [["22.1.1 Eindstadium chronische leverziekte ::: 22.1 IndicatiesEindstadium chronische leverziekte betreft met name levercirrose, maar ook bijvoorbeeld het Budd-Chiari-syndroom, in een eindstadium.", [["Eindstadium chronische leverziekte", "TEST", 7, 41], ["Eindstadium", "TEST", 61, 72], ["maar", "TEST", 127, 131]]], ["Dat wil zeggen dat er sprake is van leverfalen (zie hoofdstuk 10.1007/978-90-313-7437-3_7).", [["Dat wil zeggen dat er sprake is van leverfalen (zie hoofdstuk 10.1007/978-90-313-7437-3_7", "SPECIES", 0, 89]]], ["Bij een Child-Pugh klasse C, of B met progressie is er veelal een indicatie voor levertransplantatie.[1]", [["Pugh klasse C", "TREATMENT", 14, 27]]]], "0739cffe7d2e7b6785f9ef0a35f3286202caad3b": [["IntroductionPreventing the spread of virulent microorganisms is an essential part of infection control programmes [1] where hand disinfection plays a pivotal role.", [["hand", "ANATOMY", 124, 128], ["infection", "DISEASE", 85, 94], ["hand", "ORGANISM_SUBDIVISION", 124, 128], ["Introduction", "TREATMENT", 0, 12], ["virulent microorganisms", "PROBLEM", 37, 60], ["infection control programmes", "TREATMENT", 85, 113], ["hand disinfection", "TREATMENT", 124, 141], ["infection", "OBSERVATION", 85, 94]]], ["The microbiological flora on the hands can be classified into resident and transient groups.", [["hands", "ORGANISM_SUBDIVISION", 33, 38], ["microbiological flora", "OBSERVATION", 4, 25]]], ["Organisms in the former normal flora group are stable and reproduce locally, are generally non-virulent, and the concentrations can only be reduced with disinfection.", [["Organisms", "PROBLEM", 0, 9], ["disinfection", "PROBLEM", 153, 165], ["flora group", "OBSERVATION_MODIFIER", 31, 42], ["stable", "OBSERVATION_MODIFIER", 47, 53], ["generally", "OBSERVATION_MODIFIER", 81, 90], ["non-virulent", "OBSERVATION", 91, 103]]], ["In contrast, transient microbes do not reproduce while on the hands, and are normally only viable for a short time.", [["transient microbes", "PROBLEM", 13, 31], ["transient", "OBSERVATION_MODIFIER", 13, 22], ["microbes", "OBSERVATION", 23, 31]]], ["However, they can be pathogenic, easily transmitted or colonize skin wounds or dermatitis [1, 2] .IntroductionConsidering the necessity for frequent hand sanitization in hospitals, healthcare workers (HCW) show a high prevalence of skin irritation [3] .", [["skin wounds", "ANATOMY", 64, 75], ["hand", "ANATOMY", 149, 153], ["skin", "ANATOMY", 232, 236], ["skin wounds", "DISEASE", 64, 75], ["dermatitis", "DISEASE", 79, 89], ["skin irritation", "DISEASE", 232, 247], ["skin wounds", "PATHOLOGICAL_FORMATION", 64, 75], ["hand", "ORGANISM_SUBDIVISION", 149, 153], ["skin", "ORGAN", 232, 236], ["pathogenic", "PROBLEM", 21, 31], ["colonize skin wounds", "PROBLEM", 55, 75], ["dermatitis", "PROBLEM", 79, 89], ["frequent hand sanitization", "TREATMENT", 140, 166], ["skin irritation", "PROBLEM", 232, 247], ["skin", "ANATOMY", 64, 68], ["wounds", "OBSERVATION", 69, 75], ["dermatitis", "OBSERVATION", 79, 89], ["skin", "ANATOMY", 232, 236], ["irritation", "OBSERVATION", 237, 247]]], ["Studies have found a high prevalence of bacteria on the hands of healthcare personnel, and the Center for Disease Control have reported that frequent hand washing amongst HCW ranges from 5% to 81%, with an average of 40% [4] .IntroductionThe maintenance of healthy skin is crucial for HCW.", [["hand", "ANATOMY", 150, 154], ["skin", "ANATOMY", 265, 269], ["hand", "ORGANISM_SUBDIVISION", 150, 154], ["skin", "ORGAN", 265, 269], ["Studies", "TEST", 0, 7], ["bacteria", "PROBLEM", 40, 48], ["Disease Control", "TREATMENT", 106, 121], ["bacteria", "OBSERVATION", 40, 48], ["skin", "ANATOMY", 265, 269]]], ["In particular, the preservation of lipids, fatty acids and resident microbial flora is important [5] .", [["fatty acids", "CHEMICAL", 43, 54], ["fatty acids", "CHEMICAL", 43, 54], ["lipids", "SIMPLE_CHEMICAL", 35, 41], ["fatty acids", "SIMPLE_CHEMICAL", 43, 54], ["lipids", "TEST", 35, 41], ["fatty acids", "TEST", 43, 54]]], ["Hand disinfection with alcohol has become a standard procedure, and wall-mounted dispensers can be easily found in healthcare institutions.IntroductionSoap and water hand wash is recommended more for hand cleaning, rather than disinfection.IntroductionHowever, WHO guidelines state that disinfection with alcohol is more effective for eradicating transient bacteria [1, 5] .IntroductionOzone has been reported to have a broad spectrum of antimicrobial effects.", [["wall", "ANATOMY", 68, 72], ["hand", "ANATOMY", 166, 170], ["hand", "ANATOMY", 200, 204], ["alcohol", "CHEMICAL", 23, 30], ["alcohol", "CHEMICAL", 305, 312], ["IntroductionOzone", "CHEMICAL", 374, 391], ["alcohol", "CHEMICAL", 23, 30], ["alcohol", "CHEMICAL", 305, 312], ["IntroductionOzone", "CHEMICAL", 374, 391], ["alcohol", "SIMPLE_CHEMICAL", 23, 30], ["hand", "ORGANISM_SUBDIVISION", 200, 204], ["alcohol", "SIMPLE_CHEMICAL", 305, 312], ["IntroductionOzone", "SIMPLE_CHEMICAL", 374, 391], ["Hand disinfection", "PROBLEM", 0, 17], ["a standard procedure", "TREATMENT", 42, 62], ["wall-mounted dispensers", "TREATMENT", 68, 91], ["IntroductionSoap and water hand wash", "TREATMENT", 139, 175], ["hand cleaning", "TREATMENT", 200, 213], ["eradicating transient bacteria", "PROBLEM", 335, 365], ["IntroductionOzone", "TREATMENT", 374, 391], ["antimicrobial effects", "TREATMENT", 438, 459], ["disinfection", "OBSERVATION", 5, 17], ["antimicrobial effects", "OBSERVATION", 438, 459]]], ["It was first used for disinfection of water, and is now being used in food hygiene, fish farming, air purification, hot tubs and in dentistry [6] .", [["disinfection of water", "TREATMENT", 22, 43], ["air purification", "TREATMENT", 98, 114]]], ["Appelgrein et al. reported that ozonized water was inferior to propanol based hand rubs [7] , while Nakamura et al. observed a 3 log 10 reduction in CFU after hand washing with ozonized water, or antimicrobial soap and water [8] .", [["hand", "ANATOMY", 78, 82], ["hand", "ANATOMY", 159, 163], ["propanol", "CHEMICAL", 63, 71], ["propanol", "CHEMICAL", 63, 71], ["propanol", "SIMPLE_CHEMICAL", 63, 71], ["ozonized water", "TREATMENT", 32, 46], ["hand washing", "TREATMENT", 159, 171], ["ozonized water", "TREATMENT", 177, 191], ["antimicrobial soap", "TREATMENT", 196, 214]]], ["A concern is that ozone gas is toxic to humans at high concentrations and can substantially damage the lungs.", [["lungs", "ANATOMY", 103, 108], ["ozone", "CHEMICAL", 18, 23], ["ozone", "CHEMICAL", 18, 23], ["ozone", "SIMPLE_CHEMICAL", 18, 23], ["humans", "ORGANISM", 40, 46], ["lungs", "ORGAN", 103, 108], ["humans", "SPECIES", 40, 46], ["humans", "SPECIES", 40, 46], ["ozone gas", "PROBLEM", 18, 27], ["toxic", "PROBLEM", 31, 36], ["ozone gas", "OBSERVATION", 18, 27], ["toxic", "OBSERVATION_MODIFIER", 31, 36], ["lungs", "ANATOMY", 103, 108]]], ["However, the gas can be dissolved in tap water for hand washing, and most of the gas then passes in the water through the outlet of the sink.", [["hand", "ANATOMY", 51, 55], ["tap water", "TREATMENT", 37, 46], ["hand washing", "TREATMENT", 51, 63], ["gas", "OBSERVATION", 13, 16], ["gas", "OBSERVATION", 81, 84], ["outlet", "OBSERVATION", 122, 128]]], ["Usually humans can also notice the characteristic smell of ozone gas at very low concentration.IntroductionPreviously, we compared alcohol hand disinfection with ozonized water for eradicating or removing transient Escherichia coli from contaminated hands [10] .", [["hand", "ANATOMY", 139, 143], ["ozone", "CHEMICAL", 59, 64], ["alcohol", "CHEMICAL", 131, 138], ["ozone", "CHEMICAL", 59, 64], ["alcohol", "CHEMICAL", 131, 138], ["humans", "ORGANISM", 8, 14], ["ozone", "SIMPLE_CHEMICAL", 59, 64], ["Escherichia coli", "ORGANISM", 215, 231], ["humans", "SPECIES", 8, 14], ["Escherichia coli", "SPECIES", 215, 231], ["humans", "SPECIES", 8, 14], ["Escherichia coli", "SPECIES", 215, 231], ["ozone gas", "TEST", 59, 68], ["ozonized water", "TREATMENT", 162, 176], ["transient Escherichia coli", "PROBLEM", 205, 231], ["Escherichia coli", "OBSERVATION", 215, 231]]], ["The results showed that alcohol hand disinfection, even under optimal conditions, failed in removing all transient E. coli from hands of participants and results showed higher CFU/ml values than for the ozone-water hand wash.", [["hand", "ANATOMY", 32, 36], ["alcohol", "CHEMICAL", 24, 31], ["ozone", "CHEMICAL", 203, 208], ["alcohol", "CHEMICAL", 24, 31], ["ozone", "CHEMICAL", 203, 208], ["alcohol", "SIMPLE_CHEMICAL", 24, 31], ["E. coli", "ORGANISM", 115, 122], ["ozone", "SIMPLE_CHEMICAL", 203, 208], ["E. coli", "SPECIES", 115, 122], ["participants", "SPECIES", 137, 149], ["E. coli", "SPECIES", 115, 122], ["alcohol hand disinfection", "PROBLEM", 24, 49], ["all transient E. coli", "PROBLEM", 101, 122], ["higher CFU/ml values", "PROBLEM", 169, 189], ["the ozone", "TREATMENT", 199, 208], ["water hand wash", "TREATMENT", 209, 224], ["disinfection", "OBSERVATION", 37, 49], ["E. coli", "OBSERVATION", 115, 122]]], ["Besides, several participants reported adverse skin irritation from frequent use of alcohol disinfection.IntroductionAgainst this background, we wanted to conduct a follow up study, this time including also a group using soap and water hand wash.", [["skin", "ANATOMY", 47, 51], ["hand", "ANATOMY", 236, 240], ["skin irritation", "DISEASE", 47, 62], ["alcohol", "CHEMICAL", 84, 91], ["alcohol", "CHEMICAL", 84, 91], ["skin", "ORGAN", 47, 51], ["alcohol", "SIMPLE_CHEMICAL", 84, 91], ["participants", "SPECIES", 17, 29], ["adverse skin irritation", "PROBLEM", 39, 62], ["alcohol disinfection", "TREATMENT", 84, 104], ["a follow up study", "TEST", 163, 180], ["soap and water hand wash", "TREATMENT", 221, 245], ["adverse", "OBSERVATION_MODIFIER", 39, 46], ["skin", "ANATOMY", 47, 51], ["irritation", "OBSERVATION", 52, 62]]], ["We merged the results from both crossover studies, comparing standard alcohol disinfection, ozonized-water wash and soap and water wash.MethodsA modified procedure from the standard EN 1500:2013 was used as described earlier (10) .", [["alcohol", "CHEMICAL", 70, 77], ["alcohol", "CHEMICAL", 70, 77], ["alcohol", "SIMPLE_CHEMICAL", 70, 77], ["both crossover studies", "TEST", 27, 49], ["standard alcohol disinfection", "TREATMENT", 61, 90], ["ozonized-water wash", "TREATMENT", 92, 111], ["soap and water wash", "TREATMENT", 116, 135], ["MethodsA modified procedure", "TREATMENT", 136, 163]]], ["Briefly, a non-pathogenic E. coli strain (ATCC 25922) (American Type Culture Collection, Manassan, Virginia, USA) was used to contaminate hands followed by three hand disinfectant procedures under the supervision of a hygiene nurse.", [["hand", "ANATOMY", 162, 166], ["ATCC 25922", "CHEMICAL", 42, 52], ["E. coli", "ORGANISM", 26, 33], ["ATCC 25922", "CELL", 42, 52], ["E. coli", "SPECIES", 26, 33], ["E. coli", "SPECIES", 26, 33], ["ATCC 25922", "SPECIES", 42, 52], ["a non-pathogenic E. coli strain", "PROBLEM", 9, 40], ["non-pathogenic", "OBSERVATION_MODIFIER", 11, 25], ["E. coli strain", "OBSERVATION", 26, 40]]], ["The disinfectant alcohol was Antibac with 85 % ethanol and <5%Methodspropan-2-ol and glycerine (KiiltoClean AS, Asker, Norway).", [["alcohol", "CHEMICAL", 17, 24], ["Antibac", "CHEMICAL", 29, 36], ["ethanol", "CHEMICAL", 47, 54], ["Methodspropan-2-ol", "CHEMICAL", 62, 80], ["glycerine", "CHEMICAL", 85, 94], ["alcohol", "CHEMICAL", 17, 24], ["ethanol", "CHEMICAL", 47, 54], ["Methodspropan-2-ol", "CHEMICAL", 62, 80], ["glycerine", "CHEMICAL", 85, 94], ["alcohol", "SIMPLE_CHEMICAL", 17, 24], ["Antibac", "SIMPLE_CHEMICAL", 29, 36], ["ethanol", "SIMPLE_CHEMICAL", 47, 54], ["Methodspropan-2-ol", "SIMPLE_CHEMICAL", 62, 80], ["glycerine", "SIMPLE_CHEMICAL", 85, 94], ["85 % ethanol", "TREATMENT", 42, 54], ["Methodspropan", "TREATMENT", 62, 75], ["glycerine", "TREATMENT", 85, 94]]], ["Non-alcoholic Antibac hand soap (3 mL liquid soap) (KiiltoClean AS) was used in a regular soap and water washing procedure, and 0.8 ppm ozone-water was produced (Ozonator CYS300C, Cleanzone, Bergen, Norway) directly in tap water for a hand wash procedure.MethodsThe participants were checked for any visible signs of dermatitis before included in the tests.", [["hand", "ANATOMY", 22, 26], ["hand", "ANATOMY", 235, 239], ["ozone", "CHEMICAL", 136, 141], ["dermatitis", "DISEASE", 317, 327], ["ozone", "CHEMICAL", 136, 141], ["participants", "ORGANISM", 266, 278], ["participants", "SPECIES", 266, 278], ["Non-alcoholic Antibac hand soap", "TREATMENT", 0, 31], ["KiiltoClean AS)", "TREATMENT", 52, 67], ["a regular soap", "TREATMENT", 80, 94], ["water washing procedure", "TREATMENT", 99, 122], ["a hand wash procedure", "TREATMENT", 233, 254], ["dermatitis", "PROBLEM", 317, 327], ["the tests", "TEST", 347, 356], ["soap", "OBSERVATION", 27, 31], ["dermatitis", "OBSERVATION", 317, 327]]], ["Twelve (22%) of 55 volunteers were men and 43 (78%) were women.", [["volunteers", "ORGANISM", 19, 29], ["men", "ORGANISM", 35, 38], ["women", "ORGANISM", 57, 62], ["men", "SPECIES", 35, 38], ["women", "SPECIES", 57, 62]]], ["Out of 40 participants, half were merged with 15 students from the earlier study [10] .", [["participants", "SPECIES", 10, 22]]], ["Altogether this represented 35 participants.", [["participants", "SPECIES", 31, 43]]], ["The other half washed their hands with ozone-water or regular soap and water wash.", [["ozone", "CHEMICAL", 39, 44], ["ozone", "CHEMICAL", 39, 44], ["ozone", "SIMPLE_CHEMICAL", 39, 44]]], ["The temperature of tap water was approximately 20\u00b0C and the water flow was approximately 8 L/min.", [["C", "SIMPLE_CHEMICAL", 50, 51], ["water", "SIMPLE_CHEMICAL", 60, 65], ["The temperature", "TEST", 0, 15], ["tap water", "TEST", 19, 28], ["the water flow", "TREATMENT", 56, 70], ["water flow", "OBSERVATION", 60, 70]]], ["The alcohol and ozone groups were included in a crossover design.", [["alcohol", "CHEMICAL", 4, 11], ["ozone", "CHEMICAL", 16, 21], ["alcohol", "CHEMICAL", 4, 11], ["ozone", "CHEMICAL", 16, 21], ["alcohol", "SIMPLE_CHEMICAL", 4, 11], ["ozone", "SIMPLE_CHEMICAL", 16, 21]]], ["This was not possible for the soap and water wash group due to the limited number of participants and laboratory facilities.MethodsBesides descriptive statistics, differences in outcomes were investigated using a paired -test with 1000 bootstrap samples, Wilcoxon's test or Mann Whitney U test.", [["participants", "SPECIES", 85, 97], ["the soap and water wash group", "TREATMENT", 26, 55], ["a paired -test", "TEST", 211, 225], ["bootstrap samples", "TEST", 236, 253], ["Wilcoxon's test", "TEST", 255, 270], ["Whitney U test", "TEST", 279, 293], ["not possible", "UNCERTAINTY", 9, 21]]], ["Statistical analysis was performed using SPSS v24, and figures were prepared using GraphPad Prism v8.EthicsVolunteers were informed in a separate lesson about the study, provided written information and invited to participate.", [["Statistical analysis", "TEST", 0, 20], ["SPSS", "TEST", 41, 45], ["the study", "TEST", 159, 168]]], ["All participants provided written consent.", [["participants", "SPECIES", 4, 16]]], ["The study was approved by the Regional Committee for Medical Research Ethics and Norwegian Data Inspectorate (reference no.:Results and discussionThe pre-test CFU/mL values exceeded the cut-off value of \u226530 000 in 52 of 55 participants, and for the samples from the remaining three participants, the CFU/mL values were 10 500, 10 600 and 2 900 respectively.", [["participants", "SPECIES", 223, 235], ["participants", "SPECIES", 282, 294], ["The study", "TEST", 0, 9], ["The pre-test CFU/mL values", "TEST", 146, 172], ["the cut", "TEST", 182, 189], ["the samples", "TEST", 245, 256], ["the CFU/mL values", "TEST", 296, 313]]], ["The post-test CFU/mL values are presented in Table I p=0.359).", [["The post-test CFU/mL values", "TEST", 0, 27]]], ["Figure 1 illustrates the difference in outliers with a rather high dose of E. coli left after disinfection for some of the alcohol group.Results and discussionFor the alcohol hand rub group there was also a difference between the left and right hand (mean CFU/ml of 1356 vs. 974), while the ozone and soap group showed less left or right hand side differences.Results and discussionThe measured ozone concentration in the surrounding air was 0.01 ppm or lower, but still most of the participants had noticed a mild smell of ozone gas.Results and discussionBased on self-reporting, one third of participants reported adverse skin effects (burning/dryness) from regular alcohol disinfection, even if none had active dermatitis.", [["hand", "ANATOMY", 175, 179], ["left", "ANATOMY", 230, 234], ["right hand", "ANATOMY", 239, 249], ["left", "ANATOMY", 324, 328], ["right hand", "ANATOMY", 332, 342], ["skin", "ANATOMY", 624, 628], ["alcohol", "CHEMICAL", 123, 130], ["alcohol", "CHEMICAL", 167, 174], ["ozone", "CHEMICAL", 291, 296], ["ozone", "CHEMICAL", 395, 400], ["ozone", "CHEMICAL", 524, 529], ["alcohol", "CHEMICAL", 668, 675], ["dermatitis", "DISEASE", 714, 724], ["alcohol", "CHEMICAL", 123, 130], ["alcohol", "CHEMICAL", 167, 174], ["ozone", "CHEMICAL", 291, 296], ["ozone", "CHEMICAL", 395, 400], ["ozone", "CHEMICAL", 524, 529], ["alcohol", "CHEMICAL", 668, 675], ["E. coli", "ORGANISM", 75, 82], ["alcohol", "SIMPLE_CHEMICAL", 123, 130], ["ozone", "SIMPLE_CHEMICAL", 291, 296], ["hand", "ORGANISM_SUBDIVISION", 338, 342], ["ozone", "SIMPLE_CHEMICAL", 395, 400], ["participants", "ORGANISM", 483, 495], ["ozone", "SIMPLE_CHEMICAL", 524, 529], ["skin", "ORGAN", 624, 628], ["alcohol", "SIMPLE_CHEMICAL", 668, 675], ["E. coli", "SPECIES", 75, 82], ["participants", "SPECIES", 483, 495], ["participants", "SPECIES", 594, 606], ["E. coli", "SPECIES", 75, 82], ["the difference in outliers", "PROBLEM", 21, 47], ["E. coli", "TREATMENT", 75, 82], ["disinfection", "TREATMENT", 94, 106], ["soap group", "TEST", 301, 311], ["less left or right hand side differences", "PROBLEM", 319, 359], ["The measured ozone concentration", "TREATMENT", 382, 414], ["a mild smell of ozone gas", "PROBLEM", 508, 533], ["adverse skin effects", "PROBLEM", 616, 636], ["burning/dryness", "PROBLEM", 638, 653], ["regular alcohol disinfection", "TREATMENT", 660, 688], ["active dermatitis", "PROBLEM", 707, 724], ["left", "ANATOMY_MODIFIER", 230, 234], ["right", "ANATOMY_MODIFIER", 239, 244], ["hand", "ANATOMY", 245, 249], ["left", "ANATOMY_MODIFIER", 324, 328], ["right", "ANATOMY_MODIFIER", 332, 337], ["ozone", "OBSERVATION_MODIFIER", 395, 400], ["concentration", "OBSERVATION_MODIFIER", 401, 414], ["air", "OBSERVATION_MODIFIER", 434, 437], ["lower", "OBSERVATION_MODIFIER", 454, 459], ["mild", "OBSERVATION_MODIFIER", 510, 514], ["smell", "OBSERVATION", 515, 520], ["ozone gas", "OBSERVATION", 524, 533], ["skin", "ANATOMY", 624, 628], ["alcohol disinfection", "OBSERVATION", 668, 688], ["active", "OBSERVATION_MODIFIER", 707, 713], ["dermatitis", "OBSERVATION", 714, 724]]], ["None of the participants reported unpleasant skin symptoms with the ozone-water or regular soap and water.", [["skin", "ANATOMY", 45, 49], ["ozone", "CHEMICAL", 68, 73], ["ozone", "CHEMICAL", 68, 73], ["participants", "ORGANISM", 12, 24], ["skin", "ORGAN", 45, 49], ["ozone", "SIMPLE_CHEMICAL", 68, 73], ["participants", "SPECIES", 12, 24], ["unpleasant skin symptoms", "PROBLEM", 34, 58]]], ["The majority (66%) also stated that they would prefer using ozonized tap water if the disinfection effect was similar as of other agents.Results and discussionBased on the results, the best methods seem to be hand washing with soap and water, and alternatively ozonized water.", [["hand", "ANATOMY", 209, 213], ["ozonized tap water", "TREATMENT", 60, 78], ["the disinfection effect", "PROBLEM", 82, 105], ["soap and water", "TREATMENT", 227, 241]]], ["However, the use of standard alcohol disinfection is more flexible for hand sanitization when no water supply or sinks are required, and dispensers can be easily installed in healthcare institutions or public places.", [["hand", "ANATOMY", 71, 75], ["alcohol", "CHEMICAL", 29, 36], ["alcohol", "CHEMICAL", 29, 36], ["alcohol", "SIMPLE_CHEMICAL", 29, 36], ["hand", "ORGANISM_SUBDIVISION", 71, 75], ["standard alcohol disinfection", "TREATMENT", 20, 49], ["hand sanitization", "TREATMENT", 71, 88]]], ["This method will therefore continue to play a vital role in hand disinfection.Results and discussionWe think that some of the transient bacteria on hands may be removed by the running water alone, and this should be examined further.", [["hand", "ANATOMY", 60, 64], ["hand", "ORGANISM_SUBDIVISION", 60, 64], ["hands", "ORGANISM_SUBDIVISION", 148, 153], ["hand disinfection", "TREATMENT", 60, 77], ["the transient bacteria on hands", "PROBLEM", 122, 153], ["hand", "ANATOMY", 60, 64], ["disinfection", "OBSERVATION", 65, 77], ["transient", "OBSERVATION_MODIFIER", 126, 135], ["bacteria", "OBSERVATION", 136, 144]]], ["We also suspect that the disinfection procedure with 3 mL alcohol is more complicated to perform correctly, as it fails to disinfect the hands in a substantial number of participants.", [["alcohol", "CHEMICAL", 58, 65], ["alcohol", "CHEMICAL", 58, 65], ["alcohol", "SIMPLE_CHEMICAL", 58, 65], ["participants", "SPECIES", 170, 182], ["the disinfection procedure", "TREATMENT", 21, 47], ["hands", "ANATOMY", 137, 142], ["substantial", "OBSERVATION_MODIFIER", 148, 159], ["number", "OBSERVATION_MODIFIER", 160, 166]]], ["Also, a difference in bacterial counts for the left and right hand were observed for the alcohol disinfection group.", [["left", "ANATOMY", 47, 51], ["right hand", "ANATOMY", 56, 66], ["alcohol", "CHEMICAL", 89, 96], ["alcohol", "CHEMICAL", 89, 96], ["hand", "ORGANISM_SUBDIVISION", 62, 66], ["alcohol", "SIMPLE_CHEMICAL", 89, 96], ["bacterial counts", "TEST", 22, 38], ["difference", "OBSERVATION_MODIFIER", 8, 18], ["bacterial counts", "OBSERVATION", 22, 38], ["left", "ANATOMY_MODIFIER", 47, 51], ["right", "ANATOMY_MODIFIER", 56, 61]]], ["In regular public use, the disinfection failure rate may be expected to be even higher, and this should be further scrutinized.Results and discussionThe WHO guidelines for hand hygiene in health care do not take in to account ozonized water as an alternative method [1] .", [["hand", "ANATOMY", 172, 176], ["hand", "ORGANISM_SUBDIVISION", 172, 176], ["the disinfection failure rate", "PROBLEM", 23, 52], ["higher", "OBSERVATION_MODIFIER", 80, 86]]], ["However, we found that it is a simple and skin friendly method that leaves no residual chemicals to the environment.", [["skin", "ANATOMY", 42, 46], ["skin", "ORGAN", 42, 46], ["a simple and skin friendly method", "PROBLEM", 29, 62], ["skin", "ANATOMY", 42, 46], ["no", "UNCERTAINTY", 75, 77], ["residual chemicals", "OBSERVATION", 78, 96]]], ["An environmental and economic incentive to use ozone in water could be that this device once installed, require no need for transportation or stocking of refill.Results and discussionEthanol and soap distribution and packaging waste is huge, compared to none with ozone gas.ConclusionsWe observed that washing with a mild disinfectant such as ozonized water, besides a regular soap and water hand wash, may be more effective than only alcohol for the removal of transient E. coli from artificially contaminated hands.", [["ozone", "CHEMICAL", 47, 52], ["discussionEthanol", "CHEMICAL", 173, 190], ["ozone", "CHEMICAL", 264, 269], ["alcohol", "CHEMICAL", 435, 442], ["ozone", "CHEMICAL", 47, 52], ["ozone", "CHEMICAL", 264, 269], ["alcohol", "CHEMICAL", 435, 442], ["ozone", "SIMPLE_CHEMICAL", 47, 52], ["discussionEthanol", "SIMPLE_CHEMICAL", 173, 190], ["ozone", "SIMPLE_CHEMICAL", 264, 269], ["alcohol", "SIMPLE_CHEMICAL", 435, 442], ["E. coli", "ORGANISM", 472, 479], ["hands", "ORGANISM_SUBDIVISION", 511, 516], ["E. coli", "SPECIES", 472, 479], ["E. coli", "SPECIES", 472, 479], ["this device", "TREATMENT", 76, 87], ["packaging waste", "TREATMENT", 217, 232], ["ozone gas", "TEST", 264, 273], ["a mild disinfectant", "PROBLEM", 315, 334], ["ozonized water", "TREATMENT", 343, 357], ["a regular soap and water hand wash", "TREATMENT", 367, 401], ["the removal", "TREATMENT", 447, 458], ["transient E. coli", "PROBLEM", 462, 479], ["artificially contaminated hands", "PROBLEM", 485, 516], ["packaging waste", "OBSERVATION", 217, 232], ["huge", "OBSERVATION_MODIFIER", 236, 240], ["mild", "OBSERVATION_MODIFIER", 317, 321], ["disinfectant", "OBSERVATION", 322, 334], ["E. coli", "OBSERVATION", 472, 479]]], ["Based on this work, ozonized water might be an alternative to traditional hand disinfectants.", [["hand", "ANATOMY", 74, 78], ["ozonized water", "TREATMENT", 20, 34], ["traditional hand disinfectants", "TREATMENT", 62, 92]]], ["However, larger studies in clinical settings would be required to validate its efficacy.", [["larger studies", "TEST", 9, 23], ["larger", "OBSERVATION_MODIFIER", 9, 15]]], ["The potential use of ozonized water against viruses should also be further examined, including a possible effect on the new COVID-19.", [["COVID-19", "DNA", 124, 132], ["ozonized water against viruses", "TREATMENT", 21, 51], ["the new COVID", "TEST", 116, 129]]]], "f52eaf9b1a5f1c66cdf800be68051bdd931aeeac": [["IntroductionMiddle East respiratory syndrome coronavirus (MERS-CoV) is capable of causing acute respiratory infection, although its spectrum ranges from asymptomatic laboratory-confirmed cases to mild infection to life-threatening disease with a high case fatality rate [1, 2] .", [["respiratory", "ANATOMY", 96, 107], ["Middle East respiratory syndrome coronavirus", "DISEASE", 12, 56], ["acute respiratory infection", "DISEASE", 90, 117], ["infection", "DISEASE", 201, 210], ["Middle East respiratory syndrome coronavirus", "ORGANISM", 12, 56], ["MERS-CoV", "ORGANISM", 58, 66], ["Middle East respiratory syndrome coronavirus", "SPECIES", 12, 56], ["MERS-CoV", "SPECIES", 58, 66], ["Middle East respiratory syndrome coronavirus", "PROBLEM", 12, 56], ["acute respiratory infection", "PROBLEM", 90, 117], ["asymptomatic laboratory", "PROBLEM", 153, 176], ["mild infection", "PROBLEM", 196, 210], ["threatening disease", "PROBLEM", 219, 238], ["Middle", "ANATOMY_MODIFIER", 12, 18], ["respiratory syndrome", "OBSERVATION", 24, 44], ["acute", "OBSERVATION_MODIFIER", 90, 95], ["respiratory", "ANATOMY", 96, 107], ["infection", "OBSERVATION", 108, 117], ["mild", "OBSERVATION_MODIFIER", 196, 200], ["infection", "OBSERVATION", 201, 210]]], ["MERS-CoV was first described in 2012 in a 60-year-old man hospitalized with suspected communityacquired pneumonia, who developed renal and respiratory failure, ultimately succumbing to progressive disease [3] .", [["renal", "ANATOMY", 129, 134], ["respiratory", "ANATOMY", 139, 150], ["pneumonia", "DISEASE", 104, 113], ["renal and respiratory failure", "DISEASE", 129, 158], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 0, 8], ["man", "ORGANISM", 54, 57], ["renal", "ORGAN", 129, 134], ["man", "SPECIES", 54, 57], ["MERS-CoV", "SPECIES", 0, 8], ["communityacquired pneumonia", "PROBLEM", 86, 113], ["renal and respiratory failure", "PROBLEM", 129, 158], ["progressive disease", "PROBLEM", 185, 204], ["pneumonia", "OBSERVATION", 104, 113], ["renal", "ANATOMY", 129, 134], ["respiratory", "ANATOMY", 139, 150], ["failure", "OBSERVATION", 151, 158], ["progressive", "OBSERVATION_MODIFIER", 185, 196], ["disease", "OBSERVATION", 197, 204]]], ["The first reported healthcare-associated MERS-CoV infection was described among multiple facilities in Al-Hasa, Saudi Arabia [4] .", [["MERS-CoV infection", "DISEASE", 41, 59], ["MERS-CoV", "ORGANISM", 41, 49], ["MERS-CoV", "SPECIES", 41, 49], ["CoV infection", "PROBLEM", 46, 59], ["infection", "OBSERVATION", 50, 59]]], ["However, a later retrospective analysis of a respiratory outbreak in a public hospital in Jordan determined that this cluster dated back earlier, becoming the first recognized healthcare-associated MERS-CoV infection in April 2012 [5] .", [["MERS-CoV infection", "DISEASE", 198, 216], ["MERS-CoV", "ORGANISM", 198, 206], ["MERS-CoV", "SPECIES", 198, 206], ["a later retrospective analysis", "TEST", 9, 39], ["CoV infection", "PROBLEM", 203, 216]]], ["The disease has also been recognized in many countries with secondary transmissions.", [["The disease", "PROBLEM", 0, 11], ["disease", "OBSERVATION", 4, 11]]], ["The first case of MERS-CoV infection in France caused one secondary transmission among 123 contacts [6] .", [["MERS-CoV infection", "DISEASE", 18, 36], ["MERS-CoV", "ORGANISM", 18, 26], ["MERS-CoV", "SPECIES", 18, 26], ["MERS", "PROBLEM", 18, 22], ["CoV infection", "PROBLEM", 23, 36], ["infection", "OBSERVATION", 27, 36]]], ["In a study of 51 outbreaks, nosocomial transmissions were observed in 80.4% of clusters [7] .", [["a study", "TEST", 3, 10], ["nosocomial transmissions", "TEST", 28, 52]]], ["Another study found that 37.5% of 1797 cases were ascribed to healthcareassociated infections [8] .", [["infections", "DISEASE", 83, 93], ["Another study", "TEST", 0, 13], ["healthcareassociated infections", "PROBLEM", 62, 93], ["infections", "OBSERVATION", 83, 93]]], ["The percentage of healthcare workers (HCWs) involved in different outbreaks is variable, and ranges between 14% and 64% [9] .", [["percentage", "OBSERVATION_MODIFIER", 4, 14], ["variable", "OBSERVATION_MODIFIER", 79, 87]]], ["The risk of severe disease seems to be higher in people with comorbid diseases and older patients [8] .IntroductionAs of March 2018, the World Health Organization reported 2189 laboratory-confirmed cases of MERS-CoV from 27 countries, including 782 (35.7%) deaths [10] .", [["deaths", "DISEASE", 257, 263], ["people", "ORGANISM", 49, 55], ["patients", "ORGANISM", 89, 97], ["MERS-CoV", "ORGANISM", 207, 215], ["people", "SPECIES", 49, 55], ["patients", "SPECIES", 89, 97], ["MERS-CoV", "SPECIES", 207, 215], ["severe disease", "PROBLEM", 12, 26], ["comorbid diseases", "PROBLEM", 61, 78], ["severe", "OBSERVATION_MODIFIER", 12, 18], ["disease", "OBSERVATION", 19, 26], ["seems to be", "UNCERTAINTY", 27, 38], ["higher", "OBSERVATION_MODIFIER", 39, 45]]], ["Among the reported cases, peaks occurred in 2014 (due to the Jeddah outbreak) and 2015 (South Korea outbreak) ( Figure 1 ).IntroductionThere are three patterns of MERS-CoV transmission [1] : sporadic community cases from presumed non-human exposure [1] , family clusters resulting from contact with an infected family index case [11e13] , and healthcare-acquired infections between patients and from patients to HCWs [1,4,5,14e31] .IntroductionAlthough MERS-CoV has a documented ability to transmit between humans, especially in healthcare settings, there does not appear to be sustained human-to-human transmission.", [["infections", "DISEASE", 363, 373], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 163, 171], ["patients", "ORGANISM", 382, 390], ["patients", "ORGANISM", 400, 408], ["MERS-CoV", "ORGANISM", 453, 461], ["humans", "ORGANISM", 507, 513], ["human", "ORGANISM", 588, 593], ["human", "ORGANISM", 597, 602], ["patients", "SPECIES", 382, 390], ["patients", "SPECIES", 400, 408], ["humans", "SPECIES", 507, 513], ["human", "SPECIES", 588, 593], ["human", "SPECIES", 597, 602], ["MERS-CoV", "SPECIES", 163, 171], ["MERS-CoV", "SPECIES", 453, 461], ["humans", "SPECIES", 507, 513], ["human", "SPECIES", 588, 593], ["human", "SPECIES", 597, 602]]], ["This is likely due to the relatively low reproduction number of MERS-CoV of 0.8e1.3 [29, 30] .", [["MERS-CoV", "SPECIES", 64, 72], ["CoV", "TEST", 69, 72], ["likely due to", "UNCERTAINTY", 8, 21], ["relatively", "OBSERVATION_MODIFIER", 26, 36], ["low", "OBSERVATION_MODIFIER", 37, 40]]], ["The upper reproduction estimates were probably derived from lack of sufficient infection control measures, and the estimates were lowered with improved detection and prevention practices over time.", [["infection", "DISEASE", 79, 88], ["sufficient infection control measures", "PROBLEM", 68, 105], ["upper", "ANATOMY_MODIFIER", 4, 9], ["infection", "OBSERVATION", 79, 88]]], ["This review focuses on the available literature on healthcare-associated infections and transmission of MERS-CoV to elucidate the contributing risk factors.Search strategyThe search was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (http://www.prismastatement.org).", [["infections", "DISEASE", 73, 83], ["MERS-CoV", "ORGANISM", 104, 112], ["MERS-CoV", "SPECIES", 104, 112], ["associated infections", "PROBLEM", 62, 83], ["Systematic Reviews", "TEST", 243, 261], ["infections", "OBSERVATION", 73, 83]]], ["The search included MEDLINE and Scopus databases for articles published in English, as follows: #1: 'MERS' OR 'MERS-CoV' OR 'Middle East respiratory syndrome coronavirus' #2: 'Transmission' OR 'Outbreak' OR 'Healthcare associated infection' OR 'Nosocomial' or 'cluster'; #3: #1 AND #2.Search strategyIn addition, the Saudi Ministry of Health website was searched for updates, and the World Health Organization website and ProMed website were searched for any listed outbreaks.Search strategyInclusion criteria were: published papers written in English if the studies described any healthcare-associated outbreak, and included factors contributing to the outbreak or factors that were used to limit and control the spread of the infection.", [["respiratory syndrome coronavirus", "DISEASE", 137, 169], ["infection", "DISEASE", 230, 239], ["infection", "DISEASE", 728, 737], ["Middle East respiratory syndrome coronavirus", "SPECIES", 125, 169], ["Middle East respiratory syndrome coronavirus'", "PROBLEM", 125, 170], ["the studies", "TEST", 555, 566], ["the infection", "PROBLEM", 724, 737], ["respiratory syndrome", "OBSERVATION", 137, 157], ["infection", "OBSERVATION", 728, 737]]], ["In total, 22 articles were included in the final analyses for contributing factors for MERS-CoV outbreaks in healthcare settings ( Figure 2 ) .", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 87, 95], ["MERS-CoV", "SPECIES", 87, 95], ["MERS", "PROBLEM", 87, 91]]], ["105 100 95 90 85 80 75 70 65 60 55 50 45 Number of cases 40 35 30 25 20 15 10 5 110 0 18 24 30 36 42 48 01 07 13 19 25 31 37 43 49 03 09 15 21 27 33 39 45 51 05 11 17 23 29 35 41 47 01 07 13 19 25 31 37 43 49 03 09 15 21 12 27 2017 2016 2015 2014 WeekTimeline of healthcare-associated infectionsMany healthcare-associated outbreaks have occurred in Saudi Arabia, and a large outbreak arose in South Korea in 2015 [1] .", [["infections", "DISEASE", 285, 295], ["associated infections", "PROBLEM", 274, 295], ["infections", "OBSERVATION", 285, 295], ["large", "OBSERVATION_MODIFIER", 369, 374], ["outbreak", "OBSERVATION_MODIFIER", 375, 383]]], ["The first outbreak in Saudi Arabia occurred in Al-Hasa [4] , followed by a significant epidemic in Jeddah in 2014 [14, 16] .", [["outbreak", "OBSERVATION_MODIFIER", 10, 18], ["significant", "OBSERVATION_MODIFIER", 75, 86], ["epidemic", "OBSERVATION", 87, 95]]], ["A multi-facility outbreak of MERS-CoV infection occurred in September 2014eJanuary 2015 in Taif, Saudi Arabia in four healthcare facilities [27] .Observed infection control practices among various outbreaksJordan hospital outbreak, April 2012Observed infection control practices among various outbreaksThe outbreak in Zarqa, Jordan involved 13 HCWs with pneumonia [5] .", [["MERS-CoV infection", "DISEASE", 29, 47], ["infection", "DISEASE", 155, 164], ["infection", "DISEASE", 251, 260], ["pneumonia", "DISEASE", 354, 363], ["MERS-CoV", "ORGANISM", 29, 37], ["MERS-CoV", "SPECIES", 29, 37], ["CoV infection", "PROBLEM", 34, 47], ["infection control practices", "TREATMENT", 155, 182], ["infection control practices", "TREATMENT", 251, 278], ["pneumonia", "PROBLEM", 354, 363], ["CoV", "OBSERVATION_MODIFIER", 34, 37], ["infection", "OBSERVATION", 38, 47], ["infection", "OBSERVATION", 155, 164], ["pneumonia", "OBSERVATION", 354, 363]]], ["Following the identification of MERS-CoV, specimens from two fatal cases were retrospectively confirmed to be MERS-CoV by real-time reverse transcription polymerase chain reaction (RT-PCR) [5] .", [["specimens", "ANATOMY", 42, 51], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 32, 40], ["specimens", "CANCER", 42, 51], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 110, 118], ["MERS-CoV", "SPECIES", 32, 40], ["MERS-CoV", "SPECIES", 110, 118], ["MERS", "PROBLEM", 32, 36]]], ["Based on serology and PCR testing, the attack rate was 10% among potentially exposed HCWs [15] .", [["serology", "TEST", 9, 17], ["PCR testing", "TEST", 22, 33], ["the attack rate", "TEST", 35, 50]]], ["In this outbreak, multiple infection control issues were observed and included: absence of physical barriers between different beds in intensive care units apart from cloth drapes, lack of isolation and negative pressure rooms, and non-adherence to infection control measures [15] .", [["infection", "DISEASE", 27, 36], ["infection", "DISEASE", 249, 258], ["multiple infection control issues", "PROBLEM", 18, 51], ["cloth drapes", "TREATMENT", 167, 179], ["negative pressure rooms", "TREATMENT", 203, 226], ["infection control measures", "TREATMENT", 249, 275], ["multiple", "OBSERVATION_MODIFIER", 18, 26], ["infection", "OBSERVATION", 27, 36], ["infection", "OBSERVATION", 249, 258]]], ["Patients were transferred to two other hospitals with no further evidence of intrahospital transmission, believed to be due to adequate infection control measures in the accepting institutions [15] .Al-Hasa 2013 outbreak, AprileMay 2013The outbreak involved four hospitals with 21 of the 23 cases acquired by person-to-person transmission within haemodialysis units, intensive care units or other in-patient areas [4] .", [["infection", "DISEASE", 136, 145], ["Patients", "ORGANISM", 0, 8], ["patient", "ORGANISM", 400, 407], ["Patients", "SPECIES", 0, 8], ["person", "SPECIES", 309, 315], ["person", "SPECIES", 319, 325], ["patient", "SPECIES", 400, 407], ["intrahospital transmission", "PROBLEM", 77, 103], ["adequate infection control measures", "PROBLEM", 127, 162], ["haemodialysis units", "TREATMENT", 346, 365], ["intensive care units", "TREATMENT", 367, 387], ["infection", "OBSERVATION", 136, 145]]], ["Factors contributing to this outbreak included the use of aerosolgenerating procedures and the performance of resuscitations [4] .", [["aerosolgenerating procedures", "TREATMENT", 58, 86]]], ["A super-spreading event may also have occurred in the Al-Hasa outbreak where one patient infected seven secondary cases [4] .", [["patient", "ORGANISM", 81, 88], ["patient", "SPECIES", 81, 88]]], ["The outbreak abated by emphasizing basic infection control measures: hand hygiene, droplet and contact precautions for febrile patients, testing all febrile patients for MERS-CoV, use of surgical masks for all patients undergoing haemodialysis, and N95 respirators for HCWs during aerosol-generating procedures.", [["hand", "ANATOMY", 69, 73], ["infection", "DISEASE", 41, 50], ["febrile", "DISEASE", 119, 126], ["febrile", "DISEASE", 149, 156], ["hand", "ORGANISM_SUBDIVISION", 69, 73], ["patients", "ORGANISM", 127, 135], ["patients", "ORGANISM", 157, 165], ["patients", "ORGANISM", 210, 218], ["patients", "SPECIES", 127, 135], ["patients", "SPECIES", 157, 165], ["patients", "SPECIES", 210, 218], ["MERS-CoV", "SPECIES", 170, 178], ["basic infection control measures", "TREATMENT", 35, 67], ["hand hygiene", "TREATMENT", 69, 81], ["droplet", "TREATMENT", 83, 90], ["contact precautions", "TREATMENT", 95, 114], ["febrile patients", "PROBLEM", 119, 135], ["testing", "TEST", 137, 144], ["MERS", "PROBLEM", 170, 174], ["surgical masks", "TREATMENT", 187, 201], ["haemodialysis", "TREATMENT", 230, 243], ["N95 respirators", "TREATMENT", 249, 264], ["aerosol-generating procedures", "TREATMENT", 281, 310], ["infection", "OBSERVATION", 41, 50]]], ["Additional measures included enhanced environmental cleaning, and excluding non-essential staff and visitors [4] .", [["enhanced environmental cleaning", "TREATMENT", 29, 60]]], ["A flow diagram of the search strategy according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines [88] .France cases, May 2013patient, only one (0.8%) hospitalized patient tested positive and 39 contacts of the second patient tested negative [6] .Abu Dhabi outbreak, July 2013A patient developed community-acquired infection through camel contact, and received care in two different hospitals.", [["infection", "DISEASE", 350, 359], ["patient", "ORGANISM", 161, 168], ["patient", "ORGANISM", 199, 206], ["patient", "ORGANISM", 253, 260], ["patient", "ORGANISM", 313, 320], ["camel", "ORGANISM", 368, 373], ["patient", "SPECIES", 161, 168], ["patient", "SPECIES", 199, 206], ["patient", "SPECIES", 253, 260], ["patient", "SPECIES", 313, 320], ["A flow diagram", "TEST", 0, 14], ["Systematic Reviews", "TEST", 85, 103], ["community-acquired infection", "PROBLEM", 331, 359], ["flow diagram", "OBSERVATION", 2, 14], ["infection", "OBSERVATION", 350, 359]]], ["Of the 277 healthcare contacts, four (1.4%) had healthcareassociated infections.", [["infections", "DISEASE", 69, 79], ["healthcareassociated infections", "PROBLEM", 48, 79], ["infections", "OBSERVATION", 69, 79]]], ["These four patients were exposed to the index case before the diagnosis of MERS-CoV and institution of any respiratory protection measures [28] .Al-Madinah Al-Munawarrah outbreak, 24 th August to 3 rd September 2013From 24 th August to 3 rd September 2014, 18 cases were linked to one cluster involving 11 healthcare-associated infections [21] .", [["respiratory", "ANATOMY", 107, 118], ["infections", "DISEASE", 328, 338], ["patients", "ORGANISM", 11, 19], ["patients", "SPECIES", 11, 19], ["MERS-CoV", "SPECIES", 75, 83], ["MERS", "PROBLEM", 75, 79], ["any respiratory protection measures", "TREATMENT", 103, 138], ["associated infections", "PROBLEM", 317, 338]]], ["The outbreak was thought to be secondary to under-recognition and poor infection control measures [21] .Abu Dhabi outbreak, MarcheApril 2014In this cluster, the index case arose from camel exposure.", [["infection", "DISEASE", 71, 80], ["camel", "ORGANISM_SUBDIVISION", 183, 188], ["poor infection control measures", "PROBLEM", 66, 97], ["MarcheApril", "TREATMENT", 124, 135], ["thought to be", "UNCERTAINTY", 17, 30], ["poor", "OBSERVATION_MODIFIER", 66, 70], ["infection", "OBSERVATION", 71, 80]]], ["Only two (2.2%) of 90 hospital contacts were positive for MERS-CoV [28] .", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 58, 66], ["MERS-CoV", "SPECIES", 58, 66], ["MERS", "PROBLEM", 58, 62]]], ["Evaluation of 224 contacts identified 15 (6.7%) positive cases [28] .Prince Sultan Military Medical City outbreak, March and April 2014Among multiple outbreaks in this hospital, the largest outbreak came from 15 patients acquiring infection within the emergency room [20] .", [["infection", "DISEASE", 231, 240], ["patients", "ORGANISM", 212, 220], ["patients", "SPECIES", 212, 220], ["Evaluation", "TEST", 0, 10], ["positive cases", "TEST", 48, 62], ["multiple", "OBSERVATION_MODIFIER", 141, 149], ["outbreaks", "OBSERVATION", 150, 159], ["largest", "OBSERVATION_MODIFIER", 182, 189]]], ["The outbreak abated after application of infection control measures.Jeddah 2014 outbreak, 2 nd Marche10 th May 2014Involving 14 hospitals and more than 200 cases, 60% of infected cases resulted from healthcare-associated transmission [14, 16, 33] .", [["infection", "DISEASE", 41, 50], ["infected", "DISEASE", 170, 178], ["infection control measures", "TREATMENT", 41, 67], ["infection", "OBSERVATION", 41, 50]]], ["Factors contributing to intrahospital transmission included inadequate separation of suspected MERS patients, crowding, and inconsistent use of infection control precautions [33] .", [["MERS", "DISEASE", 95, 99], ["infection", "DISEASE", 144, 153], ["patients", "ORGANISM", 100, 108], ["patients", "SPECIES", 100, 108], ["intrahospital transmission", "PROBLEM", 24, 50], ["crowding", "PROBLEM", 110, 118], ["infection control precautions", "TREATMENT", 144, 173], ["infection", "OBSERVATION", 144, 153]]], ["There was no triaging or isolation of patients with respiratory illness, and patients remained in the emergency department for many days [33] .", [["respiratory", "ANATOMY", 52, 63], ["respiratory illness", "DISEASE", 52, 71], ["patients", "ORGANISM", 38, 46], ["patients", "ORGANISM", 77, 85], ["patients", "SPECIES", 38, 46], ["patients", "SPECIES", 77, 85], ["triaging", "PROBLEM", 13, 21], ["respiratory illness", "PROBLEM", 52, 71], ["no", "UNCERTAINTY", 10, 12]]], ["In addition, uncontrolled patient movements and high visitor traffic contributed to the outbreak [23] .Taif, Saudi Arabia outbreak, September 2014eJanuary 2015The outbreak in Taif, Saudi Arabia included four healthcare settings, with the largest number traced to a haemodialysis unit involving 15 patients [27] .", [["patient", "ORGANISM", 26, 33], ["patients", "ORGANISM", 297, 305], ["patient", "SPECIES", 26, 33], ["patients", "SPECIES", 297, 305], ["uncontrolled patient movements", "PROBLEM", 13, 43], ["a haemodialysis unit", "TREATMENT", 263, 283], ["uncontrolled", "OBSERVATION_MODIFIER", 13, 25], ["outbreak", "OBSERVATION_MODIFIER", 163, 171]]], ["The implicated cause was close spacing between patients of less than 2 m [27] .South Korea outbreak, MayeJuly 2015In the most prominent outbreak outside the Arabian Peninsula, approximately 17,000 contacts were quarantined by the summer of 2015 [34] .", [["patients", "ORGANISM", 47, 55], ["patients", "SPECIES", 47, 55], ["most", "OBSERVATION_MODIFIER", 121, 125], ["prominent", "OBSERVATION_MODIFIER", 126, 135], ["outbreak", "OBSERVATION", 136, 144], ["Arabian", "ANATOMY_MODIFIER", 157, 164], ["Peninsula", "ANATOMY_MODIFIER", 165, 174]]], ["The index patient had been in contact with 742 people between 11 th and 20 th May 2015 in one hospital, subsequently infecting 28 patients [35] .", [["patient", "ORGANISM", 10, 17], ["people", "ORGANISM", 47, 53], ["patients", "ORGANISM", 130, 138], ["patient", "SPECIES", 10, 17], ["people", "SPECIES", 47, 53], ["patients", "SPECIES", 130, 138]]], ["A total of 186 MERS-CoV cases were identified in more than 17 healthcare settings [31,36e39] .", [["MERS-CoV", "ORGANISM", 15, 23], ["MERS-CoV", "SPECIES", 15, 23], ["CoV cases", "TEST", 20, 29]]], ["Among the contributory reasons for MERS-CoV advancing within South Korea were HCWs unfamiliarity with MERS, suboptimal infection prevention and control measures, overcrowded emergency departments, multi-bed hospital rooms, 'medical shopping' by patients, visitors to infected patients, extensive MERS patient movements, and the use of aerosol-generating procedures [40e42].", [["infection", "DISEASE", 119, 128], ["MERS-CoV", "ORGANISM", 35, 43], ["patients", "ORGANISM", 245, 253], ["patients", "ORGANISM", 276, 284], ["patient", "ORGANISM", 301, 308], ["patients", "SPECIES", 245, 253], ["patients", "SPECIES", 276, 284], ["patient", "SPECIES", 301, 308], ["MERS-CoV", "SPECIES", 35, 43], ["MERS", "PROBLEM", 35, 39], ["suboptimal infection prevention", "TREATMENT", 108, 139], ["aerosol-generating procedures", "TREATMENT", 335, 364]]], ["The first case in the Republic of Korea infected 27 secondary cases; one secondary patient infected 24 tertiary cases, and another secondary patient infected 73 tertiary cases [34] .", [["patient", "ORGANISM", 83, 90], ["patient", "ORGANISM", 141, 148], ["patient", "SPECIES", 83, 90], ["patient", "SPECIES", 141, 148]]], ["Another report from South Korea found 85, 28, 23, 11 and six secondary cases arising from individual patients with MERS-CoV [40] .", [["patients", "ORGANISM", 101, 109], ["patients", "SPECIES", 101, 109], ["MERS-CoV", "SPECIES", 115, 123]]], ["A secondary patient was described causing 91 tertiary MERS cases, of which 39% occurred within the emergency department and 13% were HCWs [44] .", [["patient", "ORGANISM", 12, 19], ["patient", "SPECIES", 12, 19]]], ["Delayed isolation of suspected patients was an important factor that contributed to the spread of MERS-CoV.", [["patients", "ORGANISM", 31, 39], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 98, 106], ["patients", "SPECIES", 31, 39], ["MERS-CoV", "SPECIES", 98, 106]]], ["This was higher in super-spreaders compared with other patients (mean 6.6 vs 2.9 days; P \u00bc 0.061) [45] .", [["patients", "ORGANISM", 55, 63], ["patients", "SPECIES", 55, 63], ["mean", "TEST", 65, 69], ["higher", "OBSERVATION_MODIFIER", 9, 15]]], ["Multibedded rooms and nebulization treatments may also have contributed to the spread of MERS-CoV in South Korea [46] .South Korea outbreak, MayeJuly 2015King Abdulaziz Medical City, Riyadh outbreak, JuneeAugust 2015South Korea outbreak, MayeJuly 2015One of the largest MERS outbreaks occurred in King Abdulaziz Medical City, Riyadh.", [["MERS-CoV", "ORGANISM", 89, 97], ["MERS-CoV", "SPECIES", 89, 97], ["nebulization treatments", "TREATMENT", 22, 45], ["largest", "OBSERVATION_MODIFIER", 262, 269], ["MERS", "OBSERVATION_MODIFIER", 270, 274], ["outbreaks", "OBSERVATION", 275, 284]]], ["Transmission appeared to be related to care in the emergency department before suspicion or diagnosis of MERS, causing 130 cases [23e25].", [["MERS", "DISEASE", 105, 109], ["MERS", "PROBLEM", 105, 109]]], ["There were human-to-human transmissions in both cardiac care and intensive care units of two hospitals [36] .", [["cardiac", "ANATOMY", 48, 55], ["human", "ORGANISM", 11, 16], ["human", "ORGANISM", 20, 25], ["human", "SPECIES", 11, 16], ["human", "SPECIES", 20, 25], ["human", "SPECIES", 11, 16], ["human", "SPECIES", 20, 25], ["cardiac", "ANATOMY", 48, 55]]], ["Analysed viral isolates were similar to those recovered in Riyadh, except for deletions in open reading frames 4a, although the impact of this on transmissibility or virulence remains unknown [48] .Riyadh outbreak, June 2016A healthcare associated MERS outbreak was reported in Riyadh, Saudi Arabia between 19 th and 22 nd June 2016.", [["Riyadh", "DNA", 59, 65], ["open reading frames 4a", "DNA", 91, 113], ["Analysed viral isolates", "PROBLEM", 0, 23], ["deletions", "PROBLEM", 78, 87], ["virulence", "PROBLEM", 166, 175]]], ["This outbreak appeared to start with a woman admitted to the vascular surgery ward through the emergency department.", [["vascular", "ANATOMY", 61, 69], ["woman", "ORGANISM", 39, 44], ["vascular", "MULTI-TISSUE_STRUCTURE", 61, 69], ["woman", "SPECIES", 39, 44], ["vascular", "ANATOMY", 61, 69]]], ["Her initial symptoms were not characteristic of MERS-CoV infection.", [["MERS-CoV infection", "DISEASE", 48, 66], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 48, 56], ["MERS-CoV", "SPECIES", 48, 56], ["Her initial symptoms", "PROBLEM", 0, 20], ["MERS", "PROBLEM", 48, 52], ["CoV infection", "PROBLEM", 53, 66], ["CoV", "OBSERVATION_MODIFIER", 53, 56], ["infection", "OBSERVATION", 57, 66]]], ["After confirmation of the diagnosis, active screening revealed 24 positive contacts (including 20 HCWs), and of all contacts, 20 (83.3%) were asymptomatic [49] .Riyadh outbreak, 1 st Junee3 rd July 2017The index case was a 47-year-old male who underwent emergency intubation in the emergency department.", [["male", "ORGANISM", 235, 239], ["active screening", "TEST", 37, 53], ["emergency intubation", "TREATMENT", 254, 274]]], ["This cluster was linked to a smaller cluster of five cases in another hospital with the involvement of three household contacts, one patient contact and one HCW [10] .", [["patient", "ORGANISM", 133, 140], ["patient", "SPECIES", 133, 140], ["smaller", "OBSERVATION_MODIFIER", 29, 36]]], ["A third unrelated outbreak also occurred in Riyadh in June 2017 and involved nine cases, with eight HCWs (four asymptomatic and four with mild disease) [10] .DiscussionThe World Health Organization continues to tally laboratory-confirmed MERS-CoV infections.", [["MERS-CoV infections", "DISEASE", 238, 257], ["MERS-CoV", "ORGANISM", 238, 246], ["MERS-CoV", "SPECIES", 238, 246], ["mild disease)", "PROBLEM", 138, 151], ["CoV infections", "PROBLEM", 243, 257], ["CoV", "OBSERVATION_MODIFIER", 243, 246], ["infections", "OBSERVATION", 247, 257]]], ["In the recent update from September 2012 to July 2017, there were 2040 cases with healthcare-associated infections (40 HCWs, patients and visitors), representing 31% of cases [10] .", [["infections", "DISEASE", 104, 114], ["patients", "ORGANISM", 125, 133], ["patients", "SPECIES", 125, 133]]], ["The initial symptoms of MERS-CoV are non-specific, often thought to be pedestrian respiratory infections, and thus may go unnoticed.", [["respiratory", "ANATOMY", 82, 93], ["respiratory infections", "DISEASE", 82, 104], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 24, 32], ["MERS-CoV", "SPECIES", 24, 32], ["The initial symptoms", "PROBLEM", 0, 20], ["MERS", "PROBLEM", 24, 28], ["CoV", "PROBLEM", 29, 32], ["pedestrian respiratory infections", "PROBLEM", 71, 104], ["respiratory", "ANATOMY", 82, 93], ["infections", "OBSERVATION", 94, 104]]], ["Adherence to standard precautions at all times, given the unpredictability of MERS-CoV infection, appears to be the critical factor for the prevention of transmission in healthcare facilities [10] .", [["MERS-CoV infection", "DISEASE", 78, 96], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 78, 86], ["MERS-CoV", "SPECIES", 78, 86], ["standard precautions", "TREATMENT", 13, 33], ["MERS", "PROBLEM", 78, 82], ["CoV infection", "PROBLEM", 83, 96], ["infection", "OBSERVATION", 87, 96]]], ["Additionally, environmental contamination may play a role in some transmission of MERS, as viral RNA has been detected for up to five days on surfaces [36] .DiscussionMultiple factors contribute to the development of hospital outbreaks of MERS infections as summarized in Table I .", [["MERS infections", "DISEASE", 239, 254], ["MERS", "GENE_OR_GENE_PRODUCT", 82, 86], ["MERS", "PROTEIN", 82, 86], ["viral RNA", "RNA", 91, 100], ["environmental contamination", "PROBLEM", 14, 41], ["viral RNA", "PROBLEM", 91, 100], ["MERS infections", "PROBLEM", 239, 254]]], ["A wellcharacterized outbreak in Abu Dhabi, United Arab Emirates offers insights into important infection control issues.", [["infection", "DISEASE", 95, 104], ["important infection control issues", "PROBLEM", 85, 119], ["wellcharacterized", "OBSERVATION_MODIFIER", 2, 19], ["outbreak", "OBSERVATION_MODIFIER", 20, 28], ["infection", "OBSERVATION", 95, 104]]], ["The overwhelming reason for MERS-CoV spread centred on the delayed diagnosis of MERS-CoV, as 93% of infected contacts were exposed before the patient's diagnosis.", [["MERS-CoV", "ORGANISM", 80, 88], ["patient", "ORGANISM", 142, 149], ["patient", "SPECIES", 142, 149], ["MERS-CoV", "SPECIES", 80, 88], ["MERS", "PROBLEM", 28, 32], ["CoV spread", "PROBLEM", 33, 43], ["CoV", "PROBLEM", 85, 88], ["infected contacts", "PROBLEM", 100, 117]]], ["Also, use of personal protective equipment (PPE) during care was inconsistent among these HCWs, especially during aerosolgenerating procedures.", [["personal protective equipment", "TREATMENT", 13, 42], ["aerosolgenerating procedures", "TREATMENT", 114, 142]]], ["Although improved PPE use would be of benefit, a larger preventative impact would be to place patients presenting with respiratory complaints and potentialMERS-CoV infection in proper isolation with infection control practices until MERS-CoV infection is ruled out using the standard PCR diagnostic method.Protocols to address such patients in emergency departments or patients developing an apparent viral illness while hospitalized for other conditions should include the ability to rapidly isolate patients and run laboratory testing, which would likely mitigate spread within healthcare systems.", [["respiratory", "ANATOMY", 119, 130], ["respiratory complaints", "DISEASE", 119, 141], ["infection", "DISEASE", 164, 173], ["infection", "DISEASE", 199, 208], ["infection", "DISEASE", 242, 251], ["viral illness", "DISEASE", 401, 414], ["patients", "ORGANISM", 94, 102], ["potentialMERS-CoV", "GENE_OR_GENE_PRODUCT", 146, 163], ["MERS-CoV", "ORGANISM", 233, 241], ["patients", "ORGANISM", 332, 340], ["patients", "ORGANISM", 369, 377], ["patients", "ORGANISM", 501, 509], ["patients", "SPECIES", 94, 102], ["patients", "SPECIES", 332, 340], ["patients", "SPECIES", 369, 377], ["patients", "SPECIES", 501, 509], ["MERS-CoV", "SPECIES", 233, 241], ["respiratory complaints", "PROBLEM", 119, 141], ["potentialMERS", "PROBLEM", 146, 159], ["CoV infection", "PROBLEM", 160, 173], ["infection control practices", "TREATMENT", 199, 226], ["CoV infection", "PROBLEM", 238, 251], ["an apparent viral illness", "PROBLEM", 389, 414], ["other conditions", "PROBLEM", 438, 454], ["run laboratory testing", "TEST", 514, 536], ["infection", "OBSERVATION", 164, 173]]], ["Proper triaging of patients with acute respiratory illness is a fundamental step towards the application of a unified process to deal with such patients, as suggested by the World Health Organization and the United States Centers for Disease Control and Prevention [50, 51] .", [["respiratory", "ANATOMY", 39, 50], ["acute respiratory illness", "DISEASE", 33, 58], ["patients", "ORGANISM", 19, 27], ["patients", "ORGANISM", 144, 152], ["patients", "SPECIES", 19, 27], ["patients", "SPECIES", 144, 152], ["acute respiratory illness", "PROBLEM", 33, 58], ["Disease Control", "TREATMENT", 234, 249], ["acute", "OBSERVATION_MODIFIER", 33, 38], ["respiratory", "ANATOMY", 39, 50], ["illness", "OBSERVATION", 51, 58]]], ["Despite such advice, not all healthcare systems in regions endemic for MERS-CoV or in non-endemic regions caring for a potentially infected traveller follow these steps.", [["MERS-CoV", "ORGANISM", 71, 79], ["MERS-CoV", "SPECIES", 71, 79], ["CoV", "PROBLEM", 76, 79]]], ["In a simulation of a 'mystery' infectious patient, 95 drills including 42 drills specifically for patients with possible MERS were conducted in 49 emergency departments in New York, USA.", [["patient", "ORGANISM", 42, 49], ["patients", "ORGANISM", 98, 106], ["patient", "SPECIES", 42, 49], ["patients", "SPECIES", 98, 106]]], ["Hospitals were variable in the identification of potentially infectious patients and implementation of appropriate infection control measures, such as suboptimal adherence to hand hygiene, PPE use and isolation signage posting [52] .MERS-CoV infection in proper isolation with infection control practices until MERS-CoV infection is ruled out using the standard PCR diagnostic method.The Saudi Ministry of Health has recently introduced visual triage using a scoring system to aid in the assessment of patients presenting with respiratory symptoms in emergency departments, dialysis units and other clinical settings [53] .", [["hand", "ANATOMY", 175, 179], ["respiratory", "ANATOMY", 527, 538], ["infection", "DISEASE", 115, 124], ["infection", "DISEASE", 242, 251], ["infection", "DISEASE", 277, 286], ["infection", "DISEASE", 320, 329], ["respiratory symptoms", "DISEASE", 527, 547], ["patients", "ORGANISM", 72, 80], ["hand", "ORGANISM_SUBDIVISION", 175, 179], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 233, 241], ["MERS-CoV", "ORGANISM", 311, 319], ["patients", "ORGANISM", 502, 510], ["patients", "SPECIES", 72, 80], ["patients", "SPECIES", 502, 510], ["MERS-CoV", "SPECIES", 233, 241], ["MERS-CoV", "SPECIES", 311, 319], ["appropriate infection control measures", "TREATMENT", 103, 141], ["hand hygiene", "TREATMENT", 175, 187], ["PPE use", "TREATMENT", 189, 196], ["isolation signage", "TREATMENT", 201, 218], ["CoV infection", "PROBLEM", 238, 251], ["infection control practices", "TREATMENT", 277, 304], ["CoV infection", "PROBLEM", 316, 329], ["a scoring system", "TREATMENT", 457, 473], ["the assessment", "TEST", 484, 498], ["respiratory symptoms", "PROBLEM", 527, 547], ["dialysis units", "TREATMENT", 574, 588], ["infectious", "OBSERVATION", 61, 71], ["infection", "OBSERVATION", 115, 124], ["CoV", "OBSERVATION_MODIFIER", 238, 241], ["infection", "OBSERVATION", 242, 251], ["infection", "OBSERVATION", 277, 286], ["infection", "OBSERVATION", 320, 329]]], ["Also, the Saudi Ministry of Health has developed a rapid response team that visits hospitals upon the identification of any positive MERS cases to help streamline contact tracing and implementation of infection control measures [54] .", [["infection", "DISEASE", 201, 210], ["any positive MERS cases", "PROBLEM", 120, 143], ["streamline contact tracing", "TEST", 152, 178], ["infection control measures", "TREATMENT", 201, 227]]], ["A similar rapid response team was also formed following the MERS outbreak in South Korea [55] .", [["similar", "OBSERVATION_MODIFIER", 2, 9], ["rapid", "OBSERVATION_MODIFIER", 10, 15]]], ["An interesting observation of the outbreaks of MERS-CoV infection is the variability in intrahospital transmission of the virus.", [["MERS-CoV infection", "DISEASE", 47, 65], ["MERS-CoV", "ORGANISM", 47, 55], ["MERS-CoV", "SPECIES", 47, 55], ["MERS", "PROBLEM", 47, 51], ["CoV infection", "PROBLEM", 52, 65], ["the virus", "PROBLEM", 118, 127], ["CoV", "OBSERVATION_MODIFIER", 52, 55], ["infection", "OBSERVATION", 56, 65]]], ["The South Korea and Jeddah outbreaks witnessed patients causing significant spread of secondary cases, while in other outbreaks, the index patient resulted in few secondary cases despite lack of infection control practices [1] .", [["infection", "DISEASE", 195, 204], ["patients", "ORGANISM", 47, 55], ["patient", "ORGANISM", 139, 146], ["patients", "SPECIES", 47, 55], ["patient", "SPECIES", 139, 146], ["secondary cases", "PROBLEM", 86, 101], ["few secondary cases", "PROBLEM", 159, 178], ["infection control practices", "TREATMENT", 195, 222], ["significant", "OBSERVATION_MODIFIER", 64, 75], ["spread", "OBSERVATION_MODIFIER", 76, 82], ["infection", "OBSERVATION", 195, 204]]], ["One reason may lie with prolonged viral shedding, observed more commonly in patients with multiple comorbidities [1] .", [["patients", "ORGANISM", 76, 84], ["patients", "SPECIES", 76, 84], ["prolonged viral shedding", "PROBLEM", 24, 48], ["multiple comorbidities", "PROBLEM", 90, 112]]], ["One study found that 30% of contacts and 76% of cases were still positive for MERS-CoV by PCR 12 days after initial positive samples [56] .", [["samples", "ANATOMY", 125, 132], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 78, 86], ["MERS-CoV", "SPECIES", 78, 86], ["One study", "TEST", 0, 9], ["cases", "TEST", 48, 53], ["MERS", "PROBLEM", 78, 82], ["PCR", "TEST", 90, 93], ["initial positive samples", "PROBLEM", 108, 132]]], ["Whether viral detection by molecular methods always equates to an infectious risk remains unclear.", [["viral detection", "TEST", 8, 23], ["an infectious risk", "PROBLEM", 63, 81], ["infectious", "OBSERVATION", 66, 76]]], ["An additional factor likely rests in patient movements.", [["patient", "ORGANISM", 37, 44], ["patient", "SPECIES", 37, 44], ["factor likely", "UNCERTAINTY", 14, 27]]], ["Intra-and interhospital transmission were documented arising from patient movements within and between hospitals [4] [42, 44] .", [["patient", "ORGANISM", 66, 73], ["patient", "SPECIES", 66, 73], ["Intra-and interhospital transmission", "PROBLEM", 0, 36]]], ["Control of patient flow within and between healthcare settings with proper infection prevention measures is necessary to decrease the chance of transmission of MERS-CoV.MERS-CoV infection in proper isolation with infection control practices until MERS-CoV infection is ruled out using the standard PCR diagnostic method.It is not clear how much asymptomatic and mildly symptomatic patients contribute to viral dissemination in the healthcare setting.", [["infection", "DISEASE", 75, 84], ["infection", "DISEASE", 178, 187], ["infection", "DISEASE", 213, 222], ["infection", "DISEASE", 256, 265], ["patient", "ORGANISM", 11, 18], ["MERS-CoV.MERS-CoV", "ORGANISM", 160, 177], ["MERS-CoV", "ORGANISM", 247, 255], ["patients", "ORGANISM", 381, 389], ["patient", "SPECIES", 11, 18], ["patients", "SPECIES", 381, 389], ["MERS-CoV.MERS-CoV", "SPECIES", 160, 177], ["MERS-CoV", "SPECIES", 247, 255], ["patient flow", "TEST", 11, 23], ["healthcare settings", "TREATMENT", 43, 62], ["proper infection prevention measures", "TREATMENT", 68, 104], ["CoV infection", "PROBLEM", 174, 187], ["infection control practices", "TREATMENT", 213, 240], ["CoV infection", "PROBLEM", 252, 265], ["mildly symptomatic", "PROBLEM", 362, 380], ["viral dissemination", "PROBLEM", 404, 423], ["flow", "OBSERVATION", 19, 23], ["infection", "OBSERVATION", 75, 84], ["infection", "OBSERVATION", 178, 187], ["mildly", "OBSERVATION_MODIFIER", 362, 368], ["symptomatic", "OBSERVATION_MODIFIER", 369, 380], ["viral dissemination", "OBSERVATION", 404, 423]]], ["Studies have found variable percentages of asymptomatic individuals from 7% to 66% [10,16,23,24,33,58].MERS-CoV infection in proper isolation with infection control practices until MERS-CoV infection is ruled out using the standard PCR diagnostic method.Data from South Korea showed that none of 82 contacts of an asymptomatic carrier were positive [59] , and transmission occurred from asymptomatic individuals [11, 60, 61] .", [["infection", "DISEASE", 112, 121], ["infection", "DISEASE", 147, 156], ["infection", "DISEASE", 190, 199], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 103, 111], ["MERS-CoV", "ORGANISM", 181, 189], ["MERS-CoV", "SPECIES", 103, 111], ["MERS-CoV", "SPECIES", 181, 189], ["Studies", "TEST", 0, 7], ["asymptomatic individuals", "PROBLEM", 43, 67], ["CoV infection", "PROBLEM", 108, 121], ["infection control practices", "TREATMENT", 147, 174], ["CoV infection", "PROBLEM", 186, 199], ["an asymptomatic carrier", "PROBLEM", 311, 334], ["variable", "OBSERVATION_MODIFIER", 19, 27], ["percentages", "OBSERVATION_MODIFIER", 28, 39], ["CoV", "OBSERVATION_MODIFIER", 108, 111], ["infection", "OBSERVATION", 112, 121], ["infection", "OBSERVATION", 147, 156], ["infection", "OBSERVATION", 190, 199]]], ["These differences do not yet provide defined answers for the variability in intrahospital transmission; however, they do highlight the need to review and refine infection control practices to help prevent the spread of infection within healthcare settings, and prevent unwitting spread, especially by asymptomatic individuals, by screening HCW contacts by PCR.MERS-CoV infection in proper isolation with infection control practices until MERS-CoV infection is ruled out using the standard PCR diagnostic method.What is the contribution of the persistence of the MERS-CoV virus in the environment to its spread?", [["infection", "DISEASE", 161, 170], ["infection", "DISEASE", 219, 228], ["infection", "DISEASE", 369, 378], ["infection", "DISEASE", 404, 413], ["infection", "DISEASE", 447, 456], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 360, 368], ["MERS-CoV", "ORGANISM", 438, 446], ["MERS-CoV virus", "ORGANISM", 562, 576], ["CoV virus", "SPECIES", 567, 576], ["MERS-CoV", "SPECIES", 360, 368], ["MERS-CoV", "SPECIES", 438, 446], ["MERS-CoV virus", "SPECIES", 562, 576], ["infection control practices", "TREATMENT", 161, 188], ["infection", "PROBLEM", 219, 228], ["CoV infection", "PROBLEM", 365, 378], ["infection control practices", "TREATMENT", 404, 431], ["CoV infection", "PROBLEM", 443, 456], ["the MERS", "PROBLEM", 558, 566], ["CoV virus", "PROBLEM", 567, 576], ["infection", "OBSERVATION", 219, 228], ["CoV", "OBSERVATION_MODIFIER", 365, 368], ["infection", "OBSERVATION", 369, 378], ["infection", "OBSERVATION", 404, 413], ["infection", "OBSERVATION", 447, 456]]], ["As an RNA virus, MERS-CoV survives surprisingly well on surfaces and in the air, especially at low temperature and low humidity [62] .", [["MERS-CoV", "ORGANISM", 17, 25], ["MERS-CoV", "SPECIES", 17, 25], ["an RNA virus", "PROBLEM", 3, 15], ["air", "ANATOMY", 76, 79], ["low temperature", "OBSERVATION_MODIFIER", 95, 110]]], ["Sixty minutes after aerosolization, the virus remains infectious at 63.5% at 25 C and 79% humidity, compared with only 4.7% at conditions 38 C and 24% humidity [63] .", [["aerosolization", "TREATMENT", 20, 34], ["the virus", "PROBLEM", 36, 45], ["infectious", "PROBLEM", 54, 64], ["24% humidity", "TEST", 147, 159], ["infectious", "OBSERVATION", 54, 64]]], ["MERS-CoV was detected by RT-PCR and viral culture up to 18e27 days after symptom onset from most of the touchable environments in patients' rooms [64] .", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 0, 8], ["patients", "ORGANISM", 130, 138], ["MERS-CoV", "DNA", 0, 8], ["patients", "SPECIES", 130, 138], ["MERS-CoV", "SPECIES", 0, 8], ["CoV", "PROBLEM", 5, 8], ["PCR", "TEST", 28, 31], ["viral culture", "TEST", 36, 49], ["symptom onset", "PROBLEM", 73, 86]]], ["Bed controller devices and thermometers were PCR positive until five days after the last positive PCR result from the patient's respiratory specimen [64] .", [["respiratory specimen", "ANATOMY", 128, 148], ["patient", "ORGANISM", 118, 125], ["patient", "SPECIES", 118, 125], ["Bed controller devices", "TREATMENT", 0, 22], ["PCR", "TEST", 45, 48], ["the last positive PCR result", "PROBLEM", 80, 108], ["the patient's respiratory specimen", "TEST", 114, 148]]], ["MERS-CoV was cultured in four of seven air samples from patients' rooms, a restroom and a common corridor, and from 15 (22%) of 68 surface swabs [37] .", [["samples", "ANATOMY", 43, 50], ["surface swabs", "ANATOMY", 131, 144], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 0, 8], ["patients", "ORGANISM", 56, 64], ["MERS-CoV", "DNA", 0, 8], ["patients", "SPECIES", 56, 64], ["MERS-CoV", "SPECIES", 0, 8], ["surface swabs", "TEST", 131, 144]]], ["MERS-CoV RNA was detected from anterooms, medical devices, air-ventilating equipment, bed sheets, bed rails, intravenous fluid hangers and X-ray devices [65] .", [["intravenous", "ANATOMY", 109, 120], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 0, 8], ["MERS-CoV RNA", "RNA", 0, 12], ["MERS-CoV", "SPECIES", 0, 8], ["CoV RNA", "PROBLEM", 5, 12], ["medical devices", "TREATMENT", 42, 57], ["air-ventilating equipment", "TREATMENT", 59, 84], ["bed sheets", "TREATMENT", 86, 96], ["bed rails", "TREATMENT", 98, 107], ["intravenous fluid hangers", "TREATMENT", 109, 134], ["X-ray devices", "TREATMENT", 139, 152]]], ["These data suggest that environmental cleaning needs to be meticulous, and that laboratory data may be required to prove adequate disinfection to allow discontinuation of isolation procedures.", [["environmental cleaning", "TREATMENT", 24, 46], ["laboratory data", "TEST", 80, 95], ["isolation procedures", "TREATMENT", 171, 191]]], ["Further studies are required to assess infectious risks of the environment in the presence of molecularly detected MERS-CoV RNA.MERS-CoV infection in proper isolation with infection control practices until MERS-CoV infection is ruled out using the standard PCR diagnostic method.The prospect for control of MERS-CoV relies on multifaceted programmes to educate HCWs on the disease, to identify potential patients early in their course of illness, to isolate suspected and confirmed cases appropriately, and to implement proper infection control (Table II) .", [["infection", "DISEASE", 137, 146], ["infection", "DISEASE", 172, 181], ["infection", "DISEASE", 215, 224], ["infection", "DISEASE", 527, 536], ["MERS-CoV RNA.MERS-CoV", "ORGANISM", 115, 136], ["MERS-CoV", "ORGANISM", 206, 214], ["MERS-CoV", "ORGANISM", 307, 315], ["patients", "ORGANISM", 404, 412], ["patients", "SPECIES", 404, 412], ["MERS-CoV RNA.MERS-CoV", "SPECIES", 115, 136], ["MERS-CoV", "SPECIES", 206, 214], ["MERS-CoV", "SPECIES", 307, 315], ["Further studies", "TEST", 0, 15], ["CoV infection", "PROBLEM", 133, 146], ["infection control practices", "TREATMENT", 172, 199], ["CoV infection", "PROBLEM", 211, 224], ["multifaceted programmes", "TREATMENT", 326, 349], ["illness", "PROBLEM", 438, 445], ["proper infection control", "TREATMENT", 520, 544], ["CoV", "OBSERVATION_MODIFIER", 133, 136], ["infection", "OBSERVATION", 137, 146], ["infection", "OBSERVATION", 527, 536]]], ["The best prospect for MERS prevention and control rests on basic principles of infection prevention and control in healthcare settings.", [["infection", "DISEASE", 79, 88], ["MERS prevention", "TREATMENT", 22, 37], ["infection prevention", "TREATMENT", 79, 99], ["infection", "OBSERVATION", 79, 88]]], ["Balkhy argues that three pillars are necessary: policies and procedures, facility and human resources, and accountability and leadership [66, 67] .", [["human", "ORGANISM", 86, 91], ["human", "SPECIES", 86, 91], ["human", "SPECIES", 86, 91]]], ["How these goals could be achieved is demonstrated, in part, in one study using a core group of nurses for an education programme consisting of an online skill module, donning and doffing of PPE, and hands-on practice to obtain nasopharyngeal swabs [68] .", [["nasopharyngeal swabs", "ANATOMY", 227, 247], ["an education programme", "TREATMENT", 106, 128], ["PPE", "TREATMENT", 190, 193], ["nasopharyngeal swabs", "TEST", 227, 247], ["hands", "ANATOMY", 199, 204], ["nasopharyngeal", "ANATOMY", 227, 241]]], ["Another study called for the use of the '3Is' (identifyeisolateeinform) tool in the emergency department to rapidly identify and isolate suspected cases with any emerging infectious disease [69] .", [["infectious disease", "DISEASE", 171, 189], ["Another study", "TEST", 0, 13], ["any emerging infectious disease", "PROBLEM", 158, 189], ["infectious", "OBSERVATION", 171, 181]]], ["Table II provides a summary of potential concern and possible interventions in infection prevention and control to halt MERS-CoV transmission with appropriate interventions.", [["infection", "DISEASE", 79, 88], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 120, 128], ["MERS-CoV", "SPECIES", 120, 128], ["interventions in infection prevention", "TREATMENT", 62, 99], ["appropriate interventions", "TREATMENT", 147, 172], ["infection", "OBSERVATION", 79, 88]]], ["Some listed items are, by nature, parochial, including facility structure, knowledge and skills of HCWs, and patient-related issues.", [["patient", "ORGANISM", 109, 116], ["patient", "SPECIES", 109, 116]]], ["In a survey of 607 HCWs, hospital infrastructure and design, staffing shortfalls, and absence of infection control training were cited as the primary contributing factors for the spread of MERS-CoV infection in healthcare facilities [71] .", [["infection", "DISEASE", 97, 106], ["MERS-CoV infection", "DISEASE", 189, 207], ["MERS-CoV", "ORGANISM", 189, 197], ["MERS-CoV", "SPECIES", 189, 197], ["infection control training", "TREATMENT", 97, 123], ["CoV infection", "PROBLEM", 194, 207]]], ["Raising public awareness and recognition of the disease will also assist in preventing transmission [74] .MERS-CoV infection in proper isolation with infection control practices until MERS-CoV infection is ruled out using the standard PCR diagnostic method.MERS-CoV presents with a variety of clinical and laboratory findings [4, 13, 75] .", [["infection", "DISEASE", 115, 124], ["infection", "DISEASE", 150, 159], ["infection", "DISEASE", 193, 202], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 106, 114], ["MERS-CoV", "ORGANISM", 184, 192], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 257, 265], ["MERS-CoV", "SPECIES", 106, 114], ["MERS-CoV", "SPECIES", 184, 192], ["MERS-CoV", "SPECIES", 257, 265], ["the disease", "PROBLEM", 44, 55], ["CoV infection", "PROBLEM", 111, 124], ["infection control practices", "TREATMENT", 150, 177], ["CoV infection", "PROBLEM", 189, 202], ["CoV", "OBSERVATION_MODIFIER", 111, 114], ["infection", "OBSERVATION", 115, 124], ["infection", "OBSERVATION", 150, 159], ["infection", "OBSERVATION", 193, 202]]], ["There are notable challenges in diagnosis through laboratory and radiological methods, including the possibility of negative swab results by PCR methodology.", [["radiological methods", "TEST", 65, 85], ["notable", "OBSERVATION_MODIFIER", 10, 17], ["challenges", "OBSERVATION", 18, 28]]], ["Currently, the diagnosis of MERS-CoV infection best relies on viral detection by RT-PCR [75e77].", [["infection", "DISEASE", 37, 46], ["MERS-CoV", "ORGANISM", 28, 36], ["MERS-CoV", "SPECIES", 28, 36], ["MERS", "PROBLEM", 28, 32], ["CoV infection", "PROBLEM", 33, 46], ["viral detection", "TEST", 62, 77], ["PCR", "TEST", 84, 87]]], ["Lower respiratory samples have been shown to yield better diagnostic results than nasal or oral swabs.", [["respiratory samples", "ANATOMY", 6, 25], ["nasal", "ANATOMY", 82, 87], ["oral swabs", "ANATOMY", 91, 101], ["nasal", "ORGANISM_SUBDIVISION", 82, 87], ["oral", "ORGANISM_SUBDIVISION", 91, 95], ["swabs", "ORGANISM_SUBSTANCE", 96, 101], ["Lower respiratory samples", "PROBLEM", 0, 25], ["respiratory", "ANATOMY", 6, 17]]], ["In two studies, lower respiratory samples showed higher Ct values than upper respiratory samples, and MERS-CoV virus was detected later in the course of the disease [76, 78] .", [["lower respiratory samples", "ANATOMY", 16, 41], ["upper respiratory samples", "ANATOMY", 71, 96], ["MERS-CoV virus", "ORGANISM", 102, 116], ["CoV virus", "SPECIES", 107, 116], ["MERS-CoV virus", "SPECIES", 102, 116], ["two studies", "TEST", 3, 14], ["lower respiratory samples", "TEST", 16, 41], ["higher Ct values", "PROBLEM", 49, 65], ["upper respiratory samples", "TEST", 71, 96], ["MERS-CoV virus", "PROBLEM", 102, 116], ["respiratory", "ANATOMY", 77, 88]]], ["The World Health Organization recommends that both upper and lower respiratory tract specimens should be collected whenever possible [79] .", [["lower respiratory tract specimens", "ANATOMY", 61, 94], ["upper", "ORGANISM_SUBDIVISION", 51, 56], ["both upper and lower respiratory tract specimens", "PROBLEM", 46, 94], ["upper", "ANATOMY_MODIFIER", 51, 56], ["lower", "ANATOMY_MODIFIER", 61, 66], ["respiratory tract", "ANATOMY", 67, 84]]], ["Improved diagnostic tools are needed for early diagnosis of the disease.MERS-CoV infection in proper isolation with infection control practices until MERS-CoV infection is ruled out using the standard PCR diagnostic method.In conclusion, MERS-CoV, like severe acute respiratory syndrome (SARS), requires leadership insisting on formal and continued training of HCWs to be sufficiently prepared for emerging respiratory infectious diseases.", [["infection", "DISEASE", 81, 90], ["infection", "DISEASE", 116, 125], ["infection", "DISEASE", 159, 168], ["acute respiratory syndrome", "DISEASE", 260, 286], ["SARS", "DISEASE", 288, 292], ["respiratory infectious diseases", "DISEASE", 407, 438], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 72, 80], ["MERS-CoV", "ORGANISM", 150, 158], ["MERS-CoV", "ORGANISM", 238, 246], ["MERS-CoV", "SPECIES", 72, 80], ["MERS-CoV", "SPECIES", 150, 158], ["MERS-CoV", "SPECIES", 238, 246], ["the disease", "PROBLEM", 60, 71], ["CoV infection", "PROBLEM", 77, 90], ["infection control practices", "TREATMENT", 116, 143], ["CoV infection", "PROBLEM", 155, 168], ["severe acute respiratory syndrome", "PROBLEM", 253, 286], ["HCWs", "TREATMENT", 361, 365], ["emerging respiratory infectious diseases", "PROBLEM", 398, 438], ["disease", "OBSERVATION", 64, 71], ["CoV", "OBSERVATION_MODIFIER", 77, 80], ["infection", "OBSERVATION", 81, 90], ["infection", "OBSERVATION", 116, 125], ["infection", "OBSERVATION", 159, 168], ["severe", "OBSERVATION_MODIFIER", 253, 259], ["acute", "OBSERVATION_MODIFIER", 260, 265], ["respiratory syndrome", "OBSERVATION", 266, 286], ["infectious", "OBSERVATION", 419, 429]]], ["Hospitals have varied in their ability to correctly identify potentially infectious patients and quickly implement appropriate infection control measures [52] .", [["infection", "DISEASE", 127, 136], ["patients", "ORGANISM", 84, 92], ["patients", "SPECIES", 84, 92], ["appropriate infection control measures", "TREATMENT", 115, 153]]], ["Prompt recognition, isolation and management of the suspected cases are vital factors for the prevention of MERS transmission.", [["isolation", "TREATMENT", 20, 29], ["management", "TREATMENT", 34, 44], ["vital factors", "PROBLEM", 72, 85], ["MERS transmission", "PROBLEM", 108, 125]]], ["It has been shown that MERS-CoV nucleic acid was detected by PCR in serum, faeces and urine [80e84].", [["serum", "ANATOMY", 68, 73], ["faeces", "ANATOMY", 75, 81], ["urine", "ANATOMY", 86, 91], ["nucleic acid", "CHEMICAL", 32, 44], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 23, 31], ["serum", "ORGANISM_SUBSTANCE", 68, 73], ["faeces", "ORGANISM_SUBSTANCE", 75, 81], ["urine", "ORGANISM_SUBSTANCE", 86, 91], ["MERS-CoV", "SPECIES", 23, 31], ["CoV nucleic acid", "TEST", 28, 44], ["PCR in serum", "TEST", 61, 73], ["urine", "TEST", 86, 91]]], ["Thus, it is important to maintain proper infection control practices when caring for these patients.MERS-CoV infection in proper isolation with infection control practices until MERS-CoV infection is ruled out using the standard PCR diagnostic method.Repeated assessments of infection control and monitoring implementation of corrective measures leading to constant readiness will change the course of an outbreak or halt it before it starts [85] .", [["infection", "DISEASE", 41, 50], ["infection", "DISEASE", 109, 118], ["infection", "DISEASE", 144, 153], ["infection", "DISEASE", 187, 196], ["infection", "DISEASE", 275, 284], ["patients", "ORGANISM", 91, 99], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 100, 108], ["MERS-CoV", "ORGANISM", 178, 186], ["patients", "SPECIES", 91, 99], ["MERS-CoV", "SPECIES", 100, 108], ["MERS-CoV", "SPECIES", 178, 186], ["proper infection control practices", "TREATMENT", 34, 68], ["CoV infection", "PROBLEM", 105, 118], ["infection control practices", "TREATMENT", 144, 171], ["CoV infection", "PROBLEM", 183, 196], ["Repeated assessments", "TEST", 251, 271], ["infection control", "TREATMENT", 275, 292], ["corrective measures", "TREATMENT", 326, 345], ["constant readiness", "PROBLEM", 357, 375], ["infection", "OBSERVATION", 41, 50], ["CoV", "OBSERVATION_MODIFIER", 105, 108], ["infection", "OBSERVATION", 109, 118], ["infection", "OBSERVATION", 144, 153], ["infection", "OBSERVATION", 187, 196], ["infection", "OBSERVATION", 275, 284]]], ["Limiting the number of contacts and hospital visits are also important factors to decrease the spread Table II A summary of highlights of areas for concern and possible interventions to control Middle East respiratory syndrome (MERS) infection of infection [86] .", [["Middle East respiratory syndrome", "DISEASE", 194, 226], ["infection", "DISEASE", 234, 243], ["infection", "DISEASE", 247, 256], ["Middle East respiratory syndrome (MERS)", "SPECIES", 194, 233], ["interventions", "TREATMENT", 169, 182], ["Middle East respiratory syndrome (MERS) infection of infection", "PROBLEM", 194, 256], ["respiratory syndrome", "OBSERVATION", 206, 226]]], ["Healthcare facilities should take all the steps to learn from past experiences and build capacity for the prevention of outbreaks such as MERS, SARS and Ebola.", [["MERS", "DISEASE", 138, 142], ["SARS", "DISEASE", 144, 148], ["Ebola", "DISEASE", 153, 158], ["Ebola", "ORGANISM", 153, 158], ["outbreaks", "PROBLEM", 120, 129], ["SARS", "PROBLEM", 144, 148]]], ["Failure to do so would mean that lessons learned from SARS, MERS and Ebola would be relegated to history, leaving patients, hospitals and HCWs vulnerable.", [["SARS", "DISEASE", 54, 58], ["Ebola", "DISEASE", 69, 74], ["Ebola", "ORGANISM", 69, 74], ["patients", "ORGANISM", 114, 122], ["patients", "SPECIES", 114, 122], ["Failure", "PROBLEM", 0, 7], ["SARS", "PROBLEM", 54, 58]]], ["Many infection control questions remain requiring further research, including a better understanding of the disease dynamics.", [["infection", "DISEASE", 5, 14], ["Many infection control questions", "PROBLEM", 0, 32], ["the disease dynamics", "PROBLEM", 104, 124], ["infection", "OBSERVATION", 5, 14]]], ["Leading concerns include the role of asymptomatic individuals in transmission of the disease, and precise risk factors for transmission in healthcare facilities.", [["asymptomatic individuals", "PROBLEM", 37, 61], ["the disease", "PROBLEM", 81, 92], ["disease", "OBSERVATION", 85, 92]]], ["Although data accrued have concentrated on respiratory transmission, the role of other body fluids and the built environment in transmission remains unknown.", [["respiratory", "ANATOMY", 43, 54], ["body fluids", "ANATOMY", 87, 98], ["body", "ORGANISM_SUBDIVISION", 87, 91], ["other body fluids", "TREATMENT", 81, 98], ["concentrated", "OBSERVATION_MODIFIER", 27, 39], ["respiratory transmission", "OBSERVATION", 43, 67]]], ["As zoonotic reservoirs for MERS-CoV may continue to produce sporadic human infections, rigorous infection control practices should prevent the virus from spreading past the hospital door.", [["infections", "DISEASE", 75, 85], ["infection", "DISEASE", 96, 105], ["MERS-CoV", "ORGANISM", 27, 35], ["human", "ORGANISM", 69, 74], ["human", "SPECIES", 69, 74], ["MERS-CoV", "SPECIES", 27, 35], ["human", "SPECIES", 69, 74], ["zoonotic reservoirs", "TREATMENT", 3, 22], ["MERS", "PROBLEM", 27, 31], ["CoV", "PROBLEM", 32, 35], ["sporadic human infections", "PROBLEM", 60, 85], ["rigorous infection control practices", "TREATMENT", 87, 123], ["the virus", "PROBLEM", 139, 148], ["infections", "OBSERVATION", 75, 85], ["infection", "OBSERVATION", 96, 105]]]], "PMC3136934": [["IntroductionDuring embryonic development, the generation of three major neural cell types (neurons, astrocytes, and oligodendrocytes) in the central nervous system (CNS) sequentially occurs, whereby almost all neurons are generated before the appearance of glial cells [1], [2].", [["embryonic", "ANATOMY", 19, 28], ["neural cell", "ANATOMY", 72, 83], ["neurons", "ANATOMY", 91, 98], ["astrocytes", "ANATOMY", 100, 110], ["oligodendrocytes", "ANATOMY", 116, 132], ["central nervous system", "ANATOMY", 141, 163], ["CNS", "ANATOMY", 165, 168], ["neurons", "ANATOMY", 210, 217], ["glial cells", "ANATOMY", 257, 268], ["embryonic", "DEVELOPING_ANATOMICAL_STRUCTURE", 19, 28], ["neural cell", "CELL", 72, 83], ["neurons", "CELL", 91, 98], ["astrocytes", "CELL", 100, 110], ["oligodendrocytes", "CELL", 116, 132], ["central nervous system", "ANATOMICAL_SYSTEM", 141, 163], ["CNS", "ANATOMICAL_SYSTEM", 165, 168], ["neurons", "CELL", 210, 217], ["glial cells", "CELL", 257, 268], ["neural cell types", "CELL_TYPE", 72, 89], ["neurons", "CELL_TYPE", 91, 98], ["astrocytes", "CELL_TYPE", 100, 110], ["oligodendrocytes", "CELL_TYPE", 116, 132], ["glial cells", "CELL_TYPE", 257, 268], ["neural cell types", "OBSERVATION", 72, 89], ["central", "ANATOMY_MODIFIER", 141, 148], ["nervous system", "ANATOMY", 149, 163], ["CNS", "ANATOMY", 165, 168], ["glial cells", "OBSERVATION", 257, 268]]], ["Recent findings demonstrated that glial cells are important in critical neuronal maturation processes such as axonal pathfinding, synapse formation, neurotransmitter transport, metabolic functions, and the response to CNS injury [3]\u2013[6].", [["glial cells", "ANATOMY", 34, 45], ["neuronal", "ANATOMY", 72, 80], ["axonal", "ANATOMY", 110, 116], ["synapse", "ANATOMY", 130, 137], ["CNS", "ANATOMY", 218, 221], ["glial cells", "CELL", 34, 45], ["neuronal", "CELL", 72, 80], ["axonal", "CELLULAR_COMPONENT", 110, 116], ["synapse", "CELLULAR_COMPONENT", 130, 137], ["glial cells", "CELL_TYPE", 34, 45], ["glial cells", "PROBLEM", 34, 45], ["CNS injury", "PROBLEM", 218, 228], ["glial cells", "OBSERVATION", 34, 45], ["neuronal maturation", "OBSERVATION", 72, 91]]], ["Although rodent brain cultures and neuronal and glial cell lines have provided us with important information about the structure and function of the mammalian CNS, we have scanty understanding of astrocytic differentiation.IntroductionThere has been longstanding interest in understanding how the process by which progenitors differentiate into different cell types is regulated.", [["brain cultures", "ANATOMY", 16, 30], ["neuronal", "ANATOMY", 35, 43], ["glial cell lines", "ANATOMY", 48, 64], ["CNS", "ANATOMY", 159, 162], ["astrocytic", "ANATOMY", 196, 206], ["progenitors", "ANATOMY", 314, 325], ["cell", "ANATOMY", 355, 359], ["brain cultures", "CELL", 16, 30], ["neuronal", "CELL", 35, 43], ["glial cell lines", "CELL", 48, 64], ["CNS", "ANATOMICAL_SYSTEM", 159, 162], ["astrocytic", "CELL", 196, 206], ["progenitors", "CELL", 314, 325], ["cell", "CELL", 355, 359], ["rodent brain cultures", "CELL_LINE", 9, 30], ["neuronal and glial cell lines", "CELL_LINE", 35, 64], ["progenitors", "CELL_TYPE", 314, 325], ["rodent", "SPECIES", 9, 15], ["rodent brain cultures", "TEST", 9, 30], ["glial cell lines", "TREATMENT", 48, 64], ["brain", "ANATOMY", 16, 21], ["glial cell lines", "OBSERVATION", 48, 64], ["mammalian CNS", "ANATOMY", 149, 162], ["astrocytic differentiation", "OBSERVATION", 196, 222], ["different cell types", "OBSERVATION", 345, 365]]], ["In a mouse model, the fate of progenitors in the developing brain is believed to be determined by external cues that involve various types of cytokines and internal cellular programs.", [["progenitors", "ANATOMY", 30, 41], ["brain", "ANATOMY", 60, 65], ["cellular", "ANATOMY", 165, 173], ["mouse", "ORGANISM", 5, 10], ["progenitors", "CELL", 30, 41], ["brain", "ORGAN", 60, 65], ["cellular", "CELL", 165, 173], ["progenitors", "CELL_TYPE", 30, 41], ["cytokines", "PROTEIN", 142, 151], ["mouse", "SPECIES", 5, 10], ["mouse", "SPECIES", 5, 10], ["cytokines", "TREATMENT", 142, 151], ["internal cellular programs", "TREATMENT", 156, 182], ["brain", "ANATOMY", 60, 65]]], ["External cues such as bone morphogenetic proteins, leukemia inhibitory factor, ciliary neurotrophic factor, Notch-Delta, and basic fibroblast growth factor promote astrocytic differentiation [7]\u2013[13], and most of these factors influence the essential astrogliogenic Janus kinase-signal transducer and activator of transcription pathway [14]\u2013[17].", [["bone", "ANATOMY", 22, 26], ["astrocytic", "ANATOMY", 164, 174], ["bone", "TISSUE", 22, 26], ["leukemia inhibitory factor", "GENE_OR_GENE_PRODUCT", 51, 77], ["ciliary neurotrophic factor", "GENE_OR_GENE_PRODUCT", 79, 106], ["Notch-Delta", "GENE_OR_GENE_PRODUCT", 108, 119], ["basic fibroblast growth factor", "GENE_OR_GENE_PRODUCT", 125, 155], ["Janus kinase", "GENE_OR_GENE_PRODUCT", 266, 278], ["bone morphogenetic proteins", "PROTEIN", 22, 49], ["leukemia inhibitory factor", "PROTEIN", 51, 77], ["ciliary neurotrophic factor", "PROTEIN", 79, 106], ["Notch", "PROTEIN", 108, 113], ["Delta", "PROTEIN", 114, 119], ["basic fibroblast growth factor", "PROTEIN", 125, 155], ["astrogliogenic Janus kinase", "PROTEIN", 251, 278], ["External cues", "TREATMENT", 0, 13], ["bone morphogenetic proteins", "PROBLEM", 22, 49], ["leukemia inhibitory factor", "PROBLEM", 51, 77], ["ciliary neurotrophic factor", "PROBLEM", 79, 106], ["Notch-Delta", "PROBLEM", 108, 119], ["basic fibroblast growth factor", "PROBLEM", 125, 155], ["these factors", "PROBLEM", 213, 226], ["transcription pathway", "TEST", 314, 335], ["bone", "ANATOMY", 22, 26]]], ["A molecular basis for the cooperative action between these families of cytokines involves the formation of a STAT3-Smad1 complex with the coactivator, p300/CBP, that initiates astrocyte-specific gene expression [15], [18]\u2013[20].IntroductionIntrinsic programs regulating cell fate determination of progenitors include epigenetic modifications such as DNA methylation and chromatin remodeling.", [["astrocyte", "ANATOMY", 176, 185], ["cell", "ANATOMY", 269, 273], ["progenitors", "ANATOMY", 296, 307], ["chromatin", "ANATOMY", 369, 378], ["STAT3", "GENE_OR_GENE_PRODUCT", 109, 114], ["Smad1", "GENE_OR_GENE_PRODUCT", 115, 120], ["p300", "GENE_OR_GENE_PRODUCT", 151, 155], ["CBP", "GENE_OR_GENE_PRODUCT", 156, 159], ["astrocyte", "CELL", 176, 185], ["[18]\u2013[20]", "SIMPLE_CHEMICAL", 217, 226], ["cell", "CELL", 269, 273], ["progenitors", "CELL", 296, 307], ["DNA", "CELLULAR_COMPONENT", 349, 352], ["chromatin", "CELLULAR_COMPONENT", 369, 378], ["cytokines", "PROTEIN", 71, 80], ["STAT3", "PROTEIN", 109, 114], ["Smad1 complex", "PROTEIN", 115, 128], ["coactivator", "PROTEIN", 138, 149], ["p300", "PROTEIN", 151, 155], ["CBP", "PROTEIN", 156, 159], ["progenitors", "CELL_TYPE", 296, 307], ["chromatin", "DNA", 369, 378], ["cytokines", "TREATMENT", 71, 80], ["p300/CBP", "TEST", 151, 159], ["epigenetic modifications", "TREATMENT", 316, 340], ["DNA methylation and chromatin remodeling", "TREATMENT", 349, 389], ["cell fate", "OBSERVATION", 269, 278], ["chromatin remodeling", "OBSERVATION", 369, 389]]], ["Methylation of the STAT-binding element within the glial fibrillary acidic protein (GFAP) promoter in mice was shown to inhibit the association of activated STATs with the glial promoter, thereby repressing transcription of the GFAP gene [10], [16], [21].", [["glial", "ANATOMY", 172, 177], ["STAT", "GENE_OR_GENE_PRODUCT", 19, 23], ["glial fibrillary acidic protein", "GENE_OR_GENE_PRODUCT", 51, 82], ["GFAP", "GENE_OR_GENE_PRODUCT", 84, 88], ["mice", "ORGANISM", 102, 106], ["STATs", "GENE_OR_GENE_PRODUCT", 157, 162], ["glial", "CELL", 172, 177], ["GFAP", "GENE_OR_GENE_PRODUCT", 228, 232], ["STAT-binding element", "DNA", 19, 39], ["glial fibrillary acidic protein (GFAP) promoter", "DNA", 51, 98], ["STATs", "PROTEIN", 157, 162], ["glial promoter", "DNA", 172, 186], ["GFAP gene", "DNA", 228, 237], ["mice", "SPECIES", 102, 106], ["mice", "SPECIES", 102, 106], ["the STAT-binding element", "PROBLEM", 15, 39], ["the glial promoter", "TREATMENT", 168, 186]]], ["Furthermore, conditional deletion of the maintenance DNA methyltransferase I from neural progenitor cells (NPCs) suggests that DNA methylation regulates the timing and magnitude of astrogliogenesis [22].", [["neural progenitor cells", "ANATOMY", 82, 105], ["NPCs", "ANATOMY", 107, 111], ["DNA", "CELLULAR_COMPONENT", 53, 56], ["methyltransferase I", "GENE_OR_GENE_PRODUCT", 57, 76], ["neural progenitor cells", "CELL", 82, 105], ["NPCs", "CELL", 107, 111], ["DNA", "CELLULAR_COMPONENT", 127, 130], ["maintenance DNA methyltransferase I", "PROTEIN", 41, 76], ["neural progenitor cells", "CELL_TYPE", 82, 105], ["NPCs", "CELL_TYPE", 107, 111], ["conditional deletion", "PROBLEM", 13, 33], ["the maintenance DNA methyltransferase I", "TREATMENT", 37, 76], ["neural progenitor cells", "TREATMENT", 82, 105], ["DNA methylation regulates", "PROBLEM", 127, 152], ["astrogliogenesis", "TEST", 181, 197], ["progenitor cells", "OBSERVATION", 89, 105]]], ["Another class of epigenetic modifications was found from FGF2, which regulates the ability of ciliary neurotrophic factor to enhance astrocyte differentiation by inducing H3 Lys4 dimethylation and suppressing H3 Lys9 dimethylation at the STAT3-binding site, resulting in access of the STAT/CBP complex to the GFAP promoter and activation of GFAP expression [16].", [["astrocyte", "ANATOMY", 133, 142], ["FGF2", "GENE_OR_GENE_PRODUCT", 57, 61], ["ciliary neurotrophic factor", "GENE_OR_GENE_PRODUCT", 94, 121], ["astrocyte", "CELL", 133, 142], ["H3 Lys4", "GENE_OR_GENE_PRODUCT", 171, 178], ["H3 Lys9", "GENE_OR_GENE_PRODUCT", 209, 216], ["STAT3", "GENE_OR_GENE_PRODUCT", 238, 243], ["STAT", "GENE_OR_GENE_PRODUCT", 285, 289], ["CBP", "GENE_OR_GENE_PRODUCT", 290, 293], ["GFAP", "GENE_OR_GENE_PRODUCT", 309, 313], ["GFAP", "GENE_OR_GENE_PRODUCT", 341, 345], ["FGF2", "PROTEIN", 57, 61], ["ciliary neurotrophic factor", "PROTEIN", 94, 121], ["H3", "PROTEIN", 171, 173], ["H3", "PROTEIN", 209, 211], ["STAT3-binding site", "DNA", 238, 256], ["STAT", "PROTEIN", 285, 289], ["CBP complex", "PROTEIN", 290, 301], ["GFAP promoter", "DNA", 309, 322], ["GFAP", "PROTEIN", 341, 345], ["epigenetic modifications", "PROBLEM", 17, 41], ["FGF2", "TREATMENT", 57, 61], ["ciliary neurotrophic factor", "PROBLEM", 94, 121], ["H3 Lys4 dimethylation", "TREATMENT", 171, 192], ["suppressing H3 Lys9 dimethylation", "TREATMENT", 197, 230], ["the STAT/CBP complex", "TREATMENT", 281, 301], ["the GFAP promoter", "TREATMENT", 305, 322], ["GFAP expression", "TEST", 341, 356], ["epigenetic modifications", "OBSERVATION", 17, 41]]], ["Those reports highlight the diverse epigenetic mechanisms that control lineage-specific gene expression; however, it remains unclear how the interplay among DNA methylation, transcriptional repressors or activators, and histone modifications contributes to regulation of the processes.IntroductionIn this study, we used a human embryonal carcinoma cell line, NTera-2, to develop a model that induces the differentiation of these cells into an astrocyte-like lineage.", [["embryonal carcinoma cell line", "ANATOMY", 328, 357], ["NTera-2", "ANATOMY", 359, 366], ["cells", "ANATOMY", 429, 434], ["astrocyte-like lineage", "ANATOMY", 443, 465], ["embryonal carcinoma", "DISEASE", 328, 347], ["DNA", "CELLULAR_COMPONENT", 157, 160], ["histone", "GENE_OR_GENE_PRODUCT", 220, 227], ["human", "ORGANISM", 322, 327], ["embryonal carcinoma cell line", "CELL", 328, 357], ["NTera-2", "CELL", 359, 366], ["cells", "CELL", 429, 434], ["astrocyte-like lineage", "CELL", 443, 465], ["transcriptional repressors", "PROTEIN", 174, 200], ["histone", "PROTEIN", 220, 227], ["human embryonal carcinoma cell line", "CELL_LINE", 322, 357], ["NTera-2", "CELL_LINE", 359, 366], ["astrocyte-like lineage", "CELL_TYPE", 443, 465], ["human", "SPECIES", 322, 327], ["human", "SPECIES", 322, 327], ["the diverse epigenetic mechanisms", "PROBLEM", 24, 57], ["DNA methylation", "TREATMENT", 157, 172], ["transcriptional repressors", "TREATMENT", 174, 200], ["activators", "TREATMENT", 204, 214], ["histone modifications", "TREATMENT", 220, 241], ["this study", "TEST", 300, 310], ["a human embryonal carcinoma cell line", "TREATMENT", 320, 357], ["embryonal carcinoma", "OBSERVATION", 328, 347], ["cell line", "OBSERVATION", 348, 357], ["astrocyte", "ANATOMY", 443, 452]]], ["NTera-2 is derived from a human teratocarcinoma which shares many characteristics of neuroepithelial precursor cells and is widely used as a tool to study the early development of the human CNS and identify new genes involved in neurogenesis [23]\u2013[25].", [["teratocarcinoma", "ANATOMY", 32, 47], ["neuroepithelial precursor cells", "ANATOMY", 85, 116], ["CNS", "ANATOMY", 190, 193], ["human teratocarcinoma", "DISEASE", 26, 47], ["NTera-2", "GENE_OR_GENE_PRODUCT", 0, 7], ["human", "ORGANISM", 26, 31], ["teratocarcinoma", "CANCER", 32, 47], ["neuroepithelial precursor cells", "CELL", 85, 116], ["human", "ORGANISM", 184, 189], ["CNS", "ANATOMICAL_SYSTEM", 190, 193], ["NTera", "PROTEIN", 0, 5], ["neuroepithelial precursor cells", "CELL_TYPE", 85, 116], ["human", "SPECIES", 26, 31], ["human", "SPECIES", 184, 189], ["human", "SPECIES", 26, 31], ["human", "SPECIES", 184, 189], ["a human teratocarcinoma", "PROBLEM", 24, 47], ["neuroepithelial precursor cells", "PROBLEM", 85, 116], ["teratocarcinoma", "OBSERVATION", 32, 47], ["neuroepithelial precursor cells", "OBSERVATION", 85, 116]]], ["We also used this system to investigate the mechanisms underlying GFAP activation.", [["GFAP", "GENE_OR_GENE_PRODUCT", 66, 70], ["GFAP", "PROTEIN", 66, 70], ["this system", "TREATMENT", 13, 24], ["GFAP activation", "OBSERVATION", 66, 81]]], ["We identified components of the Sin3A-HDAC complex coupled with MeCP2 present at the GFAP promoter under undifferentiated conditions.", [["Sin3A", "GENE_OR_GENE_PRODUCT", 32, 37], ["HDAC", "GENE_OR_GENE_PRODUCT", 38, 42], ["MeCP2", "GENE_OR_GENE_PRODUCT", 64, 69], ["GFAP", "GENE_OR_GENE_PRODUCT", 85, 89], ["Sin3A", "PROTEIN", 32, 37], ["HDAC complex", "PROTEIN", 38, 50], ["MeCP2", "PROTEIN", 64, 69], ["GFAP promoter", "DNA", 85, 98], ["the Sin3A-HDAC complex", "TREATMENT", 28, 50], ["MeCP2", "PROBLEM", 64, 69], ["MeCP2", "OBSERVATION", 64, 69], ["undifferentiated conditions", "OBSERVATION", 105, 132]]], ["Upon differentiation, the promoter underwent a conformational change triggered by STAT3 binding, which contributes to CBP/p300-mediated histone modification and assembly of a transcription preinitiation complex, resulting in GFAP gene activation.Cell lines and reagents ::: Materials and MethodsNTera-2, 3T3, and 293T cells were obtained from the American Type Culture Collection (Rockville, MD, USA).", [["Cell lines", "ANATOMY", 246, 256], ["MethodsNTera-2, 3T3", "ANATOMY", 288, 307], ["293T cells", "ANATOMY", 313, 323], ["STAT3", "GENE_OR_GENE_PRODUCT", 82, 87], ["CBP", "GENE_OR_GENE_PRODUCT", 118, 121], ["p300", "GENE_OR_GENE_PRODUCT", 122, 126], ["histone", "GENE_OR_GENE_PRODUCT", 136, 143], ["GFAP", "GENE_OR_GENE_PRODUCT", 225, 229], ["Cell lines", "CELL", 246, 256], ["MethodsNTera-2", "CELL", 288, 302], ["3T3", "CELL", 304, 307], ["293T cells", "CELL", 313, 323], ["STAT3", "PROTEIN", 82, 87], ["CBP", "PROTEIN", 118, 121], ["p300", "PROTEIN", 122, 126], ["histone", "PROTEIN", 136, 143], ["transcription preinitiation complex", "PROTEIN", 175, 210], ["GFAP", "PROTEIN", 225, 229], ["MethodsNTera-2, 3T3", "CELL_LINE", 288, 307], ["293T cells", "CELL_LINE", 313, 323], ["a conformational change", "PROBLEM", 45, 68], ["STAT3 binding", "PROBLEM", 82, 95], ["CBP/p300-mediated histone modification", "TREATMENT", 118, 156], ["a transcription preinitiation complex", "PROBLEM", 173, 210], ["GFAP gene activation", "PROBLEM", 225, 245], ["Materials", "TEST", 274, 283], ["MethodsNTera", "TEST", 288, 300]]], ["Cells were cultured in Dulbecco's modified Eagle medium (DMEM; Invitrogen, Durham, NC, USA) containing 10% fetal bovine serum (FBS; JRH Bioscience, Lenexa, KS, USA), 0.2 mM GlutaMax-1 (Invitrogen), and penicillin/streptomycin (100 units/mL; Invitrogen).", [["Cells", "ANATOMY", 0, 5], ["fetal bovine serum", "ANATOMY", 107, 125], ["FBS", "ANATOMY", 127, 130], ["GlutaMax-1", "CHEMICAL", 173, 183], ["penicillin", "CHEMICAL", 202, 212], ["streptomycin", "CHEMICAL", 213, 225], ["GlutaMax-1", "CHEMICAL", 173, 183], ["penicillin", "CHEMICAL", 202, 212], ["streptomycin", "CHEMICAL", 213, 225], ["Cells", "CELL", 0, 5], ["bovine", "ORGANISM", 113, 119], ["serum", "ORGANISM_SUBSTANCE", 120, 125], ["FBS", "ORGANISM_SUBSTANCE", 127, 130], ["GlutaMax-1", "SIMPLE_CHEMICAL", 173, 183], ["Invitrogen", "SIMPLE_CHEMICAL", 185, 195], ["penicillin", "SIMPLE_CHEMICAL", 202, 212], ["streptomycin", "SIMPLE_CHEMICAL", 213, 225], ["bovine", "SPECIES", 113, 119], ["bovine", "SPECIES", 113, 119], ["Cells", "TEST", 0, 5], ["Dulbecco", "TEST", 23, 31], ["Invitrogen", "TEST", 63, 73], ["fetal bovine serum", "TEST", 107, 125], ["FBS", "TEST", 127, 130], ["JRH", "TEST", 132, 135], ["Lenexa", "TEST", 148, 154], ["GlutaMax", "TEST", 173, 181], ["Invitrogen", "TEST", 185, 195], ["penicillin", "TREATMENT", 202, 212], ["streptomycin", "TREATMENT", 213, 225], ["Invitrogen", "TREATMENT", 241, 251]]], ["Cells were split every 2 days in a 0.5% trypsin-EDTA solution and maintained until used.Design of the Oct-4 RNAi vector ::: Materials and MethodsAn oligonucleotide containing a stem-loop structure targeting the Oct-4 gene was designed using the RNAi program (http://athena.bioc.uvic.ca/).", [["Cells", "ANATOMY", 0, 5], ["trypsin-EDTA", "CHEMICAL", 40, 52], ["trypsin-EDTA", "CHEMICAL", 40, 52], ["Cells", "CELL", 0, 5], ["trypsin-", "SIMPLE_CHEMICAL", 40, 48], ["Oct-4", "GENE_OR_GENE_PRODUCT", 102, 107], ["Oct-4", "GENE_OR_GENE_PRODUCT", 211, 216], ["Oct-4 RNAi vector", "DNA", 102, 119], ["Oct-4 gene", "DNA", 211, 221], ["a 0.5% trypsin-EDTA solution", "TREATMENT", 33, 61], ["the Oct", "TEST", 98, 105], ["Materials", "TREATMENT", 124, 133], ["MethodsAn oligonucleotide", "TREATMENT", 138, 163], ["a stem-loop structure", "TREATMENT", 175, 196], ["the RNAi program", "TREATMENT", 241, 257], ["stem", "OBSERVATION_MODIFIER", 177, 181]]], ["The targeted sequence was GCGAACCAGTATCGAGAAC in the Oct-4/POU5F1 gene (515\u223c534 nt; accession no. NM_203289).", [["NM_203289", "CHEMICAL", 98, 107], ["Oct-4", "GENE_OR_GENE_PRODUCT", 53, 58], ["POU5F1", "GENE_OR_GENE_PRODUCT", 59, 65], ["Oct-4", "DNA", 53, 58], ["POU5F1 gene", "DNA", 59, 70], ["515\u223c534 nt", "DNA", 72, 82], ["The targeted sequence", "TEST", 0, 21], ["GCGAACCAGTATCGAGAAC", "TEST", 26, 45], ["the Oct", "TEST", 49, 56]]], ["This sequence was first cloned into a pBS/U6 vector.", [["pBS", "GENE_OR_GENE_PRODUCT", 38, 41], ["U6", "GENE_OR_GENE_PRODUCT", 42, 44], ["pBS/U6 vector", "DNA", 38, 51], ["a pBS/U6 vector", "TREATMENT", 36, 51], ["U6 vector", "OBSERVATION", 42, 51]]], ["Then the U6-RNAi cassette was subcloned into a lentiviral vector, pFUGW [26], and the sequences were verified by DNA sequencing.Lentiviral production and NTera-2 cell transduction ::: Materials and MethodsLentiviral vectors were produced by transient co-transfection of pCMV\u0394R8.9 (10 \u00b5g), VSV-G (pMD.G; 10 \u00b5g), and the lentiviral vector (pFUGW; 10 \u00b5g) into 293T cells.", [["NTera-2 cell", "ANATOMY", 154, 166], ["293T cells", "ANATOMY", 357, 367], ["pCMV\u0394R8.9", "CHEMICAL", 270, 279], ["pCMV\u0394R8.9", "CHEMICAL", 270, 279], ["U6", "GENE_OR_GENE_PRODUCT", 9, 11], ["lentiviral", "ORGANISM", 47, 57], ["DNA", "CELLULAR_COMPONENT", 113, 116], ["Lentiviral", "ORGANISM", 128, 138], ["NTera-2 cell", "CELL", 154, 166], ["pCMV\u0394R8.9", "SIMPLE_CHEMICAL", 270, 279], ["VSV-G", "SIMPLE_CHEMICAL", 289, 294], ["lentiviral", "ORGANISM", 319, 329], ["293T cells", "CELL", 357, 367], ["U6-RNAi cassette", "DNA", 9, 25], ["pFUGW [26]", "DNA", 66, 76], ["lentiviral vector", "DNA", 319, 336], ["293T cells", "CELL_LINE", 357, 367], ["lentiviral", "SPECIES", 319, 329], ["the U6-RNAi cassette", "TREATMENT", 5, 25], ["a lentiviral vector", "TREATMENT", 45, 64], ["the sequences", "TEST", 82, 95], ["DNA sequencing", "TEST", 113, 127], ["Lentiviral production", "TREATMENT", 128, 149], ["MethodsLentiviral vectors", "TREATMENT", 198, 223], ["pCMV\u0394R8.9", "TEST", 270, 279], ["VSV", "TEST", 289, 292], ["MD.G", "TEST", 297, 301], ["pFUGW", "TEST", 338, 343], ["293T cells", "OBSERVATION", 357, 367]]], ["Viral supernatants were concentrated by ultracentrifugation to produce viruses with titers of 1\u00d7108 infection units/mL.", [["supernatants", "ANATOMY", 6, 18], ["infection", "DISEASE", 100, 109], ["Viral", "ORGANISM", 0, 5], ["Viral supernatants", "PROBLEM", 0, 18], ["viruses", "PROBLEM", 71, 78], ["titers", "TEST", 84, 90]]], ["Multiplicities of infection of 10 and 25 were used to infect NTera-2 cells in the presence of 8 \u00b5g/mL polybrene (Sigma, St. Louis, MO, USA).", [["NTera-2 cells", "ANATOMY", 61, 74], ["infection", "DISEASE", 18, 27], ["polybrene", "CHEMICAL", 102, 111], ["polybrene", "CHEMICAL", 102, 111], ["NTera-2 cells", "CELL", 61, 74], ["polybrene", "SIMPLE_CHEMICAL", 102, 111], ["NTera-2 cells", "CELL_LINE", 61, 74], ["infection", "PROBLEM", 18, 27], ["NTera", "TEST", 61, 66], ["infection", "OBSERVATION", 18, 27]]], ["These transduced cells expressed green fluorescent protein (GFP) and were analyzed by fluorescence-activated cell sorting (FACS).Cell-cycle analysis ::: Materials and MethodsCells were resuspended in PBS and fixed with ethanol overnight at \u221220\u00b0C. Cells were then resuspended in PBS and treated with 100 \u00b5g/ml of ribonuclease A (bovine pancreas; Sigma), 0.1% Triton-X100, and 40 \u00b5g/ml propidium iodide (PI) for 30 min at 37\u00b0C. Cell cycles were detected with FACSCalibur, and analyzed by the ModFit LT program (Verity Software House, Topsham, ME, USA).Reverse-transcription polymerase chain reaction (RT-PCR) ::: Materials and MethodsTotal RNA was extracted from NTera-2 cells using the Qiagen RNeasy Mini kit following the manufacturer's protocol (Qiagen, Valencia, CA, USA).", [["cells", "ANATOMY", 17, 22], ["cell", "ANATOMY", 109, 113], ["Cell", "ANATOMY", 129, 133], ["Cells", "ANATOMY", 247, 252], ["pancreas", "ANATOMY", 335, 343], ["Cell", "ANATOMY", 426, 430], ["NTera-2 cells", "ANATOMY", 661, 674], ["ethanol", "CHEMICAL", 219, 226], ["Triton-X100", "CHEMICAL", 358, 369], ["propidium iodide", "CHEMICAL", 384, 400], ["PI", "CHEMICAL", 402, 404], ["ethanol", "CHEMICAL", 219, 226], ["propidium iodide", "CHEMICAL", 384, 400], ["cells", "CELL", 17, 22], ["green fluorescent protein", "GENE_OR_GENE_PRODUCT", 33, 58], ["GFP", "GENE_OR_GENE_PRODUCT", 60, 63], ["cell", "CELL", 109, 113], ["Cell", "CELL", 129, 133], ["ethanol", "SIMPLE_CHEMICAL", 219, 226], ["Cells", "CELL", 247, 252], ["ribonuclease A", "GENE_OR_GENE_PRODUCT", 312, 326], ["bovine", "ORGANISM", 328, 334], ["pancreas", "ORGAN", 335, 343], ["Sigma", "SIMPLE_CHEMICAL", 345, 350], ["Triton-X100", "SIMPLE_CHEMICAL", 358, 369], ["propidium iodide", "SIMPLE_CHEMICAL", 384, 400], ["PI", "SIMPLE_CHEMICAL", 402, 404], ["Cell", "CELL", 426, 430], ["NTera-2 cells", "CELL", 661, 674], ["transduced cells", "CELL_LINE", 6, 22], ["green fluorescent protein", "PROTEIN", 33, 58], ["GFP", "PROTEIN", 60, 63], ["ribonuclease A", "PROTEIN", 312, 326], ["MethodsTotal RNA", "RNA", 625, 641], ["NTera-2 cells", "CELL_LINE", 661, 674], ["bovine", "SPECIES", 328, 334], ["These transduced cells", "TEST", 0, 22], ["Materials", "TREATMENT", 153, 162], ["MethodsCells", "TREATMENT", 167, 179], ["ethanol", "TREATMENT", 219, 226], ["Cells", "TEST", 247, 252], ["ribonuclease A (bovine pancreas", "TREATMENT", 312, 343], ["Cell cycles", "TEST", 426, 437], ["Reverse-transcription polymerase chain reaction", "PROBLEM", 550, 597], ["MethodsTotal RNA", "TREATMENT", 625, 641], ["the Qiagen RNeasy Mini kit", "TREATMENT", 681, 707], ["the manufacturer's protocol", "TREATMENT", 718, 745], ["pancreas", "ANATOMY", 335, 343]]], ["The target RNA was amplified by a one-step RT-PCR kit (GMbiolab, Taichung, Taiwan).", [["target RNA", "RNA", 4, 14]]], ["Forward and reverse primers were as follows: GFAP (forward), 5\u2032-GTGGGCAGGTGGGAGCTTGATTCT-3\u2032 and (reverse), 5\u2032-CTGGGGCGGCCTGGTATGACA-3\u2032[27]; and internal control \u03b2-actin (forward), 5\u2032-TGGAATCCTGTGGCATCCATGAAAC-3\u2032 and (reverse), 5\u2032-TAAAACGCAGCTCAGTAACAGTCCG-3\u2032.", [["GFAP", "GENE_OR_GENE_PRODUCT", 45, 49], ["Forward and reverse primers", "DNA", 0, 27], ["GFAP", "PROTEIN", 45, 49], ["\u03b2-actin", "PROTEIN", 161, 168], ["Forward and reverse primers", "PROBLEM", 0, 27], ["GTGGGCAGGTGGGAGCTTGATTCT", "TEST", 64, 88], ["CTGGGGCGGCCTGGTATGACA", "TEST", 110, 131], ["internal control \u03b2-actin (forward)", "TREATMENT", 144, 178], ["TGGAATCCTGTGGCATCCATGAAAC", "TEST", 183, 208], ["TAAAACGCAGCTCAGTAACAGTCCG", "TEST", 230, 255]]], ["The RT-PCR consisted of two programs.", [["The RT-PCR", "TEST", 0, 10]]], ["First was complementary cDNA synthesis: one cycle at 50\u00b0C for 30 min and one cycle at 94\u00b0C for 2 min.", [["complementary cDNA", "DNA", 10, 28]]], ["The other was second-strand cDNA synthesis and the PCR consisted of 35 cycles at 94\u00b0C for 30 s, 59\u00b0C for 30 s, and 72\u00b0C for 45 s; followed by a final extension step at 72\u00b0C for 10 min.Western blotting ::: Materials and MethodsAt different times after viral infection, cells were lysed in lysis buffer (4 M urea, 1 mM MgCl2, 50 mM HEPES, and 100 U benezonase/107 cells).", [["cells", "ANATOMY", 268, 273], ["cells", "ANATOMY", 362, 367], ["viral infection", "DISEASE", 251, 266], ["urea", "CHEMICAL", 306, 310], ["urea", "CHEMICAL", 306, 310], ["MgCl2", "CHEMICAL", 317, 322], ["HEPES", "CHEMICAL", 330, 335], ["cells", "CELL", 268, 273], ["urea", "SIMPLE_CHEMICAL", 306, 310], ["MgCl2", "SIMPLE_CHEMICAL", 317, 322], ["cells", "CELL", 362, 367], ["strand cDNA synthesis", "PROBLEM", 21, 42], ["the PCR", "TEST", 47, 54], ["Materials", "TREATMENT", 205, 214], ["MethodsAt", "TREATMENT", 219, 228], ["viral infection", "PROBLEM", 251, 266], ["lysis buffer", "TREATMENT", 288, 300], ["urea", "TEST", 306, 310], ["MgCl2", "TEST", 317, 322], ["mM HEPES", "TEST", 327, 335], ["100 U benezonase", "TEST", 341, 357], ["infection", "OBSERVATION", 257, 266]]], ["Lysates containing the equivalent of 2\u00d7105 cells per lane were separated by electrophoresis on 10% polyacrylamide gels and electrotransferred onto polyvinylidene difluoride membranes overnight.", [["Lysates", "ANATOMY", 0, 7], ["cells", "ANATOMY", 43, 48], ["membranes", "ANATOMY", 173, 182], ["polyacrylamide", "CHEMICAL", 99, 113], ["polyvinylidene", "CHEMICAL", 147, 161], ["difluoride", "CHEMICAL", 162, 172], ["Lysates", "ORGANISM_SUBSTANCE", 0, 7], ["cells", "CELL", 43, 48], ["membranes", "CELLULAR_COMPONENT", 173, 182], ["2\u00d7105 cells", "CELL_LINE", 37, 48], ["Lysates", "TEST", 0, 7], ["10% polyacrylamide gels", "TREATMENT", 95, 118], ["polyvinylidene difluoride membranes", "TREATMENT", 147, 182]]], ["The membrane was blocked with 5% fat-free milk in a TBST solution for 1 h and then probed separately with a mouse monoclonal antibody (mAb) against Oct-4 (Santa-Cruz Biotechnology, Santa Cruz, CA, USA) at a concentration of 0.2 \u00b5g/mL, 1\u22361000 of an anti-GFAP rabbit polyclonal antibody (pAb; Chemicon International, Temecula, CA, USA), and 1\u2236500 of an anti-glutamine synthetase mouse mAb (Chemicon International).", [["membrane", "ANATOMY", 4, 12], ["milk", "ANATOMY", 42, 46], ["anti-glutamine", "CHEMICAL", 351, 365], ["membrane", "CELLULAR_COMPONENT", 4, 12], ["fat", "SIMPLE_CHEMICAL", 33, 36], ["milk", "ORGANISM_SUBSTANCE", 42, 46], ["mouse", "ORGANISM", 108, 113], ["Oct-4", "GENE_OR_GENE_PRODUCT", 148, 153], ["rabbit", "ORGANISM", 258, 264], ["anti-glutamine", "GENE_OR_GENE_PRODUCT", 351, 365], ["mouse", "ORGANISM", 377, 382], ["mouse monoclonal antibody", "PROTEIN", 108, 133], ["mAb", "PROTEIN", 135, 138], ["Oct-4", "PROTEIN", 148, 153], ["anti-GFAP rabbit polyclonal antibody", "PROTEIN", 248, 284], ["pAb", "PROTEIN", 286, 289], ["anti-glutamine synthetase mouse mAb", "PROTEIN", 351, 386], ["mouse", "SPECIES", 108, 113], ["rabbit", "SPECIES", 258, 264], ["mouse", "SPECIES", 377, 382], ["mouse", "SPECIES", 108, 113], ["rabbit", "SPECIES", 258, 264], ["mouse", "SPECIES", 377, 382], ["a TBST solution", "TREATMENT", 50, 65], ["a mouse monoclonal antibody (mAb", "TREATMENT", 106, 138], ["Oct", "TEST", 148, 151], ["an anti-GFAP rabbit polyclonal antibody", "TREATMENT", 245, 284], ["an anti-glutamine synthetase mouse mAb", "TREATMENT", 348, 386]]], ["Mouse \u03b2-actin was used as an internal control (Sigma).", [["Mouse", "ORGANISM", 0, 5], ["\u03b2-actin", "GENE_OR_GENE_PRODUCT", 6, 13], ["Mouse \u03b2-actin", "PROTEIN", 0, 13], ["Mouse", "SPECIES", 0, 5], ["Mouse", "SPECIES", 0, 5], ["Mouse \u03b2-actin", "TREATMENT", 0, 13]]], ["Horseradish peroxidase (HRP)-conjugated anti-mouse immunoglobulin G (IgG) and anti-rabbit IgG (Sigma) were used as the secondary antibodies.", [["Horseradish peroxidase", "SIMPLE_CHEMICAL", 0, 22], ["HRP", "SIMPLE_CHEMICAL", 24, 27], ["anti-mouse immunoglobulin G", "GENE_OR_GENE_PRODUCT", 40, 67], ["IgG", "GENE_OR_GENE_PRODUCT", 69, 72], ["anti-rabbit IgG", "GENE_OR_GENE_PRODUCT", 78, 93], ["Sigma", "GENE_OR_GENE_PRODUCT", 95, 100], ["Horseradish peroxidase (HRP)-conjugated anti-mouse immunoglobulin G", "PROTEIN", 0, 67], ["IgG", "PROTEIN", 69, 72], ["anti-rabbit IgG", "PROTEIN", 78, 93], ["Sigma", "PROTEIN", 95, 100], ["secondary antibodies", "PROTEIN", 119, 139], ["Horseradish", "SPECIES", 0, 11], ["anti-mouse", "SPECIES", 40, 50], ["anti-rabbit", "SPECIES", 78, 89], ["Horseradish", "SPECIES", 0, 11], ["anti-rabbit", "SPECIES", 78, 89], ["Horseradish peroxidase", "TEST", 0, 22], ["HRP", "TEST", 24, 27], ["conjugated anti-mouse immunoglobulin G", "TREATMENT", 29, 67], ["IgG", "TEST", 69, 72], ["anti-rabbit IgG (Sigma)", "TREATMENT", 78, 101]]], ["Signals were detected using an enhanced chemiluminescence (ECL) kit (Perkin Elmer, Wellesley, MA, USA).Immunoprecipitation ::: Materials and MethodsMock-, vector-, and RNAi-treated cells were solubilized in NP40 lysis buffer (10 mM Tris at pH 7.5, 150 mM NaCl, 0.5% NP40, 5 mM EDTA, 5 mg/ml aprotinine, and 3 mM pAPMSF) and then centrifuged at 12,000 rpm for 10 min at 4\u00b0C. The lysates were subjected to immunoprecipitation with an anti-STAT3 antibody (Santa Cruz Biotechnology).", [["cells", "ANATOMY", 181, 186], ["lysates", "ANATOMY", 378, 385], ["NaCl", "CHEMICAL", 255, 259], ["aprotinine", "CHEMICAL", 291, 301], ["NaCl", "CHEMICAL", 255, 259], ["NP40", "CHEMICAL", 266, 270], ["EDTA", "CHEMICAL", 277, 281], ["aprotinine", "CHEMICAL", 291, 301], ["MethodsMock", "SIMPLE_CHEMICAL", 141, 152], ["vector-", "SIMPLE_CHEMICAL", 155, 162], ["cells", "CELL", 181, 186], ["NP40", "SIMPLE_CHEMICAL", 207, 211], ["EDTA", "SIMPLE_CHEMICAL", 277, 281], ["aprotinine", "SIMPLE_CHEMICAL", 291, 301], ["lysates", "ORGANISM_SUBSTANCE", 378, 385], ["MethodsMock-, vector-, and RNAi-treated cells", "CELL_LINE", 141, 186], ["anti-STAT3 antibody", "PROTEIN", 432, 451], ["Santa Cruz Biotechnology", "PROTEIN", 453, 477], ["an enhanced chemiluminescence", "TEST", 28, 57], ["Immunoprecipitation", "TEST", 103, 122], ["Materials", "TEST", 127, 136], ["MethodsMock", "TEST", 141, 152], ["vector-", "TEST", 155, 162], ["RNAi-treated cells", "TREATMENT", 168, 186], ["NP40 lysis buffer", "TREATMENT", 207, 224], ["pH", "TEST", 240, 242], ["NaCl", "TEST", 255, 259], ["5 mM EDTA", "TREATMENT", 272, 281], ["aprotinine", "TREATMENT", 291, 301], ["The lysates", "TREATMENT", 374, 385], ["immunoprecipitation", "TEST", 404, 423]]], ["Then, these immunocomplexes were analyzed as described for the Western blot assay.", [["immunocomplexes", "PROTEIN", 12, 27], ["these immunocomplexes", "TEST", 6, 27], ["the Western blot assay", "TEST", 59, 81]]], ["These immunocomplexes were detected by an anti-p300 antibody (Santa-Cruz Biotechnology).Immunocytochemistry ::: Materials and MethodsNTera-2 cells were grown on 12-well plates.", [["MethodsNTera-2 cells", "ANATOMY", 126, 146], ["MethodsNTera-2 cells", "CELL", 126, 146], ["immunocomplexes", "PROTEIN", 6, 21], ["anti-p300 antibody", "PROTEIN", 42, 60], ["Santa-Cruz Biotechnology", "PROTEIN", 62, 86], ["These immunocomplexes", "TEST", 0, 21], ["an anti-p300 antibody", "TEST", 39, 60], ["Immunocytochemistry", "TEST", 88, 107], ["Materials", "TEST", 112, 121], ["MethodsNTera", "TEST", 126, 138]]], ["These cells were washed with phosphate-buffered saline (PBS) and fixed with 3% paraformaldehyde.", [["cells", "ANATOMY", 6, 11], ["phosphate", "CHEMICAL", 29, 38], ["phosphate", "CHEMICAL", 29, 38], ["paraformaldehyde", "CHEMICAL", 79, 95], ["cells", "CELL", 6, 11], ["phosphate-buffered saline", "SIMPLE_CHEMICAL", 29, 54], ["paraformaldehyde", "SIMPLE_CHEMICAL", 79, 95], ["phosphate-buffered saline (PBS", "TREATMENT", 29, 59], ["3% paraformaldehyde", "TREATMENT", 76, 95]]], ["Then, cells were permeabilized in 0.25% Triton X-100 and incubated with the following primary antibodies overnight at 4\u00b0C: anti-Oct-4 rabbit Ab (1\u2236200), anti-Pax6 mouse Ab (1\u223650), anti-Olig2 rabbit Ab (1\u223650; Santa-Cruz Biotechnology), anti-nestin mouse Ab (1\u2236100), anti-A2B5 mouse Ab (1\u2236200), anti-glial fibrillary acidic protein rabbit Ab (1\u22361000), anti-MAP2 rabbit Ab (1\u22361000), anti-glutamine synthetase mouse Ab (1\u2236500; Chemicon International).", [["cells", "ANATOMY", 6, 11], ["Triton X-100", "CHEMICAL", 40, 52], ["anti-glutamine", "CHEMICAL", 380, 394], ["cells", "CELL", 6, 11], ["Triton X-100", "SIMPLE_CHEMICAL", 40, 52], ["rabbit", "ORGANISM", 134, 140], ["Pax6", "GENE_OR_GENE_PRODUCT", 158, 162], ["mouse", "ORGANISM", 163, 168], ["Olig2", "GENE_OR_GENE_PRODUCT", 185, 190], ["mouse", "ORGANISM", 247, 252], ["mouse", "ORGANISM", 275, 280], ["anti-glial fibrillary acidic", "GENE_OR_GENE_PRODUCT", 293, 321], ["rabbit", "ORGANISM", 330, 336], ["rabbit", "ORGANISM", 360, 366], ["anti-glutamine", "SIMPLE_CHEMICAL", 380, 394], ["mouse", "ORGANISM", 406, 411], ["primary antibodies", "PROTEIN", 86, 104], ["anti-Oct-4 rabbit Ab", "PROTEIN", 123, 143], ["1\u2236200", "PROTEIN", 145, 150], ["Pax6 mouse Ab", "PROTEIN", 158, 171], ["1\u223650", "PROTEIN", 173, 177], ["Olig2 rabbit Ab (1\u223650; Santa-Cruz Biotechnology", "PROTEIN", 185, 232], ["anti-nestin mouse Ab", "PROTEIN", 235, 255], ["1\u2236100", "PROTEIN", 257, 262], ["anti", "PROTEIN", 265, 269], ["A2B5 mouse Ab", "PROTEIN", 270, 283], ["1\u2236200", "PROTEIN", 285, 290], ["anti-glial fibrillary acidic protein rabbit Ab", "PROTEIN", 293, 339], ["1\u22361000", "PROTEIN", 341, 347], ["anti-MAP2 rabbit Ab", "PROTEIN", 350, 369], ["1\u22361000", "PROTEIN", 371, 377], ["anti-glutamine synthetase mouse Ab", "PROTEIN", 380, 414], ["1\u2236500", "PROTEIN", 416, 421], ["rabbit", "SPECIES", 134, 140], ["mouse", "SPECIES", 163, 168], ["rabbit", "SPECIES", 191, 197], ["mouse", "SPECIES", 247, 252], ["mouse", "SPECIES", 275, 280], ["rabbit", "SPECIES", 330, 336], ["rabbit", "SPECIES", 360, 366], ["mouse", "SPECIES", 406, 411], ["rabbit", "SPECIES", 134, 140], ["mouse", "SPECIES", 163, 168], ["rabbit", "SPECIES", 191, 197], ["mouse", "SPECIES", 247, 252], ["mouse", "SPECIES", 275, 280], ["rabbit", "SPECIES", 330, 336], ["rabbit", "SPECIES", 360, 366], ["mouse", "SPECIES", 406, 411], ["primary antibodies", "TEST", 86, 104], ["anti", "TEST", 123, 127], ["Oct", "TEST", 128, 131], ["rabbit Ab", "TEST", 134, 143], ["anti-Pax6 mouse Ab", "TREATMENT", 153, 171], ["anti-Olig2 rabbit Ab", "TREATMENT", 180, 200], ["anti-nestin mouse Ab", "TREATMENT", 235, 255], ["anti-A2B5 mouse Ab", "TREATMENT", 265, 283], ["anti-glial fibrillary acidic protein rabbit Ab", "TEST", 293, 339], ["anti-MAP2 rabbit Ab", "TREATMENT", 350, 369], ["anti-glutamine synthetase mouse Ab", "TREATMENT", 380, 414]]], ["The next day, cells were washed with PBS and secondary antibodies of 1\u2236500 of goat-mouse-594 (Molecular Probe, Carlsbad, CA, USA), 1\u2236500 of goat-rabbit-cy3, and 1\u2236200 of goat-mouse-cy3-IgM (Jackson ImmunoResearch, Suffolk, UK) which were used accordingly for 1 h at 37\u00b0C. Cells were then washed with PBS and counter-stained with Hoechst for 10 min.", [["cells", "ANATOMY", 14, 19], ["Cells", "ANATOMY", 272, 277], ["Hoechst", "CHEMICAL", 329, 336], ["cells", "CELL", 14, 19], ["goat", "ORGANISM", 78, 82], ["mouse", "ORGANISM", 83, 88], ["goat", "ORGANISM", 140, 144], ["rabbit", "ORGANISM", 145, 151], ["cy3", "GENE_OR_GENE_PRODUCT", 152, 155], ["goat", "ORGANISM", 170, 174], ["mouse", "ORGANISM", 175, 180], ["cy3-IgM", "GENE_OR_GENE_PRODUCT", 181, 188], ["Cells", "CELL", 272, 277], ["Hoechst", "SIMPLE_CHEMICAL", 329, 336], ["cy3", "PROTEIN", 152, 155], ["cy3", "PROTEIN", 181, 184], ["IgM", "PROTEIN", 185, 188], ["goat", "SPECIES", 78, 82], ["mouse", "SPECIES", 83, 88], ["goat", "SPECIES", 140, 144], ["rabbit", "SPECIES", 145, 151], ["goat", "SPECIES", 170, 174], ["mouse", "SPECIES", 175, 180], ["goat-mouse-594", "SPECIES", 78, 92], ["goat", "SPECIES", 140, 144], ["goat", "SPECIES", 170, 174], ["mouse", "SPECIES", 175, 180], ["PBS", "TREATMENT", 37, 40], ["secondary antibodies", "TEST", 45, 65], ["Molecular Probe", "TEST", 94, 109], ["goat", "TEST", 140, 144], ["goat", "TEST", 170, 174], ["PBS", "TREATMENT", 300, 303], ["Hoechst", "TREATMENT", 329, 336]]], ["Cells were detected under florescence microscopy.Label-free quantitation method ::: Materials and MethodsPreparation of Protein Extracts: Cell pellets were first washed three times with PBS and lysed in lysis buffer (0.25 M Tris-HCl at pH 6.8, 1% SDS).", [["Cells", "ANATOMY", 0, 5], ["Cell", "ANATOMY", 138, 142], ["Tris-HCl", "CHEMICAL", 224, 232], ["Tris-HCl", "CHEMICAL", 224, 232], ["Cells", "CELL", 0, 5], ["Cell", "CELL", 138, 142], ["Tris-HCl", "SIMPLE_CHEMICAL", 224, 232], ["microscopy", "TEST", 38, 48], ["MethodsPreparation of Protein Extracts", "TREATMENT", 98, 136], ["Cell pellets", "TREATMENT", 138, 150], ["PBS", "TREATMENT", 186, 189], ["lysis buffer", "TREATMENT", 203, 215], ["Tris", "TEST", 224, 228], ["pH", "TEST", 236, 238]]], ["Protein concentration was obtained by BCA\u2122 protein assay.", [["Protein concentration", "TEST", 0, 21], ["protein assay", "TEST", 43, 56]]], ["Cell lysate was then dried and stored in \u221230\u00b0C.Label-free quantitation method ::: Materials and MethodsGel-assisted Digestion [28]: Acrylamide/bisacrylamide (40%, 29\u22361), 10% APS, and TEMED were then applied to protein solution to polymerize as a gel directly in the eppendorf.", [["Cell lysate", "ANATOMY", 0, 11], ["Acrylamide", "CHEMICAL", 132, 142], ["bisacrylamide", "CHEMICAL", 143, 156], ["APS", "DISEASE", 174, 177], ["Acrylamide", "CHEMICAL", 132, 142], ["bisacrylamide", "CHEMICAL", 143, 156], ["Cell", "CELL", 0, 4], ["Acrylamide/bisacrylamide", "SIMPLE_CHEMICAL", 132, 156], ["APS", "SIMPLE_CHEMICAL", 174, 177], ["TEMED", "SIMPLE_CHEMICAL", 183, 188], ["Cell lysate", "TREATMENT", 0, 11], ["MethodsGel-assisted Digestion", "TREATMENT", 96, 125], ["Acrylamide", "TREATMENT", 132, 142], ["bisacrylamide", "TREATMENT", 143, 156], ["TEMED", "TREATMENT", 183, 188], ["protein solution to polymerize", "TREATMENT", 210, 240]]], ["The gel was cut into small pieces and washed several times with TEABC containing 50% ACN.", [["ACN", "CHEMICAL", 85, 88], ["ACN", "CHEMICAL", 85, 88], ["ACN", "SIMPLE_CHEMICAL", 85, 88], ["The gel", "TREATMENT", 0, 7], ["TEABC", "TREATMENT", 64, 69], ["small pieces", "OBSERVATION_MODIFIER", 21, 33]]], ["The gel samples were further dehydrated with ACN and the completely dried by vacuum centrifugation.", [["samples", "ANATOMY", 8, 15], ["ACN", "CHEMICAL", 45, 48], ["ACN", "CHEMICAL", 45, 48], ["ACN", "SIMPLE_CHEMICAL", 45, 48], ["The gel samples", "TEST", 0, 15], ["ACN", "TREATMENT", 45, 48], ["vacuum centrifugation", "TREATMENT", 77, 98], ["vacuum centrifugation", "OBSERVATION", 77, 98]]], ["Proteolytic digestion was then performed with trypsin (protein:trypsin = 50\u22361, g/g) in 25 mM TEABC with incubation overnight at 37\u00b0C and peptides were extracted by 5% FA in 50% ACN, dried in a SpeedVac and stored in \u221230\u00b0C.Label-free quantitation method ::: Materials and MethodsImmobilized Metal Affinity Chromatography (IMAC) [29]: The IMAC column was first capping one end with a 0.5 \u00b5m frit disk enclosed in stainless steel column-end fitting.", [["TEABC", "CHEMICAL", 93, 98], ["FA", "CHEMICAL", 167, 169], ["ACN", "CHEMICAL", 177, 180], ["TEABC", "CHEMICAL", 93, 98], ["ACN", "CHEMICAL", 177, 180], ["trypsin", "GENE_OR_GENE_PRODUCT", 46, 53], ["trypsin", "GENE_OR_GENE_PRODUCT", 63, 70], ["TEABC", "SIMPLE_CHEMICAL", 93, 98], ["C", "SIMPLE_CHEMICAL", 131, 132], ["FA", "SIMPLE_CHEMICAL", 167, 169], ["ACN", "SIMPLE_CHEMICAL", 177, 180], ["SpeedVac", "SIMPLE_CHEMICAL", 193, 201], ["trypsin", "PROTEIN", 46, 53], ["trypsin", "PROTEIN", 63, 70], ["Proteolytic digestion", "PROBLEM", 0, 21], ["trypsin", "TEST", 63, 70], ["C and peptides", "PROBLEM", 131, 145], ["MethodsImmobilized Metal Affinity Chromatography", "TEST", 271, 319], ["IMAC", "TEST", 321, 325], ["The IMAC column", "TREATMENT", 333, 348], ["a 0.5 \u00b5m frit disk enclosed in stainless steel column", "TREATMENT", 380, 433], ["stainless steel column", "OBSERVATION", 411, 433]]], ["The Ni-NTA resin was extracted from spin column and packed into a 5-cm microcolumn (500 \u00b5m id PEEK column).", [["Ni-NTA", "CHEMICAL", 4, 10], ["Ni-NTA", "CHEMICAL", 4, 10], ["Ni-NTA", "SIMPLE_CHEMICAL", 4, 10], ["The Ni-NTA resin", "TREATMENT", 0, 16], ["a 5-cm microcolumn (500 \u00b5m id PEEK column", "TREATMENT", 64, 105], ["spin column", "OBSERVATION", 36, 47], ["5-cm", "OBSERVATION_MODIFIER", 66, 70]]], ["Automatic purification of phosphopeptides was performed using the IMAC microcolumn connected with autosampler and HP1100 solvent delivery system with a flow rate 13 \u00b5l/min.", [["HP1100", "SIMPLE_CHEMICAL", 114, 120], ["Automatic purification of phosphopeptides", "TREATMENT", 0, 41], ["the IMAC microcolumn", "TREATMENT", 62, 82], ["autosampler", "TREATMENT", 98, 109], ["HP1100 solvent delivery system", "TREATMENT", 114, 144], ["a flow rate", "TEST", 150, 161]]], ["First, the Ni2+ ions were removed with 100 \u00b5l EDTA (50 mM) in NaCl (1 M).", [["Ni2", "CHEMICAL", 11, 14], ["NaCl", "CHEMICAL", 62, 66], ["Ni2+", "CHEMICAL", 11, 15], ["EDTA", "CHEMICAL", 46, 50], ["NaCl", "CHEMICAL", 62, 66], ["Ni2+ ions", "SIMPLE_CHEMICAL", 11, 20], ["EDTA", "SIMPLE_CHEMICAL", 46, 50], ["the Ni2+ ions", "TREATMENT", 7, 20], ["ions", "OBSERVATION", 16, 20]]], ["Then the IMAC column was activated with 100 \u00b5l FeCl3 (0.2 M) and equilibrated with loading buffer for 30 min before sample loading.", [["sample", "ANATOMY", 116, 122], ["FeCl3", "CHEMICAL", 47, 52], ["FeCl3", "CHEMICAL", 47, 52], ["FeCl3", "SIMPLE_CHEMICAL", 47, 52], ["the IMAC column", "TREATMENT", 5, 20], ["loading buffer", "TREATMENT", 83, 97]]], ["For optimization of the phosphopeptide enrichment, the loading/condition buffer (designated as loading buffer) was 6% (v/v) AA and the pH was adjusted to 3.0 with NaOH (0.1 M at pH 12.8).", [["AA", "CHEMICAL", 124, 126], ["NaOH", "CHEMICAL", 163, 167], ["NaOH", "CHEMICAL", 163, 167], ["NaOH", "SIMPLE_CHEMICAL", 163, 167], ["the phosphopeptide enrichment", "TREATMENT", 20, 49], ["the loading/condition buffer", "TREATMENT", 51, 79], ["loading buffer)", "TREATMENT", 95, 110], ["the pH", "TEST", 131, 137], ["NaOH", "TREATMENT", 163, 167], ["pH", "TEST", 178, 180], ["phosphopeptide enrichment", "OBSERVATION", 24, 49]]], ["The peptide samples from trypsin digestion were reconstituted in loading buffer and loaded into the IMAC column that had been equilibrated with the same loading buffer for 20 min.", [["samples", "ANATOMY", 12, 19], ["trypsin", "GENE_OR_GENE_PRODUCT", 25, 32], ["trypsin", "PROTEIN", 25, 32], ["The peptide samples", "TEST", 0, 19], ["trypsin digestion", "TREATMENT", 25, 42], ["loading buffer", "TREATMENT", 65, 79], ["the IMAC column", "TREATMENT", 96, 111], ["the same loading buffer", "TREATMENT", 144, 167], ["IMAC column", "OBSERVATION", 100, 111]]], ["Then the unbound peptides were removed with 100 \u00b5l washing solution consisting of 75% (v/v) loading buffer and 25% (v/v) ACN, followed by equilibration with loading buffer for 15 min.", [["ACN", "CHEMICAL", 121, 124], ["ACN", "CHEMICAL", 121, 124], ["ACN", "SIMPLE_CHEMICAL", 121, 124], ["the unbound peptides", "TREATMENT", 5, 25], ["100 \u00b5l washing solution", "TREATMENT", 44, 67], ["v/v) loading buffer", "TREATMENT", 87, 106], ["v/v) ACN", "TREATMENT", 116, 124], ["loading buffer", "TREATMENT", 157, 171]]], ["Finally, the bound peptides were eluted from the IMAC column with 100 \u00b5l NH4H2PO4 (200 mM at pH 4.4).", [["NH4H2PO4", "CHEMICAL", 73, 81], ["NH4H2PO4", "CHEMICAL", 73, 81], ["NH4H2PO4", "SIMPLE_CHEMICAL", 73, 81], ["the bound peptides", "TEST", 9, 27], ["pH", "TEST", 93, 95]]], ["Eluted peptide samples were dried under vacuum and reconstituted in 0.1% (v/v) FA for LC- MS/MS analysis.Label-free quantitation method ::: Materials and MethodsLC-MS/MS Analysis: Purified phosphopeptide samples were reconstituted in 4 \u00b5l buffer A (0.1% FA in H2O) and analyzed by LC-Q-TOF MS (Waters Q-TOFTM Premier from Waters Corp).", [["samples", "ANATOMY", 15, 22], ["samples", "ANATOMY", 204, 211], ["FA", "CHEMICAL", 79, 81], ["FA", "CHEMICAL", 254, 256], ["H2O", "CHEMICAL", 260, 263], ["H2O", "CHEMICAL", 260, 263], ["/v) FA", "SIMPLE_CHEMICAL", 75, 81], ["FA", "SIMPLE_CHEMICAL", 254, 256], ["Eluted peptide samples", "TEST", 0, 22], ["vacuum", "TREATMENT", 40, 46], ["LC", "TEST", 86, 88], ["MS/MS analysis", "TEST", 90, 104], ["Materials", "TEST", 140, 149], ["MethodsLC", "TEST", 154, 163], ["MS Analysis", "TEST", 167, 178], ["Purified phosphopeptide samples", "TREATMENT", 180, 211], ["LC", "TEST", 281, 283], ["LC", "ANATOMY", 281, 283]]], ["For LC-MS/MS analysis by Waters Q-TOFTM Premier, samples were injected into a 2 cm\u00d7180 \u00b5m capillary trap column and separated by 20 cm\u00d775 mm Waters1 ACQUITYTM 1.7 mm BEH C18 column using a nanoACQUITY Ultra Performance LCTM system (Waters Corp).", [["samples", "ANATOMY", 49, 56], ["LC", "TEST", 4, 6], ["MS analysis", "TEST", 10, 21], ["a 2 cm\u00d7180 \u00b5m capillary trap column", "TREATMENT", 76, 111], ["Waters1 ACQUITYTM 1.7 mm BEH C18 column", "TREATMENT", 141, 180], ["a nanoACQUITY Ultra Performance LCTM system", "TREATMENT", 187, 230]]], ["The column was maintained at 35\u00b0C and eluted with a linear gradient of 0\u201380% buffer B (0.1% FA in ACN) for 80, 120, 210 and 270 min.", [["FA", "CHEMICAL", 92, 94], ["ACN", "CHEMICAL", 98, 101], ["ACN", "CHEMICAL", 98, 101], ["C", "SIMPLE_CHEMICAL", 32, 33], ["FA", "SIMPLE_CHEMICAL", 92, 94], ["ACN", "SIMPLE_CHEMICAL", 98, 101], ["a linear gradient", "TEST", 50, 67], ["column", "ANATOMY", 4, 10], ["linear", "OBSERVATION_MODIFIER", 52, 58], ["gradient", "OBSERVATION_MODIFIER", 59, 67]]], ["NanoLockSpray source was used for accurate mass measurement and the lock mass channel was sampled every 30 s.", [["NanoLockSpray source", "TREATMENT", 0, 20], ["accurate mass measurement", "TEST", 34, 59], ["the lock mass channel", "TREATMENT", 64, 85], ["mass", "OBSERVATION", 43, 47]]], ["The mass spectrometer was calibrated with a synthetic human [Glu1]-Fibrinopeptide B solution (1 pmol/\u00b5l; Sigma) delivered through the NanoLockSpray source.", [["Fibrinopeptide B", "CHEMICAL", 67, 83], ["[Glu1]-Fibrinopeptide B", "CHEMICAL", 60, 83], ["human", "ORGANISM", 54, 59], ["Glu1]-Fibrinopeptide B", "SIMPLE_CHEMICAL", 61, 83], ["human", "SPECIES", 54, 59], ["human", "SPECIES", 54, 59], ["The mass spectrometer", "PROBLEM", 0, 21], ["a synthetic human [Glu1]-Fibrinopeptide B solution", "TREATMENT", 42, 92], ["mass", "OBSERVATION", 4, 8]]], ["Data acquisition was operated in the data directed analysis (DDA).", [["Data acquisition", "TEST", 0, 16]]], ["The method included a full MS scan (m/z 400\u20131600, 0.6 s) and 3 MS/MS (m/z 100\u20131990, 1.2 s each scan) sequentially on the most three intense ions present in the full scan mass spectrum.Label-free quantitation method ::: Materials and MethodsDatabase Search, Protein Identification and Quantitation: Raw data were processed using Mascot Distiller v 2.1.1.0 (Matrix science).", [["a full MS scan", "TEST", 20, 34], ["MS", "TEST", 66, 68], ["m/z", "TEST", 70, 73], ["s each scan", "TEST", 88, 99], ["Protein Identification", "TEST", 257, 279], ["Mascot Distiller v", "TEST", 328, 346], ["mass", "OBSERVATION", 170, 174]]], ["The resulting MS/MS dataset was exported to *mzdata data file format.", [["The resulting MS/MS dataset", "PROBLEM", 0, 27]]], ["We performed the peptide identification and assignment of partial post-translational modifications using an in-house version of Mascot v. 2.2 (Matrix science).", [["the peptide identification", "TEST", 13, 39]]], ["The datasets were searched against International Protein Index (IPI_human v. 3.29, 68161 sequences) using the following constraints: only tryptic peptides with up to two missed cleavage sites were allowed; 0.3-Da mass tolerances for MS and 0.1-Da mass tolerances for MS/MS fragment ions.", [["The datasets", "TEST", 0, 12], ["International Protein Index", "TEST", 35, 62], ["tryptic peptides", "TREATMENT", 138, 154], ["MS", "TEST", 233, 235], ["MS", "PROBLEM", 267, 269], ["MS fragment ions", "PROBLEM", 270, 286]]], ["Phosphorylation (STY), oxidation (M) was specified as variable modifications.", [["Phosphorylation (STY)", "TREATMENT", 0, 21]]], ["Only unique peptide with scores higher than 25 was confidently assigned.", [["scores", "TEST", 25, 31]]], ["When unique peptides were identified to multiple members of a protein family, proteins having the highest sequence coverage were selected from the Mascot search output result.", [["protein family", "PROTEIN", 62, 76], ["the highest sequence coverage", "TREATMENT", 94, 123], ["the Mascot search output", "TEST", 143, 167]]], ["To evaluate the protein identification false-positive rate, we repeated the searches using identical search parameters and validation criteria against a random database (from the 68161 sequence).", [["68161 sequence", "DNA", 179, 193], ["the protein identification", "TEST", 12, 38], ["validation criteria", "TEST", 123, 142], ["a random database", "TEST", 151, 168]]], ["Relative quantification of peptides was performed by IDEAL-Q software [30], [31].DNA methylation analysis ::: Materials and MethodsGenomic DNA sodium bisulfite conversion was performed using an EZ-96 DNA methylation kit (Zymo Research, Orange, CA, USA).", [["sodium bisulfite", "CHEMICAL", 143, 159], ["sodium bisulfite", "CHEMICAL", 143, 159], ["DNA", "CELLULAR_COMPONENT", 81, 84], ["DNA", "CELLULAR_COMPONENT", 139, 142], ["DNA", "CELLULAR_COMPONENT", 200, 203], ["Relative quantification of peptides", "PROBLEM", 0, 35], ["DNA methylation analysis", "TEST", 81, 105], ["Materials", "TREATMENT", 110, 119], ["MethodsGenomic DNA sodium bisulfite conversion", "TREATMENT", 124, 170], ["an EZ", "TEST", 191, 196]]], ["The manufacture's protocol was followed using 1 \u00b5g of genomic DNA and an alternative conversion protocol (two-temperature DNA denaturation).DNA methylation analysis ::: Materials and MethodsSeqqunom's (San Diego, CA, USA) MassARRAY platform was used to perform the quantitative methylation analysis.", [["DNA", "CELLULAR_COMPONENT", 62, 65], ["DNA", "CELLULAR_COMPONENT", 122, 125], ["DNA", "CELLULAR_COMPONENT", 140, 143], ["genomic DNA", "DNA", 54, 65], ["The manufacture's protocol", "TREATMENT", 0, 26], ["genomic DNA", "TREATMENT", 54, 65], ["an alternative conversion protocol", "TREATMENT", 70, 104], ["two-temperature DNA denaturation", "TREATMENT", 106, 138], ["DNA methylation analysis", "TEST", 140, 164], ["Materials", "TEST", 169, 178], ["the quantitative methylation analysis", "TEST", 261, 298]]], ["This system utilizes MALDI-TOF mass spectrometry in combination with RNA base-specific cleavage (MassCLEAVE kit).", [["MALDI-TOF mass spectrometry", "TREATMENT", 21, 48], ["RNA base", "TREATMENT", 69, 77], ["specific cleavage (MassCLEAVE kit", "TREATMENT", 78, 111], ["mass", "OBSERVATION", 31, 35]]], ["PCR primers were designed using EpiDesigner (Sequenom).", [["PCR primers", "DNA", 0, 11], ["PCR primers", "TEST", 0, 11]]], ["Amplicons were designed to cover the CpG sites from an approximately 4500-bp region upstream of the GFAP transcription start site to the intron 1 region.", [["CpG", "CHEMICAL", 37, 40], ["GFAP", "GENE_OR_GENE_PRODUCT", 100, 104], ["CpG sites", "DNA", 37, 46], ["4500-bp region", "DNA", 69, 83], ["GFAP transcription start site", "DNA", 100, 129], ["intron 1 region", "DNA", 137, 152], ["Amplicons", "TREATMENT", 0, 9], ["the CpG sites", "TREATMENT", 33, 46], ["the GFAP transcription", "TREATMENT", 96, 118]]], ["For each reverse primer, an additional T7 promoter tag for in vivo transcription was added, as well as a 10-mer tag on the forward primer to adjust for differences in melting temperatures.", [["reverse primer", "DNA", 9, 23], ["T7 promoter tag", "DNA", 39, 54], ["10-mer tag", "DNA", 105, 115], ["forward primer", "DNA", 123, 137], ["each reverse primer", "TREATMENT", 4, 23], ["an additional T7 promoter tag", "TREATMENT", 25, 54], ["the forward primer", "TREATMENT", 119, 137], ["melting temperatures", "PROBLEM", 167, 187]]], ["The PCRs were carried out in a 5-\u00b5l format with 10 ng/\u00b5l bisulfite-treated DNA, 0.2 units of HotStart Taq DNA polymerase (Qiagen), 1\u00d7 supplied HotStart buffer, and 200 \u00b5M PCR primers.", [["bisulfite", "CHEMICAL", 57, 66], ["bisulfite", "CHEMICAL", 57, 66], ["bisulfite", "SIMPLE_CHEMICAL", 57, 66], ["DNA", "CELLULAR_COMPONENT", 75, 78], ["DNA", "CELLULAR_COMPONENT", 106, 109], ["HotStart Taq DNA polymerase", "PROTEIN", 93, 120], ["The PCRs", "TEST", 0, 8], ["ng/\u00b5l bisulfite", "TREATMENT", 51, 66], ["HotStart Taq DNA polymerase (Qiagen)", "TREATMENT", 93, 129], ["HotStart buffer", "TREATMENT", 143, 158], ["200 \u00b5M PCR primers", "TREATMENT", 164, 182]]], ["Amplification of the PCR was as follows: preactivation at 95\u00b0C for 15 min, 45 cycles of 95\u00b0C denaturation for 20 s, 56\u00b0C annealing for 30 s, and 72\u00b0C extension for 30 s, with a final 72\u00b0C incubation for 4 min.", [["the PCR", "TEST", 17, 24]]], ["Dephosphorylation of unincorporated dNTPs was performed by adding 1.7 \u00b5l of H2O and 0.3 units of shrimp alkaline phosphatase (Sequenom), followed by incubation at 37\u00b0C for 20 min and then at 85\u00b0C for 10 min to deactivate the enzyme.", [["dNTPs", "CHEMICAL", 36, 41], ["H2O", "CHEMICAL", 76, 79], ["dNTPs", "CHEMICAL", 36, 41], ["H2O", "CHEMICAL", 76, 79], ["dNTPs", "SIMPLE_CHEMICAL", 36, 41], ["shrimp alkaline phosphatase", "PROTEIN", 97, 124], ["enzyme", "PROTEIN", 225, 231], ["Dephosphorylation of unincorporated dNTPs", "TREATMENT", 0, 41], ["H2O", "TREATMENT", 76, 79], ["shrimp alkaline phosphatase", "TREATMENT", 97, 124], ["the enzyme", "TEST", 221, 231]]], ["Next, in vivo transcription and RNA cleavage were achieved by adding 2 \u00b5l of the PCR product to 5 \u00b5l of the transcription/cleavage reaction and incubation at 37\u00b0C for 3 h.", [["RNA cleavage", "TREATMENT", 32, 44], ["the PCR product", "TREATMENT", 77, 92], ["the transcription/cleavage reaction", "TREATMENT", 104, 139]]], ["The transcription/cleavage reaction contained 27 units of T7 R&DNA polymerase (EpiCentre, Palmerston North, New Zealand), 0.64\u00d7 of T7 R&DNA polymerase buffer, 0.22 \u00b5l T Cleavage Mix (Sequenom), 3.14 mM DTT, 3.21 \u00b5l H2O, and 0.09 mg/ml RNaseA (Sequenom).", [["H2O", "CHEMICAL", 215, 218], ["DTT", "CHEMICAL", 202, 205], ["H2O", "CHEMICAL", 215, 218], ["T7 R&DNA polymerase", "PROTEIN", 58, 77], ["The transcription/cleavage reaction", "TREATMENT", 0, 35], ["T7 R&DNA polymerase", "TREATMENT", 58, 77], ["T7 R&DNA polymerase buffer", "TREATMENT", 131, 157], ["T Cleavage Mix (Sequenom)", "TREATMENT", 167, 192]]], ["Reactions were additionally diluted with 27 \u00b5l of H2O and conditioned with 6 mg of CLEAN Resin (Sequenom) for optimal mass-spectrum analysis.", [["H2O", "CHEMICAL", 50, 53], ["H2O", "CHEMICAL", 50, 53], ["H2O", "SIMPLE_CHEMICAL", 50, 53], ["H2O", "TREATMENT", 50, 53], ["CLEAN Resin (Sequenom)", "TREATMENT", 83, 105], ["optimal mass-spectrum analysis", "TEST", 110, 140]]], ["Samples were then dispensed with the MassARRAY nanodispenser (Samsung, Irvine, CA, USA) on a 384-well SpectroChip (Sequenom).", [["Samples", "ANATOMY", 0, 7], ["Samples", "TEST", 0, 7]]], ["Mass spectra were acquired using a MassARRAY Compact MALDI-TOF (Sequenom), and the methylation ratios were calculated by comparing the difference in spectra intensity derived from methylated and non-methylated template DNA by the Epityper software version 1.0 (Sequenom).Bisulfite sequencing ::: Materials and MethodsGenomic DNA (500 ng) was bisulfite converted with the EZ DNA methylation-Gold kit (D5005; Zymo Research, Orange, CA, USA) according to the manufacturer's recommendations.", [["Bisulfite", "CHEMICAL", 271, 280], ["bisulfite", "CHEMICAL", 342, 351], ["Bisulfite", "CHEMICAL", 271, 280], ["bisulfite", "CHEMICAL", 342, 351], ["DNA", "CELLULAR_COMPONENT", 219, 222], ["Bisulfite", "SIMPLE_CHEMICAL", 271, 280], ["DNA", "CELLULAR_COMPONENT", 325, 328], ["bisulfite", "SIMPLE_CHEMICAL", 342, 351], ["DNA", "CELLULAR_COMPONENT", 374, 377], ["non-methylated template DNA", "DNA", 195, 222], ["MethodsGenomic DNA", "DNA", 310, 328], ["Mass spectra", "PROBLEM", 0, 12], ["a MassARRAY Compact MALDI", "TEST", 33, 58], ["the methylation ratios", "TEST", 79, 101], ["methylated and non-methylated template DNA", "TREATMENT", 180, 222], ["Bisulfite sequencing", "TEST", 271, 291], ["MethodsGenomic DNA", "PROBLEM", 310, 328], ["the EZ DNA methylation", "TREATMENT", 367, 389]]], ["Modified DNA was amplified with the primers listed in Table S1.", [["DNA", "CELLULAR_COMPONENT", 9, 12], ["Modified DNA", "PROBLEM", 0, 12], ["the primers", "TREATMENT", 32, 43]]], ["The PCRs were carried out with 25 ng bisulfite-treated DNA, 1 \u00b5l of HotStart Taq DNA polymerase (Qiagen), 10\u00d7 supplied HotStart buffer, 4 \u00b5l of dNTP (25 mM), and 3 \u00b5l of PCR primers (5 \u00b5M).", [["bisulfite", "CHEMICAL", 37, 46], ["dNTP", "CHEMICAL", 144, 148], ["bisulfite", "CHEMICAL", 37, 46], ["dNTP", "CHEMICAL", 144, 148], ["bisulfite", "SIMPLE_CHEMICAL", 37, 46], ["DNA", "CELLULAR_COMPONENT", 55, 58], ["DNA", "CELLULAR_COMPONENT", 81, 84], ["dNTP", "SIMPLE_CHEMICAL", 144, 148], ["HotStart Taq DNA polymerase", "PROTEIN", 68, 95], ["The PCRs", "TEST", 0, 8], ["25 ng bisulfite", "TREATMENT", 31, 46], ["HotStart Taq DNA polymerase", "TREATMENT", 68, 95], ["dNTP", "TREATMENT", 144, 148], ["PCR primers", "TREATMENT", 170, 181]]], ["PCR conditions were 94\u00b0C for 15 min, then 40 cycles of 94\u00b0C for 30 s, 57\u00b0C for 30 s, and 72\u00b0C for 30 s.", [["PCR conditions", "TEST", 0, 14]]], ["The PCR products were subjected to purification using the PCR cleanup kit (28160; Qiagen) following the manufacturer's instructions.", [["PCR products", "DNA", 4, 16], ["The PCR products", "TREATMENT", 0, 16], ["the PCR cleanup kit", "TREATMENT", 54, 73]]], ["The purified PCR products (150 ng) were then subcloned into a TA cloning vector (50 ng) (pGEM-T Easy vector; Promega, Madison, WI, USA).", [["TA cloning vector", "DNA", 62, 79], ["The purified PCR products", "TREATMENT", 0, 25], ["a TA cloning vector", "TREATMENT", 60, 79]]], ["Several clones of each sample were verified by sequencing with the T7 universal primer.Chromatin immunoprecipitation (ChIP) and quantitative real-time PCR ::: Materials and MethodsChIP was performed as previously described [32] with some modifications.", [["sample", "ANATOMY", 23, 29], ["Chromatin", "ANATOMY", 87, 96], ["Chromatin", "CELLULAR_COMPONENT", 87, 96], ["T7 universal primer", "DNA", 67, 86], ["MethodsChIP", "DNA", 173, 184], ["Several clones of each sample", "PROBLEM", 0, 29], ["the T7 universal primer", "TREATMENT", 63, 86], ["Chromatin immunoprecipitation", "TREATMENT", 87, 116]]], ["Briefly, ChIP assays were carried out on 5\u00d7105 NTera-2 and RNAi-treated cells.", [["cells", "ANATOMY", 72, 77], ["NTera-2", "CELL", 47, 54], ["cells", "CELL", 72, 77], ["RNAi-treated cells", "CELL_LINE", 59, 77], ["ChIP assays", "TEST", 9, 20], ["NTera", "TEST", 47, 52], ["RNAi-treated cells", "TREATMENT", 59, 77]]], ["Cells were harvested by trypsinization, washed, and resuspended to 2\u00d7106 cells/ml in PBS with 20 mM sodium butyrate.", [["Cells", "ANATOMY", 0, 5], ["cells", "ANATOMY", 73, 78], ["sodium butyrate", "CHEMICAL", 100, 115], ["sodium butyrate", "CHEMICAL", 100, 115], ["Cells", "CELL", 0, 5], ["cells", "CELL", 73, 78], ["sodium butyrate", "SIMPLE_CHEMICAL", 100, 115], ["2\u00d7106 cells", "CELL_LINE", 67, 78], ["20 mM sodium butyrate", "TREATMENT", 94, 115]]], ["The protein-DNA complexes were fixed using 1% formaldehyde for 8 min, and crosslinking fixation was stopped by adding glycine to a final concentration of 125 mM for 5 min.", [["formaldehyde", "CHEMICAL", 46, 58], ["glycine", "CHEMICAL", 118, 125], ["formaldehyde", "CHEMICAL", 46, 58], ["glycine", "CHEMICAL", 118, 125], ["DNA", "CELLULAR_COMPONENT", 12, 15], ["formaldehyde", "SIMPLE_CHEMICAL", 46, 58], ["glycine", "SIMPLE_CHEMICAL", 118, 125], ["protein-DNA complexes", "PROTEIN", 4, 25], ["The protein-DNA complexes", "TREATMENT", 0, 25], ["1% formaldehyde", "TREATMENT", 43, 58], ["crosslinking fixation", "TREATMENT", 74, 95], ["crosslinking fixation", "OBSERVATION", 74, 95]]], ["Cross-linked cells were washed twice with cold PBS/20 mM butyrate, resuspended in 100 \u00b5l of lysis buffer (50 mM Tris-HCl at pH 8, 10 mM EDTA, 1% SDS, 1 mM PMSF, and 20 mM sodium butyrate supplemented with a fresh protease inhibitor cocktail (Sigma) and then sonicated to an average size of 250 bp by a MISONIX Sonicator 3000 for 30 min (with pulses of 30 s on and 30 s off).", [["cells", "ANATOMY", 13, 18], ["butyrate", "CHEMICAL", 57, 65], ["Tris-HCl", "CHEMICAL", 112, 120], ["sodium butyrate", "CHEMICAL", 171, 186], ["butyrate", "CHEMICAL", 57, 65], ["Tris-HCl", "CHEMICAL", 112, 120], ["EDTA", "CHEMICAL", 136, 140], ["PMSF", "CHEMICAL", 155, 159], ["sodium butyrate", "CHEMICAL", 171, 186], ["cells", "CELL", 13, 18], ["butyrate", "SIMPLE_CHEMICAL", 57, 65], ["Tris-HCl", "SIMPLE_CHEMICAL", 112, 120], ["EDTA", "SIMPLE_CHEMICAL", 136, 140], ["PMSF", "SIMPLE_CHEMICAL", 155, 159], ["sodium butyrate", "SIMPLE_CHEMICAL", 171, 186], ["Cross-linked cells", "CELL_LINE", 0, 18], ["Cross-linked cells", "TREATMENT", 0, 18], ["cold PBS/20 mM butyrate", "TREATMENT", 42, 65], ["lysis buffer", "TREATMENT", 92, 104], ["Tris", "TEST", 112, 116], ["pH", "TEST", 124, 126], ["EDTA", "TEST", 136, 140], ["SDS", "TEST", 145, 148], ["PMSF", "TEST", 155, 159], ["20 mM sodium butyrate", "TREATMENT", 165, 186], ["a fresh protease inhibitor cocktail", "TREATMENT", 205, 240], ["pulses", "TEST", 342, 348], ["size", "OBSERVATION_MODIFIER", 282, 286]]], ["We used 5 \u00b5g of anti-Sin3A, 20 \u00b5g of anti-MeCP2 (sc-994X and sc-20700X; Santa Cruz Biotechnology), 5 \u00b5g of anti-STAT3 (05-485; Upstate-Millipore, New York, NY, USA), 5 \u00b5g of anti-CBP, 5 \u00b5g of anti-p300, 20 \u00b5g of anti-polII (sc-369X, sc-585X and sc-899X; Santa Cruz Biotechnology), 5 \u00b5g of anti-H3K9Ac, 5 \u00b5g of anti-H3K14Ac (06-942 and 06-911; Upstate-Millipore), and 2.5 \u00b5g of anti-H3K4me3 (ab8580; Abcam, Cambridge, MA, USA) for immunoprecipitation, which was performed at 4\u00b0C with the indicated antibodies by incubation with Protein A Dynabeads (Invitrogen) equilibrated with 1 ml RIPA buffer (10 mM Tris-HCl at pH 7.5, 1 mM EDTA, 0.5 mM EGTA 1% Triton X-100, 0.1% SDS, 0.1% Na-deoxycholate, and 140 mM NaCl) and protease inhibitors for 2 h.", [["anti-Sin3A", "CHEMICAL", 16, 26], ["sc-994X and sc-20700X", "CHEMICAL", 49, 70], ["anti-STAT3", "CHEMICAL", 107, 117], ["anti-CBP", "CHEMICAL", 174, 182], ["anti-p300", "CHEMICAL", 192, 201], ["anti-H3K9Ac", "CHEMICAL", 289, 300], ["anti-H3K14Ac", "CHEMICAL", 310, 322], ["Tris-HCl", "CHEMICAL", 602, 610], ["EGTA", "CHEMICAL", 640, 644], ["Triton X-100", "CHEMICAL", 648, 660], ["Na-deoxycholate", "CHEMICAL", 677, 692], ["NaCl", "CHEMICAL", 705, 709], ["anti-H3K14Ac", "CHEMICAL", 310, 322], ["Tris-HCl", "CHEMICAL", 602, 610], ["EDTA", "CHEMICAL", 627, 631], ["EGTA", "CHEMICAL", 640, 644], ["Triton X-100", "CHEMICAL", 648, 660], ["Na-deoxycholate", "CHEMICAL", 677, 692], ["NaCl", "CHEMICAL", 705, 709], ["anti-Sin3A", "SIMPLE_CHEMICAL", 16, 26], ["anti-MeCP2", "SIMPLE_CHEMICAL", 37, 47], ["anti-STAT3", "SIMPLE_CHEMICAL", 107, 117], ["anti-CBP", "SIMPLE_CHEMICAL", 174, 182], ["anti-polII", "SIMPLE_CHEMICAL", 212, 222], ["sc-585X", "GENE_OR_GENE_PRODUCT", 233, 240], ["anti-H3K9Ac", "SIMPLE_CHEMICAL", 289, 300], ["anti-H3K4me3", "GENE_OR_GENE_PRODUCT", 377, 389], ["Invitrogen", "SIMPLE_CHEMICAL", 548, 558], ["Tris-HCl", "SIMPLE_CHEMICAL", 602, 610], ["EDTA", "SIMPLE_CHEMICAL", 627, 631], ["Triton X-100", "SIMPLE_CHEMICAL", 648, 660], ["Na-deoxycholate", "SIMPLE_CHEMICAL", 677, 692], ["anti-H3K4me3", "PROTEIN", 377, 389], ["Protein A Dynabeads", "PROTEIN", 527, 546], ["anti-Sin3A", "TREATMENT", 16, 26], ["anti-MeCP2", "TREATMENT", 37, 47], ["anti-CBP", "TREATMENT", 174, 182], ["anti-p", "TREATMENT", 192, 198], ["anti-polII", "TREATMENT", 212, 222], ["anti-H3K9Ac", "TREATMENT", 289, 300], ["anti-H3K14Ac", "TREATMENT", 310, 322], ["anti-H3K4me3", "TREATMENT", 377, 389], ["immunoprecipitation", "TEST", 430, 449], ["Protein A Dynabeads (Invitrogen)", "TREATMENT", 527, 559], ["1 ml RIPA buffer", "TREATMENT", 578, 594], ["Tris", "TEST", 602, 606], ["pH", "TEST", 614, 616], ["EDTA", "TEST", 627, 631], ["EGTA", "TEST", 640, 644], ["Na-deoxycholate", "TREATMENT", 677, 692], ["140 mM NaCl)", "TREATMENT", 698, 710], ["protease inhibitors", "TREATMENT", 715, 734]]], ["The immunocomplexes were further incubated with chromatin at 4\u00b0C overnight.", [["chromatin", "ANATOMY", 48, 57], ["chromatin", "CELLULAR_COMPONENT", 48, 57], ["immunocomplexes", "PROTEIN", 4, 19], ["chromatin", "DNA", 48, 57], ["The immunocomplexes", "PROBLEM", 0, 19]]], ["The bound fraction was isolated by Protein A Dynabeads according to the manufacturer's instructions, and the immunoprecipitated complexes were eluted by using 300 \u00b5l of elution buffer (20 mM Tris-HCl at pH 7.5, 5 mM EDTA, 50 mM NaCl and 20 mM sodium butyrate) for 30 min at 65\u00b0C then for 10 min at room temperature on a rotator.", [["Tris-HCl", "CHEMICAL", 191, 199], ["NaCl", "CHEMICAL", 228, 232], ["sodium butyrate", "CHEMICAL", 243, 258], ["Tris-HCl", "CHEMICAL", 191, 199], ["EDTA", "CHEMICAL", 216, 220], ["NaCl", "CHEMICAL", 228, 232], ["sodium butyrate", "CHEMICAL", 243, 258], ["Tris-HCl", "SIMPLE_CHEMICAL", 191, 199], ["EDTA", "SIMPLE_CHEMICAL", 216, 220], ["sodium butyrate", "SIMPLE_CHEMICAL", 243, 258], ["Protein A Dynabeads", "PROTEIN", 35, 54], ["immunoprecipitated complexes", "PROTEIN", 109, 137], ["The bound fraction", "TEST", 0, 18], ["the immunoprecipitated complexes", "PROBLEM", 105, 137], ["elution buffer", "TREATMENT", 169, 183], ["pH", "TEST", 203, 205], ["EDTA", "TEST", 216, 220], ["NaCl", "TREATMENT", 228, 232], ["20 mM sodium butyrate", "TREATMENT", 237, 258], ["a rotator", "TREATMENT", 318, 327], ["bound fraction", "OBSERVATION", 4, 18], ["rotator", "ANATOMY", 320, 327]]], ["Chromatin was eluted from the antibody and de-cross-linked by added of 30 \u00b5l pronase (20 mg/ml) and 1 \u00b5l CaCl2 (1 M) then incubating it at 42\u00b0C for 2 h and 65\u00b0C for 6 h.", [["Chromatin", "ANATOMY", 0, 9], ["CaCl2", "CHEMICAL", 105, 110], ["CaCl2", "CHEMICAL", 105, 110], ["Chromatin", "CELLULAR_COMPONENT", 0, 9], ["the antibody", "TEST", 26, 38], ["1 \u00b5l CaCl2", "TREATMENT", 100, 110]]], ["The immunoprecipitated DNA was recovered by a PCR purification kit (Qiagen) according to the manufacturer's instructions, and the purified samples were analyzed by real-time quantitative PCR using an SYBR Green master mix and a LightCycler 480 sequence detection system (Roche Applied Science, Mannheim, Germany).", [["samples", "ANATOMY", 139, 146], ["DNA", "CELLULAR_COMPONENT", 23, 26], ["immunoprecipitated DNA", "DNA", 4, 26], ["The immunoprecipitated DNA", "PROBLEM", 0, 26], ["a PCR purification kit", "TREATMENT", 44, 66], ["the purified samples", "TEST", 126, 146]]], ["PCR primers were designed using the software program Primer Express (Roche Applied Science), and the amplification primers are listed in Table S2.", [["PCR primers", "DNA", 0, 11], ["amplification primers", "DNA", 101, 122], ["PCR primers", "TEST", 0, 11], ["the amplification primers", "TREATMENT", 97, 122]]], ["For each sample, the PCR analysis was performed in triplicate, and the bound fraction was compared with 1\u223640 diluted input DNA of 1\u00d7105 cells.", [["sample", "ANATOMY", 9, 15], ["1\u00d7105 cells", "ANATOMY", 130, 141], ["DNA", "CELLULAR_COMPONENT", 123, 126], ["1\u00d7105 cells", "CELL", 130, 141], ["1\u223640 diluted input DNA", "DNA", 104, 126], ["1\u00d7105 cells", "CELL_LINE", 130, 141], ["each sample", "TEST", 4, 15], ["the PCR analysis", "TEST", 17, 33], ["the bound fraction", "TEST", 67, 85]]], ["The results are reported as the ratio of immunoprecipitated (IP) DNA to input DNA (IP/input).", [["DNA", "CELLULAR_COMPONENT", 65, 68], ["DNA", "CELLULAR_COMPONENT", 78, 81]]], ["To obtain relative occupancy values, the IP/input ratio was further normalized to the level observed at a control region, h, which was defined as 1.0.", [["the IP/input ratio", "TEST", 37, 55]]], ["Values of NTera-2 cells were compared to those of RNAi-treated samples.Induction of differentiation of NTera-2 cells toward an astrocyte-like lineage ::: ResultsNTera-2 cells are capable of differentiating into mixtures of neural and glial cells depending upon the induction conditions [33]\u2013[35].", [["NTera-2 cells", "ANATOMY", 10, 23], ["samples", "ANATOMY", 63, 70], ["NTera-2 cells", "ANATOMY", 103, 116], ["astrocyte-like lineage", "ANATOMY", 127, 149], ["ResultsNTera-2 cells", "ANATOMY", 154, 174], ["neural", "ANATOMY", 223, 229], ["glial cells", "ANATOMY", 234, 245], ["NTera-2 cells", "CELL", 10, 23], ["NTera-2 cells", "CELL", 103, 116], ["astrocyte-like lineage", "CELL", 127, 149], ["ResultsNTera-2 cells", "CELL", 154, 174], ["neural", "CELL", 223, 229], ["glial cells", "CELL", 234, 245], ["NTera-2 cells", "CELL_LINE", 10, 23], ["NTera-2 cells", "CELL_LINE", 103, 116], ["astrocyte-like lineage", "CELL_TYPE", 127, 149], ["ResultsNTera-2 cells", "CELL_LINE", 154, 174], ["neural and glial cells", "CELL_TYPE", 223, 245], ["Values", "TEST", 0, 6], ["NTera", "TEST", 10, 15], ["RNAi", "TEST", 50, 54], ["NTera", "TEST", 103, 108], ["an astrocyte", "TEST", 124, 136], ["ResultsNTera", "TEST", 154, 166], ["neural and glial cells", "PROBLEM", 223, 245], ["the induction conditions", "TEST", 261, 285], ["astrocyte", "ANATOMY", 127, 136], ["neural", "ANATOMY", 223, 229], ["glial cells", "OBSERVATION", 234, 245]]], ["Since NTera-2 cells express high levels of Oct-4 [36], [37], we used a lentiviral vector carrying a short hairpin (sh)RNA (Fig. 1A) to downregulate Oct-4 expression in order to develop a new protocol for cell differentiation.", [["NTera-2 cells", "ANATOMY", 6, 19], ["cell", "ANATOMY", 204, 208], ["NTera-2 cells", "CELL", 6, 19], ["Oct-4", "GENE_OR_GENE_PRODUCT", 43, 48], ["lentiviral", "ORGANISM", 71, 81], ["Oct-4", "GENE_OR_GENE_PRODUCT", 148, 153], ["cell", "CELL", 204, 208], ["NTera-2 cells", "CELL_LINE", 6, 19], ["Oct", "PROTEIN", 43, 46], ["short hairpin (sh)RNA", "RNA", 100, 121], ["Oct-4", "DNA", 148, 153], ["NTera", "TEST", 6, 11], ["Oct", "TEST", 43, 46], ["a lentiviral vector", "TREATMENT", 69, 88], ["a short hairpin (sh)RNA", "TREATMENT", 98, 121], ["Oct", "TEST", 148, 151], ["a new protocol", "TREATMENT", 185, 199], ["cell differentiation", "PROBLEM", 204, 224], ["cell differentiation", "OBSERVATION", 204, 224]]], ["Three days after transduction with the shRNA lentivirus, Oct-4 expression was greatly diminished (Fig. 1B).", [["lentivirus", "ORGANISM", 45, 55], ["Oct-4", "GENE_OR_GENE_PRODUCT", 57, 62], ["Oct-4", "DNA", 57, 62], ["the shRNA lentivirus", "TREATMENT", 35, 55], ["Oct", "TEST", 57, 60], ["greatly diminished", "PROBLEM", 78, 96], ["diminished", "OBSERVATION_MODIFIER", 86, 96]]], ["As shown in Fig. 1C, the cellular morphology remained the same as control NTera-2 cells at 3 days.", [["cellular", "ANATOMY", 25, 33], ["NTera-2 cells", "ANATOMY", 74, 87], ["cellular", "CELL", 25, 33], ["NTera-2 cells", "CELL", 74, 87], ["NTera-2 cells", "CELL_LINE", 74, 87], ["the cellular morphology", "TEST", 21, 44]]], ["However, dramatic morphological transformation was observed after 21 days of transduction, and cells had become flattened and enlarged, and showed a bushy morphology with numerous short and highly branched processes (Fig. 1C).", [["cells", "ANATOMY", 95, 100], ["cells", "CELL", 95, 100], ["dramatic morphological transformation", "PROBLEM", 9, 46], ["transduction", "TEST", 77, 89], ["numerous short and highly branched processes", "PROBLEM", 171, 215], ["dramatic", "OBSERVATION_MODIFIER", 9, 17], ["morphological transformation", "OBSERVATION", 18, 46], ["flattened", "OBSERVATION_MODIFIER", 112, 121], ["enlarged", "OBSERVATION_MODIFIER", 126, 134], ["bushy morphology", "OBSERVATION", 149, 165], ["numerous", "OBSERVATION_MODIFIER", 171, 179], ["short", "OBSERVATION_MODIFIER", 180, 185], ["highly", "OBSERVATION_MODIFIER", 190, 196], ["branched", "OBSERVATION_MODIFIER", 197, 205]]], ["Such a cell morphology exhibited characteristics similar to protoplasmic astrocytes, distinct from \u201cfibrous astrocytes\u201d [38].", [["cell", "ANATOMY", 7, 11], ["protoplasmic astrocytes", "ANATOMY", 60, 83], ["fibrous astrocytes", "ANATOMY", 100, 118], ["cell", "CELL", 7, 11], ["protoplasmic astrocytes", "CELL", 60, 83], ["fibrous astrocytes", "CELL", 100, 118], ["protoplasmic astrocytes", "CELL_TYPE", 60, 83], ["\u201cfibrous astrocytes", "CELL_TYPE", 99, 118], ["a cell morphology", "TEST", 5, 22], ["protoplasmic astrocytes", "PROBLEM", 60, 83], ["protoplasmic astrocytes", "OBSERVATION", 60, 83], ["fibrous astrocytes", "OBSERVATION", 100, 118]]], ["In addition to these morphological changes, the reduction in Oct-4 expression by NTera-2 cells was accompanied by a marked reduction in cell proliferation (Fig. S1A).", [["NTera-2 cells", "ANATOMY", 81, 94], ["cell", "ANATOMY", 136, 140], ["Oct-4", "GENE_OR_GENE_PRODUCT", 61, 66], ["NTera-2 cells", "CELL", 81, 94], ["cell", "CELL", 136, 140], ["Oct-4", "PROTEIN", 61, 66], ["NTera-2 cells", "CELL_LINE", 81, 94], ["these morphological changes", "PROBLEM", 15, 42], ["the reduction", "TEST", 44, 57], ["Oct", "TEST", 61, 64], ["a marked reduction in cell proliferation", "PROBLEM", 114, 154], ["reduction", "OBSERVATION_MODIFIER", 48, 57], ["marked", "OBSERVATION_MODIFIER", 116, 122], ["reduction", "OBSERVATION_MODIFIER", 123, 132], ["cell proliferation", "OBSERVATION", 136, 154]]], ["The growth potential of NTera-2 cells after transduction was studied by flow cytometry, and these cells had almost ceased cell cycling with accumulations of cells in the G0/G1 phase on days 4 and 14 (40.6% and 69.1%, respectively, in Fig. S1B).", [["NTera-2 cells", "ANATOMY", 24, 37], ["cells", "ANATOMY", 98, 103], ["cell", "ANATOMY", 122, 126], ["cells", "ANATOMY", 157, 162], ["NTera-2 cells", "CELL", 24, 37], ["cells", "CELL", 98, 103], ["cell", "CELL", 122, 126], ["cells", "CELL", 157, 162], ["S1B", "GENE_OR_GENE_PRODUCT", 239, 242], ["NTera-2 cells", "CELL_LINE", 24, 37], ["S1B", "PROTEIN", 239, 242], ["NTera-2 cells", "TREATMENT", 24, 37], ["flow cytometry", "TEST", 72, 86], ["these cells", "TEST", 92, 103], ["accumulations of cells", "PROBLEM", 140, 162], ["the G0/G1 phase", "TEST", 166, 181], ["growth", "OBSERVATION_MODIFIER", 4, 10], ["accumulations of cells", "OBSERVATION", 140, 162], ["G1 phase", "OBSERVATION_MODIFIER", 173, 181]]], ["Thereafter, these cells remained mostly in the G0/G1 phase (e.g., on day 14) and underwent significant morphological changes, as described above.", [["cells", "ANATOMY", 18, 23], ["cells", "CELL", 18, 23], ["these cells", "PROBLEM", 12, 23], ["significant morphological changes", "PROBLEM", 91, 124], ["significant", "OBSERVATION_MODIFIER", 91, 102], ["morphological changes", "OBSERVATION", 103, 124]]], ["In addition, downregulation of Oct-4 expression often leads to upregulation of Cdx2 in ES cells [39], [40].", [["ES cells", "ANATOMY", 87, 95], ["Oct-4", "GENE_OR_GENE_PRODUCT", 31, 36], ["Cdx2", "GENE_OR_GENE_PRODUCT", 79, 83], ["ES cells", "CELL", 87, 95], ["Oct-4", "PROTEIN", 31, 36], ["Cdx2", "PROTEIN", 79, 83], ["ES cells", "CELL_TYPE", 87, 95], ["Oct", "TEST", 31, 34], ["Cdx2 in ES cells", "TEST", 79, 95]]], ["In NTera-2 cells, however, Cdx2 expression was not detected in RNAi- transduced cells (data not shown), indicating that this cell line may be derived from cells at a stage of embryogenesis later than the origin of the ES cell line.", [["NTera-2 cells", "ANATOMY", 3, 16], ["cells", "ANATOMY", 80, 85], ["cell line", "ANATOMY", 125, 134], ["cells", "ANATOMY", 155, 160], ["ES cell line", "ANATOMY", 218, 230], ["NTera-2 cells", "CELL", 3, 16], ["Cdx2", "GENE_OR_GENE_PRODUCT", 27, 31], ["cells", "CELL", 80, 85], ["cell line", "CELL", 125, 134], ["cells", "CELL", 155, 160], ["ES cell line", "CELL", 218, 230], ["NTera-2 cells", "CELL_LINE", 3, 16], ["Cdx2", "PROTEIN", 27, 31], ["RNAi- transduced cells", "CELL_LINE", 63, 85], ["ES cell line", "CELL_LINE", 218, 230], ["Cdx2 expression", "TEST", 27, 42], ["this cell line", "PROBLEM", 120, 134], ["cell line", "OBSERVATION", 125, 134], ["origin", "ANATOMY_MODIFIER", 204, 210], ["ES cell line", "OBSERVATION", 218, 230]]], ["In addition, NTera-2 cells normally express the intermediate filament protein, nestin (Fig. 1C), a marker of neuroglial progenitor cells.", [["NTera-2 cells", "ANATOMY", 13, 26], ["neuroglial progenitor cells", "ANATOMY", 109, 136], ["NTera-2 cells", "CELL", 13, 26], ["nestin", "GENE_OR_GENE_PRODUCT", 79, 85], ["Fig. 1C", "GENE_OR_GENE_PRODUCT", 87, 94], ["neuroglial progenitor cells", "CELL", 109, 136], ["NTera-2 cells", "CELL_LINE", 13, 26], ["intermediate filament protein", "PROTEIN", 48, 77], ["nestin", "PROTEIN", 79, 85], ["Fig. 1C", "PROTEIN", 87, 94], ["neuroglial progenitor cells", "CELL_TYPE", 109, 136], ["a marker of neuroglial progenitor cells", "TREATMENT", 97, 136], ["intermediate filament", "OBSERVATION_MODIFIER", 48, 69], ["neuroglial progenitor cells", "OBSERVATION", 109, 136]]], ["But, the expression of nestin disappeared 3 days after transduction (Fig. 1C).Induction of differentiation of NTera-2 cells toward an astrocyte-like lineage ::: ResultsThe morphological transformation and cessation of proliferation in RNAi-transduced cells suggested that NTera-2 cells might undergo a process of differentiation.", [["NTera-2 cells", "ANATOMY", 110, 123], ["astrocyte", "ANATOMY", 134, 143], ["cells", "ANATOMY", 251, 256], ["NTera-2 cells", "ANATOMY", 272, 285], ["nestin", "GENE_OR_GENE_PRODUCT", 23, 29], ["NTera-2 cells", "CELL", 110, 123], ["astrocyte", "CELL", 134, 143], ["-like lineage", "CELL", 143, 156], ["cells", "CELL", 251, 256], ["NTera-2 cells", "CELL", 272, 285], ["nestin", "PROTEIN", 23, 29], ["NTera-2 cells", "CELL_LINE", 110, 123], ["astrocyte-like lineage", "CELL_TYPE", 134, 156], ["RNAi-transduced cells", "CELL_LINE", 235, 256], ["NTera-2 cells", "CELL_LINE", 272, 285], ["NTera", "TEST", 110, 115], ["The morphological transformation", "PROBLEM", 168, 200], ["proliferation in RNAi-transduced cells", "PROBLEM", 218, 256], ["NTera-2 cells", "TREATMENT", 272, 285], ["astrocyte", "ANATOMY", 134, 143], ["morphological transformation", "OBSERVATION", 172, 200], ["proliferation", "OBSERVATION_MODIFIER", 218, 231]]], ["To further verify that these changes were accompanied by differentiation toward an astrocyte-like lineage, cells were examined for the expression of astrocytic markers.", [["astrocyte-like lineage", "ANATOMY", 83, 105], ["cells", "ANATOMY", 107, 112], ["astrocytic", "ANATOMY", 149, 159], ["astrocyte-like lineage", "CELL", 83, 105], ["cells", "CELL", 107, 112], ["astrocyte-like lineage", "CELL_TYPE", 83, 105], ["astrocytic markers", "PROTEIN", 149, 167], ["an astrocyte", "TEST", 80, 92], ["astrocytic markers", "OBSERVATION", 149, 167]]], ["The intermediate filament protein, GFAP, is considered a cell type-specific marker for astrocytes.", [["cell", "ANATOMY", 57, 61], ["astrocytes", "ANATOMY", 87, 97], ["GFAP", "GENE_OR_GENE_PRODUCT", 35, 39], ["cell", "CELL", 57, 61], ["astrocytes", "CELL", 87, 97], ["intermediate filament protein", "PROTEIN", 4, 33], ["GFAP", "PROTEIN", 35, 39], ["astrocytes", "CELL_TYPE", 87, 97], ["astrocytes", "PROBLEM", 87, 97], ["intermediate", "OBSERVATION_MODIFIER", 4, 16], ["filament protein", "OBSERVATION", 17, 33]]], ["GFAP expression was observed in differentiated cells examined by immunofluorescence and Western blot assays (Fig. 1D).", [["cells", "ANATOMY", 47, 52], ["GFAP", "GENE_OR_GENE_PRODUCT", 0, 4], ["cells", "CELL", 47, 52], ["GFAP", "PROTEIN", 0, 4], ["differentiated cells", "CELL_TYPE", 32, 52], ["GFAP expression", "TEST", 0, 15], ["immunofluorescence", "TEST", 65, 83], ["Western blot assays", "TEST", 88, 107], ["differentiated cells", "OBSERVATION", 32, 52]]], ["Another astrocyte-specific marker, glutamine synthetase (GS) [41], was also detected by immunofluorescence and Western blot assays in differentiated cells (Fig. 1E).", [["astrocyte", "ANATOMY", 8, 17], ["cells", "ANATOMY", 149, 154], ["glutamine", "CHEMICAL", 35, 44], ["glutamine", "CHEMICAL", 35, 44], ["astrocyte", "CELL", 8, 17], ["glutamine synthetase (GS) [41]", "GENE_OR_GENE_PRODUCT", 35, 65], ["cells", "CELL", 149, 154], ["Fig. 1E", "CELL", 156, 163], ["glutamine synthetase", "PROTEIN", 35, 55], ["differentiated cells", "CELL_TYPE", 134, 154], ["Another astrocyte", "TEST", 0, 17], ["glutamine synthetase (GS)", "TEST", 35, 60], ["Western blot assays", "TEST", 111, 130]]], ["In addition, we detected neither the oligodendrocyte markers, A2B5 [42] and Gal-C [43], nor the neuron-specific markers, MAP-2 and Pax6 [44], after 21 days of transduction (Fig. S1C).", [["oligodendrocyte", "ANATOMY", 37, 52], ["neuron", "ANATOMY", 96, 102], ["oligodendrocyte", "CELL", 37, 52], ["A2B5 [42]", "GENE_OR_GENE_PRODUCT", 62, 71], ["Gal-C [43]", "GENE_OR_GENE_PRODUCT", 76, 86], ["MAP-2", "GENE_OR_GENE_PRODUCT", 121, 126], ["Pax6", "GENE_OR_GENE_PRODUCT", 131, 135], ["oligodendrocyte markers", "PROTEIN", 37, 60], ["A2B5", "PROTEIN", 62, 66], ["neuron-specific markers", "PROTEIN", 96, 119], ["MAP", "PROTEIN", 121, 124], ["Pax6", "PROTEIN", 131, 135], ["the oligodendrocyte markers", "TEST", 33, 60], ["A2B5", "TEST", 62, 66], ["Gal-C", "TEST", 76, 81], ["the neuron", "TEST", 92, 102], ["specific markers", "TEST", 103, 119], ["MAP", "TEST", 121, 124], ["Pax6", "TEST", 131, 135]]], ["Taken together, these differentiated NTera-2 cells produced by our newly developed protocol had an astrocyte-like morphology and expressed the astrocyte-specific markers, GFAP and GS, suggesting differentiation toward an astrocytic lineage.", [["NTera-2 cells", "ANATOMY", 37, 50], ["astrocyte", "ANATOMY", 99, 108], ["astrocyte", "ANATOMY", 143, 152], ["astrocytic lineage", "ANATOMY", 221, 239], ["NTera-2 cells", "CELL", 37, 50], ["astrocyte", "CELL", 99, 108], ["astrocyte", "CELL", 143, 152], ["GFAP", "GENE_OR_GENE_PRODUCT", 171, 175], ["GS", "GENE_OR_GENE_PRODUCT", 180, 182], ["astrocytic lineage", "CELL", 221, 239], ["NTera-2 cells", "CELL_LINE", 37, 50], ["astrocyte-specific markers", "PROTEIN", 143, 169], ["GFAP", "PROTEIN", 171, 175], ["GS", "PROTEIN", 180, 182], ["astrocytic lineage", "CELL_TYPE", 221, 239], ["GFAP and GS", "TEST", 171, 182], ["an astrocytic lineage", "PROBLEM", 218, 239], ["astrocytic lineage", "OBSERVATION", 221, 239]]], ["Therefore, these differentiated cells distinctly differed from previous reports of a mixture of different neuronal cell types after retinoic acid induction [35].Nuclear export of olig2 and STAT3 activation during cell differentiation ::: ResultsOligo 2 is a basic HLH transcription factor, and its expression in the nucleus is required for oligodendrocyte development by preventing the formation of the STAT3 and p300 complex in the nucleus [45], [46].", [["cells", "ANATOMY", 32, 37], ["neuronal cell", "ANATOMY", 106, 119], ["Nuclear", "ANATOMY", 161, 168], ["cell", "ANATOMY", 213, 217], ["nucleus", "ANATOMY", 316, 323], ["oligodendrocyte", "ANATOMY", 340, 355], ["nucleus", "ANATOMY", 433, 440], ["retinoic acid", "CHEMICAL", 132, 145], ["HLH", "DISEASE", 264, 267], ["retinoic acid", "CHEMICAL", 132, 145], ["cells", "CELL", 32, 37], ["neuronal cell", "CELL", 106, 119], ["retinoic acid", "SIMPLE_CHEMICAL", 132, 145], ["Nuclear", "CELLULAR_COMPONENT", 161, 168], ["olig2", "GENE_OR_GENE_PRODUCT", 179, 184], ["STAT3", "GENE_OR_GENE_PRODUCT", 189, 194], ["cell", "CELL", 213, 217], ["ResultsOligo 2", "GENE_OR_GENE_PRODUCT", 238, 252], ["nucleus", "CELLULAR_COMPONENT", 316, 323], ["oligodendrocyte", "CELL", 340, 355], ["STAT3", "GENE_OR_GENE_PRODUCT", 403, 408], ["p300", "GENE_OR_GENE_PRODUCT", 413, 417], ["nucleus", "CELLULAR_COMPONENT", 433, 440], ["differentiated cells", "CELL_TYPE", 17, 37], ["neuronal cell types", "CELL_TYPE", 106, 125], ["olig2", "PROTEIN", 179, 184], ["STAT3", "PROTEIN", 189, 194], ["basic HLH transcription factor", "PROTEIN", 258, 288], ["STAT3", "PROTEIN", 403, 408], ["p300 complex", "PROTEIN", 413, 425], ["these differentiated cells", "PROBLEM", 11, 37], ["different neuronal cell types", "TREATMENT", 96, 125], ["retinoic acid induction", "TREATMENT", 132, 155], ["a basic HLH transcription factor", "PROBLEM", 256, 288], ["oligodendrocyte development", "TREATMENT", 340, 367], ["neuronal cell types", "OBSERVATION", 106, 125], ["nucleus", "ANATOMY", 316, 323], ["nucleus", "ANATOMY", 433, 440]]], ["To confirm the cellular differentiation of NTera-2 cells, we examined the expression of olig2 and found that olig2 was expressed in nuclei of undifferentiated NTera-2 cells (Fig. 2A).", [["cellular", "ANATOMY", 15, 23], ["NTera-2 cells", "ANATOMY", 43, 56], ["nuclei", "ANATOMY", 132, 138], ["NTera-2 cells", "ANATOMY", 159, 172], ["cellular", "CELL", 15, 23], ["NTera-2 cells", "CELL", 43, 56], ["olig2", "GENE_OR_GENE_PRODUCT", 88, 93], ["olig2", "GENE_OR_GENE_PRODUCT", 109, 114], ["nuclei", "CELLULAR_COMPONENT", 132, 138], ["NTera-2 cells", "CELL", 159, 172], ["Fig. 2A", "CELL", 174, 181], ["NTera-2 cells", "CELL_LINE", 43, 56], ["olig2", "PROTEIN", 88, 93], ["olig2", "PROTEIN", 109, 114], ["undifferentiated NTera-2 cells", "CELL_LINE", 142, 172], ["olig2", "PROBLEM", 88, 93], ["olig2", "PROBLEM", 109, 114]]], ["During specification for an astrocyte-like lineage, there was a striking translocation in the distribution of olig2 from nuclei to the cytoplasm (Fig. 2A).", [["astrocyte-like lineage", "ANATOMY", 28, 50], ["nuclei", "ANATOMY", 121, 127], ["cytoplasm", "ANATOMY", 135, 144], ["astrocyte-like lineage", "CELL", 28, 50], ["olig2", "GENE_OR_GENE_PRODUCT", 110, 115], ["nuclei", "CELLULAR_COMPONENT", 121, 127], ["cytoplasm", "ORGANISM_SUBSTANCE", 135, 144], ["astrocyte-like lineage", "CELL_TYPE", 28, 50], ["olig2", "PROTEIN", 110, 115], ["a striking translocation", "PROBLEM", 62, 86], ["striking translocation", "OBSERVATION", 64, 86]]], ["Thus, the translocation of olig2 from nuclei may suggest activation of STAT3 in nuclei.", [["nuclei", "ANATOMY", 38, 44], ["nuclei", "ANATOMY", 80, 86], ["olig2", "GENE_OR_GENE_PRODUCT", 27, 32], ["nuclei", "CELLULAR_COMPONENT", 38, 44], ["STAT3", "GENE_OR_GENE_PRODUCT", 71, 76], ["nuclei", "CELLULAR_COMPONENT", 80, 86], ["olig2", "PROTEIN", 27, 32], ["STAT3", "PROTEIN", 71, 76], ["STAT3 in nuclei", "PROBLEM", 71, 86], ["STAT3", "OBSERVATION", 71, 76]]], ["Therefore, we analyzed the phosphorylation status of STAT3 and found that there was significant accumulation of phosphorylated STAT3 in differentiated cells compared to undifferentiated cells (Fig. 2B).", [["cells", "ANATOMY", 151, 156], ["undifferentiated cells", "ANATOMY", 169, 191], ["STAT3", "GENE_OR_GENE_PRODUCT", 53, 58], ["STAT3", "GENE_OR_GENE_PRODUCT", 127, 132], ["cells", "CELL", 151, 156], ["cells", "CELL", 186, 191], ["Fig. 2B", "CELL", 193, 200], ["STAT3", "PROTEIN", 53, 58], ["phosphorylated STAT3", "PROTEIN", 112, 132], ["differentiated cells", "CELL_TYPE", 136, 156], ["undifferentiated cells", "CELL_TYPE", 169, 191], ["significant accumulation of phosphorylated STAT3 in differentiated cells", "PROBLEM", 84, 156], ["undifferentiated cells", "PROBLEM", 169, 191], ["significant", "OBSERVATION_MODIFIER", 84, 95], ["accumulation of", "OBSERVATION", 96, 111], ["phosphorylated STAT3", "OBSERVATION", 112, 132], ["differentiated cells", "OBSERVATION", 136, 156], ["undifferentiated cells", "OBSERVATION", 169, 191]]], ["Furthermore, specific antibodies against STAT3 were found to have co-immunoprecipitated p300 in differentiated cells, but not in undifferentiated cells, suggesting specific formation of STAT3-p300 complexes in differentiated cells (Fig. 2C).", [["cells", "ANATOMY", 111, 116], ["cells", "ANATOMY", 146, 151], ["cells", "ANATOMY", 225, 230], ["STAT3", "GENE_OR_GENE_PRODUCT", 41, 46], ["p300", "GENE_OR_GENE_PRODUCT", 88, 92], ["cells", "CELL", 111, 116], ["cells", "CELL", 146, 151], ["STAT3", "GENE_OR_GENE_PRODUCT", 186, 191], ["p300", "GENE_OR_GENE_PRODUCT", 192, 196], ["cells", "CELL", 225, 230], ["Fig. 2C", "CELL", 232, 239], ["STAT3", "PROTEIN", 41, 46], ["p300", "PROTEIN", 88, 92], ["differentiated cells", "CELL_TYPE", 96, 116], ["undifferentiated cells", "CELL_TYPE", 129, 151], ["STAT3", "PROTEIN", 186, 191], ["p300 complexes", "PROTEIN", 192, 206], ["differentiated cells", "CELL_TYPE", 210, 230], ["specific antibodies", "TEST", 13, 32], ["co-immunoprecipitated p300 in differentiated cells", "PROBLEM", 66, 116], ["undifferentiated cells", "PROBLEM", 129, 151], ["STAT3-p300 complexes in differentiated cells", "PROBLEM", 186, 230], ["differentiated cells", "OBSERVATION", 96, 116], ["not in", "UNCERTAINTY", 122, 128], ["undifferentiated cells", "OBSERVATION", 129, 151], ["differentiated cells", "OBSERVATION", 210, 230]]], ["These findings suggest activation of the STAT3 signaling pathway during the differentiation of NTera-2 cells.Reduction of histone co-repressor complexes during cell differentiation ::: ResultsIn order to investigate the mechanism of suppression and de-suppression of astrocyte differentiation-related genes in NTera-2 cells, we investigated and quantified differentially phosphorylated proteins using a newly developed label-free quantitation technology platform [30].", [["NTera-2 cells", "ANATOMY", 95, 108], ["cell", "ANATOMY", 160, 164], ["astrocyte", "ANATOMY", 267, 276], ["NTera-2 cells", "ANATOMY", 310, 323], ["STAT3", "GENE_OR_GENE_PRODUCT", 41, 46], ["NTera-2 cells", "CELL", 95, 108], ["histone", "GENE_OR_GENE_PRODUCT", 122, 129], ["cell", "CELL", 160, 164], ["astrocyte", "CELL", 267, 276], ["NTera-2 cells", "CELL", 310, 323], ["STAT3", "PROTEIN", 41, 46], ["NTera-2 cells", "CELL_LINE", 95, 108], ["histone co-repressor complexes", "PROTEIN", 122, 152], ["NTera-2 cells", "CELL_LINE", 310, 323], ["the STAT3 signaling pathway", "PROBLEM", 37, 64], ["suppression", "PROBLEM", 233, 244], ["astrocyte differentiation", "PROBLEM", 267, 292], ["genes in NTera-2 cells", "PROBLEM", 301, 323], ["differentially phosphorylated proteins", "PROBLEM", 356, 394], ["histone", "OBSERVATION", 122, 129], ["co-repressor complexes", "OBSERVATION", 130, 152], ["cell differentiation", "OBSERVATION", 160, 180]]], ["Briefly, phosphoproteins were digested in an optimized gel-assisted digestion and purified by a highly specific and reproducible automatic IMAC nanotechnology, followed by LC-MS/MS analysis.", [["phosphoproteins", "PROTEIN", 9, 24], ["phosphoproteins", "TREATMENT", 9, 24], ["an optimized gel-assisted digestion", "TREATMENT", 42, 77], ["MS analysis", "TEST", 178, 189]]], ["The relative quantification method was performed by software \u201cIDEAL-Q\u201d which was developed by SEMI alignment approach (Fig. 3A).Reduction of histone co-repressor complexes during cell differentiation ::: ResultsUsing NTera-2, it was found that the dynamic phosphoproteomic profile was observed after induction toward astrocyte differentiation.", [["cell", "ANATOMY", 179, 183], ["astrocyte", "ANATOMY", 317, 326], ["histone", "GENE_OR_GENE_PRODUCT", 141, 148], ["cell", "CELL", 179, 183], ["NTera-2", "GENE_OR_GENE_PRODUCT", 217, 224], ["astrocyte", "CELL", 317, 326], ["histone co-repressor complexes", "PROTEIN", 141, 171], ["NTera", "PROTEIN", 217, 222], ["the dynamic phosphoproteomic profile", "PROBLEM", 244, 280], ["histone", "OBSERVATION", 141, 148], ["co-repressor complexes", "OBSERVATION", 149, 171], ["cell differentiation", "OBSERVATION", 179, 199], ["astrocyte differentiation", "OBSERVATION", 317, 342]]], ["We found that there was a slightly increased in the overall phosphoproteomic profile levels at day 14 after induction for differentiation.", [["slightly", "OBSERVATION_MODIFIER", 26, 34], ["increased", "OBSERVATION_MODIFIER", 35, 44]]], ["In contrast, the upregulation and downregulation levels of phosphoproteomic profile increased dramatically and more than 50% phosphorylation sites have differential levels after stimulation for 21days, suggesting the dramatic change in phosphoproteomic pattern.Reduction of histone co-repressor complexes during cell differentiation ::: ResultsTo gain insight into the putative biological functions of the identified proteins, differentially phosphorylated proteins were functionally annotated and classified by using the functional annotation tool of Database for Annotation, Visualization and Integrated Discovery (DAVID) [47], [48] bioinformatics resources (http://david.abcc.ncifcrf.gov) on the National Institute of Allergy and Infectious Disease (NIAID).", [["cell", "ANATOMY", 312, 316], ["Allergy and Infectious Disease", "DISEASE", 721, 751], ["histone", "GENE_OR_GENE_PRODUCT", 274, 281], ["cell", "CELL", 312, 316], ["histone co-repressor complexes", "PROTEIN", 274, 304], ["differentially phosphorylated proteins", "PROTEIN", 427, 465], ["the upregulation", "TEST", 13, 29], ["downregulation levels", "TEST", 34, 55], ["phosphoproteomic profile", "TEST", 59, 83], ["the dramatic change in phosphoproteomic pattern", "PROBLEM", 213, 260], ["differentially phosphorylated proteins", "PROBLEM", 427, 465], ["downregulation", "OBSERVATION_MODIFIER", 34, 48], ["levels", "OBSERVATION_MODIFIER", 49, 55], ["phosphoproteomic", "OBSERVATION_MODIFIER", 59, 75], ["profile", "OBSERVATION_MODIFIER", 76, 83], ["increased", "OBSERVATION_MODIFIER", 84, 93], ["dramatically", "OBSERVATION_MODIFIER", 94, 106], ["dramatic", "OBSERVATION_MODIFIER", 217, 225], ["change", "OBSERVATION_MODIFIER", 226, 232], ["phosphoproteomic pattern", "OBSERVATION", 236, 260], ["histone", "OBSERVATION", 274, 281], ["co-repressor complexes", "OBSERVATION", 282, 304], ["cell differentiation", "OBSERVATION", 312, 332], ["Infectious", "OBSERVATION", 733, 743]]], ["This software performed a statistical analysis based on gene ontologies to identify groups that were significantly overrepresented (enriched) in this filtered data set.", [["a statistical analysis", "TEST", 24, 46], ["gene ontologies", "TEST", 56, 71]]], ["Upon DAVID gene functional classification, there were two groups of annotated proteins identified that showed statistically significant enrichment scores; they included phosphoproteins and those that were posttranslationally modified by acetylation (Fig. 3B).", [["phosphoproteins", "PROTEIN", 169, 184], ["annotated proteins", "TEST", 68, 86], ["statistically significant enrichment scores", "PROBLEM", 110, 153], ["phosphoproteins", "TREATMENT", 169, 184], ["significant", "OBSERVATION_MODIFIER", 124, 135], ["enrichment scores", "OBSERVATION", 136, 153]]], ["In addition, these proteins with significant enrichment scores were separated to nucleus and cytoplasm in location.", [["nucleus", "ANATOMY", 81, 88], ["cytoplasm", "ANATOMY", 93, 102], ["nucleus", "CELLULAR_COMPONENT", 81, 88], ["cytoplasm", "ORGANISM_SUBSTANCE", 93, 102], ["significant enrichment scores", "PROBLEM", 33, 62], ["significant", "OBSERVATION_MODIFIER", 33, 44], ["enrichment scores", "OBSERVATION", 45, 62], ["nucleus", "ANATOMY", 81, 88], ["cytoplasm", "OBSERVATION_MODIFIER", 93, 102]]], ["And the proteins that function in the nucleus were remarkably represented by those that control mRNA processing, chromosome organization, chromatin assembly/disassembly, DNA packaging, etc, (Fig. 3B).Reduction of histone co-repressor complexes during cell differentiation ::: ResultsAmong several potential chromatin related functions, we chose to study epigenetic regulation and chromatin remodeling during cellular differentiation in more depth.", [["nucleus", "ANATOMY", 38, 45], ["chromosome", "ANATOMY", 113, 123], ["chromatin", "ANATOMY", 138, 147], ["cell", "ANATOMY", 251, 255], ["chromatin", "ANATOMY", 307, 316], ["chromatin", "ANATOMY", 380, 389], ["cellular", "ANATOMY", 408, 416], ["nucleus", "CELLULAR_COMPONENT", 38, 45], ["chromosome", "CELLULAR_COMPONENT", 113, 123], ["chromatin", "CELLULAR_COMPONENT", 138, 147], ["DNA", "CELLULAR_COMPONENT", 170, 173], ["histone", "GENE_OR_GENE_PRODUCT", 213, 220], ["cell", "CELL", 251, 255], ["chromatin", "CELLULAR_COMPONENT", 307, 316], ["chromatin", "CELLULAR_COMPONENT", 380, 389], ["cellular", "CELL", 408, 416], ["chromatin", "DNA", 138, 147], ["histone co-repressor complexes", "PROTEIN", 213, 243], ["chromatin", "DNA", 307, 316], ["chromatin", "DNA", 380, 389], ["mRNA processing", "PROBLEM", 96, 111], ["chromosome organization", "PROBLEM", 113, 136], ["DNA packaging", "TREATMENT", 170, 183], ["chromatin remodeling", "PROBLEM", 380, 400], ["nucleus", "ANATOMY", 38, 45], ["histone", "OBSERVATION", 213, 220], ["co-repressor complexes", "OBSERVATION", 221, 243], ["cell differentiation", "OBSERVATION", 251, 271], ["chromatin remodeling", "OBSERVATION", 380, 400], ["cellular differentiation", "OBSERVATION", 408, 432], ["more depth", "OBSERVATION_MODIFIER", 436, 446]]], ["Three important themes emerge from the shift in the expression of several known, classifiable proteins (Fig. 3C).", [["classifiable proteins", "PROTEIN", 81, 102], ["Fig. 3C", "PROTEIN", 104, 111]]], ["First, the data set contains histone modifying complexes such as Sin3A and SUDS3.", [["histone", "GENE_OR_GENE_PRODUCT", 29, 36], ["Sin3A", "GENE_OR_GENE_PRODUCT", 65, 70], ["SUDS3", "GENE_OR_GENE_PRODUCT", 75, 80], ["histone modifying complexes", "PROTEIN", 29, 56], ["Sin3A", "PROTEIN", 65, 70], ["SUDS3", "PROTEIN", 75, 80], ["histone modifying complexes", "TREATMENT", 29, 56]]], ["Second group of proteins are the components of chromatin remodeling complexes including BAZ1B, SMARCC1 and CHD7.", [["chromatin", "ANATOMY", 47, 56], ["chromatin", "CELLULAR_COMPONENT", 47, 56], ["BAZ1B", "GENE_OR_GENE_PRODUCT", 88, 93], ["SMARCC1", "GENE_OR_GENE_PRODUCT", 95, 102], ["CHD7", "GENE_OR_GENE_PRODUCT", 107, 111], ["chromatin remodeling complexes", "PROTEIN", 47, 77], ["BAZ1B", "PROTEIN", 88, 93], ["SMARCC1", "PROTEIN", 95, 102], ["CHD7", "PROTEIN", 107, 111], ["chromatin remodeling complexes", "PROBLEM", 47, 77], ["BAZ1B", "TREATMENT", 88, 93], ["SMARCC1 and CHD7", "TREATMENT", 95, 111], ["proteins", "OBSERVATION", 16, 24], ["chromatin remodeling complexes", "OBSERVATION", 47, 77]]], ["They are thought to regulate chromatin structures using ATPase activity.", [["chromatin", "ANATOMY", 29, 38], ["chromatin", "CELLULAR_COMPONENT", 29, 38], ["ATPase", "GENE_OR_GENE_PRODUCT", 56, 62], ["ATPase", "PROTEIN", 56, 62]]], ["The third is a group of chromatin associating proteins, such that RB1, MCM2, TRIM24, HMGA1 and RCC1.", [["chromatin", "ANATOMY", 24, 33], ["chromatin", "CELLULAR_COMPONENT", 24, 33], ["RB1", "GENE_OR_GENE_PRODUCT", 66, 69], ["MCM2", "GENE_OR_GENE_PRODUCT", 71, 75], ["TRIM24", "GENE_OR_GENE_PRODUCT", 77, 83], ["HMGA1", "GENE_OR_GENE_PRODUCT", 85, 90], ["RCC1", "GENE_OR_GENE_PRODUCT", 95, 99], ["chromatin associating proteins", "PROTEIN", 24, 54], ["RB1", "PROTEIN", 66, 69], ["MCM2", "PROTEIN", 71, 75], ["TRIM24", "PROTEIN", 77, 83], ["HMGA1", "PROTEIN", 85, 90], ["RCC1", "PROTEIN", 95, 99], ["chromatin associating proteins", "PROBLEM", 24, 54], ["RB1", "TEST", 66, 69], ["MCM2", "TEST", 71, 75], ["RCC1", "PROBLEM", 95, 99]]], ["They are involved in diverse functions such as transcriptional control, DNA replication and chromosome condensation.Reduction of histone co-repressor complexes during cell differentiation ::: ResultsOf particular interest is the significant reduction of Sin3A in the phosphoproteomic pattern after 3 days of transduction.", [["chromosome", "ANATOMY", 92, 102], ["cell", "ANATOMY", 167, 171], ["DNA", "CELLULAR_COMPONENT", 72, 75], ["chromosome", "CELLULAR_COMPONENT", 92, 102], ["histone", "GENE_OR_GENE_PRODUCT", 129, 136], ["cell", "CELL", 167, 171], ["Sin3A", "GENE_OR_GENE_PRODUCT", 254, 259], ["histone co-repressor complexes", "PROTEIN", 129, 159], ["Sin3A", "PROTEIN", 254, 259], ["transcriptional control", "TREATMENT", 47, 70], ["DNA replication", "TREATMENT", 72, 87], ["chromosome condensation", "PROBLEM", 92, 115], ["transduction", "TREATMENT", 308, 320], ["histone", "OBSERVATION", 129, 136], ["co-repressor complexes", "OBSERVATION", 137, 159], ["cell differentiation", "OBSERVATION", 167, 187], ["significant", "OBSERVATION_MODIFIER", 229, 240], ["reduction", "OBSERVATION_MODIFIER", 241, 250]]], ["Sin3A is a component of Sin3A/HDAC co-repressor complexes, which functions in transcription repression [49]\u2013[51], but its role in astrocyte differentiation has not been characterized.", [["astrocyte", "ANATOMY", 130, 139], ["Sin3A", "GENE_OR_GENE_PRODUCT", 0, 5], ["Sin3A", "GENE_OR_GENE_PRODUCT", 24, 29], ["HDAC", "GENE_OR_GENE_PRODUCT", 30, 34], ["astrocyte", "CELL", 130, 139], ["Sin3A", "PROTEIN", 0, 5], ["Sin3A", "PROTEIN", 24, 29], ["HDAC co-repressor complexes", "PROTEIN", 30, 57], ["Sin3A/HDAC co-repressor complexes", "TREATMENT", 24, 57], ["astrocyte differentiation", "OBSERVATION", 130, 155]]], ["By a Western blot analysis of samples through the course of differentiation (control, 7, 14, and 21 days), we further confirmed that the protein expression of Sin3A decreased significantly and continuously after differentiation (Fig. 3D).", [["samples", "ANATOMY", 30, 37], ["Sin3A", "GENE_OR_GENE_PRODUCT", 159, 164], ["Sin3A", "PROTEIN", 159, 164], ["the protein expression of Sin3A", "PROBLEM", 133, 164]]], ["Reduction of the expression of Sin3A may lead to disintegration of Sin3A/HDAC complexes thus causing de-suppression of the transcriptional program that favors astrocyte-like differentiation, such as activation of GFAP.Locus-specific reduction in Sin3A and MeCP2 occupancy ::: ResultsSince there was a significant reduction in the expression of Sin3A at the cellular level after cell differentiation in NTera-2 cells, we next investigated regional alterations in chromatin around the STAT3-binding site at the promoter and transcription initiation sites of GFAP before and after astrocyte-like differentiation.", [["astrocyte", "ANATOMY", 159, 168], ["cellular", "ANATOMY", 357, 365], ["cell", "ANATOMY", 378, 382], ["NTera-2 cells", "ANATOMY", 402, 415], ["chromatin", "ANATOMY", 462, 471], ["astrocyte", "ANATOMY", 578, 587], ["Sin3A", "GENE_OR_GENE_PRODUCT", 31, 36], ["Sin3A", "GENE_OR_GENE_PRODUCT", 67, 72], ["HDAC", "GENE_OR_GENE_PRODUCT", 73, 77], ["astrocyte", "CELL", 159, 168], ["GFAP", "GENE_OR_GENE_PRODUCT", 213, 217], ["Sin3A", "GENE_OR_GENE_PRODUCT", 246, 251], ["MeCP2", "GENE_OR_GENE_PRODUCT", 256, 261], ["Sin3A", "GENE_OR_GENE_PRODUCT", 344, 349], ["cellular", "CELL", 357, 365], ["cell", "CELL", 378, 382], ["NTera-2 cells", "CELL", 402, 415], ["chromatin", "CELLULAR_COMPONENT", 462, 471], ["STAT3", "GENE_OR_GENE_PRODUCT", 483, 488], ["GFAP", "GENE_OR_GENE_PRODUCT", 556, 560], ["astrocyte", "CELL", 578, 587], ["Sin3A", "PROTEIN", 31, 36], ["Sin3A", "PROTEIN", 67, 72], ["HDAC complexes", "PROTEIN", 73, 87], ["GFAP", "PROTEIN", 213, 217], ["Sin3A", "PROTEIN", 246, 251], ["MeCP2", "PROTEIN", 256, 261], ["Sin3A", "PROTEIN", 344, 349], ["NTera-2 cells", "CELL_LINE", 402, 415], ["chromatin", "DNA", 462, 471], ["STAT3-binding site", "DNA", 483, 501], ["transcription initiation sites", "DNA", 522, 552], ["GFAP", "PROTEIN", 556, 560], ["Sin3A/HDAC complexes", "TREATMENT", 67, 87], ["astrocyte-like differentiation", "PROBLEM", 159, 189], ["GFAP", "TEST", 213, 217], ["a significant reduction", "PROBLEM", 299, 322], ["cell differentiation", "TEST", 378, 398], ["regional alterations in chromatin", "PROBLEM", 438, 471], ["GFAP", "TEST", 556, 560], ["HDAC", "ANATOMY", 73, 77], ["specific", "OBSERVATION_MODIFIER", 224, 232], ["reduction", "OBSERVATION_MODIFIER", 233, 242], ["MeCP2 occupancy", "OBSERVATION", 256, 271], ["significant", "OBSERVATION_MODIFIER", 301, 312], ["reduction", "OBSERVATION_MODIFIER", 313, 322], ["cell differentiation", "OBSERVATION", 378, 398], ["regional", "OBSERVATION_MODIFIER", 438, 446], ["alterations", "OBSERVATION", 447, 458]]], ["To ascertain local changes in transcription factor binding, we performed ChIP assays with specific antibodies against Sin3A and MeCP2.", [["Sin3A", "GENE_OR_GENE_PRODUCT", 118, 123], ["MeCP2", "GENE_OR_GENE_PRODUCT", 128, 133], ["transcription factor", "PROTEIN", 30, 50], ["Sin3A", "PROTEIN", 118, 123], ["MeCP2", "PROTEIN", 128, 133], ["local changes in transcription factor binding", "PROBLEM", 13, 58], ["ChIP assays", "TEST", 73, 84], ["specific antibodies", "TEST", 90, 109], ["MeCP2", "PROBLEM", 128, 133], ["MeCP2", "OBSERVATION", 128, 133]]], ["In addition, the binding of these two co-repressors was quantitated by a real-time PCR using primers spanning from the STAT3 binding site at the promoter to exon 1 relative to the transcription start site of GFAP (primer sets a\u2013g in Fig. 4A).", [["STAT3", "GENE_OR_GENE_PRODUCT", 119, 124], ["GFAP", "GENE_OR_GENE_PRODUCT", 208, 212], ["co-repressors", "PROTEIN", 38, 51], ["STAT3 binding site", "DNA", 119, 137], ["exon 1", "DNA", 157, 163], ["transcription start site", "DNA", 180, 204], ["GFAP", "PROTEIN", 208, 212], ["primer sets a\u2013g", "DNA", 214, 229], ["primers", "PROBLEM", 93, 100], ["the STAT3 binding site", "PROBLEM", 115, 137]]], ["In addition, a pair of primer, h (Fig. 4A), located between exons 6 and 7 near the end of GFAP gene and remote from the transcription regulatory region, served as a negative control.", [["GFAP", "GENE_OR_GENE_PRODUCT", 90, 94], ["exons 6 and 7", "DNA", 60, 73], ["GFAP gene", "DNA", 90, 99], ["transcription regulatory region", "DNA", 120, 151]]], ["It was found that upon cellular differentiation, the binding of Sin3A significantly and specifically diminished around the STAT3 binding site about 1500 bp upstream of the GFAP start site in the promoter region (primer sets a\u2013c in Fig. 4A) (Fig. 4B).", [["cellular", "ANATOMY", 23, 31], ["cellular", "CELL", 23, 31], ["Sin3A", "GENE_OR_GENE_PRODUCT", 64, 69], ["STAT3", "GENE_OR_GENE_PRODUCT", 123, 128], ["GFAP", "GENE_OR_GENE_PRODUCT", 172, 176], ["Sin3A", "PROTEIN", 64, 69], ["STAT3 binding site", "DNA", 123, 141], ["1500 bp upstream", "DNA", 148, 164], ["GFAP start site", "DNA", 172, 187], ["promoter region", "DNA", 195, 210], ["primer sets a\u2013c", "DNA", 212, 227], ["the STAT3 binding site", "PROBLEM", 119, 141], ["cellular differentiation", "OBSERVATION", 23, 47], ["diminished", "OBSERVATION", 101, 111]]], ["In addition, we also identified that Sin3A occupancy at primer set g in the vicinity of exon 1 was strongly reduced after cell differentiation, whereas binding levels of Sin3A across the exon 1 locus (primer sets e and f) were not altered.", [["cell", "ANATOMY", 122, 126], ["Sin3A", "GENE_OR_GENE_PRODUCT", 37, 42], ["cell", "CELL", 122, 126], ["Sin3A", "GENE_OR_GENE_PRODUCT", 170, 175], ["Sin3A", "PROTEIN", 37, 42], ["exon 1", "DNA", 88, 94], ["Sin3A", "PROTEIN", 170, 175], ["exon 1 locus", "DNA", 187, 199], ["primer sets", "DNA", 201, 212], ["Sin3A occupancy", "PROBLEM", 37, 52], ["cell differentiation", "TEST", 122, 142], ["binding levels", "TEST", 152, 166]]], ["Since Sin3A lacks an intrinsic DNA-binding capacity, it must target itself to promoters via interactions with other DNA-binding or adaptor proteins, such as MeCP2, a methyl-CpG-binding protein, which was reported to interact with Sin3A in Xenopus laevis oocytes [52].", [["oocytes", "ANATOMY", 254, 261], ["methyl-CpG", "CHEMICAL", 166, 176], ["methyl", "CHEMICAL", 166, 172], ["CpG", "CHEMICAL", 173, 176], ["Sin3A", "GENE_OR_GENE_PRODUCT", 6, 11], ["DNA", "CELLULAR_COMPONENT", 31, 34], ["DNA", "CELLULAR_COMPONENT", 116, 119], ["MeCP2", "GENE_OR_GENE_PRODUCT", 157, 162], ["Sin3A", "GENE_OR_GENE_PRODUCT", 230, 235], ["Xenopus laevis", "ORGANISM", 239, 253], ["oocytes", "ORGANISM", 254, 261], ["Sin3A", "PROTEIN", 6, 11], ["promoters", "DNA", 78, 87], ["adaptor proteins", "PROTEIN", 131, 147], ["MeCP2", "PROTEIN", 157, 162], ["methyl-CpG-binding protein", "PROTEIN", 166, 192], ["Sin3A", "PROTEIN", 230, 235], ["Xenopus laevis", "SPECIES", 239, 253], ["Xenopus laevis", "SPECIES", 239, 253], ["an intrinsic DNA-binding capacity", "PROBLEM", 18, 51], ["adaptor proteins", "PROBLEM", 131, 147], ["a methyl-CpG-binding protein", "TREATMENT", 164, 192], ["binding capacity", "OBSERVATION", 35, 51]]], ["To test the possibility that MeCP2 may target Sin3A to the GFAP promoter, we performed a ChIP analysis to inspect the binding of MeCP2 around the STAT3-binding site at the GFAP promoter and in the proximity of exon 1 before and after cell differentiation.", [["cell", "ANATOMY", 234, 238], ["MeCP2", "GENE_OR_GENE_PRODUCT", 29, 34], ["Sin3A", "GENE_OR_GENE_PRODUCT", 46, 51], ["GFAP", "GENE_OR_GENE_PRODUCT", 59, 63], ["MeCP2", "GENE_OR_GENE_PRODUCT", 129, 134], ["STAT3", "GENE_OR_GENE_PRODUCT", 146, 151], ["GFAP", "GENE_OR_GENE_PRODUCT", 172, 176], ["cell", "CELL", 234, 238], ["MeCP2", "PROTEIN", 29, 34], ["Sin3A", "PROTEIN", 46, 51], ["GFAP promoter", "DNA", 59, 72], ["MeCP2", "PROTEIN", 129, 134], ["STAT3-binding site", "DNA", 146, 164], ["GFAP promoter", "DNA", 172, 185], ["exon 1", "DNA", 210, 216], ["MeCP2", "PROBLEM", 29, 34], ["a ChIP analysis", "TEST", 87, 102], ["the binding of MeCP2", "PROBLEM", 114, 134]]], ["As shown in Fig. 4B, the level of specific binding between MeCP2 and the STAT3-binding site at the GFAP promoter (primer sets a\u2013c) and in the proximity of exon 1 (primer sets d\u2013g, except site e) regions of GFAP in undifferentiated NTera-2 cells was substantially reduced in differentiated astrocyte-like cells.", [["undifferentiated NTera-2 cells", "ANATOMY", 214, 244], ["astrocyte-like cells", "ANATOMY", 289, 309], ["Fig. 4B", "GENE_OR_GENE_PRODUCT", 12, 19], ["MeCP2", "GENE_OR_GENE_PRODUCT", 59, 64], ["STAT3", "GENE_OR_GENE_PRODUCT", 73, 78], ["GFAP", "GENE_OR_GENE_PRODUCT", 99, 103], ["GFAP", "GENE_OR_GENE_PRODUCT", 206, 210], ["NTera-2 cells", "CELL", 231, 244], ["astrocyte-like cells", "CELL", 289, 309], ["MeCP2", "PROTEIN", 59, 64], ["STAT3-binding site", "DNA", 73, 91], ["GFAP promoter", "DNA", 99, 112], ["primer sets a\u2013c", "DNA", 114, 129], ["exon 1", "DNA", 155, 161], ["primer sets d\u2013g", "DNA", 163, 178], ["GFAP", "PROTEIN", 206, 210], ["undifferentiated NTera-2 cells", "CELL_LINE", 214, 244], ["differentiated astrocyte-like cells", "CELL_TYPE", 274, 309], ["specific binding between MeCP2", "PROBLEM", 34, 64], ["the STAT3-binding site", "PROBLEM", 69, 91], ["primer sets d\u2013g", "TEST", 163, 178], ["GFAP", "TEST", 206, 210], ["reduced", "OBSERVATION_MODIFIER", 263, 270], ["differentiated astrocyte", "OBSERVATION", 274, 298], ["like cells", "OBSERVATION", 299, 309]]], ["As the binding patterns for MeCP2 and Sin3A at the GFAP promoter and exon 1 occurred in a coordinated manner, these results suggest that MeCP2 may be responsible for recruiting the Sin3A co-repressor complex to the area surrounding the GFAP promoter.Locus-specific reduction in Sin3A and MeCP2 occupancy ::: ResultsMeCP2 is capable of binding to methylated DNA.", [["area", "ANATOMY", 215, 219], ["MeCP2", "GENE_OR_GENE_PRODUCT", 28, 33], ["Sin3A", "GENE_OR_GENE_PRODUCT", 38, 43], ["GFAP", "GENE_OR_GENE_PRODUCT", 51, 55], ["MeCP2", "GENE_OR_GENE_PRODUCT", 137, 142], ["Sin3A", "GENE_OR_GENE_PRODUCT", 181, 186], ["GFAP", "GENE_OR_GENE_PRODUCT", 236, 240], ["Sin3A", "GENE_OR_GENE_PRODUCT", 278, 283], ["MeCP2", "GENE_OR_GENE_PRODUCT", 288, 293], ["ResultsMeCP2", "GENE_OR_GENE_PRODUCT", 308, 320], ["DNA", "CELLULAR_COMPONENT", 357, 360], ["MeCP2", "PROTEIN", 28, 33], ["Sin3A", "PROTEIN", 38, 43], ["GFAP promoter", "DNA", 51, 64], ["exon 1", "DNA", 69, 75], ["MeCP2", "PROTEIN", 137, 142], ["Sin3A co-repressor complex", "PROTEIN", 181, 207], ["GFAP promoter", "DNA", 236, 249], ["Sin3A", "PROTEIN", 278, 283], ["MeCP2", "PROTEIN", 288, 293], ["ResultsMeCP2", "PROTEIN", 308, 320], ["methylated DNA", "DNA", 346, 360], ["MeCP2", "PROBLEM", 28, 33], ["Sin3A at the GFAP promoter", "TREATMENT", 38, 64], ["MeCP2", "PROBLEM", 137, 142], ["the Sin3A co-repressor complex", "TREATMENT", 177, 207], ["methylated DNA", "PROBLEM", 346, 360], ["GFAP promoter", "OBSERVATION", 236, 249], ["specific", "OBSERVATION_MODIFIER", 256, 264], ["reduction", "OBSERVATION_MODIFIER", 265, 274], ["MeCP2 occupancy", "OBSERVATION", 288, 303], ["methylated DNA", "OBSERVATION", 346, 360]]], ["There is a possibility that the reduction in MeCP2 occupancy at the GFAP promoter was triggered by DNA demethylation of the same region; we therefore examined the DNA methylation status of the GFAP gene in NTera-2 cells and differentiated astrocyte-like cells.", [["NTera-2 cells", "ANATOMY", 206, 219], ["astrocyte-like cells", "ANATOMY", 239, 259], ["MeCP2", "GENE_OR_GENE_PRODUCT", 45, 50], ["GFAP", "GENE_OR_GENE_PRODUCT", 68, 72], ["DNA", "CELLULAR_COMPONENT", 99, 102], ["DNA", "CELLULAR_COMPONENT", 163, 166], ["GFAP", "GENE_OR_GENE_PRODUCT", 193, 197], ["NTera-2 cells", "CELL", 206, 219], ["astrocyte-like cells", "CELL", 239, 259], ["MeCP2", "PROTEIN", 45, 50], ["GFAP promoter", "DNA", 68, 81], ["GFAP gene", "DNA", 193, 202], ["NTera-2 cells", "CELL_LINE", 206, 219], ["differentiated astrocyte-like cells", "CELL_TYPE", 224, 259], ["the reduction in MeCP2 occupancy", "PROBLEM", 28, 60], ["DNA demethylation of the same region", "PROBLEM", 99, 135], ["the GFAP gene", "TEST", 189, 202], ["reduction", "OBSERVATION_MODIFIER", 32, 41], ["MeCP2 occupancy", "OBSERVATION", 45, 60], ["differentiated astrocyte", "OBSERVATION", 224, 248], ["like cells", "OBSERVATION", 249, 259]]], ["However, the bisulfite sequencing analysis showed that upon differentiation toward an astrocyte-like lineage, the CpG dinucleotide around the STAT3-binding site at the promoter (primer sets P1 and P2 in Fig. 4C) and exon 1 (primer sets E1 and E2) was not demethylated (Fig. 4C).", [["astrocyte-like lineage", "ANATOMY", 86, 108], ["bisulfite", "CHEMICAL", 13, 22], ["bisulfite", "CHEMICAL", 13, 22], ["CpG", "CHEMICAL", 114, 117], ["astrocyte", "CELL", 86, 95], ["STAT3", "GENE_OR_GENE_PRODUCT", 142, 147], ["astrocyte-like lineage", "CELL_TYPE", 86, 108], ["CpG dinucleotide", "DNA", 114, 130], ["STAT3-binding site", "DNA", 142, 160], ["promoter", "DNA", 168, 176], ["primer sets", "DNA", 178, 189], ["P1", "DNA", 190, 192], ["P2", "DNA", 197, 199], ["exon 1", "DNA", 216, 222], ["primer sets E1", "DNA", 224, 238], ["E2", "DNA", 243, 245], ["the bisulfite sequencing analysis", "TEST", 9, 42], ["an astrocyte-like lineage", "PROBLEM", 83, 108], ["the CpG dinucleotide", "TREATMENT", 110, 130], ["the STAT3-binding site", "TREATMENT", 138, 160], ["exon 1 (primer sets E1 and E2)", "TEST", 216, 246], ["Fig", "OBSERVATION_MODIFIER", 203, 206]]], ["To further confirm these findings, we performed a quantitative methylation analysis using MALDI-TOF/MS to examine the mass signal shift of methylated DNA compared to unmethylated DNA extracted from undifferentiated NTera-2 cells, differentiated cells, and control human monocytes.", [["NTera-2 cells", "ANATOMY", 215, 228], ["cells", "ANATOMY", 245, 250], ["monocytes", "ANATOMY", 270, 279], ["DNA", "CELLULAR_COMPONENT", 150, 153], ["DNA", "CELLULAR_COMPONENT", 179, 182], ["NTera-2 cells", "CELL", 215, 228], ["cells", "CELL", 245, 250], ["human", "ORGANISM", 264, 269], ["monocytes", "CELL", 270, 279], ["methylated DNA", "DNA", 139, 153], ["unmethylated DNA", "DNA", 166, 182], ["NTera-2 cells", "CELL_LINE", 215, 228], ["differentiated cells", "CELL_TYPE", 230, 250], ["human monocytes", "CELL_TYPE", 264, 279], ["human", "SPECIES", 264, 269], ["human", "SPECIES", 264, 269], ["a quantitative methylation analysis", "TEST", 48, 83], ["MALDI", "TEST", 90, 95], ["the mass", "PROBLEM", 114, 122], ["methylated DNA", "PROBLEM", 139, 153], ["unmethylated DNA", "PROBLEM", 166, 182], ["differentiated cells", "PROBLEM", 230, 250], ["mass", "OBSERVATION", 118, 122], ["methylated DNA", "OBSERVATION", 139, 153], ["human monocytes", "OBSERVATION", 264, 279]]], ["This study confirmed that CpG sites scattered in the approximately 4500-bp region upstream of the GFAP transcription start site were stably methylated before and after differentiation (Fig. 4D).", [["CpG", "CHEMICAL", 26, 29], ["GFAP", "GENE_OR_GENE_PRODUCT", 98, 102], ["CpG sites", "DNA", 26, 35], ["4500-bp region", "DNA", 67, 81], ["GFAP transcription start site", "DNA", 98, 127], ["This study", "TEST", 0, 10], ["CpG sites", "PROBLEM", 26, 35], ["the GFAP transcription", "TREATMENT", 94, 116], ["CpG", "OBSERVATION_MODIFIER", 26, 29], ["sites", "OBSERVATION_MODIFIER", 30, 35], ["scattered", "OBSERVATION_MODIFIER", 36, 45]]], ["We concluded that the DNA methylation status of the GFAP promoter and exon 1 remained unchanged during cellular differentiation.", [["cellular", "ANATOMY", 103, 111], ["DNA", "CELLULAR_COMPONENT", 22, 25], ["GFAP", "GENE_OR_GENE_PRODUCT", 52, 56], ["exon 1", "GENE_OR_GENE_PRODUCT", 70, 76], ["cellular", "CELL", 103, 111], ["GFAP promoter", "DNA", 52, 65], ["exon 1", "DNA", 70, 76], ["the DNA methylation status of the GFAP promoter", "PROBLEM", 18, 65], ["unchanged", "OBSERVATION_MODIFIER", 86, 95], ["cellular differentiation", "OBSERVATION", 103, 127]]], ["Our results showed that reduced expression of Sin3A is accompanied by decreased occupancy of Sin3A and MeCP2 around the STAT3-binding site of the GFAP promoter, which was not necessarily accompanied by DNA demethylation in the same region for the induction of GFAP expression.", [["Sin3A", "GENE_OR_GENE_PRODUCT", 46, 51], ["Sin3A", "GENE_OR_GENE_PRODUCT", 93, 98], ["MeCP2", "GENE_OR_GENE_PRODUCT", 103, 108], ["STAT3", "GENE_OR_GENE_PRODUCT", 120, 125], ["GFAP", "GENE_OR_GENE_PRODUCT", 146, 150], ["DNA", "CELLULAR_COMPONENT", 202, 205], ["GFAP", "GENE_OR_GENE_PRODUCT", 260, 264], ["Sin3A", "PROTEIN", 46, 51], ["Sin3A", "PROTEIN", 93, 98], ["MeCP2", "PROTEIN", 103, 108], ["STAT3-binding site", "DNA", 120, 138], ["GFAP promoter", "DNA", 146, 159], ["GFAP", "PROTEIN", 260, 264], ["reduced expression of Sin3A", "PROBLEM", 24, 51], ["decreased occupancy of Sin3A", "PROBLEM", 70, 98], ["MeCP2", "PROBLEM", 103, 108], ["DNA demethylation", "PROBLEM", 202, 219], ["reduced", "OBSERVATION_MODIFIER", 24, 31], ["decreased", "OBSERVATION_MODIFIER", 70, 79], ["occupancy", "OBSERVATION_MODIFIER", 80, 89], ["not necessarily", "UNCERTAINTY", 171, 186]]], ["These results suggest a critical role for Sin3A in regulating GFAP expression during astrocytic differentiation.Activation of GFAP expression ::: ResultsThe binding of activated STAT3 to a STAT3 recognition element (\u22121518 to \u22121510 bp in relation to the transcription start site) in the mouse GFAP promoter plays a major role in the transcriptional activation of GFAP [53].", [["astrocytic", "ANATOMY", 85, 95], ["Sin3A", "GENE_OR_GENE_PRODUCT", 42, 47], ["GFAP", "GENE_OR_GENE_PRODUCT", 62, 66], ["GFAP", "GENE_OR_GENE_PRODUCT", 126, 130], ["STAT3", "GENE_OR_GENE_PRODUCT", 178, 183], ["STAT3", "GENE_OR_GENE_PRODUCT", 189, 194], ["mouse", "ORGANISM", 286, 291], ["GFAP", "GENE_OR_GENE_PRODUCT", 292, 296], ["GFAP [53]", "GENE_OR_GENE_PRODUCT", 362, 371], ["Sin3A", "PROTEIN", 42, 47], ["GFAP", "PROTEIN", 62, 66], ["GFAP", "PROTEIN", 126, 130], ["STAT3", "PROTEIN", 178, 183], ["STAT3 recognition element", "DNA", 189, 214], ["transcription start site", "DNA", 253, 277], ["mouse GFAP promoter", "DNA", 286, 305], ["GFAP", "PROTEIN", 362, 366], ["mouse", "SPECIES", 286, 291], ["mouse", "SPECIES", 286, 291], ["Sin3A", "TREATMENT", 42, 47], ["bp", "TEST", 231, 233], ["the mouse GFAP promoter", "TREATMENT", 282, 305], ["GFAP expression", "OBSERVATION", 62, 77], ["astrocytic differentiation", "OBSERVATION", 85, 111]]], ["Activation of STAT3 was also identified in astrocyte-like cells (Fig. 2B), which suggested that STAT3 may be responsible for GFAP activation.", [["astrocyte-like cells", "ANATOMY", 43, 63], ["STAT3", "GENE_OR_GENE_PRODUCT", 14, 19], ["astrocyte-like cells", "CELL", 43, 63], ["Fig. 2B", "CELL", 65, 72], ["STAT3", "GENE_OR_GENE_PRODUCT", 96, 101], ["GFAP", "GENE_OR_GENE_PRODUCT", 125, 129], ["STAT3", "PROTEIN", 14, 19], ["astrocyte-like cells", "CELL_TYPE", 43, 63], ["STAT3", "PROTEIN", 96, 101], ["GFAP", "PROTEIN", 125, 129], ["Activation of STAT3", "PROBLEM", 0, 19], ["GFAP activation", "PROBLEM", 125, 140], ["astrocyte", "ANATOMY", 43, 52], ["may be responsible for", "UNCERTAINTY", 102, 124]]], ["To test this, the occupancy of activated STAT3 was examined by a ChIP assay, using similar primer sets a\u2013g as shown in Fig. 4A.", [["STAT3", "GENE_OR_GENE_PRODUCT", 41, 46], ["STAT3", "PROTEIN", 41, 46], ["primer sets a\u2013g", "DNA", 91, 106], ["a ChIP assay", "TEST", 63, 75]]], ["As anticipated, the occupancy of activated STAT3 was more abundant around the STAT3- binding site at the GFAP promoter (primer sets b and c, especially primer set b at the STAT3 binding site) in differentiated cells compared to undifferentiated cells (Fig. 5A).", [["cells", "ANATOMY", 210, 215], ["undifferentiated cells", "ANATOMY", 228, 250], ["STAT3", "GENE_OR_GENE_PRODUCT", 43, 48], ["STAT3", "GENE_OR_GENE_PRODUCT", 78, 83], ["GFAP", "GENE_OR_GENE_PRODUCT", 105, 109], ["STAT3", "GENE_OR_GENE_PRODUCT", 172, 177], ["cells", "CELL", 210, 215], ["cells", "CELL", 245, 250], ["Fig. 5A", "CELL", 252, 259], ["STAT3", "PROTEIN", 43, 48], ["STAT3- binding site", "DNA", 78, 97], ["GFAP promoter", "DNA", 105, 118], ["primer sets b and c", "DNA", 120, 139], ["primer set b", "DNA", 152, 164], ["STAT3 binding site", "DNA", 172, 190], ["differentiated cells", "CELL_TYPE", 195, 215], ["undifferentiated cells", "CELL_TYPE", 228, 250], ["activated STAT3", "PROBLEM", 33, 48], ["differentiated cells", "OBSERVATION", 195, 215], ["undifferentiated cells", "OBSERVATION", 228, 250]]], ["Interestingly, at the exon 1 coding region and the 3\u2032 end of the exon 1 region of the GFAP gene, we also detected a second peak of activated STAT3 binding signals (primer sets e\u2013g) in differentiated cells but not in undifferentiated NTera-2 cells (Fig. 5A).", [["cells", "ANATOMY", 199, 204], ["NTera-2 cells", "ANATOMY", 233, 246], ["GFAP", "GENE_OR_GENE_PRODUCT", 86, 90], ["STAT3", "GENE_OR_GENE_PRODUCT", 141, 146], ["cells", "CELL", 199, 204], ["NTera-2 cells", "CELL", 233, 246], ["Fig. 5A", "CELL", 248, 255], ["exon 1 coding region", "DNA", 22, 42], ["3\u2032 end", "DNA", 51, 57], ["exon 1 region", "DNA", 65, 78], ["GFAP gene", "DNA", 86, 95], ["STAT3", "PROTEIN", 141, 146], ["primer sets e\u2013g", "DNA", 164, 179], ["differentiated cells", "CELL_TYPE", 184, 204], ["NTera-2 cells", "CELL_LINE", 233, 246], ["activated STAT3 binding signals", "PROBLEM", 131, 162], ["primer sets e\u2013g", "TEST", 164, 179], ["differentiated cells", "PROBLEM", 184, 204], ["differentiated cells", "OBSERVATION", 184, 204]]], ["STAT3 is a sequence-specific DNA-binding protein; in addition to the binding site at \u22121500 bp in the promoter (75% identities), we had identified a second binding site at +250 bp (TTCCTGGAA) at exon 1 of human GFAP (85% identities), based on a detailed sequence comparison with mouse GFAP gene.", [["STAT3", "GENE_OR_GENE_PRODUCT", 0, 5], ["DNA", "CELLULAR_COMPONENT", 29, 32], ["human", "ORGANISM", 204, 209], ["GFAP", "GENE_OR_GENE_PRODUCT", 210, 214], ["mouse", "ORGANISM", 278, 283], ["GFAP", "GENE_OR_GENE_PRODUCT", 284, 288], ["STAT3", "PROTEIN", 0, 5], ["DNA-binding protein", "PROTEIN", 29, 48], ["binding site", "DNA", 69, 81], ["\u22121500 bp", "DNA", 85, 93], ["promoter", "DNA", 101, 109], ["binding site", "DNA", 155, 167], ["exon 1", "DNA", 194, 200], ["human GFAP", "PROTEIN", 204, 214], ["mouse GFAP gene", "DNA", 278, 293], ["human", "SPECIES", 204, 209], ["mouse", "SPECIES", 278, 283], ["human", "SPECIES", 204, 209], ["mouse", "SPECIES", 278, 283], ["a sequence", "TEST", 9, 19], ["binding protein", "PROBLEM", 33, 48], ["the binding site", "PROBLEM", 65, 81], ["bp", "TEST", 91, 93], ["a second binding site", "PROBLEM", 146, 167], ["human GFAP", "TEST", 204, 214], ["a detailed sequence comparison", "TEST", 242, 272]]], ["These results argue that STAT3 may originally target the binding sequence that resides at the GFAP promoter, but due to the chromatin configuration between the promoter and exon 1 in differentiated cells, STAT3 is also cross-linked to chromatin at exon 1.", [["chromatin", "ANATOMY", 124, 133], ["cells", "ANATOMY", 198, 203], ["chromatin", "ANATOMY", 235, 244], ["STAT3", "GENE_OR_GENE_PRODUCT", 25, 30], ["GFAP", "GENE_OR_GENE_PRODUCT", 94, 98], ["chromatin", "CELLULAR_COMPONENT", 124, 133], ["cells", "CELL", 198, 203], ["STAT3", "GENE_OR_GENE_PRODUCT", 205, 210], ["chromatin", "CELLULAR_COMPONENT", 235, 244], ["exon 1", "CELLULAR_COMPONENT", 248, 254], ["STAT3", "PROTEIN", 25, 30], ["GFAP promoter", "DNA", 94, 107], ["chromatin", "DNA", 124, 133], ["promoter", "DNA", 160, 168], ["exon 1", "DNA", 173, 179], ["differentiated cells", "CELL_TYPE", 183, 203], ["STAT3", "PROTEIN", 205, 210], ["chromatin", "DNA", 235, 244], ["exon 1", "DNA", 248, 254], ["the binding sequence", "TEST", 53, 73], ["the promoter and exon 1 in differentiated cells", "TREATMENT", 156, 203]]], ["Alternatively, the occupancy of activated STAT3 may cause a bridge between the promoter and exon 1 which induces a stereospecific interaction on surfaces around the GFAP promoter and transcription start site.Activation of GFAP expression ::: ResultsTo further validate activation of GFAP induced by STAT3 binding, a ChIP analysis was performed to examine the recruitment of RNA polymerase II.", [["STAT3", "GENE_OR_GENE_PRODUCT", 42, 47], ["GFAP", "GENE_OR_GENE_PRODUCT", 165, 169], ["GFAP", "GENE_OR_GENE_PRODUCT", 222, 226], ["GFAP", "GENE_OR_GENE_PRODUCT", 283, 287], ["STAT3", "GENE_OR_GENE_PRODUCT", 299, 304], ["RNA polymerase II", "GENE_OR_GENE_PRODUCT", 374, 391], ["STAT3", "PROTEIN", 42, 47], ["promoter", "DNA", 79, 87], ["exon 1", "DNA", 92, 98], ["GFAP promoter", "DNA", 165, 178], ["transcription start site", "DNA", 183, 207], ["GFAP", "PROTEIN", 222, 226], ["GFAP", "PROTEIN", 283, 287], ["STAT3", "PROTEIN", 299, 304], ["RNA polymerase II", "PROTEIN", 374, 391], ["activated STAT3", "PROBLEM", 32, 47], ["a bridge between the promoter", "TREATMENT", 58, 87], ["the GFAP promoter", "TREATMENT", 161, 178], ["GFAP", "PROBLEM", 283, 287], ["STAT3 binding", "PROBLEM", 299, 312], ["a ChIP analysis", "TEST", 314, 329]]], ["A comparison of undifferentiated NTera-2 cells with differentiated cells revealed increased recruitment of RNA polymerase II to the GFAP gene transcription start site (primer set e) after differentiation, consistent with enhanced transcription (Fig. 5B).", [["NTera-2 cells", "ANATOMY", 33, 46], ["cells", "ANATOMY", 67, 72], ["NTera-2 cells", "CELL", 33, 46], ["cells", "CELL", 67, 72], ["RNA polymerase II", "GENE_OR_GENE_PRODUCT", 107, 124], ["GFAP", "GENE_OR_GENE_PRODUCT", 132, 136], ["undifferentiated NTera-2 cells", "CELL_LINE", 16, 46], ["differentiated cells", "CELL_TYPE", 52, 72], ["RNA polymerase II", "PROTEIN", 107, 124], ["GFAP gene transcription start site", "DNA", 132, 166], ["primer set e", "DNA", 168, 180], ["differentiated cells", "PROBLEM", 52, 72], ["increased recruitment of RNA polymerase II", "PROBLEM", 82, 124], ["the GFAP gene transcription", "TREATMENT", 128, 155], ["increased", "OBSERVATION_MODIFIER", 82, 91], ["recruitment of RNA polymerase", "OBSERVATION", 92, 121], ["consistent with", "UNCERTAINTY", 205, 220]]], ["Previous studies suggested that H3 Lys4 trimethylated (H3K4me3) nucleosomes occur near transcription start sites of actively transcribed genes.", [["H3 Lys4 trimethylated", "GENE_OR_GENE_PRODUCT", 32, 53], ["H3K4me3", "GENE_OR_GENE_PRODUCT", 55, 62], ["H3 Lys4 trimethylated (H3K4me3) nucleosomes", "DNA", 32, 75], ["transcription start sites", "DNA", 87, 112], ["actively transcribed genes", "DNA", 116, 142], ["Previous studies", "TEST", 0, 16], ["H3 Lys4 trimethylated (H3K4me3) nucleosomes", "TREATMENT", 32, 75], ["transcribed genes", "OBSERVATION", 125, 142]]], ["Moreover, several large-scale and genome-wide analyses revealed that about 91% of all RNA polymerase II-binding sites are correlated with H3K4me3-binding sites and were positively correlated with gene expression levels [54], [55].", [["RNA polymerase II", "GENE_OR_GENE_PRODUCT", 86, 103], ["H3K4me3", "GENE_OR_GENE_PRODUCT", 138, 145], ["RNA polymerase II-binding sites", "DNA", 86, 117], ["H3K4me3-binding sites", "DNA", 138, 159], ["genome-wide analyses", "TEST", 34, 54], ["all RNA polymerase II-binding sites", "PROBLEM", 82, 117], ["H3K4me3-binding sites", "TEST", 138, 159], ["gene expression levels", "TEST", 196, 218], ["large", "OBSERVATION_MODIFIER", 18, 23]]], ["Using a ChIP assay, we also found that H3K4me3 was enriched at sites of transcription initiation (primer sets e\u2013g), with maximal enrichment immediately downstream of the start site (primer sets e and f) and overlapping the peak of RNA polymerase II at the transcription start site (primer set e) in differentiated cells compared to undifferentiated cells (Fig. 5C).", [["cells", "ANATOMY", 314, 319], ["undifferentiated cells", "ANATOMY", 332, 354], ["H3K4me3", "GENE_OR_GENE_PRODUCT", 39, 46], ["RNA polymerase II", "GENE_OR_GENE_PRODUCT", 231, 248], ["cells", "CELL", 314, 319], ["cells", "CELL", 349, 354], ["Fig. 5C", "CELL", 356, 363], ["H3K4me3", "PROTEIN", 39, 46], ["primer sets e\u2013g", "DNA", 98, 113], ["start site", "DNA", 170, 180], ["RNA polymerase II", "PROTEIN", 231, 248], ["transcription start site", "DNA", 256, 280], ["primer set e", "DNA", 282, 294], ["differentiated cells", "CELL_TYPE", 299, 319], ["undifferentiated cells", "CELL_TYPE", 332, 354], ["a ChIP assay", "TEST", 6, 18], ["H3K4me3", "PROBLEM", 39, 46], ["transcription initiation", "TREATMENT", 72, 96], ["primer sets e\u2013g", "TEST", 98, 113], ["maximal enrichment", "PROBLEM", 121, 139], ["RNA polymerase II", "PROBLEM", 231, 248], ["peak", "OBSERVATION_MODIFIER", 223, 227], ["differentiated cells", "OBSERVATION", 299, 319], ["undifferentiated cells", "OBSERVATION", 332, 354]]], ["These results suggest a close correlation among STAT3-mediated chromatin remodeling, RNA polymerase II recruitment, and GFAP activation.Activation of GFAP expression ::: Results", [["chromatin", "ANATOMY", 63, 72], ["STAT3", "GENE_OR_GENE_PRODUCT", 48, 53], ["chromatin", "CELLULAR_COMPONENT", 63, 72], ["RNA polymerase II", "GENE_OR_GENE_PRODUCT", 85, 102], ["GFAP", "GENE_OR_GENE_PRODUCT", 120, 124], ["GFAP", "GENE_OR_GENE_PRODUCT", 150, 154], ["STAT3", "PROTEIN", 48, 53], ["chromatin", "DNA", 63, 72], ["RNA polymerase II", "PROTEIN", 85, 102], ["GFAP", "PROTEIN", 120, 124], ["GFAP", "PROTEIN", 150, 154], ["STAT3-mediated chromatin remodeling", "TREATMENT", 48, 83], ["RNA polymerase II recruitment", "PROBLEM", 85, 114], ["chromatin remodeling", "OBSERVATION", 63, 83]]]], "PMC7213773": [["Coronavirus disease 19 (COVID-19) is the condition caused by severe acute respiratory syndrome coronavirus 2 (SARS-2-CoV-2) infections which is now prevalent in all 50 states with clustering of cases in major cities in New York, Michigan, California, and New Jersey.", [["Coronavirus disease", "DISEASE", 0, 19], ["acute respiratory syndrome coronavirus", "DISEASE", 68, 106], ["infections", "DISEASE", 124, 134], ["SARS-2-CoV-2", "ORGANISM", 110, 122], ["Coronavirus disease 19 (COVID-19", "SPECIES", 0, 32], ["severe acute respiratory syndrome coronavirus", "SPECIES", 61, 106], ["SARS-2-CoV-2", "SPECIES", 110, 122], ["Coronavirus disease", "PROBLEM", 0, 19], ["COVID", "TEST", 24, 29], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 61, 106], ["SARS", "TEST", 110, 114], ["infections", "PROBLEM", 124, 134], ["severe", "OBSERVATION_MODIFIER", 61, 67], ["acute", "OBSERVATION_MODIFIER", 68, 73], ["respiratory syndrome", "OBSERVATION", 74, 94], ["infections", "OBSERVATION", 124, 134], ["New", "OBSERVATION_MODIFIER", 255, 258], ["Jersey", "OBSERVATION_MODIFIER", 259, 265]]], ["COVID-19 that was initially thought to be the great equalizer\u2014no discrimination with who can become infected\u2014now reveals patterns of disparities for low-income persons and racial and ethnic minority populations.", [["persons", "SPECIES", 160, 167], ["COVID", "TEST", 0, 5], ["racial and ethnic minority populations", "PROBLEM", 172, 210]]], ["This novel coronavirus which results in increased rates of respiratory failure and death among infected individuals1, 2 is found to disproportionally affect those with comorbidities such as diabetes, heart disease, and asthma.", [["respiratory", "ANATOMY", 59, 70], ["heart", "ANATOMY", 200, 205], ["respiratory failure", "DISEASE", 59, 78], ["death", "DISEASE", 83, 88], ["diabetes", "DISEASE", 190, 198], ["heart disease", "DISEASE", 200, 213], ["asthma", "DISEASE", 219, 225], ["coronavirus", "ORGANISM", 11, 22], ["heart", "ORGAN", 200, 205], ["This novel coronavirus", "PROBLEM", 0, 22], ["respiratory failure", "PROBLEM", 59, 78], ["death", "PROBLEM", 83, 88], ["infected individuals1", "PROBLEM", 95, 116], ["diabetes", "PROBLEM", 190, 198], ["heart disease", "PROBLEM", 200, 213], ["asthma", "PROBLEM", 219, 225], ["coronavirus", "OBSERVATION", 11, 22], ["increased", "OBSERVATION_MODIFIER", 40, 49], ["respiratory failure", "OBSERVATION", 59, 78], ["diabetes", "OBSERVATION", 190, 198], ["heart", "ANATOMY", 200, 205], ["disease", "OBSERVATION", 206, 213], ["asthma", "OBSERVATION", 219, 225]]]]}